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Abstract 
Acute myeloid leukaemia (AML) encompasses a group of aggressive haematological neoplasms. It 
is a cancer stem cell (CSC) disorder. The Hedgehog (Hh) signalling pathway is one of the self-
renewal pathways, highly conserved across species and important in determining stem cell fate, 
affecting a number of clinically important downstream targets including the Bcl-2 family. 
Abnormal Hh signalling has been associated with a diverse range of human malignancies. In 
myeloid malignancies, Hh signalling has been found to be vital in the maintenance and expansion 
of the CSC.  
Primary immotile cilia regulate canonical Hh signal transduction. These highly specialised 
organelles are present in single-celled eukaryotes through to humans, with defective primary 
cilia expression being linked to disease.  
It is unclear whether haematopoietic cells, normal or malignant, express primary cilia and the 
role the Hh pathway plays in the pathophysiology of AML. We sought to answer these questions, 
and further, to determine whether the Hh signalling pathway represented a therapeutic target in 
AML. 
Analysis of primary human AML mononuclear cells (MNCs) (n=76) showed the Hh pathway to be 
deregulated. SMO was significantly deregulated (p<0.0001) with two divergent cohorts 
identified. GLI-1, indicative of pathway activity, was detected in 52.6% of samples. Sanger 
sequencing (n=36) did not identify a mutation in SMO to account for the pathway deregulation 
though a number of silent and missense mutations were identified (mean 1; range 1-3). 25% of 
our AML samples (9/37) showed expression of GLI-1 in >10% of cells by immunohistochemistry 
(IHC) on formalin fixed paraffin embedded (FFPE) primary human bone marrow trephines (BMTs) 
compared to none of our normal controls (n=10) (p<0.0001). GLI-1 expression was independent of 
SMO and PTCH-1. SHH was significantly down-regulated (p<0.001) within the blast population 
whilst secreted SHH, measured by enzyme-linked immunosorbant assay, was up-regulated 
suggesting paracrine activity. Impaired post-translational modification of SHH was demonstrated 
with protein located within the nuclei by IHC and immunocytochemistry (ICC). Nuclear 
expression of SHH was limited to primitive (CD34+) haematopoietic cells and absent from mature 
haematopoietic (CD14+, CD15+) cells. This correlated with a 20-fold reduction in HHAT, the 
acetyltransferase involved in Hh processing, in normal primitive haematopoietic cells compared 
to normal MNCs (p<0.01). There was no correlation between subtype, mutational profile or 
clinical outcome and any of the components of the Hh pathway. 
Primary immotile cilia were identified in all AML (n=23), and 20% of normal (n=10) primary 
human FFPE BMTs by ICC. Primary cilia were not identified in AML cell lines (n=7) or primitive 
(n=4) or mature haematopoietic cells (n=6) isolated from peripheral blood, suggesting they are 
lost once cells migrate from the bone marrow (BM) microenvironment. 
In vitro, SMO inhibition with 20µM cyclopamine reduced cell proliferation by trypan blue 
exclusion in select, genetically diverse AML cell lines (HL-60, Kasumi-1, KG1a, MOLM-13, MV4-11, 
OCI-AML3 and THP-1). No change in early or late apoptosis was seen in HL-60, KG1a, MV4-11, 
OCI-AML3 and THP-1 by flow cytometry (FACS). In contrast an increase in the number of dead 
cells by trypan blue exclusion was seen in Kasumi-1 (p<0.01) and MOLM-13 (p<0.05) with 
apoptosis confirmed by FACS (both p<0.05). Culture of the OCI-AML3 cell line with cyclopamine 
led to cell cycle arrest with an increase in G0-G1 cells (p<0.05), and a 3-fold reduction in cell 
division by CFSE (p=ns); striking morphological changes were seen with an increase in cytoplasm, 
granules and vacuoles and loss of nucleoli, with FACS analysis demonstrating increased 
expression of CD11b (p<0.001) and CD11c (p<0.0001) consistent with a more mature phenotype. 
Early haematopoietic markers NAB2, GATA1, EGR2, SCL, IRF8 and EGR1 were down-regulated 
whilst PU1, GCSF and MPO involved in differentiation and maturation were up-regulated (p=ns) in 
cyclopamine treated cells.  
	 3	
Colony forming cell (CFC) assays showed a statistically significant reduction in the more 
pluripotent CFU-GM (p=0.006) colonies and an increase in omnipotent CFU-G (p=0.013) colonies 
following culture with cyclopamine 20µM.  
There is extensive evidence supporting Bcl-2 is altered in malignancy; its role in AML cell 
maintenance and survival, is well recognised. Further, Bcl-2 is a key downstream target of the 
Hh signalling pathway. Complete linkage analysis found key members of the Bcl-2 family and cell 
cycle regulators to cluster with components of the Hh signalling pathway. Sensitivity to the BH3 
mimetic ABT-199 was not solely dependent on the expression of Bcl-2, rather a complex 
interplay between the pro-apoptotic and anti-apoptotic family members. Targeting Bcl-2 had a 
variable effect on KG1a, MOLM-13, MV4-11, OCI-AML3 and THP-1 cells; combination treatment 
with ABT-199 and Ara-C showed a highly synergistic effect on cell death in MOLM-13 cells (Chou-
Talalay CI<0.47 (range 0.13-0.47) and DRI>2 (range 2-70) for all dose combinations).   
We show the Hh signalling pathway to be deregulated in AML, expression of components of the 
pathway changing with myeloid maturation. We demonstrate primary cilia on haematopoietic 
cells within the BM, with an increased frequency observed in AML. Their absence when cells 
migrate from the BM fits with their function and suggests a ‘switching off’ of canonical signalling 
on maturation. In the absence of primary cilia, we show the Hh pathway remains active, 
suggesting a role for non-canonical signalling in AML. Pharmacological inhibition led to both 
apoptosis and differentiation; preliminary results suggest the effect is dependent upon the 
degree of SMO inhibition. We believe further work is required to determine the role of the Hh 
signalling pathway in normal and malignant haematopoiesis but that our data, considered 
especially in context with other recently published studies provides a rationale to continue to 
explore SMO or downstream Bcl-2 pathway inhibition as potential therapies in AML.  
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with glasdegib (2.67µM, 5.34µM and 10.68µM; clinically achievable concentrations) for 72hrs 
Figure 4.1.10.3: SSC MFI, and representative FACS plot, following culture of the OCI-AML3 cell 
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1. Introduction 
1.1 Stem cells 
Irrespective of stage in life or tissue of origin, stem cell (SCs) are unique, undifferentiated cells 
defined by three key properties: long life, multipotency, and the capacity to self-renew 2,3. SC 
phenotype and potential being defined by characteristics intrinsic to the SC and environmental 
influences 3. 
The first experimental evidence of the SC, and thus of cellular hierarchy in the haematopoietic 
system, was in 1961, in a murine model 4. The haematopoietic system was eradicated by whole-
body radiation, donor blood cells injected via the tail vein, and assays performed to determine 
the cell number capable of restoring a functioning haematopoietic system. Colonies of cells were 
seen within the spleen. Further, some of these were capable of producing all of the mature, 
differentiated haematopoietic cells required to sustain life following transplantation into 
secondary recipients 4. Whilst experimental models have evolved, the principle remains the 
same: to demonstrate the cardinal properties of the SC - self-renewal and differentiation. 
SCs are broadly defined by origin into three groups: embryonic stem cells (ESCs), umbilical stem 
cells (USCs) and somatic stem cells (SSCs) 5. As their name would suggest, ESCs derive from an 
embryo, USCs from cord blood and SSCs are found in all postnatal organs. Additionally, they are 
defined by their developmental plasticity or potency with SCs being characterised as: totipotent, 
pluripotent and multipotent. Totipotent cells are capable of producing any cell type, indeed 
producing all the cells required for the developing embryo and extra-embryonic tissues including 
the placenta; the term is therefore limited to those cells found within the zygote and morula. 
Pluripotent cells are able to produce cells from any of the embryonic germ layers: endoderm, 
mesoderm and ectoderm, these cells compose the inner cell mass of the blastocyst 6. These 
primitive cell types develop into all tissues of the body 6. Multipotent cells, whilst retaining the 
key characteristics that define a SC, are capable of differentiating into a limited number of 
cells. These SCs are responsible for both tissue development and maintenance throughout life 7. 
Figure 1.1: Schematic diagram depicting stem cell hierarchy. 
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SCs are slow cycling, capable of self-renewal cell division, producing another SC with the same 
development and replication potential, and differentiation, producing tissue-specific specialised 
cells 8. This process is tightly regulated, ensuring the maintenance of the SC pool specific to that 
tissue, and enabling the SC to respond to both local and systemic proliferation signals whilst 
preventing uncontrolled growth 9.  
Whilst classically SC fate was believed to be controlled by growth factors, more recently work 
has shown it to be controlled by a complex interaction between highly conserved embryonic 
signalling pathways, transcription factors, and the surrounding extracellular matrix (ECM) or 
‘stem cell niche’ 10–14, discussed in more detail below in Section 1.1.1. Further, deregulated SC 
interactions have been shown to be fundamental in disease pathogenesis 11,15–17.  
Much of what we know about extrinsic regulators of SC fate comes from bulk population studies. 
It is however increasingly evident that cell fate decisions are made at the level of individual cells 
18–20, with researchers currently seeking to address this recognised flaw in our understanding of 
SC biology through advances in technology and computational skills. Utilising single cell gene 
expression analysis, researchers have begun to understand the transcriptional programmes 
underpinning SC behaviour, whilst electrical impedance spectroscopy has allowed for the 
quantitative analysis of each SC’s cellular processes 18,19,21,22. 
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Figure 1.1: Stem cell hierarchy 
Stem cells are defined by their self-renewal and multilineage differentiation capacities, placing them 
at the top of a cellular hierarchy within a given tissue.  
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Finally, despite regulatory systems, cell division carries the risk of aberrant mitosis. SCs being no 
exception, though the implications are far graver. Further, SCs may be at greater risk as they are 
long-lived, and therefore exposed to more genotoxic events 23,24. Fortunately, whilst mutations 
occur, most are inconsequential. A low frequency may accumulate however, eventually leading 
to an array of diseases including cancer. Most mutations resulting in cancer have been shown to 
affect cell division, DNA damage, and signal transduction thereby conferring a survival and 
proliferation advantage to the transformed SC 25.   
 
1.1.1 Stem cell niche 
The concept of the SC niche was considered almost in parallel to the discovery of the SC, in 1968 
26,27. Research, building upon that of Till and McCulloch, demonstrated the importance of the 
niche in preserving the reconstituting ability of SCs 28. This work recognised the inferior ability of 
the SCs isolated from colony-forming units within the spleen (CFU-S) to reconstitute 
haematopoiesis in irradiated animals compared to those of the bone marrow (BM). Additionally, 
heterotrophic transplantation of BM cells had shown these cells to not only form a bony capsule 
but to be capable of supporting the production of haematopoietic cells of recipient origin 29–31. 
Further work determined these BM cells to be fibroblasts, referred to as colony-forming unit-
fibroblasts (CFU-F) 32. Additional work analysing the media collected following CFU-F in vitro 
culture demonstrating their ability to produce haematopoietic growth factors 33–35. In 1986, work 
confirmed purified BM-derived fibroblasts were able to support haematopoiesis 36.  
Currently the term mesenchymal stem cell (MSC) is preferentially used when referring to these 
CFU-F / multipotent BM stromal cells. MSCs are defined by the International Society of Cellular 
Therapy (ISCT) as: plastic adherent, multipotent fibroblast-like cells which express CD73 and 
CD105, are negative for CD14, CD34 and CD45, and are capable of differentiating into 
osteoblasts, chondrocytes and adipocytes 37. However these properties are also shared by CFU-
Fs. Whilst more recent work analysing the expression of SSEA-1, SSEA-4 and GD2 appears to 
suggest a hierarchy of mesenchymal differentiation; at present it is not possible to definitively 
differentiate between MSCs and CFU-Fs 38–43. For the purpose of this thesis the term MSC will be 
used.  
The SC niche is defined by anatomy and function as a local tissue microenvironment that 
regulates and supports the tissue-specific SCs and progenitor cells 14,44,45. Although the SC niche 
remains incompletely defined it is clear there is considerable variation in niche design, and 
therefore possibly importance. SCs that support tissues undergoing constant cellular renewal, for 
example the haematopoietic system, being shown to be dependent upon the niche and the 
specific intercellular interactions and cellular organisation it provides 14,46. In contrast, muscle 
SCs for example, which are normally quiescent, appear content in relative isolation, residing on 
the basal lamina of the muscle fibre unit they support 47.  
 
1.1.2 Haematopoiesis and the haematopoietic stem cell  
‘All mammals make blood in their bones’ David T Scadden, E Donnall Thomas Lecture, ASH, San 
Diego, USA, December 2016.  
The site of blood cell production changes through the early stages of development. Primitive 
haematopoiesis occurs first in the yolk sac whereas definitive haematopoiesis occurs later with 
the first HSCs originating from the aorta-gonad-mesonephros region, these HSCs subsequently 
migrate to the placenta, foetal liver and spleen 48,49. During bone cavity formation the HSCs 
begin to migrate to the endosteum, forming the BM, with migration completing after birth 50.  
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After birth, and throughout life, haematopoiesis, in the healthy state, occurs within this BM. In 
response to stress however, haematopoiesis can occur in extramedullary sites such as the spleen. 
It is a highly metabolically active system, and it is estimated that greater than 1x108 blood cells 
are produced every minute in the average healthy adult.  
Haematopoiesis is an incredibly dynamic and highly organised hierarchy, homeostasis being 
maintained by self-renewing HSCs. These rare, multipotent cells produce a population of more 
committed, progenitor cells. In turn, through successive cell divisions and a complex series of 
differentiation steps, progenitor cells give rise to terminally differentiated mature blood cells of 
all lineages 51. Within this model common myeloid progenitors (CMPs) represent the critical 
progenitor cell from which the myeloid, megakaryocyte and erythroid cell lineages are 
ultimately derived, Figure 1.2: Haematopoietic hierarchy in humans.  
 
 
Investigation of haematopoietic hierarchical transitions, from a stem to progenitor to precursor 
state, through cell purification, transcriptional studies and functional clonal assays has however, 
provided insight into the cellular and molecular mechanisms underlying haematopoiesis, 
challenging the previously accepted model 52. These studies hypothesised that common myeloid 
progenitors (CMPs) are functionally heterogeneous unipotent progenitors, derived from putative 
multilineage HSPCs. Further, results suggest oligopotent progenitors may be a negligible 
component, the human haematopoietic hierarchy behaving rather as a ‘two-tier’ system: a top 
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Figure 1.2: Human haematopoietic hierarchy 
Long-term self-renewing multipotent haematopoietic stem cells (HSCs) are at the apex of the 
hierarchy. HSCs are followed by a series of progenitor cells (HPCs) with increasingly limited 
differentiation and self-renewal potential and finally by terminally differentiated mature 
haematopoietic cells. Distinct populations can be identified by their surface marker expression (as 
shown) and functional properties.  
HSC, haematopoietic stem cell; LT-, long-term repopulating;;ST-, short-term repopulating; MPP, 
multipotent progenitor; CMP, common myeloid progenitor; GMP, granulocyte–macrophage progenitor; 
MEP, megakaryocyte–erythrocyte progenitor; LMPP, lymphoid-primed MPP; CLP, common lymphoid 
progenitor. 
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tier containing multipotent cells such as HSCs and multipotent progenitors (MPPs), and a bottom 
tier composed of cells committed to myeloid, erythroid and megakaryocyte lineages. It is, 
perhaps, the megakaryocyte lineage which has been the most challenged, recent studies 
suggesting megakaryocytes do not transit through a multipotent or oligipotent progenitor stage; 
additional evidence suggesting a subset of HSCs to have biased megakaryocyte potential, 
megakaryocytes directly arising from these HSCs 53. Whilst much of our understanding of 
haematopoiesis has derived from the classical model the refined model, perhaps, lends itself 
more to the notion of the HSPC as the progenitor cell in AML.  
 
 
Finally, recent work has shown that although their phenotype is tightly defined, these HSCs are 
functionally heterogeneous. The HSC compartment, in fact, comprising a limited number of 
distinct subtypes intrinsically biased in their lineage production 51,54,55.	These subtypes reside in 
close proximity within the BM microenvironment, each with its own epigenetically determined 
differentiation and proliferation programme 56–60. Further, recent research utilising single cell 
gene expression analysis has begun to unravel the structure and function of transcriptional 
programmes underpinning haematopoiesis in the adult and the process of blood development in 
the embryo 61 with HSCs being shown to be heterogeneous at a gene expression level 62,63.  
It is therefore apparent that it is not just the HSC that is responsible for healthy haematopoiesis 
but a series of complex communications between these cells and the BM microenvironment 
within which they reside 11,13.  
 
Figure 1.3: Schematic illustrating the differences between the classical and redefined models of 
the haematopoietic hierarchy.  
The classical model, proposes that many HSPCs are multipotent, defining a population of oligopotent 
progenitors, such as CMP, from which myeloid, erythroid and megakaryocyte differentiation originates.  
The redefined model proposes a developmental shift in the progenitor cell architecture with 
development. In this model, haematopoietic hierarchy is thought to follow the classical model in utero 
but by adulthood the replicative potential of the progenitor population has narrowed considerably 
whereby it is only the SCs which are multipotent, progenitors becoming unipotent.  
The planes represent theoretical tiers of differentiation. 
Mk, megakaryocyte; Mono, monocyte, Ly, lymphoid; My, myeloid; Er, erythroid.  
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1.1.3 Bone marrow microenvironment 
‘In the two hundred million years since fish diverged from our evolutionary tree, animals with 
blood and bones have made blood in their BM. This lengthy co-evolution has made the BM a 
special place where multiple non-haematopoietic cells contribute to the orderly regulation of 
blood cell production.’ David T Scadden, E Donnall Thomas Lecture, ASH, San Diego, USA, 
December 2016. 
The BM niche is an interactive system; complex regulatory relationships operating between the 
haematopoietic, mesenchymal, endothelial and neural cells residing within it, with HSCs 
distributed throughout. It is this microenvironment that is responsible for supporting and 
influencing HSC fate. Regulatory signals provided by cytokines, ECM proteins and cues provided 
through cell-cell contact all influencing SC behaviour down to the level of single stem and 
progenitor cells; Figure 1.4. 
 
 
The cellular identity of the cells that regulate HSCs within the BM niche has been a contentious 
issue for the past decade. The endosteal region, as an anatomical location for HSCs, is well 
documented, with many types of cells existing in close proximity within this region: osteoblasts, 
osteoclasts and endosteal monocytes or macrophages have all been demonstrated to influence 
SC fate 64,65. However, whilst osteoblastic cells were the first cell population shown to influence 
HSC frequency 66,67 more recent work raised concern this may be an artifact of the experimental 
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Figure 1.4: Bone marrow microenvironment 
The bone marrow (BM) is a specialised microenvironment referred to as the SC niche where HSCs 
reside, their fate being determined by a complex interplay of extrinsic and intrinsic signals including 
cytokines, chemokines .and the self-renewal signalling pathways. The BM contains at least two 
distinctive HSC supportive niches: an endosteal osteoblastic niche, which appears to support 
quiescence and self-renewal and the perivascular niche that appears to promote HSC proliferation and 
differentiation.  
TGFβ / BMP 
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method. In vivo imaging studies found few HSCs in contact with osteoblastic cells 68–70. 
Additionally, manipulation of osteoblast cell numbers had no acute effect on HSC frequency 71–73; 
HSC proliferation and differentiation being altered following the genetic modification of 
primitive osteolineage cells but not mature osteoblasts 74. Finally, less than 20% of HSCs are 
located within 10µm of the endosteum; most HSCs being found in the trabecular region of the BM 
69,71,75,76. The location of large numbers of HSCs in the trabecular region implies osteolineage 
cells do have a role in HSC fate, and that it is not experimental artifact 68,77–79. The precise 
nature of this role however remains to be determined.   
More recent work has focused on the perivascular area 12,80. Perivascular MSCs have been shown 
to express a number of markers directly involved in HSC maintenance including CD146 78, CXCL12 
70,81,82 and Nestin 83. Perivascular stromal cells in culture have been shown to both promote HSC 
maintenance 84 and long-term expansion 85,86. Further, HSC quiescence was enhanced and self-
renewal potential increased in an E-selectin knock out model, with HSCs also showing increased 
resistance to irradiation 87. Interestingly, HSCs are five times more likely than other 
haematopoietic cells to be located adjacent to a sinusoid 71,76,88. Many cell types are thought to 
directly or indirectly regulate the perivascular niche; for example the sympathetic nervous 
system has been shown to regulate Cxcl12 expression and thus HSC retention in the BM 12,89,90. 
Additionally blood may serve to transport long-range signals integrating HSC activity with overall 
physiology 91.   
Current data suggests there are specialised niches, composed of many cell types, for distinct 
haematopoietic stem and progenitor cell (HSPC) functions 92. Further, some stromal cells affect 
SCs while others affect more mature, lineage-restricted cells, with niche composition and 
function thought to change under different physiological conditions. Finally, it is apparent 
stromal sub-populations participate in the malignant process. The extent that malignancies 
disrupt the SC niche and the ability to exploit this is an exciting area of ongoing research.   
 
1.2 Cancer 
The term ‘cancer’ encompasses a spectrum of diseases resulting from abnormal cell growth and 
behaviour. Clinically, simplistically, cancer can vary from those that are relatively indolent, not 
requiring treatment, to those that are highly aggressive necessitating early treatment in order to 
prevent death, and anything in between.  
Two models of cancer have been described, the stochastic model and the hierarchical model, 
depicted in Figure 1.5: Cancer cell model 93. The stochastic model suggests tumour cell growth 
to be dependent on both extrinsic and intrinsic signals, each malignant cell possessing cancer 
initiating potential. In contrast, the hierarchical model proposes heterogeneity within, with only 
a select few cancer cells capable of cancer initiation; these cells are termed cancer stem cells 
(CSCs) 93.  
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1.2.1 Cancer stem cells 
The concept of the CSC was first demonstrated in 1963 94. Malignant haematopoietic cells, like 
their normal counterparts, were demonstrated to be capable of forming splenic colonies when 
transplanted into irradiated hosts. Definitive evidence, through work in chronic myeloid 
leukaemia (CML), that a single progenitor cell was capable of driving leukaemia was provided in 
1977 95. Utilising Glucose-6-phosphate dehydrogenase isoenzymes, CML cell behaviour was 
studied, the results shaping the future of oncology research. A single pluripotent SC, following 
transformation, was shown to produce clonal malignant progeny. Further, normal myeloid, 
lymphoid and erythroid cells and platelets were shown to harbour the same isoenzyme as the 
malignant population suggesting a common cell of origin / clonal origin 95.  
During this period, the concept of a malignant cell hierarchy, and importantly halted 
differentiation, was established and hence the phase ‘oncogeny is blocked ontogeny’ was 
introduced in 1968 96. Malignant tissues were shown to resemble foetal tissue, though they 
strikingly lacked the ability to differentiate into the full complement of mature specialised cells 
required for functional tissue development 97. Proliferation studies, within squamous cell 
carcinoma, demonstrated undifferentiated malignant cells to be capable of producing mature, 
benign cells 98; whilst enzymatic studies revealed the similarities, and important differences, 
between hepatic tumour cells and those within the foetal liver 97.  
The CSC theory proposes a cancer to have cellular hierarchy similar to that of the normal tissue, 
with the CSC reflecting the intrinsic SC’s multipotency. The hypothesis is supported by two main 
experimental findings. First, cancers are intrinsically heterogeneous 99–103; different cell types 
demonstrated within a cancer. Second, the cancer cells themselves have been shown to be 
heterogeneous, with differing phenotypes and varying proliferative potential 99,104,105. This 
heterogeneity is thought to be due to genomic instability, interactions with the tumour 
microenvironment and, to a degree, maintenance of the cellular hierarchy seen in the normal 
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Figure 1.5: Cancer cell model 
In the stochastic model all malignant cells have the ability to function as a cancer stem cell (CSC), 
their ultimate fate being affected by both intrinsic and extrinsic factors. Whilst within the hierarchical 
model only a small fraction of the malignant cell population have the ability to function as CSCs, to 
produce both CSCs and progeny with limited self-renewal potential, in other words the cancerous cells 
are biologically diverse. 
CSC, cancer stem cell.  
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healthy tissue 106,107. Additionally, a large number of cancer cells are necessary for a cancer to 
develop and grow 108,109. Finally, the progression to cancer is usually associated with genomic 
instability, generating both clonal and non-clonal populations 110. 
There is now extensive evidence to support the CSC theory in a wide array of malignancies 2,111. 
These CSCs are understood to exist as a minority population, sharing many properties with 
normal SCs, including self-renewal and differentiation, and are capable of tumour initiation in 
secondary transplanted hosts 112.  
Malignancies with evidence of CSC origin include haematological cancers 112,113 and several solid 
tumours including: colon 114, breast 115, prostate 116, pancreas 117, lung 118 and certain 
neurological malignancies 119.  
Classically the CSC was believed to arise from normal SCs; mutations allowing the CSCs to 
undergo unregulated expansion. In leukaemia, for example, the CSCs were shown to be capable 
of producing multiple mature lineages and, further, to express certain markers expressed by 
normal HSCs 120,121. More recently however, as our ability to identify and distinguish between the 
primitive cell populations has improved, evidence has shown the CSC can also arise from 
progenitor cells which have gained the ability to self renew 23,122,123. This is especially true in 
haematopoietic malignancies 124,125. 
Whilst there is still much to learn in respect of the CSC, various experimental models have shown 
these cells to be innately less sensitive to treatment, to continually develop genomic and 
epigenomic changes and to uniquely interact with the SC niche 23,126. The influence each of these 
factors has on the CSC’s treatment-resistant phenotype is however, unclear. It is therefore vital 
to continue to seek to unravel the complex and likely intertwined, molecular mechanisms 
regulating SC fate.  
 
1.2.2 Leukaemic stem cell 
Leukaemic stem cells (LSCs) were first demonstrated in acute myeloid leukaemia (AML) in 1994 
112,121. Using a severe combined immunodeficiency disease (SCID) immunodeficient mouse model 
and phenotypic cell isolation strategy the proliferation and self-renewal potential of 
transplanted human AML cell populations were studied 127,128. This beautifully showed only a 
subset of cells capable of serial engraftment in recipient mice, these cells were defined as 
CD34+CD38−. Further work in 2004 used lineage tracing proved that LSCs are not functionally 
homogeneous, rather LSCs were shown to have a heterogeneous self-renewal potential closely 
resembling their normal counterparts 129.  
More recent studies have expanded the phenotypic definition of the human AML LSC: 
CD34+CD38−CD90−IL−3R+CD71−HLA−DR−CD117− 130–133.  
Whilst initial work appeared to indicate LSCs arose following the transformation of a normal HSC, 
subsequent work showed the LSC population to resemble haematopoietic progenitor cells (HPCs), 
rather than the HSC 113,134,135. This suggested LSCs either arose from HPCs or the differences 
reflected a change in surface marker expression upon malignant transformation 131,133,136,137. The 
weight of evidence from subsequent research however appears to support the idea that LSCs are 
in fact derived from HPCs.  
Initial studies used mouse models to study the effect of leukaemia inducing mutations on 
myeloid progenitor populations 138,139. In a transgenic mouse leukaemia model, both HSCs and 
HPCs transduced with a chimeric minigene encoding MLL-AF9 (originating from t(9;11)(p22;q23), 
associated with myelomonocytic AML (FAB M4 / M5) and linked to  t-AML resulted in LSCs and 
leukaemia though many more transduced HPCs had to be transplanted to establish leukaemia 
compared with HSCs 123,140. Similar results were demonstrated when the MLL-ENL fusion gene 
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(originating from t(11;19)(q23;p13.3) was expressed in haematopoietic cells, transplantation 
efficiency shown to progressively fall with cellular differentiation from HSCs to CMPs and finally 
granulocyte-macrophage progenitors (GMPs) 122,141. These results suggesting, more committed 
progenitor cells when transformed, whilst not being as efficient as HSCs retained SC 
characteristics, notably the experimentally defined ability to give rise to disease following 
transplantation. Another study assayed the ability of different leukaemogenic genes to transform 
progenitor populations. CMPs transduced with a MOZ-TIF2 fusion oncogene (originating from 
inv(8)(p11q13), associated with FAB M4/5 morphology, involved in histone acetylation 142 143,144 
could be serially replated in vitro and induce transplantable AML in vivo. However, a BCR-ABL 
(arising from the Philadelphia chromosome, a reciprocal translocation t(9;22)(q34;q11) resulting 
in a constitutively active tyrosine kinase fusion gene was not able to transform GMPs into LSCs 
145,146. These results suggested that whilst LSCs did arise from HPCs, HPCs required additional 
mutations to acquire self-renewal ability before they are capable of transforming into LSCs. 
Further, not all leukaemic cells were capable of giving rise to disease on transplantation, 
suggesting the LSCs gave rise to both self-renewing and non-self-renewing daughter cells 124,147. 
Additional evidence to support HPCs as the cell of origin in myeloid malignancies came from 
lineage analysis of LSCs in human chronic myeloid leukaemia (CML) 125. Analysing the colony 
forming and transplantation potential of different populations of leukaemic cells from patients 
with CML-blast crisis (BC) revealed those cells with self-renewal potential phenotypically 
resembled HPCs rather than HSCs 125,148. Whilst myeloid CML-BC is managed clinically as AML, 
allowing comparisons to be made, it is important to remember the differences in these entities, 
not least in the preceding disease and initiating lesion, the heterogeneity of AML precluding such 
definitive evidence. More recently however two molecularly distinct, hierarchically ordered, 
populations with stem cell qualities have been identified in CD34+ AML; a CD34+CD38-CD45RA+ 
lymphoid-primed multipotent progenitor (LMPP) population and a more mature 
CD34+CD38+CD45RA+ granulocyte-macrophage progenitors (GMP) population 149. Interestingly, 
molecular studies have shown these populations to closely resemble normal progenitor cells 
suggesting CD34+ AML is a progenitor disease arising following LSC acquisition of abnormal self-
renewal potential.  
 
1.3 Leukaemia		
The term leukaemia implies a neoplastic process resulting from the uncontrolled expansion of 
haematopoietic cells, encompassing a broad spectrum of BM disorders. The reality however, is 
far more complicated, and interesting! 
The first case described in the literature was in 1827. The term “leukaemia”, derived from the 
Ancient Greek meaning white blood however, was not introduced until 1856, and then, in 1889 
“acute leukaemia” was used to differentiate rapidly progressive leukaemia from the more 
indolent chronic forms. Finally, in 1900 the myeloblast was characterised, dividing leukaemia 
into ''myeloid'' and ''lymphoid'' depending on the predominant cell type; 85% of adult leukaemia 
being myeloid.  
 
1.3.1 Acute myeloid leukaemia  
AML encompasses a group of aggressive haematological neoplasms. It arises from impairment in 
differentiation and over-proliferation of the HPSC compartment, resulting in the accumulation of 
a clone or clones of abnormal, non-functional, immature myeloid progenitor cells termed 
myeloblasts. However while substantial progress has been made in understanding AML there are 
still distinct areas that require major advances. 
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It is a clinically, morphologically and genetically heterogeneous disease involving one or all of 
the myeloid lineages 150. Whole-genome sequencing has shown AML to be polyclonal, with a 
dominant clone tending to emerge at relapse 151.  
AML is the most common malignant myeloid disorder in adults with an annual incidence of 
approximately 5 per 100,000, increasing progressively with age, to a peak of 21 per 100,000 
adults aged 65 years and older 152,153. Its incidence has increased by 73% since the 1970s, with 
the largest increase in those aged over 80 years; 2942 new cases were diagnosed in 2013 in the 
UK alone 152. This increase is considered to reflect our aging population in addition to 
improvements in diagnostic techniques and data registration rather than a true increase in 
disease incidence. It affects all ages, though the median age at presentation is 70 years. 
Unexplainably, there is a slightly higher incidence in men than women, with a ratio of 
approximately 1.4:1 152.  
The diagnosis of AML requires a minimum of 20% myeloid blasts within the BM. AML is then 
classified according to the World Health Organization (WHO) Classification of Tumours of the 
Haematopoietic and Lymphoid Tissues, defining four major categories; Table 1.1 154.  
 
Table 1.1: WHO Classification 154 
Name Description 
AML with 
recurrent 
genetic 
abnormalities 
AML with translocations between chromosome 8 and 21 - t(8;21)(q22;q22); 
RUNX1/RUNX1T1  
AML with inversions in chromosome 16 - inv(16)(p13.1q22) or internal 
translocations - t(16;16)(p13.1;q22); CBFB/MYH11 
APL with PML-RARA with translocations between chromosome 15 and 17 - 
t(15;17)(q22;q12); RARA/PML  
AML with translocations between chromosome 9 and 11 - t(9;11)(p22;q23); 
MLLT3/MLL  
AML with translocations between chromosome 6 and 9 - t(6;9)(p23;q34); 
DEK/NUP214 
AML with inversions in chromosome 3 - inv(3)(q21q26.2) GATA2, MECOM or 
internal translocations - t(3;3)(q21;q26.2); RPN1/EVI1  
Megakaryoblastic AML with translocations between chromosome 1 and 22 - 
t(1;22)(p13;q13); RBM15/MLK1  
AML with mutated NPM1  
AML with biallelic mutations of CEBPA 
PROVISIONAL ENTITY:  
AML with BCR-ABL1 
AML with mutated RUNX1 
AML with 
myelodysplasia-
related changes 
This category includes patients with a prior diagnosis of MDS 
(myelodysplasia) or MPN (myeloproliferative neoplasm), or cytogenetic 
abnormalities characteristic for this sub-type  
	 35	
AML with complex karyotype 
Unbalanced abnormalities:  
AML with deletions of chromosome 7 - del(7q) 
AML with deletions of chromosome 5 - del(5q) 
AML with unbalanced chromosomal aberrations in chromosome 17 - 
i(17q)/t(17p) 
AML with deletions of chromosome 13 - del(13q) 
AML with deletions of chromosome 11 - del(11q) 
AML with unbalanced chromosomal aberrations in chromosome 12 - 
del(12p)/t(12p) 
AML with deletions of chromosome 9 - del(9q) 
AML with aberrations in chromosome X - idic(X)(q13) 
Balanced abnormalities:  
AML with translocations between chromosome 11 and 16 - 
t(11;16)(q23;q13.3), unrelated to previous chemotherapy or ionizing 
radiation 
AML with translocations between chromosome 3 and 21 - 
t(3;21)(q26.2;q22.1), unrelated to previous chemotherapy or ionizing 
radiation 
AML with translocations between chromosome 1 and 3 - t(1;3)(p36.3;q21.1) 
AML with translocations between chromosome 2 and 11 - t(2;11)(p21;q23), 
unrelated to previous chemotherapy or ionizing radiation 
AML with translocations between chromosome 5 and 12 - t(5;12)(q33;p12) 
AML with translocations between chromosome 5 and 7 - t(5;7)(q33;q11.2) 
AML with translocations between chromosome 5 and 17 - t(5;17)(q33;p13) 
AML with translocations between chromosome 5 and 10 - t(5;10)(q33;q21) 
AML with translocations between chromosome 3 and 5 - t(3;5)(q25;q34) 
Therapy-related 
myeloid 
neoplasms 
This category includes patients who have received prior chemotherapy 
and/or radiation and subsequently develop AML or MDS.  
AML not 
otherwise 
categorised 
This category includes subtypes which do not fall into the above categories:  
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
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Acute monoblastic and monocytic leukaemia 
Acute erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma  
Myeloid 
proliferations 
related to Down 
syndrome 
Transient abnormal myelopoiesis 
Myeloid leukaemia associated Down syndrome 
 
This is a revision of the 2008 classification 153. The classification utilises clinical, morphological 
and genetic features, developing upon the previous morphologically based French-American-
British (FAB) system.  
Cytogenetic abnormalities, the majority of which are non-random chromosomal translocations 
are detected in 50% to 60% of de novo AML 155. The fusion protein being found to primarily alter 
expression of genes involved in differentiation, proliferation and/or survival.  
The WHO subcategory AML with recurrent genetic abnormalities contains a number of clinically 
relevant onco-fusion proteins 156,157: runt-related transcription factor 1 (RUNX1/RUNX1T1), 
CCAAT/enhancer-binding protein β/Myosin-11 (CBPβ/MYH11), retinoic acid receptor 
α/promyelocytic leukaemia (RARα/PML), mixed lineage leukaemia (MLLT3/MLL), DEK/NUP214, 
ribophorin-1/MDS1 and EVI1 complex locus (RPN1/EVI1), RNA binding motif protein 15/mitogen-
activated protein kinase kinase kinase 9 (RBM15/MLK1), nucleoplasmin 1 (NPM1) and 
CCAAT/enhancer-binding protein α (CEBPα).  
t(8;21), RUNX1/RUNX1T1 is expressed in 5-12% of AML, whilst CBPβ/MYH11 is found in 
approximately 8% of AML 158–160. Both are associated with a favourable prognosis 161,162, and are 
believed to function as transcriptional repressors. The t(15;17), RARA/PML translocation is found 
in approximately 13% of all AML, and 95% of acute promyelocytic leukaemia (APML) 158; 
RARα/PML acting as a transcriptional repressor interfering with cellular differentiation, 
apoptosis, and self-renewal. APML represents a distinct subtype of AML, response to current 
treatments exceeding 90% 163,164, thus serving as the first malignancy largely cured by targeted 
therapies. MLLT3/MLL is found in 5-10% of AML 158,165,166. The fusion protein thought to act as an 
oncogene, conferring a variable prognosis 165. inv(3)/t(3;3), RPN1/EVI1 occurs in 1-2% of AML, is 
involved in cellular differentiation, proliferation and apoptosis, and is characterised by a poor 
clinical outcome 167,168. t(6;9) DEK/NUP214 is found in approximately 1% of AML, increasing 
cellular proliferation, and conferring a poor prognosis 158. The t(1;22), RBM15-MKL1 is found in 
<0.5%, being found almost exclusively in infants and children, and associated with acute 
megakaryoblastic leukaemia (FAB M7). It is also associated with a poor prognosis 167,169,170.  
NPM1 and CEBPα mutations affect cell proliferation and survival 171. NPM1 has been detected in 
approximately 35% of AML, and is associated with a favourable outcome 172–174. Several 
mechanisms of action have been proposed including regulation of the tumour suppressor p53 and 
components of the cell cycle 175,176. CEBPα is found in 5 to 14% of AML, with biallelic but not 
monoallelic mutations being strongly associated with a favourable prognosis 177. CEBPα is 
involved in cell differentiation and has been found to serve as a tumour suppressor 178,179.  
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40% to 50% of AML cases have a normal karyotype, classified as intermediate risk by the WHO 
Classification. However, these cases are clinically highly diverse, reflecting the genetic 
heterogeneity seen within this subgroup. The mutations found are broadly defined by function: 
class I affect cellular proliferation and/or survival, whilst class II result in impaired 
differentiation. Class I mutations include stem cell growth factor receptor c-KIT, fms-like 
tyrosine kinase 3 (FLT3), neuroblastoma RAS viral oncogene homolog (NRAS) and kirsten rat 
sarcoma viral oncogene homolog (KRAS). Studies have shown activating KIT mutations to be 
associated with a higher incidence of relapse and significantly lower survival, negating 
favourable prognostic genetic abnormalities including RUNX1/RUNX1T1 and CBPβ/MYH11. FLT3, 
a receptor tyrosine kinase vital in determining HSC cell fate, is one of the most frequently 
encountered mutations in AML being found in approximately 30% of AML 180; the prognostic 
impact dependent on the nature of the mutation and its genetic context 181. FLT3 mutations can 
be divided into two categories: internal tandem duplications (FLT3-ITD) in or near the 
juxtamembrane region 182 or point mutations within the activation loop of the tyrosine kinase 
domain (FLT3-TKD) 183. Both result in constitutive tyrosine kinase activity in the absence of 
ligand, which signal through different mechanisms, thereby accounting for the biological 
differences. FLT3-ITD typically associates with NPM1 or DNMT3a mutations 181; studies 
demonstrating an NPM1 mutation to mitigate the negative prognostic effect of FLT3-ITD 184,185. 
FLT3-ITD occurs in approximately 25% of de novo AML cases. Gene expression profiling has 
confirmed FLT3-ITD to be an independent poor risk factor in AML with trials such as the NCRI AML 
19 186 stratifying patients bearing the FLT3-ITD mutation as high risk 187. Interestingly the 
incidence of FLT3-ITD varies with age, being relatively rare in paediatric AML 188. FLT3-TKD is 
less frequent, occurring in approximately 7% of patients, being more common in favourable risk 
AML 189. A number of FLT3 tyrosine kinase inhibitors (TKIs) have been developed, being trialled 
clinically either as a monotherapy or in combination with other agents 190. Mutations in NRAS and 
KRAS occur in approximately 10% and 5% of AML, respectively. 
Class II mutations include MLL and Wilms tumor gene (WT-1). MLL fusion genes are found in 5-
10% of AML 191; abrogating p53 function 192. 11q23 abnormalities are associated with a poor 
prognosis, whilst t(9;11)(p22;q23) is associated with a more favourable outcome. WT-1 mutations 
occur as secondary events, being found in approximately 14% of AML; the significance is 
dependent on preceding mutations 193.  
Novel small molecule inhibitors to target a number of these mutations are in development 
181,194,195. Interestingly, considering other therapeutic approaches, a WT1 peptide vaccination has 
been trialed in a small number of patients with myelodysplasia (MDS) and/or AML. Whilst the 
numbers are small, and the cases heterogeneous vaccination has been shown to be safe and 
feasible, and further clinical responses have been reported 196. Larger, randomised clinical trials 
are however needed to further determine the role of WT1 peptide vaccination, and other 
immunotherapeutic approaches in the management of AML. 
AML with myelodysplasia-related changes is a heterogeneous disorder defined by morphologic, 
genetic and clinical features. It has an adverse prognosis, with many cases preceded by MDS or a 
myeloproliferative neoplasm (MPN) 154. 
Therapy-related myeloid neoplasms (t-MN) occur as a late complication following chemotherapy 
and or radiotherapy, though the mechanism remains unclear 197,198. Within this category there is 
considerable heterogeneity - distinct clinical and cytogenetic subtypes being well recognised. 
Clonal chromosome abnormalities are found in the majority; abnormalities of chromosome 5, 7 
or both account for approximately 75% of cases with an abnormal karyotype 199. The latency 
ranges from a few months to several years, dependent upon the nature of the preceding 
treatment, intensity and cumulative dose 198.  
AML not otherwise specified encompasses the cases not belonging to the other categories. It 
utilises the FAB classification to morphologically sub-categorise each case. Interestingly, FAB M0 
was independently associated with an inferior overall survival (OS) and reduced likelihood of 
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achieving a complete remission (CR) compared with FAB M1, M2, M4, M5, and M6 200. However 
this prognostic significance was lost when the NPM1 and CEBPα mutational status was accounted 
for 200. With our ever expanding knowledge and ability to molecularly define AML it will be 
interesting to see how, or even if, morphological sub-classification, once so vital, provides any 
clinical benefit in the future. 
In keeping with the heterogeneity of the disease, many factors govern treatment decisions and 
crucially the patient’s prognosis – including those that determine the patient’s WHO subtype and 
patient age 201,202; cytogenetics being the most important prognostic factor for predicting OS, 
remission and relapse 154,155,158,165.  
However, despite advances in understanding of the pathophysiology the basic therapeutic 
approach to AML has changed little over the last few decades. The approach to adults aged 18–60 
years with AML classically involves two phases: achieving CR, defined as a BM with less than 5% 
blasts, a neutrophil count greater than 1000/µL, and a platelet count greater than 100 000/µL 203   
and prolonging / maintaining remission. The standard treatment for AML, excluding patients with 
APML, consists of 3 days of an anthracycline and 10 days of cytarabine (“3+10”) 201. A number of 
clinical trials have sought to intensify treatment or minimise toxicity; these trials have used 
alternative anthracyclines such as idarubicin, added or substituted high-dose cytarabine, or 
added etoposide. While these alternative regimes have been tolerated, whether they offer OS 
benefit has yet to be proven. Table 1.2 shows select current phase III trials for previously 
untreated AML, categorised according to patient age. It does not show investigational therapies 
and early phase trials, these are discussed later, in Section 1.3.5. 
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Table 1.2: Current Phase III clinical trials for untreated AML 
Funder 
Sponsor (where applicable) 
Trial name 
Treatment  
18-60, and those >60 years for whom intensive therapy is considered appropriate 
HOVON 
132 AML 
DA/IA followed by high dose consolidation +/- lenalidomide 
(immunomodulatory agent) 
CR-UK 
Cardiff University 
NCRI AML19 
 
FLAG-Ida vs DA +/- GO (anti-CD33 immunoconjugate) 
High risk: FLAG-Ida vs CPX-351 followed by allogeneic SCT  
Standard risk: +/- Ganetespib (Heat shock protein 90 inhibitor)  
FLT3+: +/- AC220 (FLT3 inhibitor) 
APML - AIDA  
Sprycel DA + Histone deacetylase (HDAC) inhibitor +/- Dasatinib (dual 
ABL/SRC inhibitor) in CBF-AML 
SWOG DA vs IA vs IA + Vorinostat (HDAC) inhibitor 
>60 years fit for intensive therapy 
EORTC 
1301 
DA vs Decitabine followed by allogeneic SCT  
 
HOVON 
97 AML 
+/- Azacitadine (DNA methyltransferase inhibitor) maintenance 
Bloodwise 
Cardiff University 
NCR1 LI-1 
 
Low dose Ara-C  
Low dose Ara-C + AC220 
Low dose Ara-C + Tosedostat (aminopeptidase inhibitor) 
Low dose Ara-C + Selinexor (selective inhibitor of nuclear export) 
Low dose Ara-C + Lenalidomide  
CR-UK 
Cardiff University 
NCRI AML 18 
 
DA +/- GO  
CR & MRD negative after #1: 2 vs 3 cycles DA 
Lack of CR or MRD positive after #1: DA vs DAC or FLAG-Ida 
followed by non-intensive allogeneic SCT  
+/- AC220  
+/- Ganetespib 
Abbreviations: DA: daunorubicin + cytarabine; DAC: daunorubicin + cytarabine + cladribine; IA: 
idarubicin + cytarabine; FLAG-Ida: fludarabine + high dose cytarabine + idarubicin + granulocyte 
colony-stimulating factor (G-CSF); GO: Gemtuzumab ozogamicin; AC220: Quizartinib; SCT: stem 
cell transplant; AIDA: all-trans retinoic acid + idarubicin; HDAC: Histone deacetylase inhibitor; 
Ara-C: cytarabine; CR: complete remission; MRD: minimal residual disease. 
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In the UK, eligible, consenting patients are treated within a clinical trial. For those aged 
between 18 and 60 years and those aged over 60 years for whom intensive therapy is considered 
appropriate, there is the recently opened National Cancer Research Institute (NCRI) AML19 trial. 
This large, multi-centered randomised trial seeks to build on previous trial data combining 
cytogenetic and mutation status with emerging new treatments to improve outlook for younger 
patients. Briefly, it aims to compare four induction schedules (DA plus Gemtuzumab ozogamicin 
(GO) / DA plus GOx2 / fludarabine, high dose cytarabine, idarubicin, granulocyte colony-
stimulating factor (G-CSF) (FLAG-Ida) plus GO / FLAG-Ida plus GOx2), provided adverse 
cytogenetics are not already known. Patients are subsequently segregated according to 
molecular / genetic characteristics, and a validated risk score 204. For those with adverse 
cytogenetics the trial seeks to compare the novel treatment agent CPX-351 against FLAG-Ida. 
CPX-351 is a liposomal formulation of cytarabine and daunorubicin designed to deliver synergistic 
drug ratios. High-risk, or refractory (resistant disease or <50% reduction in blast percentage) 
patients will receive allogeneic stem cell transplant providing a suitable donor is available.  
Standard treatment regimens however, are associated with considerable morbidity and 
mortality. Further, although treatment results in a favourable response, with high remission 
rates of 60-80% in younger patients, only 30-40% survive 5 years (45% of those achieving CR) 205.  
Outlook for the older population, those most affected, however remains poor with a median 
survival of a few months. Patients over 60 years have a 40%–60% chance of CR, with only 5%–15% 
surviving 5 years 201,202. Further, whilst those over 70 years can attain a CR with intensive 
therapy, the chance is reduced yet further to 30%, with <10% of treated patients remaining alive 
at one year. The difference in prognosis is a reflection of co-morbidities associated with ageing 
and disease biology 202. Older adults with AML are also considered more likely to have HSCs with 
a reduced proliferative capacity 206, which may affect blood count recovery following 
chemotherapy. Table 1.3 is modified from the American Society of Haematology (ASH) Education 
handbook demonstrating some of the key differences between young and old AML biology 207.  
Given that for 85-95% of older patients any treatment will ultimately be palliative the balance 
between the potential for cure or survival prolongation and quality of life must be carefully 
considered in this population. Treatment options include supportive care (transfusion support 
and antibiotics), low-dose chemotherapy (hydroxycarbamide or low-dose cytarabine), 
hypomethylating agents (HMAs; azacitidine), high-dose chemotherapy (“3+10”) and novel agents 
within clinical trials. 
In summary, AML is a hugely complex disease both from the perspective of the scientist seeking 
to improve current understanding and thus patient outlook, and from the clinician treating each 
individual patient they are faced with. It is however a hugely exciting time to work within this 
field, work already being translated into improved sub-classification 154, new terminology 
discussed below, and an expanding armory of small molecule inhibitors and strategies for 
evaluating emerging treatments. 
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Table 1.3: Characteristics of older and younger adults with AML 207, 720 
Characteristic ≥60 years 18-60 years 
Incidence (rate per 100,000) 52.7 5.8 
Secondary AML 24–56% 8% 
Favourable cytogenetics  
    t(8;21) 2% 9% 
    inv 16 or t(16;16) 1–3% 10% 
    t(15;17) 4% 6–12% 
Unfavourable cytogenetics  
    −7 8–9% 3% 
    +8 6–10% 4% 
    Complex 18% 7% 
MDR1 expression 71% 35% 
CR 40-50% 60-70% 
Treatment-related mortality 25–30% 5–10% 
DFS 5–15% 30% 
CR: complete remission; DFS: disease free survival 
 
1.3.2 Pre-leukaemia 
‘The evolutionary history of most types of leukaemia starts years before clinical presentation, 
during a prolonged pre-leukemic stage’, Scott A Armstrong, Cell of Origin and Leukaemic 
Transformation, ASH, San Diego, USA, December 2016.  
This concept, of pre-leukaemia, has arisen following work studying the nature, order and 
consequences of well recognised and frequently occurring mutations within the haematopoietic 
hierarchy 208–210. Interestingly, long before this work, research into paediatric ALL provided 
evidence of an initiating event, a ‘first hit’, being detectable months or years prior to the 
clinical development of ALL. Researchers retrospectively analysed neonatal blood spots (Guthrie 
spots) of patients who had developed ALL carrying the MLL-AF4 gene rearrangement between 
the ages of five months and two years 211. The leukaemic specific molecular abnormality (MLL-
AF4) was identified in all cases providing definitive evidence ALL in its simplest is a two-step 
process with an initiation and a driver mutation required for disease development.  
More recently, next-generation DNA sequencing has shown AML to be associated with, on 
average, five somatic mutations in recurrently mutated genes. Particularly interesting is that 
there appears to be distinct patterns of mutation acquisition; mutations in genes regulating the 
epigenome (histone modifiers, DNA methylation) occurring early, whilst those involved in 
proliferative signal transduction (FLT3, RAS) occur late 100,212. Further, these patterns appear to 
correlate with distinct diagnostic features and clinical outcomes 212.  
Whilst the mechanisms that underlie the sequential acquisition of mutations in a specific cell 
type are not fully understood, evidence suggests the initiating events occur in a leukaemic HSC 
or more committed progenitor cell 210; the NPM1 mutation is found to originate in GMP cells 173. 
Further, these pre-leukaemic cells whilst maintaining multi-lineage differentiation potential 
acquire an increased ‘fitness’ compared to wild type HSC, gradually becoming the major clone 
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over time. Fractions of this pre-leukaemic population are at risk of acquiring additional 
mutations and evolving into overt leukaemia. Whether this knowledge can be harnessed clinically 
is an exciting area of intense research.  
 
1.3.3 Clonal haematopoiesis of indeterminate potential 
Another emerging and interesting concept, related to the concept of pre-leukaemia, is clonal 
haematopoiesis of indeterminate potential (CHiP). In CHiP, a clone carrying one, or occasionally 
several, somatic mutations is identified, arising from the expansion of HSPCs 213,214. These 
mutations may be those described in pre-leukaemia or distinct. This concept is in its infancy 
however, with opinion divided whether this state precedes pre-leukaemia or is a distinct entity. 
Whether ChiP is a consequence of age or a means of ‘coping’ with age also remains unclear. 
Interestingly, population-based studies have detected mutations recurrent in haematological 
malignancies, including DNMT3A and TET2, in the PB of individuals with no previous 
haematological disease history 213,214. Further, long-term follow-up appears to indicate these 
cases have an increased risk of developing a haematological disease 213,214. 
Importantly, irrespective of terminology, the existence of a pre-leukaemic HSC raises the 
possibility of early detection, prior to the development of AML potentially allowing for 
intervention therapy and disease prevention. 
 
1.3.4 Chemoresistance 
Chemoresistance is the term used to describe a cell, or cells, resistant to cytotoxic agents, with 
proposed mechanisms proving to be increasingly diverse and complex with our expanding 
knowledge. Understanding these mechanisms, and how genomic alterations result in different 
cancer phenotypes is vital when considering current treatment strategies and designing novel 
therapies. 90% of treatment failures are attributed to chemoresistance 215.  
CSCs have been shown to be innately less sensitive to treatment, potentially explaining MRD, 
relapse and disease progression, highlighting the need to target these cells in order to effect a 
cure 23,126. Current chemoresistance hypotheses include microenvironmental cellular 
interactions, epigenetic changes and deregulation of the self-renewal pathways, and cell 
proteostasis. Whilst the influence each of these factors has on the CSCs treatment-resistant 
phenotype is unclear, in reality, it is likely to be a complex interplay between some or all of 
these factors that enables the CSC to evade cell death. Interestingly, whilst mechanisms of 
chemoresistance appear common, their function and significance appears to differ depending on 
the driving genomic alterations 216,217.  
The role of each mechanism is beyond the scope of this thesis. For the purpose of context I have 
chosen to touch upon select mechanisms, discussed below, those intrinsic to my thesis will be 
discussed in greater depth later.  
Altered expression of ATP-binding cassette (ABC) transporters by CSCs is seen as one mechanism 
of chemoresistance, with anthracyclines key in the treatment of AML, being effluxed by more 
than one ABC transporter 218. Clinical trials have sought to overcome this mechanism of 
chemoresistance through the use of specific ABC transporter inhibitors. Zosuquidar, the 
multidrug resistance inhibitor was combined with DA in a Phase II clinical trial 219 whilst 
verapamil, a general ABC transporter was utilised in combination with standard treatment for 
multiple myeloma (MM) 220. These studies were discontinued due to their limited efficacy. 
Nanoparticle drug-delivery attempting to overcome this form of drug resistance has shown 
promise in both murine and in vitro models 221,222. It remains to be seen if this can be translated 
clinically. ABC transporters therefore represent a major mechanism of chemoresistance; whilst 
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early attempts to overcome this mechanism of resistance showed limited efficacy, work 
continues, and the results are keenly awaited. The European Union (EU) Clinical Trials register 
223 presently lists 8 open trials studying the effect of the ABC inhibitors whilst ClinicalTrials.gov, 
a service of the United States Institutes of Health, lists 48 open trials. 
Another mechanism of chemoresistance is the B-cell lymphoma-2 (Bcl-2) protein family, 
members being identified as critical for the development and growth of many, if not all 
malignancies 224. The Bcl-2 proteins play a critical role in regulating apoptosis and proliferation 
(discussed in Section 1.5 below). Levels of the anti-apoptotic Bcl-2 protein have prognostic 
significance in a number of malignancies including lymphoid 225 and myeloid malignancies 226; in 
AML Bcl-2 has been shown to be over-expressed in 71% of patients, associating with a reduction 
in DFS 226. In addition, evidence suggests these proteins can effect chemoresistance through 
induction of other signalling pathways such as Akt1 227,228, protein kinase C α (PKCα) 229, 
extracellular signal-regulated kinase 1/2 (Erk1/2) 230, c-Src and aurora-A 231. Whilst early drugs 
struggled with off target effects, ABT-737 a first generation BH3-mimetic causing dose limiting 
thrombocytopenia through its binding to B-cell lymphoma-extra large (Bcl-xL) 232, the second 
generation Bcl-2 inhibitors have demonstrated striking clinical efficacy with early phase clinical 
trials in both solid and haematological malignancies 233. ABT-199, a BH3-mimetic was 
subsequently granted breakthrough designation by the United States Food and Drug 
Administration (FDA) for relapsed or refractory chronic lymphocytic leukaemia (CLL) with 17p 
deletion in April 2016 
(https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm495253.htm). The EU 
Clinical Trials register 223 presently lists 12 open trials studying the effect of Bcl-2 inhibition 
whilst ClinicalTrials.gov lists 27 open trials. 
 
Several signalling pathways, with their diverse roles within malignancy, have also been linked to 
chemoresistance.  
 
Epithelial–mesenchymal transition (EMT) is the process of cell reprogramming from an epithelial 
to mesenchymal-like phenotype. Whilst a role for the EMT pathway in solid malignancies is well 
established, 234–239 recent work has shown components of the pathway including Twist1, Snail and 
Slug to be deregulated in haematological malignancies 236,240,241. Twist1 being shown to increase 
Bmi1, a member of the Polycomb family has been linked to leukaemogenesis and prognosis 242; 
whilst gain-of-function mouse models have shown deregulation of Snail and Slug pathways to 
result in an irreversible increase in haematological malignancies, particularly the acute 
leukaemias 243–246. A slug knockout mouse model has shown Slug to govern cell survival by 
inhibiting the pro-apoptotic activity of puma (Bcl-2 Binding Component 3 (BBC3)). Further, 
patterns of deregulation have been shown to associate with different AML sub-types, clinical 
phenotypes and treatment response 240 and to distinguish normal and malignant myeloid 
precursors excluding myeloid maturation dependence 247. Interestingly, the HIF-related network 
has been shown to be differentially expressed in APML relative to other AML subtypes. Further 
expression of ITGB2, HMOX1, IGFBP2 and MMP2 was reversed upon cellular differentiation 
following treatment of APL-derived NB4 cells with all-trans retinoic acid 247.  
 
Abnormal activation of the Hh pathway has been reported in a number of CSC models 248, with 
pathway inhibition sensitising CSCs from a number of malignancies including CML 249–255, gastric 
248,256,257, pancreatic 257–261, lung 257,262,263, ovarian 264,265 and prostate 266–268 cancer. The Hh 
signalling pathway is discussed in considerable detail in Section 1.4. 
 
Chemical activation of the Wnt pathway enhanced chemoresistance within hepatocellular HPSCs 
whilst a lentiviral β-catenin knockdown reversed this resistance, the link being confirmed in 
other models 269, and malignancies 270. Interestingly up-regulation of the ABC transporters is 
considered as one mechanism by which the Wnt pathway mediates chemoresistance; activation 
of the Wnt pathway, in neuroblastoma cells, being demonstrated to induce the ATP-Binding 
Cassette, Sub-Family B (ABCB1), conferring chemoresistance 270. Further, in ovarian CSCs, 
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chemoresistance was demonstrated to be mediated by the ATP-binding cassette sub-family G 
member 2 (ABCG2), expression and chemoresistance reversed by a β-catenin small interfering 
(siRNA) knockdown 271. The ABC transporters are recognised as key downstream targets of a 
number of other signalling pathways, including Hh, and therefore representing an appealing 
therapeutic target, though as discussed above this has yet to be translated clinically.  
 
The Notch signalling pathway has also been shown to contribute to chemoresistance, primarily 
through its over activation 272 in a number of malignancies: T-acute lymphoblastic leukaemia 273, 
AML 274, lung 275,276, breast 277,278, ovarian 279 and certain neurological tumours 280,281. Further, in 
glioma, colon and ovarian malignancies, treatment up-regulated and activated the Notch 
pathway, with a siRNA Notch 1 knockdown or γ-secretase inhibitor preventing chemoresistance, 
sensitising these cells to the effects of treatment 279,282. Interestingly, Notch activation has also 
been shown to mediate chemoresistance through the ABC transporter ABCC1 in prostate cancer 
283. 
The Phosphatidylinositol 3-kinase Protein kinase B (PI3K-Akt) and extracellular signal-related 
kinases (ERK) signalling pathways have also been linked to chemoresistance in gastric 284, 
endometrial 285, oeophageal 286 and colon cancer 287. Whilst the mechanisms of resistance are not 
fully understood, research has shown these pathways down regulate p53 and up-regulate c-Myc 
288, ABCB1 and ribonucleotide reductase catalytic subunit M1 (RRM1) 289.  
Finally, studies have shown constitutive activation of the nuclear factor kappa B (NFκβ) pathway, 
within ovarian and breast CSCs, correlates with chemoresistance 290–292, whilst inhibition induced 
cell death 290,293.  
The complex relationship existing between these signalling pathways is becoming increasingly 
apparent, each pathway communicating with others, and converging on key downstream targets. 
It is not surprising then that small molecule inhibitors targeting isolated components are seeing 
limited clinical efficacy. Their role in combination with other agents or in targeting specific 
disease subsets is an area of ongoing work with the results eagerly anticipated.  
Another mechanism of chemoresistance is an enhanced DNA damage response, genomic 
instability being a common feature of cancer with DNA damage induced by chemotherapy and 
radiotherapy a key factor in cancer treatment. An enhanced DNA damage response therefore 
correlates with chemoresistance. These cellular DNA damage responses are tightly coordinated 
by numerous protein kinases: the checkpoint kinases (Chks), cyclin-dependent kinases (Cdks), 
aurora kinases (Aurk) and polo-like kinases (Plks). These proteins protect cells through cell cycle 
regulation and the promotion of DNA damage repair and cell death if necessary 294–297.  
The Chks are targets of two distinct pathways: ataxia telangiectasia mutated (Atm) and Atm and 
rad-3-related (Atr). Atr targets checkpoint kinase 1 (Chk1) whilst Atm targets checkpoint kinase 
2 (Chk2), with drug development demonstrating Chk1 to be more important in cell protection 
296,298. Somatic mutations, polymorphisms and epigenetic silencing of ATM have been 
demonstrated in ALL 299, CLL 300, breast 301, colorectal 302 and lung cancer 303. Whilst mutations 
within ATR and CHK1 are less frequent, they have also been observed in a number of 
malignancies including colon, stomach and endometrial cancers 304–307. Aberrant expression of 
both pathways has been found to confer a poor prognosis in certain malignancies 307,308. The Cdks 
bind cyclins, forming an active kinase complex vital in the regulation of cell cycle progression. At 
least nine Cdks have been discovered with over-expression being demonstrated in a number of 
malignancies including sarcoma 309,310.  
The Aurks regulate spindle assembly, function of centrosomes and cytoskeleton and cytokinesis 
with aberrant expression linked to tumourigenesis 311,312. Three kinases have been discovered (A, 
B and C), with deregulated expression of Aurora A consistently associated with malignancies 
including breast and gastric cancer 311,313–315. Research into Aurora kinase inhibitors as 
therapeutic agents has shown mixed results with their importance and involvement in normal 
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cell cycle regulation raising concerns regarding toxicity; however to date this fear has not been 
realised 316.   
Epigenetics refers to heritable changes in gene expression 317. Examples include DNA and histone 
modifications; deregulated epigenetic mechanisms being shown to have an important role in the 
pathogenesis of AML 318,319. Further, epigenetic modifications are frequently reversible and found 
to be early events in leukaemogenesis 210, making them appealing therapeutic targets.  
Mutations in DNMT3A, one of the de novo DNA methyltransferases, are found in 6% to 36% of AML 
cases 320. Whilst the mechanism by which these mutations contribute to leukaemogenesis is not 
fully understood, recent work suggests DNMT3A R882H promotes chemoresistance 321. Mutations 
in TET2 are observed in 8% to 27% of patients with AML, conferring a poor prognosis in 
intermediate-risk AML 322 and chemoresistance in prostate cancer. Mutations in the mutually 
exclusive isocitrate dehydrogenase 1/2 (IDH1/2) are found in 5-19% of AML cases 323–325.  
Histone acetylation and deacetylation is the process of acetyl group transfer to and from lysine 
residues in histone proteins governed by histone lysine acetyltransferases (HATs) and histone 
deacetylases (HDACs), respectively. Acetylation of lysine residues results in open chromatin 
confirmations, whereas deacetylation results in condensed and closed chromatin. Methylation of 
histone lysine residues can result in mono-, di-, or trimethylation; this is processed by lysine 
methyltransferases (KMTs). Acetylation is associated with chemoresistance in pancreatic 326 and 
colon tumours 327, whilst deacetylation and methylation are associated with chemoresistance in 
ovarian cancer 328.  
In reality, the role each mechanism has in chemoresistance will vary, dependent on the cell of 
origin and other genetic alterations within the CSC. 
 
1.3.5 Investigational therapies 
Given the complexity of the disease, it is not surprising that single agent therapies, in the large 
part, have failed to achieve more than limited improvements in patient survival. Further, whilst 
currently AML is risk stratified according to cytogenetic analysis 154, with a dramatic difference in 
clinical outcome seen between different groups 201,202 this risk stratification is limited, lacking 
precision.  
Progress in our understanding of cancer biology and the mechanisms involved in leukaemogenesis 
now sees us entering a new era, where research based innovations are being directly translated 
into patient care. We are shifting towards a time of comprehensive genomic assessment at 
diagnosis to determine patient classification and prognosis, an awareness of functional AML 
subsets informing treatment strategies. 
A challenge posed by recent advances, including novel molecularly targeted therapies however is 
the comparatively low incidence of the disease and its intrinsic heterogeneity, making 
interpretation of results challenging. That said, as a clinician treating patients in an era with an 
ever increasing armory of new agents is hugely exciting; there are presently 271 Phase I-III open 
clinical trials listed by the EU Clinical Trials register 223 and 556 by ClinicalTrials.gov. Table 1.4 
shows select investigational therapies, and their proposed mechanism of action. These were 
selected on the basis of their presentation at the following high impact international meetings, 
ASH and American Society of Clinical Oncology (ASCO) in 2015 and 2016.  
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Table 1.4: Recently presented investigational therapies and proposed mechanism of action  
Sponsor 
NCT trial 
number 
Phase Patient characteristics Treatment  Mechanism of action 
of novel agent  
Seattle 
Genetics, Inc. 
NCT01902329 
Phase I >18yrs  
Untreated CD33+ AML 
SGN-CD33A 
+/- HMA 
Antibody-drug 
conjugate (ADC) 
targeting CD33 
Seattle Genetics  
NCT01902329 
Phase I >18yrs  
AML relapsed within 
3mths of intensive 
therapy / untreated / 
low intensity  
SGN-CD33A ADC targeting CD33 
BerGenBio AS 
NCT02488408 
Phase I >18yrs 
R/R AML & high-risk 
MDS 
BGB324 + 
LDAC 
Selective Axl kinase 
inhibitor 
Celdara Medical, 
LLC 
NCT02203825 
Phase I >18yrs 
>18yrsAML & MDS 
NKG2D  Chimeric antigen 
receptor-T cells 
Bio-Path 
Holdings, Inc. 
NCT01159028 
Phase I R/R AML & MDS & CML-
BC 
BP1001 + LDAC  Liposomal Grb2 
inhibitor 
ADC 
Therapeutics 
SARL 
NCT02588092 
Phase I >18yrs 
R/R CD25+ AML 
ADCT-301  ADC targeting CD25 
conjugated to SG3199 a 
pyrrolobenzodiazepine 
dimer cytotoxine 
Celgene 
Corporation 
NCT01915498 
AG221-C-001 
Phase 
I-II 
>18yrs  
Untreated and R/R 
mIDH2+ AML 
 
AG-221 Inhibits mutant IDH2 
specifically within the 
mitochondria  
Celgene 
Corporation 
NCT01915498 
ADHENTIFY trial 
Phase 
III 
≥60yrs  
De novo & seconday R/R 
mIDH2+ AML 
 
AG-221 vs 
conventional 
care 
Inhibits mutant IDH2 
specifically within the 
mitochondria  
Celgene 
Corporation 
NCT02223052 
Phase 
I-II 
>18yrs 
Untreated / R/R / 
secondary AML 
Extended 
dosing CC-486 
Oral azacitidine 
Genentech, Inc. 
NCT02287233 
Phase 
I-II 
≥65yrs 
Untreated AML not 
eligible for intensive tx 
Venetoclax + 
LDAC  
BH3-mimetic 
NCI consensus 
study 
NCTO1266083 
Phase 
II 
>18yrs 
AML in CR1 
SLS-001 Multivalent WT1 
peptide vaccine 
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Astellas Pharma 
Global 
Development, 
Inc. 
NCT02014558 
Phase 
II 
>18yrs  
R/R AML 
ASP2215 Inhibitor of FLT3 & Axl 
with activity against 
FLT3-ITD and FLT3-TKD 
Astellas Pharma 
Global 
Development, 
Inc 
NCT02421939 
Phase 
III 
>18yrs 
Primary refractory or 
first relapse FLT3-ITD+ 
AML  
ASP2215 vs 
salvage 
chemotherapy  
Inhibitor of FLT3 & Axl 
with activity against 
FLT3-ITD & FLT3-TKD 
MEI Pharma Inc 
NCT01873703 
Phase 
II 
≥65yrs 
Untreated & unsuitable 
for intensive tx & poor 
cytogenetics  
Pracinostat & 
Azacitidine  
Oral HDAC inhibitor 
Alliance C11001 Phase 
II 
>60yrs  
Untreated FLT3-
ITD/TKD+AML 
DA & 
Sorafenib 
tosylate 
Multi-kinase inhibitor  
University of 
Ulm 
AMLSG 16-10  
NCT01477606 
Phase 
II 
18-70yrs  
Untreated FLT3-ITD+ 
AML  
 
Induction & 
consolidation 
& Midostaurin 
Tyrosine kinase 
inhibitor  
Daiichi Sankyo 
Inc.  
NCT02039726 
QuANTUM 
Phase 
III 
18-75yrs 
Untreated FLT3-ITD+ 
AML 
Induction & 
consolidation 
& + AC220 vs 
placebo 
Tyrosine kinase 
inhibitor 
Celator 
Pharmaceuticals 
Inc. 
NCT01696084 
Phase 
III 
60-75yrs  
Untreated secondary 
AML  
CPX-351 vs DA  Liposomal DA 
HMA: hypomethylating agents (azacitidine / decitabine); CD: Cluster domain; R/R: 
relapsed/refractory; MDS: myelodysplasia; ADC: antibody drug conjugate; LDAC: low dose 
cytarabine; tx: treatment; mIDH2: mutant Isocitrate Dehydrogenase NADP+ 2; FLT3: Fms Related 
Tyrosine Kinase 3; ITD: internal tandem duplication; TKD: tyrosine kinase domain; Axl: member 
of the Tyro3-Axl-Mer receptor tyrosine kinase subfamily; HDAC: histone deacetylase; DA: 
daunorubicin + cytarabine 7+3. 
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1.4 Hedgehog signalling pathway 
The Hh signalling pathway was initially discovered in 1980 by Nüsslein-Volhard and Weischaus 
whilst studying embryonic patterning in the Drosophila fruit fly; absence of the Hh protein giving 
the Drosophila a characteristic ‘hairy’ or ‘prickly’ appearance 329,330. Subsequent work has shown 
the Hh pathway to be highly conserved across species and vitally important in embryogenesis, 
performing the function of patterning during the early stages of development through the 
expansion and contraction of SC numbers. In adult organisms, through its ability to affect SC 
behaviour in responsive tissues, it is involved in aspects of tissue maintenance and regeneration - 
proliferation, apoptosis, chromatin modelling, and self-renewal, acting in concert with other 
stimuli and the SC niche 257.   
 
1.4.1 Canonical signalling 
Classically the Hh signalling pathway is believed to be ligand-dependent. Three Hh ligands (Sonic 
(Shh), Indian (Ihh) and Desert (Dhh)) have been identified in vertebrates, affecting SC behaviour 
in a time- and concentration-dependent manner 331. Shh is widely expressed, particularly during 
embryogenesis, with Shh deficiency being embryonically lethal 330. Ihh is produced in 
haematopoietic cells, bone and cartilage 332, whilst Dhh is found in the peripheral nervous system 
and testes 333. Hh ligands are initially synthesised as an inactive 45kDa precursor, undergoing 
post-translational modifications to form a 19kDa amino-terminal active signalling molecule 334.  
This cholesterol and palmitoyl modification, catalysed solely by Hedgehog acyltransferase 
(Hhat), not only enhances ligand activity but also modifies its diffusion capacity 335,336. The Hh 
ligands bind to the 12 trans-membrane receptor protein Patched 1 (Ptch1), causing its 
internalisation and removing its repression of the 7-span trans-membrane protein Smoothened 
(Smo), allowing pathway activity 337. In vertebrates, activity of the Hh pathway is intrinsically 
related to primary immotile cilia; in the absence of ligand, Ptch1 is located within the primary 
cilia. Following ligand binding, and the internalisation of Ptch1, Smo is able to concentrate in 
the primary cilia where it interacts with Gli, maintained in an inactive yet stable state 
complexed to Suppressor of fused (Sufu), shifting the balance towards pathway activation 337.  
Whilst the intricacies of this interaction remain poorly understood, studies suggest these 
receptors do not physically interact, rather Ptch1 is thought to regulate Smo through an 
intermediary, with studies suggesting that oxysterols, including vitamin D3, are involved 338. 
The Sufu-Gli complexes ensure appropriate delivery of Gli proteins to the primary cilium where 
they dissociate from Sufu, allowing their activation in response to Hh signalling 339. This 
dissociation, and subsequent activation, is inhibited if the Sufu-Gli complex cannot travel to the 
cilium as observed in Kif3a−/− cells 340. Protein kinase A (Pka) localised at the base of cilia 341 has 
been shown to control trafficking of the Sufu-Gli complexes to cilia independent of Smo, 
suggesting a novel mechanism for Hh inhibition. Whether Hh pathway activity regulates Pka 
however, remains unclear. One hypothesis is that local inhibition of Pka enables interaction 
between active Smo and Sufu-Gli complexes at the cilia. However, it is likely that additional 
events are required to transmit the signal from active Smo to the Sufu-Gli complex. 
Smo subsequently causes accumulation of the full length active form of the zinc transcription 
factors Gli-2 and Gli-3 in the nucleus, and potentiates the activity of other positive regulators of 
the pathway including serine threonine kinase 36 (Stk36) and kinesin family member 7 (Kif7), 
resulting in transcription of key downstream targets such as Gli-1 (amplifying output of the 
pathway) 342,343 and Ptch1 (preventing uncontrolled pathway activation), regulators of chromatin 
formation, cell cycle activity including N-MYC and Cyclin D1, cell mobility and apoptosis, e.g. 
bone morphogenetic protein 4, forkhead box protein M1 and WNT2a 344; Figure 1.6A: Hh 
signalling pathway in the active state.  
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Figure 1.6: Canonical Hh signalling 
(A) The Hh pathway is activated by the binding of Hh ligands (Sonic [Shh], Indian [Ihh] or Desert [Dhh]) 
to the 12 transmembrane protein receptor Patched1 (Ptch1), causing its internalisation and removing 
repression of the 7-span trans-membrane protein Smoothened (Smo). Smo causes accumulation of the 
active form of the zinc transcription factors Gli-2 and Gli-3 in the nucleus, and potentiates the activity 
of other positive regulators of the pathway resulting in transcription of key downstream targets and 
regulators of chromatin formation, cell cycle activity, cell mobility and apoptosis.  
(B) In the inactive state the transcription factors Gli-2 and Gli-3 are non-specifically phosphorylated by 
casein kinase (CSI), glycogen synthase kinase 3β (GSK3β) and protein kinase A (PKA) and retained in the 
cytoplasm in a protein complex associated with the inhibitory molecule, suppressor of fused (SUFU). 
This complex undergoes E3 ubiquitin mediated proteolysis to the truncated repressor form which, on 
translocating to the nucleus, strongly inhibits the Hh pathway. 
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Of the transcription factors, Gli-1 functions as a positive regulator, Gli-3 a transcriptional 
repressor, and Gli-2 both a positive and negative transcriptional regulator, determined by post-
transcriptional and post-translational modifications 345. It is the balance between these 
transcription factors, their active and repressed state, which determines pathway activity 342.  
Alternatively, the Hh ligands can bind to several membrane-associated glycoproteins: Patched 2 
(Ptch2), Hh-interacting protein (Hhip) and Dispatched (Disp). Ptch2, although structurally similar 
to Ptch1, has distinct functional properties and a notably different tissue distribution. Ptch1 is 
broadly expressed whilst Ptch2 is primarily restricted to the skin and testes. Hhip is an 
endogenous Hh ligand inhibitor, with a binding affinity comparable to Ptch1, preventing pathway 
activation 346. Disp is a twelve trans-membrane receptor protein, not involved in Hh ligand 
synthesis or processing but rather in facilitating ligand movement, thereby modulating canonical 
pathway activity.  
In the inactive state the transcription factors Gli-2 and Gli-3 are retained in the cytoplasm in a 
protein complex associated with the inhibitory molecule, suppressor of fused (Sufu) 347 and non-
specifically phosphorylated by casein kinase (Ck1), glycogen synthase 3β (Gsk3β) and Pka. This 
complex subsequently undergoes E3 ubiquitin-mediated proteolysis by the Skp1-Cullin1-F-box 
protein (Scfβ-TRCP) to the truncated repressor form which, on translocating to the nucleus, 
strongly inhibits the Hh pathway 348; Figure 1.6B: Hh signalling pathway in the inactive state.  
It is the complex interplay between the active and inactive state of the pathway and the positive 
and negative feedback loops that maintains the careful balance of Hh signalling in normal tissue. 
 
1.4.2 Non-canonical signalling 
The notion of non-canonical signalling has arisen following observations that the Hh pathway 
response does not always appear to follow the classical canonical signalling paradigm. Recent 
work showing Ptch1 to regulate cell proliferation and apoptosis independent of Smo and Gli and, 
further Smo to modulate actin cytoskeleton-dependent processes particularly within the nervous 
system. This data appearing to indicate non-canonical signalling is not only involved, but 
important, in health and disease. Two broad scenarios of non-canonical Hh signalling are 
currently recognised, Figure 1.7: Non-canonical Hh signalling 349,350. In reality, it is likely the 
canonical and non-canonical pathways act in parallel.  
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1.4.2.1 Type I (Smo-independent)  
There is considerable evidence to support Hh ligands and Ptch1 can act independently of Smo. 
Cell culture experiments have shown all three Hh ligands to have an anti-apoptotic effect that 
was not blocked by Smo antagonists and was independent of Gli transcriptional activity. Further, 
the effect could not be replicated by genetic or chemical over-expression of Smo 351. Ex vivo and 
in vitro assays have shown Ptch1 to function as a dependence receptor, regulating cell survival in 
a ligand-dependent manner 352,353, with over-expression inducing apoptosis 353. Finally, Ptch1 has 
been shown to regulate the cell cycle through cyclin B1 and Grk2, this association being 
modulated by Shh and independent of Smo 354,355.  
 
1.4.2.2 Type II (Gli-independent)  
Hh pathway activity in the absence of Gli activity, in particular regulating the actin cytoskeleton 
and axonal guidance is also well recognised. The Hh ligands have been shown to regulate activity 
of the Rho family of small GTPases in a Smo-dependent manner, promoting actin stress fibre 
formation and tubulogenesis 351,356. Further, it is now established that Shh can also act, in a Smo-
dependent manner as a commissural axon guide stimulating the phosphorylation of the Src family 
kinase (Sfk) members Src and Fyn, inhibition of Sfk activity completely blocking Shh-induced 
axon movement 357,358. In both situations, the rapid response demonstrated following exposure to 
Hh ligands, absence of Gli-dependent transcriptional activity, and inability of Gli-3 to attenuate 
these processes indicates this mechanism functions in a Gli-independent manner. Additionally, 
cell-based screens analysing components of the canonical Hh signalling process have failed to 
identify Src and Fyn 359,360 and Src and Fyn double-mutant mice have been shown not to exhibit 
phenotypes suggestive of deregulated canonical Hh signalling 361.  
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Figure 1.7: Non-canonical Hh signalling 
The Hh pathway can be activated directly through PTCH1 or SMO, or via alternative pathways including 
the PI3K/AKT and RAS/RAF/MEK/ERK signalling cascades.   
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1.4.3 Hh signalling in haematopoiesis 
In vertebrates, haematopoiesis is broadly divided into two major phases, primitive (embryonic) 
and definitive. The Hh signalling pathway has a complex role in both embryonic and adult 
haematopoiesis. This role appears dependent on developmental stage, cell lineage and whether 
the haematopoietic system is under regenerative pressure 344,362. Whilst evidence has shown the 
Hh signalling pathway to be vital for early haematopoietic development 332 there remains 
controversy over its role in normal haematopoiesis in adult organisms 253,362–364, although some of 
this may be explained by experimental method. Interestingly, recent early phase clinical trials 
looking at Smo inhibition have shown little or no haematopoietic toxicity, potentially indicating 
Hh signalling may be dispensable in certain situations 365. Importantly, abrogation of canonical 
Hh signalling by knockout of Smo does not adversely affect steady state normal haematopoiesis 
363,366.  
 
1.4.4 Hh signalling in malignancy 
Crucially, abnormal Hh signalling has been associated with diverse human malignancies including 
basal cell carcinoma (BCC) 367, medulloblastoma 368, pancreatic 259 and lung cancer 262; data 
suggests different mechanisms of action in the various tumour environments. Constitutive 
pathway activation through loss-of-function mutations 367, epigenetic modifications 258 reduced 
expression of the negative regulators Ptch, Hhip and Sufu 369; or gain-of-function mutations and 
epigenetic changes 370 in the positive regulator Smo have been observed in a number of solid 
malignancies 371. To date, no mutations have been identified in haematological malignancies, 
however epigenetic modifications have been observed in a cohort of paediatric AML patients, 
correlating with disease status 372. Ligand-dependent, canonical pathway activation, involves 
autocrine or paracrine Hh signalling 373. Autocrine Hh signalling has been identified in MM 374, 
prostate 266 and lung cancer  263. Paracrine Hh signalling has been observed in lymphoma 364, 
colon and pancreatic cancer 265. 
 
1.4.4.1 Hh signalling in AML 
In myeloid malignancies, Hh signalling has been found to be vital in the maintenance and 
expansion of the CSC or LSC, either as a survival and proliferation signal or through direction of 
the LSC fate 252,344,375–377.  
There is considerable evidence to support the role of the Hh signalling pathway in AML. 
Leukaemic cell lines and primary AML cells have been shown to express Shh, Gli-1 and Gli-2, 
indicative of active Hh signalling 69; Gli-1 expression correlating with cytogenetic risk, inferior 
EFS and a reduced OS, with Gli-1 conferring drug resistance through UGT1A-dependent 
glucuronidation 378,379. Further, genetic and pharmacological inhibition of Gli-1 caused anti-
leukaemic effects and overcame associated chemoresistance 378,379. Gli-1 expression has also 
been shown to predict poor remission status and reduced OS in secondary AML 379,380 whilst Gli-2 
has been shown to be a negative prognostic indicator in a number of microarray studies in 
leukaemia 381,382. Additionally, aberrant Hh signalling has been linked to drug resistance with 
inhibition of the pathway restoring chemosensitivity in AML 349,377. Further, pathway inhibition 
with PF-04449913 sensitised AML cell lines and primary cells to cytarabine with inhibition of Smo 
being shown to modulate cell cycle and self-renewal signalling 383. In paediatric AML the hypo- 
and hypermethylation of pathway promoters was highly associated with AML diagnosis and 
relapse 372. The complex interplay between the intrinsic and extrinsic signals governing LSC 
behaviour may however, mean targeting a single pathway, such as the Hh is insufficient.  
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1.4.5 Targeting the Hh signalling pathway  
As discussed in Section 1.4.4.1, there is increasing evidence to support the role of the Hh 
signalling pathway in AML, with components representing viable therapeutic targets. Targeting 
components of the Hh pathway is therefore a very attractive potential treatment strategy. From 
a drug development perspective, inhibition of Smo and Gli-1 can be readily achieved; Table 1.5.  
 
Table 1.5: Hedgehog inhibitors 
Product name Mechanism of inhibition 
Arsenic trioxde 384 Inhibits GLI proteins 
Degradation of PML-RARA fusion protein 
AY9944 385 Inhibits Hh pathway, possibly by several mechanisms 
Ciliobrevin A 386 Hh pathway antagonist, inhibits ciliogenesis 
Cyclopamine 387 Smo antagonist 
GANT58 388 Inhibitor of GLI-1 induced transcription 
GANT61 388 Inhibitor of GLI-1 and GLI-2-induced transcription 
HPI-1 389 Inhibits Hh pathway 
Itraconazole 390 Smo antagonist 
Triazole antifungal 
Jervine 385 Inhibits Hh pathway  
JK184 391 Prevents GLI transcriptional activity 
MRT-10 392 Smo antagonist 
PF-5274857 393 Smo antagonist 
Robotnikinin 394 Inhibits SHH 
RU-SKI 43 hydrochloride 395 Hh acetyltransferase inhibitor 
SANT 387 Smo antagonist 
SMANT hydrochloride 396 Inhibits SHH-induced accumulation of SMO 
U18666A 397 Inhibits Hh pathway 
Clinical grade 
BMS-833923 398 Smo antagonist 
GDC-0449 (Vismodegib) 399 Specific Hh inhibitor 
FDA approval 30th January 2012 
IPI-926 (Saridegib) 400 Cyclopamine analogue 
LDE225 (Erismodegib) 401 Smo antagonist 
LY2940680 402 Specific Hh inhibitor 
PF-04449913 403 Smo antagonist 
 
Finally, although the primary cilium does not autonomously drive or prohibit oncogenesis, it 
potentially represents a therapeutic target in those malignances that show dependence upon its 
activity. Whether we can ‘switch off’ primary cilia is another area of exciting research.  
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1.4.5.1 Targeting the Hh signalling pathway in haematological malignancies 
There are presently a number of Phase III trials utilising Hh inhibition in solid tumours, with 
vismodegib being licensed for use in BCC in 2012. The rationale for Hh inhibition in 
haematological malignancies is to target the CSC, and potentially modulate the protective effect 
of the tumour microenvironment, with a view to affecting a cure. Whether Hh antagonism will 
be therapeutically useful however, not only depends on its ability to target the diseased cells 
but also on the anticipated level of toxicity, both haematological and systemic, although to 
date, there appears to be few grade 3-4 toxicities reported 127.  
Whether Hh inhibition can deliver meaningful clinical results in haematological malignancies is 
an area of active research; Table 1.6. Excitingly, results of the Phase II NCT01546038 study 
presented at ASH 2016 show the addition of glasdegib to LDAC significantly increased OS when 
compared to LDAC alone in patients with AML or high-risk MDS who were ineligible for intensive 
chemotherapy (HR: 0.501, 80% CI: 0.384, 0.654, one-sided log rank p-value 0.0003) 651.  
 
Table 1.6: Clinical trials in haematological malignancies involving Hh inhibitors 
Drug  
Sponsor  
Condition Phase Trial  Status  
Dasatinib combined 
with BMS-833923 
Bristol-Myers 
Squibb 
CML with resistance/ 
suboptimal response to a 
prior TKI 
Phase 
I/II 
NCT01218477 Completed 404 
Dasatinib alone or 
in combination 
with BMS-833923 
Bristol-Myers 
Squibb 
Newly diagnosed Ph+ CP CML Phase II 2011-000083-
10 
Completed 405 
GDC-0449 
(Vismodegib) 
The Lymphoma 
Academic Research 
Organisation/Roche 
Pharma AG 
Refractory or relapsed B-cell 
Lymphoma or CLL 
Phase II NCT01944943 Terminated 
(Lack of 
efficacy) 
GDC-0449 
(Vismodegib) after 
autologous SCT 
NCI 
Multiple Myeloma 
 
Phase Ib NCT01330173 Completed  
Ribavirin, GDC-
0449 (Vismodegib) 
and/or Azacitidine   
Sarit Assouline 
Adult AML Phase II NCT02073838 Recruiting 
Vismodegib 
NCI/Genentech 
Patients with Steroid-
Refractory Chronic Graft-
versus-Host Disease 
Pilot  NCT02337517 Recruiting 
IPI-926 Primary/secondary MF Phase II NCT01371617 Completed 406 
LDE225 and INC424 
Novartis 
Pharmaceuticals 
 
MF Phase 
Ib/II 
NCT01787552 Ongoing but 
not recruiting 
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LDE225  
Novartis 
Pharmaceuticals 
Patients with PTCH1 or SMO 
Mutated Tumors 
Phase II NCT02002689 Terminated 
(Low 
enrolment) 
Azacitidine or 
decitabine and 
LDE225 
Novartis 
Pharmaceuticals 
Myeloid malignancies Phase 
I/Ib 
NCT02129101 Ongoing but 
not recruiting 
PF-04449913 
Pfizer 
Haematological 
malignancies 
Phase I NCT00953758 Completed 407 
PF-04449913 alone 
or in combination 
with LDAC, 
Daunorubicin or 
Cytarabine 
Pfizer 
Japanese patients with: 
AML 
MDS 
Phase I NCT02038777 Recruiting 
PF-04449913 in 
combination with 
Intensive 
Chemotherapy, 
LDAC or Cytarabine 
or Decitabine or 
Daunorubicin 
Pfizer 
AML and high risk MDS Phase 
I/II 
NCT01546038/ 
2012-000684-
24 
Ongoing but 
not recruiting 
651 
PF-04449913 
Pfizer 
Acute leukaemia with high 
risk of post-allogeneic SCT 
relapse 
Phase II NCT01841333 Recruiting  
PF-04449913 
Pfizer 
MDS 
CMML 
Phase II NCT01842646 Ongoing but 
not recruiting 
(AML: acute myeloid leukaemia; MDS: myelodysplastic syndromes; CMML: chronic 
myelomonocytic leukaemia; MF: Myelofibrosis; MPN: myeloproliferative neoplasms; CML chronic 
myeloid leukaemia; CLL: chronic lymphoid leukaemia; SCT: stem cell transplant; Ph+: 
Philadelphia chromosome positive (BCR-ABL); TKI: tyrosine kinase inhibitor; LDAC: low dose Ara-
C; NCI: National Cancer Institute) 
 
Erivedge® (vismodegib) was the first orally bioavailable clinical grade Smo inhibitor to be 
approved for the treatment of locally advanced and metastatic BCC. The FDA approved it in 
January 2012. Vismodegib has been studied in relapsed / refractory (R/R) AML (NCT01880437). 
Analysis of two study cohorts was planned: single agent vismodegib, followed by vismodegib in 
combination with cytarabine. The study was terminated following an interim data review due to 
a lower than expected efficacy of single agent vismodegib, combination with cytarabine was 
therefore not undertaken. Vismodegib with ribavirin with or without decitabine (NCT02073838) is 
currently recruiting patients with R/R AML who are either M4 or M5 morphologically or have been 
shown to have high levels of the oncogene eIF4E. ElF4e has been shown to be a direct 
transcriptional target of NFκβ and preferentially dysregulated in AML with an M4 or M5 
phenotype 408; with ribavirin acting as a competitive inhibitor of eIF4e.	Further, the Hh pathway 
has been linked to the methyltransferases, reports showing inhibition of the Hh pathway to 
enhance the effects of the hypomethylating agents (HMAs) - azacitidine / decitabine 512.  
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Glasdegib® (1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-
cyanophenyl)urea; PF-04449913) is a potent orally bioavailable clinical grade Smo inhibitor 403. 
Glasdegib® was recently reported to improve sensitivity to cytarabine in AML cell lines and 
primary human AML cells 383. These promising in vitro results led to the NCT01546038 trial 
studying PF-04449913 in combination with LDAC in untreated AML and high-risk MDS cases 
ineligible for intensive chemotherapy. Results, presented at ASH 2016, suggest the addition of 
glasdegib to LDAC improves OS when compared to single agent LDAC (8.3months and 4.9 months 
respectively). Improved OS persisted irrespective of subgroup, although those with good / 
intermediate risk appeared to gain greater survival benefit (12.2 months vs 6 months for LDAC) 
compared to those with poor risk (4.4 months vs 2.3 months) 407. This is the first Smo inhibitor to 
show clinical benefit in AML. Glasdegib is currently being studied as first line therapy in patients 
with intermediate-2 and high risk MDS, AML and chronic myelomonocytic leukaemia 
(NCT02367456).  
Odomzo® (sonidegib, LDE225) is a potent orally bioavailable clinical grade Smo inhibitor. 
Sonidegib gained FDA approval in July 2015 and EU approval in August 2015 for locally advanced 
BCC based on the Phase II BOLT study showing a durable objective response in 56% of patients 
(NCT 01327053) 409–411. The Copland group has previously studied the effect of sonidegib in CML. 
They showed sonidegib alone, and in combination with nilotinib, was able to reduce the self-
renewal capacity of CD34+ CP-CML cells in vitro, and consequently, upon administration to 
EGFP(+)/SCLtTA/TRE-BCR-ABL mice, the combination reduced leukaemia development. No effect 
on normal HSCs was seen 412. Within AML, the NCT01826214 trial, which completed in 2016, 
failed to show a clinical benefit in patients with R / R AML treated with single agent sonidegib. 
Sonidegib in combination with azacitidine or decitabine in MDS and AML patients is an ongoing, 
but not recruiting, study (NCT02129101), the results of which are awaited with interest 
considering recent work showing silencing of SHH, SMO and GLI-3 sensitised cells to the HMAs 413. 
At present Novartis are not actively pursuing sonidegib in haematological malignancies.  
 
1.4.6 Primary cilia 
Primary immotile cilia are highly specialised organelles present in single-celled eukaryotes 
through to humans, first reported by Alexander Kowalevsky in 1867 414. They are distinct from 
motile cilia, lacking the central pair of microtubules and radial spokes required for motility; 
motile cilia were first described in protozoa in 1675 by Anthony van Leeuwenhoek 415.  
Primary cilia are regulated by the cell cycle, with ciliation and cell division being mutually 
exclusive 416,417. These organelles contain a long microtubular axoneme with a 9+0 configuration, 
surrounded by an external membrane continuous with the plasma membrane, extending from the 
basal body 418–420. The basal body is formed from a centriole, providing the nine-fold symmetric 
template to build the axonemal structure 418,421,422. It is the contention for the centriole that 
balances ciliation and the cell cycle; primary cilia may only be formed when cells are quiescent 
416,417.  
The basal body, located at the apical plasma membrane, determines cellular position, in 
accordance with cell polarity, and governs protein entry into the cilium. Protein synthesis is 
absent in the axoneme, ciliary components therefore need to be constantly imported and 
exported to render cilia functional. This function appears to be highly dependent, but not 
exclusively restricted to the intraflagellar transport (IFT) mechanism.   
Primary cilia are constructed and maintained by the evolutionarily conserved IFT mechanism, a 
specialised transport process mediated by a large multiprotein complex 423. Bidirectional 
movement of IFT particles is performed by the anterograde kinesin (Kif3a, Kif3b, and Kif3c) and 
retrograde dynein motors 419,420,424,425, Figure 1.8. It is not yet clear which IFT components are 
essential, or dispensable, for cilia formation.  
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Primary cilia are thought to be present on virtually every mammalian cell, exceptions including 
ciliated cells and most haematopoietic cells 416. However recent work in T cells has shown the 
immunological synapse to be highly dependent on IFT proteins and, therefore considered a 
functional homolog of the primary cilium426.  
These sensory organelles are vital for tissue development and homeostasis 427–429 being involved 
in cell-to-cell and cell-to-environment communication. Large-scale genetic, proteomic, and 
genotype-phenotype studies have generated an evolving list of ciliary associated proteins. 
Presently, it is thought greater than one thousand proteins comprise the ciliome 418, being 
synthesised in the cytoplasm and transported to cilia by IFT 430. 
These multi-function proteins include membrane receptors (including platelet derived growth 
factor receptor [PDGFR]) 431,432, components of signalling pathways and transcription factors 
417,433. Consequently, cilia functions have been shown to range from mechanosensation to the 
transduction of signalling pathways; disruption of the primary cilium being associated with a 
number of pathologies collectively known as ciliopathies, including Bardet-Biedl syndrome and 
polycystic kidney disease 434,435. These ciliopathies are pathologically diverse, the clinical 
phenotypes ranging from mild to highly complex and severe multi-organ failure syndromes 
incompatible with neonatal life. Presently, mutations have been recovered in more than fifty 
ciliopathies.  
Considering the ability of cilia to influence cell cycle and their involvement in signalling 
pathways including Hh, Hippo and Wnt, researchers have begun to question whether primary cilia 
have a role in oncogenesis. One hypothesis, based on the observation certain tumour phenotypes 
resemble ciliopathies and given cilia disassembly is a prerequisite for cell proliferation, is that 
cilia loss is required for tumour progression. Converse to that is the hypothesis that malignancies 
require, or even up-regulate, cilia.  
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Figure 1.8: Primary cilium 
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Although research in this area is in its infancy, data would appear to suggest a role for cilia in 
oncogenesis 436. In breast cancer, the cilia-related genes, GLI-1, RPGRIP1 and DNAH9, are 
frequently mutated 437,438 whilst NPHP9 (NEK8), which modulates cilia length and activates the 
oncogenic transcription factor TAZ is up-regulated 439,440. Aurora A (cilia disassembly promoter), 
GLI-3 and ATPKD1 are frequently mutated in colorectal cancer 441,442. In melanoma, pancreatic 
ductal adenocarcinoma, ovarian and renal carcinomas cilia have been shown to be lost through 
tumour progression 443; with cilia reduced in breast cancer tissue and cell lines compared to 
normal breast tissue 444. In each instance, Ki67 positivity has shown this to be independent of 
increased proliferation 445,446.  
Current work therefore appears to support a model where cilia can promote or repress malignant 
transformation in vivo. Loss of cilia however, does not appear sufficient to drive oncogenesis. 
Selection for the retention or disposal of cilia by malignancies, therefore, seeming dependent on 
the underlying oncogenic event; cancer driven by mutations in components dependent upon the 
primary cilia being cilia-dependent 447,448 whilst in those malignancies driven by deregulation of 
components downstream of cilia, cilia are obsolete. Interestingly, cancers that depend on cilia 
retention appear to have better survival statistics 448. This notion of cilia dependence and 
independence is supported by the absence of an oncogenic predisposition in many of the 
ciliopathies, Senior-Loken syndrome (SLNS), Leber congenital amaurosis (LCA) and 
nephronophthisis (NPHP), though reduced life expectancy may mask true malignant 
predisposition. JBN/AHI1 sensitizes tissue for Wnt activation, with consequent over-proliferation: 
oral hamartomas have been associated with Joubert Syndrome-related disorders 449. Figure 1.9. 
 
 
 
The strong connection between primary cilia and the Hh pathway, and thereby vertebrate 
development was first revealed by genetic experiments using mouse ethylnitrosourea mutants 
450. Following on from these discoveries, notable components of the Hh pathway have been 
shown to localise to the cilium: the receptors Ptch1 and Smo, the Gli transcription factors and 
proteins involved in regulating Gli activity (Pka and Sufu) 451,452. Ptch1 and Smo localise in a 
ligand-dependent manner 337,453,454 whilst the Gli proteins localise in a partially ligand-dependent 
manner: in the absence of Hh ligand, they are present at the ciliary tip in low concentration 430, 
accumulating within the ciliary tip in response to Hh stimulation 337,451,454. Sufu is shown to traffic 
in and out of primary cilia 455. Mice lacking functional cilia display patterning defects 
attributable to the loss of Gli 450,456,457, and mutant forms of Smo that fail to localise to the 
cilium cannot activate the pathway 453,454.  
 
Figure 1.9: Diagrammatic representation of how primary cilia have been linked to cancer 
(A) Cilia are lost to enable oncogenic transformation, (B) Cilia are required / up-regulated in the initial 
transforming event, (C) Cilia are required / up regulated in the initial transforming event, these cells 
then (Ci) select for cilia retention remaining cilia-dependent or (Cii) further develop into a cilia-
independent cancer. 
Cilia independent Cilia dependent 
Cilia independent 
Cilia dependent Cilia dependent 
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Whilst there is conflicting evidence regarding the effect of mutations in components of the IFT 
machinery on Hh signalling 458,459 it is now widely accepted that vertebrate canonical Hh 
signalling requires primary cilia 417. The relationship between cilia and the Hh pathway is 
exemplified by mouse knockout models of Kif3a or Ift88, with consequent inhibition of cilia 
function, showing phenotypic overlap with those bearing Hh mutations 460; with developmental 
processes which depend upon Hh signalling, such as neural tube patterning and limb 
development, also demonstrating phenotypic overlap between cilia deficient and manipulated 
pathway models 417,450,455,457. 
It is however noteworthy that primary cilia are only present in sensory neurons and sperm, and 
irrelevant to Hh signalling in Drosophila 461, the organism in which the Hh pathway was first 
discovered, indicating a unique role for primary cilia in mammalian Hh signalling. 
 
1.4.7 Downstream targets 
There are numerous downstream targets of the Hh pathway including Bcl-2, the ABC transporter 
family members, the Cdks and components of the EMT, Wnt and Notch signalling pathways, 
Figure 1.10: Downstream targets of the Hh signalling pathway.  
 
 
There is already evidence to show up-regulation and involvement of many of these pathways in 
chemoresistance in human malignancies 462,463. Additionally, studies have highlighted several of 
these downstream targets to be over-expressed in both AML and CML, with expression linked to 
chemoresistance and poorer survival 464. For further discussion please refer to Section 1.3.4.  
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1.5 Bcl-2 Family 
Bcl-2 was the first anti-apoptotic gene discovered, in 1986; deriving its name from its discovery 
in B cell non-Hodgkin’s lymphoma 465,466. Its oncogenic potential was discovered in 1988, 
activation endowing B cells with a survival advantage, promoting their neoplastic expansion 467. 
The Bcl-2 family regulates all major types of cell death 468. Approximately twenty members have 
been identified, both pro- and anti-apoptotic 469; Figure 1.11: Bcl-2 family. 
 
 
The Bcl-2 family members are related by regions of sequence and structural homology; members 
sharing at least one of the four functionally vital Bcl-2 homology domains (BH1, BH2, BH3 and 
BH4). Most family members also have a transmembrane domain, most notably allowing their 
close relationship with the mitochondria.  
Within the Bcl-2 family, there are three functionally and structurally distinct subgroups: the 
apoptosis initiating BH3-only proteins, the pro-survival proteins, and the pro-apoptotic effector 
proteins. There are six pro-survival family members, Bcl-2, Bcl-xL, Bcl-2-like protein 2 
(Bcl2l2/Bcl-w), myeloid cell leukaemia sequence 1 (Mcl-1), Bcl-2-related protein A1 (Bcl2-A1) 
and Bcl-2-like protein 10 (Bcl2l10) and three pro-apoptotic, pre-activated, effector proteins Bcl-
2-associated X protein (Bax), Bcl-2 homologous antagonist/killer (Bak) and BCL-2-related ovarian 
killer protein (Bok). These proteins share four BH domains adopting a structure consisting of 
seven amphipathic α-helices surrounding a central hydrophobic helix. Within this structure is a 
hydrophobic surface groove, responsible for interaction with other family members BH3 domain 
470,471. Interestingly, the BH3-only domain proteins are structurally disordered as discussed below 
472. 
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The pro-apoptotic family members all contain a BH3 domain, some containing only this domain, 
others sharing BH1, BH2 and / or BH4. It is the BH3 domain that is vital in the promotion of cell 
apoptosis. Interestingly, although some BH3-only proteins, Bcl-2-like protein 11 (Bim), BH3 
interacting-domain death agonist (Bid) and Bbc3, can bind to and neutralise all pro-survival 
proteins, and vice versa, others Bcl-2-associated death promoter (Bad) and Pmaip1 (Phorbol-12-
myristate-13-acetate-induced protein 1 (Noxa)), bind only a limited subset 473,474. This is thought 
to be due to subtle differences in the BH3 domains.  
In the resting, healthy state, the anti-apoptotic proteins maintain, or guard, the mitochondrial 
outer membrane. Bak is inhibited predominantly by Mcl-1, Bcl-A1 and Bcl-xL, with Bcl-2 
contributing in certain situations 474–476. Bax can be inhibited by all of the pro-survival proteins 
477. This is noteworthy when considering members of the Bcl-2 family as potential therapeutic 
targets. 
In health, adult tissue homeostasis is critical, cell life and death being carefully orchestrated, 
with the Bcl-2 family playing a pivotal role 478–480. 
 
 
1.5.1 Bcl-2 induced apoptotic cell death cascade 
Apoptosis is the process of programmed cell death. In the presence of various cytotoxic stresses, 
intracellular damage, or oncogenes, the apoptotic cell death cascade is initiated inducing the 
transcription or post-translational modification of the BH3-only family members 480. These BH3 
proteins operate by two mechanisms: the direct activation of the pro-apoptotic proteins, and the 
neutralisation of the pro-survival proteins 481–484. When sufficient apoptosis inducing BH3-only 
proteins have been stimulated, the balance is shifted in favour of apoptosis. In addition, p53 has 
been shown to induce apoptosis through the activation of Bak and Bax 485. Once activated Bak 
and Bax undergo conformational change, to form oligomers that subsequently translocate to, and 
permeabilise, the mitochondrial outer membrane. This process, referred to as mitochondrial 
outer membrane permeabilisation (MOMP), results in the release of proteolytic proteins, most 
notably cytochrome c, into the cytosol 486. Thus, the proteolytic cascade, which will ultimately 
result in cell apoptosis, is initiated.  
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Figure 1.12: Schematic illustrating the role of Bcl-2 in cell death pathways  
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Simplified, caspase activation occurs through the scaffold protein apoptotic protease-activating 
factor 1 (Apaf-1) 487–489, and neutralisation of endogenous inhibitors such as X-linked inhibitor of 
apoptosis protein (Xiap) through second mitochondria-derived activator of caspases (Smac) 490,491. 
Apoptosis can be initiated through other pathways, referred to as the death receptor or 
‘extrinsic’ pathways, for example those controlled by tumour necrosis factor-family death 
receptors, such as Fas. In certain situations however, this pathway interacts with the ‘intrinsic’ 
pathway, for example, through caspase-mediated cleavage and activation of Bid 492. 
 
1.5.1.1 Bcl-2 and necrosis 
Necrosis is the process of unprogrammed cell death. It results in autolysis of the cell usually 
through the action of external factors and often leads to inflammation. It is interesting that 
despite the significant differences in the apoptotic and necrotic pathways, and the fundamental 
role of the Bcl-2 family in apoptosis, research has found members of the Bcl-2 family, 
specifically Bcl-2 and Bcl-xL, to modulate necrosis 493,494. This is an interesting concept when 
considering the Bcl-2 family as a therapeutic target.  
 
1.5.1.2 Bcl-2 and autophagy 
Autophagy, meaning ‘self-eating’ is a physiological, regulated, process ensuring homeostasis 
during periods of cellular stress. It is a mechanism through which cells disassemble unnecessary 
or dysfunctional components enabling a rebalance of sources of energy when required by cells. 
Beclin 1, the essential inducer of autophagy, has been shown to interact with the pro-survival 
proteins, Bcl-2 and Bcl-xL, through a region bearing remarkable resemblance to a BH3 domain on 
the endoplasmic reticulum (ER). These complexes inhibit autophagy 495.  
 
1.5.1.3 Bcl-2 and haematopoiesis 
Bcl-2 is expressed to variable degrees in all haematopoietic lineages 496. In the normal, healthy 
BM, Bcl-2 expression appears topographically restricted to areas housing long-lived cells 496. 
Further studies have shown a complex highly regulated process exists between pro- and anti-
apoptotic factors within HSPCs ensuring a balance between cell death and survival 497–500. 
Within the BM, megakaryocytes have the highest level of expression. In the myeloid lineage, 
there is a progressive down-regulation through the stages of differentiation, expression being at 
its highest in the promyelocytes and myelocytes, and virtually absent in terminally differentiated 
granulocytes 496. The reverse is seen within the lymphoid cells, Bcl-2 expression increasing with 
maturation. Further, within the myeloid series the opposite pattern to that seen for Bcl-2 was 
seen for the pro-apoptotic protein Bak, expression being highest within terminally differentiated 
granulocytes 501.  
Analysing the haematopoietic progenitor populations, HSCs and early progenitor cells, studies 
have shown Bcl-2 expression to be up-regulated on transition from immature (CD34+CD38- 
population) to more committed progenitor cells (CD34+lin-) 198,225,502,503; with low levels of Bcl-2 
expression limited to the quiescent CD34+CD38-/low cells 502. Further, these haematopoietic 
progenitors have been shown to express low levels of the pro-apoptotic proteins Bak, Bad and 
Bax, with levels increasing with differentiation 502. It is important to note that analysis of CD34+ 
cells following culture for 10 days with a standard growth factor cocktail resulted in up-
regulation of both the pro-survival and pro-apoptotic proteins, the former to a greater degree 
502. This must be considered when interpreting in vitro studies manipulating members of the Bcl-
2 family and extrapolating the data to an in vivo situation.   
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1.5.1.4 Bcl-2 and malignancy 
There is extensive evidence supporting Bcl-2 to be altered in malignancy 504–508; elevated 
expression thought to occur in approximately half of all malignancies 504–508. Deregulation has 
been shown to occur through changes in gene expression, copy number, hypomethylation 509 and 
loss of repressive microRNAs 510. Data also supports the deregulation of other family members 
225,501,511; Mcl-1 being highly expressed in lung, prostate, breast, ovarian, renal, and glioma 
cancer cell lines, whilst Bcl-2 and Bfl-1 are highly expressed in leukemia/lymphoma and 
melanoma cell lines respectively 505,512. Further, CSCs in glioblastoma, colon and pancreatic 
cancer have been shown to depend on multiple-pro survival Bcl-2 family members 513.  
 
1.5.1.5 Bcl-2 in AML  
The importance of Bcl-2 in AML cell maintenance and survival has long been established. Early 
work in the 1990s demonstrated Bcl-2 to be heterogeneously over-expressed in AML. One study 
reporting Bcl-2 to be present in 87.3% of de novo cases and 100% of relapses, with greater than 
20% over-expression in 68.3% and 90% of cases respectively 514, whilst another reported a mean of 
23% (range 0-95%) 515. However, evidence regarding the association between Bcl-2 expression in 
newly diagnosed, untreated AML patients, FAB subtype, blast percentage and CR is conflicting. 
Some studies report a clear correlation 464,515,516, whilst others demonstrate no association with 
blast count or percentage, FAB classification, patient demographics or cytogenetic abnormality 
514. It is postulated that these results may simply reflect the heterogeneity of the disease, 
though study size was sufficiently powered. High BCL-2 was however convincingly shown to be an 
independent prognostic factor and predictor of remission, suggesting differing roles dependent 
on genetic abnormalities 517. It remains to be determined if there are specific genetic 
alternations responsible for Bcl-2 over-expression in AML as seen in other diseases such as CLL 
518.  
These early studies looked at bulk leukaemic cells, with more recent work concentrating on 
expression within defined cell populations. Interestingly in contrast to their normal counterparts, 
quiescent CD34+CD33-CD13- AML cells have been shown to highly express Bcl-2 519,520. Bcl-2, Bcl-
xL and Bad being differentially expressed in the CD34+ and progenitor populations 521, with levels 
up-regulated in the leukaemic cell populations compared to normal donors. Further Bcl-2 and 
Bcl-xL have been shown to be up-regulated following induction chemotherapy and to be 
expressed on MRD cells 521 with pharmacological inhibition of Bcl-2 being shown to selectively 
eradicate quiescent AML LSCs 520. This increased functional reliance upon Bcl-2 of leukaemic 
cells, in comparison to normal haematopoietic cells, makes it an exciting therapeutic target 
which to date appears to translate to the clinic. In 2015 a phase Ib, open-label, non-randomised, 
dose-escalation trial of venetoclax with decitabine or azacitidine in 22 treatment-naïve elderly 
patients with AML reported an objective response (CR/CR with incomplete marrow 
recovery/partial remission (CRi)) in 73% (16/22) (NCT02203773). None of those demonstrating an 
objective response experienced relapse. The safety profile was acceptable 522,523. The US FDA 
subsequently granted ABT-199 a breakthrough therapy designation in January 2016 for use in 
combination with HMAs in patients aged over 65 years who are not eligible for standard therapy. 
In October 2016 a phase II, single-arm study evaluating venetoclax in 32 patients with high-risk 
relapsed AML or those unfit for intensive chemotherapy was reported. The overall response rate 
(ORR) was 19% (6/32), with an additional 19% (6/32) demonstrating a partial response and 
incomplete hematologic recovery; safety profile was acceptable 524. In February 2017 a phase III 
randomised, double blind, placebo-controlled study (NCT02993523) began recruiting. This study 
aims to assess venetoclax plus azacitidine compared with placebo plus azacitidine in treatment-
naïve elderly and adult patients with AML ineligible for standard induction therapy 525. The result 
of this ongoing study is eagerly awaited.  
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1.6 ABC transporters   
The ABC family consists of 49 functionally distinct transmembrane proteins subdivided across 
seven subfamilies (ABCA through ABCG) 526. The majority of these transporters comprise of 2 
nucleotide-binding folds and 12 transmembrane domains. They play an important role in normal 
physiology, and are present in virtually all cells, normal and malignant. These transporters are 
responsible for the transport, or efflux, of a huge variety of compounds from nutrients to 
cytotoxic agents, across plasma and intracellular membranes, Table 1.7.  
Table 1.7: ABC transporter families and their functions  
Family Function 
ABCA Lipid trafficking 527 
ABCB 'MDR (multi-drug resistance) family of ABC transporters' 528; located within blood-
brain barrier and liver; toxin transport 
ABCC Diverse activities – ion and toxin transport, cell surface receptor, multidrug 
resistance; subfamily includes the cystic fibrosis gene (ABCC7) 528 
ABCD Expressed in peroxisomes, endoplasmic reticulum and lysosomes; transport of lipids, 
bile acids and vitamin B12; associate with peroxisomal disorders 529 
ABCE  No transmembrane domain therefore unlikely to have transporter function; single 
family member; promotes interferon activity 513 
ABCF No transmembrane domain therefore unlikely to have transporter functions; involved 
in inflammatory processes 513 
ABCG Transport of hydrophobic compounds; multidrug resistance 530 
 
 
1.6.1 ABC transporters and haematopoiesis 
ABC transporter function is believed to play an important role in determining HSC fate. An 
association between ABCB1, encoding multi-drug resistance gene (P-gp or MDR1), and ABCG2 
encoding breast cancer resistance protein (BCRP), and immature haematopoietic cells being well 
recognised 531, with expression being down-regulated upon differentiation. More recently, work 
has identified an additional 20 ABC transporters that are highly expressed in the normal human 
CD34+CD38− sub-population and, also down-regulated upon differentiation into CD34+CD38+ 
expressing cells. Further, it is the drug-effluxing capacity of the ABC transporters that was 
initially used experimentally to isolate HSCs.  
 
1.6.2 ABC transporters and malignancy    
Drug resistance is one of the primary causes of treatment failure and disease relapse 215,532. Cells 
exposed to cytotoxic agents have been shown to develop chemoresistance through a number of 
mechanisms, including reduced uptake and accelerated efflux, altered drug pharmacokinetics, 
mutations, deregulated cell cycle kinetics and modified death pathways 533. Often cells can 
possess several of these mechanisms, potentially affording them MDR. 
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To date increased expression of thirteen of the ABC transporters (ABCA2, ABCB1, ABCB4, 
ABCB11, ABCC1–6, ABCC10, ABCC11 and ABCG2) have been linked to chemoresistance 218,526,534. 
ABCB1, ABCC1 and ABCG2 are the best characterised. ABCB1 was discovered over 25 years ago, 
conferring resistance to amphipathic drugs including paclitaxel, anthracyclines, and vinca 
alkaloids 526,535,536, whilst ABCG2 was identified almost 20 years ago in multidrug resistant breast 
cancer cells 537,538. ABCG2 has been linked to resistance to mitoxantrone, topotecan derivatives, 
anthracyclines, bisantrene and etoposide. ABCB1 differs in that its activity is dependent upon 
the presence of glutathione. It has been shown to confer resistance to a broad range of drugs 
including doxorubicin, daunorubicin and vincristine 539–542.  
Whilst chemoresistance is primarily mediated through ATP-dependent drug efflux, the substrate 
being removed through channels formed by transmembrane domains, alternative mechanisms 
have been proposed. These include impaired substrate entry through hydrophobic and 
hydrophilic membrane interactions (termed the flippase model) and substrate removal before 
reaching the cytoplasm (the vacuum cleaner model) 543.   
 
1.6.3 ABC transporters in AML   
Chemoresistance has been demonstrated in AML at diagnosis, to arise during treatment, and to 
be present on relapse. ABCB1 has been shown to be an independent adverse prognostic factor in 
de novo AML and, expression has been shown to be up-regulated in the poor prognostic WHO 
subgroups – t-AML and AML with MDS related changes 540,544. ABCG2 has been shown to associate 
with high-risk AML, being found in approximately one third of cases, appearing to therefore 
confer an independent poor prognostic factor 537. Whilst the association between ABCB1 and 
chemoresistance is recognised, its impact on prognosis remains to be determined 539–541.  
Subsequently, research into the role of ABC transporter expression in AML has provided 
conflicting results: work demonstrating both normal haematopoietic and leukaemic CD34+CD38- 
cells to express similar patterns of the ABC transporters whilst other work has shown expression 
to be more heterogeneous in AML CD34+CD38- cells 539,540,545.   
 
AML encompasses a group of aggressive haematological neoplasms; it a clinically, 
morphologically and genetically heterogeneous disease involving one or all of the myeloid 
lineages 150. It is a CSC disorder 112,121,130–133, and whilst our knowledge and understanding is 
rapidly expanding there is still much to discover. Although the heterogeneity of this disease is, in 
part, why research is so challenging, it is also why work in this field is so interesting. Despite this 
heterogeneity however, it is important to remember each case is derived from a LSC. It is this 
LSC that is thought to be responsible for MRD, resistance and relapse. Further, whilst classically 
it was cytokines and chemokines which were thought to influences HSC fate more recent work 
has highlighted the importance of the self renewal pathways including the Hh signalling pathway 
in determining the behaviour of these LSCs. Further, work at both a gene and protein level has 
shown the complex tangled web of interactions between the different self-renewal pathways 
and, particularly interestingly, far removed downstream targets such as the ABC transporters. In 
essence it is a highly complex yet exciting field of research which promises to no doubt deliver 
some unexpected results on our journey of knowledge, and quest to translate our advances into 
the clinic.  
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Aims 
That AML is a CSC disorder is well recognised, with our knowledge and understanding evolving 
rapidly. The importance of the highly conserved self-renewal pathways in determining CSC fate 
has also been clearly demonstrated, with huge efforts being made to target components 
therapeutically. Whilst the Hh signalling pathway has been studied in both normal and malignant 
haematopoiesis the evidence is conflicting, especially in AML, and therefore warrants further 
investigation, to determine how dependent AML CSCs are on Hh signalling.  
The overall aim of this PhD was to gain a deeper understanding of the role of the Hh signalling 
pathway in normal haematopoiesis and AML and further whether Smo represents a viable 
therapeutic target in AML.  
The following questions are therefore dealt with sequentially within the relevant results 
chapters.  
1) The role of the canonical Hh signalling pathway in haematopoietic cells, both normal and 
malignant; 
2) The efficacy of the Smo inhibitors, cyclopamine, sonidegib and glasdegib in targeting select, 
genetically diverse, AML cell lines and primary AML MNCs in vitro; 
3) The effect of Smo inhibition (apoptosis, senescence, differentiation) and whether this is the 
same for different AML sub-types;  
4) The effects of Bcl-2 inhibition on select AML cell lines and primary AML MNCs in vitro. 
Each chapter begins with a brief introduction appropriate for the data presented. All results are 
summarised and discussed at the end of each chapter. Final conclusions and future work is 
presented in the final discussion chapter.  
It is important to note our aims changed during this PhD, in response to published data, results 
generated and a deeper understanding of the topic. Notably, Novartis suspended work on their 
Smo inhibitors in haematological malignancies whilst Pfizer published exciting results following 
the use of their Smo inhibitor PF-04449913 with Ara-C.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Tissue culture 
Table 2.1.1.1: Plastics for Tissue Culture and Suppliers 
Plastics Supplier 
8-well Lab-Tek II chamber slides Thermo Scientific Nunc. Massachusetts, 
USA 
Cryovial Fisher Scientific, Loughborough, UK 
Eppendorf tubes (0.5/1.5ml) Life technologies, Paisley, UK 
Falcon tubes (15ml, 50ml) Fred Baker Scientific, Cheshire, UK 
Flat bottomed culture plates (6/12/24/96-well) Greiner bio one, Gloucestershire, UK; 
Thermo Scientific Nunc. Massachusetts, 
USA 
5100 Cryo -1oC freezing container, Nalgene, ‘Mr Frosty’ Sigma-Aldrich, Dorset, UK 
Haemocytometer Hawksley, Sussex, UK 
Pasteur pipette (3ml) Greiner bio one, Gloucestershire, UK 
Pipette tips (p10/20/100/200/1000) Greiner bio one, Gloucestershire, UK 
Single use filter unit (0.22/0.45µm) Sartorius Stedim Biotech, Epsom, UK 
Sterile cell strainer (100µM) Fisher Scientific, Loughborough, UK 
Suspension dish with lid and vent (10x35mm) Thermo Scientific Nunc. Massachusetts, 
USA 
Syringes (5/10/20/50ml) Greiner bio one, Gloucestershire, UK 
Tissue culture flasks (25/75/300cm3; non-adherent) Greiner bio one, Gloucestershire, UK 
Tissue culture flasks (25/75/300cm3; adherent) Thermo Scientific Nunc. Massachusetts, 
USA 
Vacubottle Fisher Scientific, Loughborough, UK 
White opaque culture plates (96-well; flat bottomed) Greiner bio one, Gloucestershire, UK 
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Table 2.1.1.2: Reagents for Tissue Culture and Suppliers 
Reagent Supplier 
BIT 9500 Serum Substitute Stem Cell Technologies, Grenoble, 
France 
Bright Glo Luciferase system Promega, Madison, USA 
Diff-Quik®  Hergestelit von Fabrique, Dudingen, 
Switzerland 
Dimethylsulphoxide (DMSO)  Sigma-Aldrich, Dorset, UK 
DNAse I Solution (1mg/ml) – Bovine Pancreatic 
Deoxyribonuclease I 
Stem Cell Technologies, Grenoble, 
France 
Dulbecco’s Modified Eagle Medium  Life technologies, Paisley, UK 
Dulbecco’s Modified Eagle Medium: Nutrient Mixture 
F12  
Life technologies, Paisley, UK 
Dulbecco’s Modified Eagle Medium High Glucose  Life technologies, Paisley, UK 
Dulbecco’s Modified Eagle Medium Low Glucose + 
glutamax  
Life technologies, Paisley, UK 
Dulbecco’s phosphate buffered saline (without Ca2+ 
and Mg 2+)  
Life technologies, Paisley, UK 
Ethanol 100% molecular grade Sigma-Aldrich, Dorset, UK 
Foetal bovine serum Life technologies, Paisley, UK 
Geneticin Life technologies, Paisley, UK 
Ham’s F-12 Life technologies, Paisley, UK 
Heparin (stock 5000IU/ml) NHS 
Histopaque-1077 Sigma-Aldrich, Dorset, UK 
Horse serum  Life technologies, Paisley, UK 
Human albumin solution (5%) NHS, UK 
Hyclone FBS - HZSH3007003H Fisher Scientific, Loughborough, UK 
Hygromycin Life technologies, Paisley, UK 
Iscove’s Modified Dulbecco’s Medium  Life technologies, Paisley, UK 
L-glutamine (200mM)  Life technologies, Paisley, UK 
Luciferase Promega, Madison, USA 
2-mercaptoethanol (0.1µM) Sigma-Aldrich, Dorset, UK 
Methocult TM H4034 Stem Cell Technologies, BC, Canada 
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Myelocult 5100 Stem Cell Technologies, BC, Canada 
Penicillin-streptomycin (10,000U/ml) Life technologies, Paisley, UK 
Purmorphamine Santa Cruz, USA 
hFLT3L (stock – 100µg/ml) Peprotech, New Jersey, USA 
hIL-3 (stock – 100µg/ml) Peprotech, New Jersey, USA 
hIL-6 (stock – 100µg/ml) Peprotech, New Jersey, USA 
hSCF (stock – 100µg/ml) Peprotech, New Jersey, USA 
HS-5 conditioned media Made in-house 
Resazurin (7-Hydroxy-3H-phenoxazin-3-one-10-oxide 
sodium salt) (R7017) 
Sigma-Aldrich, Dorset, UK 
RPMI 1640 medium  Life technologies, Paisley, UK 
StemSpan 2 Stem Cell Technologies, Grenoble, 
France 
Trypan blue solution (0.4%) Sigma-Aldrich, Dorset, UK 
 
Table 2.1.1.3: All-inclusive ‘Kits’ for Tissue Culture and Suppliers 
Kit Supplier 
Senescence β-Galactosidase Staining Kit #9860 Cell Signalling, MA, USA 
Sonic Hedgehog Human ELISA Kit (ab100639) Abcam, Cambridge, UK 
 
Table 2.1.1.4: Equipment for Tissue Culture and Suppliers 
Equipment Supplier 
CompuSyn software ComboSyn, Inc., New Jersey, USA 
Multi-channel pipettor Thermo Scientific Nunc. Massachusetts, USA 
USA 
Spectramax M5 plate reader Molecular Devices, California, USA 
SoftMax Pro software Molecular Devices, California, USA 
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Table 2.1.1.5 AML Cell Lines and Characteristics 
Cell line Disease Characteristics Supplier 
HL60 546 AML FAB M3 or 
M2 (debated) 
Hypotetraploid karyotype with hypodiploid sideline 
and 1.5% polyploidy - 82-88<4n>XX, -X, -X, -8, -8, -
16, -17, -17, +18, +22, +2mar, 
ins(1;8)(p?31;q24hsr)x2, der(5)t(5;17)(q11;q11)x2, 
add(6)(q27)x2, 
der(9)del(9)(p13)t(9;14)(q?22;q?22)x2, 
der(14)t(9;14)(q?22;q?22)x2, 
der(16)t(16;17)(q22;q22)x1-2, add(18)(q21) – side 
line with: -2, -5, -15, del(11)(q23.1q23.2) 
High expression of c-Myc 
Derived from PB leucocytes obtained by 
leukopheresis from a 36yr old female in 1976 
In house 
Kasumi-1 
547 
AML with 
recurrent 
genetic 
abnormalities 
Hypodiploid karyotype - 45<2n>X, -Y, -9, -13, -16, 
+3mar, t(8;21)(q22;q22), der(9)t(9;?)(p22;?), 
der(15)t(?9;15)((?q11;?p11) 
CD34+ 
Carries the t(8;21) leading to the AML1-ETO fusion 
gene and the KIT mutation N822 
Derived from the PB of a 7yr old Japanese male (in 
2nd relapse after bone marrow transplantation) in 
1989 
DSMZ 
KG1a 548 AML Near-diploid karyotype with 5% polyploidy - 46(44-
47)<2n>X/XY, +8, +11, -12, -17, -20, 
der(5;17)(q10;q10)del(5)(q?11q?13), 
del(7)(q22q35), i(8q), 
der(8)t(8;12)(p11;q13)add(8)(q24), i(11q), 
add(16)(q13/21), der(19)t(14;19)(q11;q13), 
add(20)(p13)  
CD34+ 
Expresses OP2-FGFR1 fusion gene 
Established from the BM of a 59yr old male with 
erythroleukemia that developed into AML; KG-1a is 
a subclone of the AML cell line KG-1 described as 
an "undifferentiated variant" 
In house 
MOLM-13 
549 
AML FAB M5a at 
relapse after 
initial RAEB 
Human hyperdiploid karyotype with 4% polyploidy 
- 51(48-52)<2n>XY, +8, +8, +8, +13, del(8)(p1?p2?), 
ins(11;9)(q23;p22p23 
FLT3 ITD+ at gene level only; CBL deltaExon8 
mutant; carries occult insertion effecting MLL-AF9 
fusion 
Established from PB of a 20yr old male with RAEB 
DSMZ 
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that developed into AML	in	1995 
MV4-11 550 Biphenotypic B-
myelomoncytic 
leukaemia 
Hyperdiploid karyotype - 48(46-48)<2n>XY, +8, 
+18, +19, -21, t(4;11)(q21;q23)  
FLT3 ITD+ at gene and protein level 
Established from a 10yr old male at diagnosis 
DSMZ 
OCI-AML3 
551 
AML FAB M4 Hyperdiploid karyotype - 48(45-50)<2n>X/XY, +1, 
+5, +8, der(1)t(1;18)(p11;q11), i(5p), 
del(13)(q13q21), dup(17)(q21q25) 
NPM1 gene mutation (type A) and the DNMT3A 
R882C mutation 
Established from the PB of a 57yr old male at 
diagnosis in 1987 
DSMZ 
THP-1 552 AML FAB M5b Human near tetraploid karyotype - 94(88-
96)<4n>XY/XXY, -Y, +1, +3, +6, +6, -8, -13, -19, -
22, -22, +2mar, add(1)(p11), del(1)(q42.2), i(2q), 
del(6)(p21)x2-4, i(7p), 
der(9)t(9;11)(p22;q23)i(9)(p10)x2, 
der(11)t(9;11)(p22;q23)x2, add(12)(q24)x1-2, 
der(13)t(8;13)(p11;p12), add(?18)(q21)  
t(9;11)(p21;q23) leading to MLL-AF9 fusion gene 
Established from a 1yr old at relapse in 1978 
In house 
 
Table 2.1.1.6: Stromal Cell Lines and Characteristics 
Cell line  Origin  Supplier  
HS-5 553 Human marrow stromal cell line – fibroblast; established from a 30yr 
old male  
Expresses Granulocyte colony-stimulating factor (G-CSF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), 
macrophage colony-stimulating factor M-CSF, Kit ligand (KL), 
macrophage-inhibitory protein-1α (MIP-1α), interleukin- (IL-) IL-1α, 
IL-1β, interleukin-1 receptor antagonist (IL-1RA), IL-6, IL-8, IL-11, 
and leukaemia inhibitory factor (LIF) 
Supports proliferation of haematopoietic progenitor cells when co-
cultured in serum-deprived media with no exogenous factors 
In house 
M210-B4 
554,555 
BM stromal cells derived from C57BL/6J X C3H/HeJ) F1 mouse 
genetically engineered to produce hIL-3 and hG-CSF  
Support human and murine myelopoiesis in long term culture (LTC) 
In house 
SL/SL 555,556 Stromal cell line derived from SL/SL mouse genetically engineered to 
produce hIL-3 and hSCF  
In house 
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Support human and murine myelopoiesis in LTC 
TM3 557 (GLI-
Luc) 558 
Murine leydig tumour cell line with intact Hh signalling transfected with 
a retroviral vector carrying 8 Gli-responsive elements and a luciferase 
gene 
In house 
 
Table 2.1.1.7: Cell Line Culture Conditions 
Cell line Media conditions 
HS-5 DMEM High Glucose and 10% ES grade FBS and 10% HS-5 conditioned media 
Kasumi-1 RPMI, 20% FBS, 1mM L-Glutamine, 1% Pen/Strep, 
KG1a RPMI, 20% FBS, 1mM L-Glutamine, 1% Pen/Strep 
MOLM-13 RPMI, 10% FBS, 1mM L-Glutamine, 1% Pen/Strep 
MV4-11 RPMI, 20% FBS, 1mM L-Glutamine, 1% Pen/Strep 
M210-B4 DMEM, 10% FBS, 1mM L-Glutamine, 1% Pen/Strep 
G418 (to give a final concentration of 400µg/ml), Hygromycin B (to give a final 
concentration of 62.5µg/ml) 
OCI-AML3 RPMI, 20% FBS, 1mM L-Glutamine, 1% Pen/Strep 
SL/SL RPMI, 15% FBS, 1mM L-Glutamine, 1% Pen/Strep 
G418 (to give a final concentration of 800µg/ml), Hygromycin B (to give a final 
concentration of 125µg/ml) 
THP-1 RPMI, 10% FBS, 1mM L-Glutamine, 1% Pen/Strep 
TM3 DMEM/F-12, 10% horse serum, 1mM L-Glutamine and Geneticin (100µg/ml)  
To minimise proliferation of untransduced wild type SL/SL and M210-B4 cells, these were dosed 
on alternate weeks with medium supplemented with hygromycin B and G418 
 
Table 2.1.1.8: 10% Media for Cell Line Culture 
Reagent Volume 
FBS 50ml 
L-Glutamine (1MM) 5ml 
Pen/Strep (1%) 5ml 
RPMI 440ml 
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Table 2.1.1.9: 20% Media for Cell Line Culture 
Reagent Volume 
FBS 100ml 
L-Glutamine (1MM) 5ml 
Pen/Strep (1%) 5ml 
RPMI 390ml 
 
Table 2.1.1.10: Media for M210-B4 Culture 
Reagent Volume 
DMEM 390ml 
FBS 50ml 
L-Glutamine (1MM) 5ml 
Pen/Strep (1%) 5ml 
 
Table 2.1.1.11: Media for SL-SL Culture 
Reagent Volume 
DMEM 415ml 
FBS 75ml 
L-Glutamine (1MM) 5ml 
Pen/Strep (1%) 5ml 
 
Table 2.1.1.12: Media for TM3 Culture 
Reagent Volume 
DMEM/F-12 445ml 
Geneticin  100µl/10ml 
Horse serum 50ml 
L-Glutamine (1MM) 5ml 
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Table 2.1.1.13: Media for Cell Line Cryopreservation 
Reagent Volume 
DMSO 5ml 
FBS 45ml 
 
Table 2.1.1.14: Media for Primary AML Cell Culture 
Reagent Volume 
hFLT3L (stock – 100µg/ml) 5µl 
hIL-3 (stock – 10µg/ml) 50µl 
hIL-6 (stock – 100µg/ml) 5µl 
hSCF (stock – 100µg/ml) 5µl 
HS-5 conditioned media 5.5ml 
Myelocult  5ml (5%) 
StemSpan 2 45ml 
All cytokines are made up in filter sterilized PBS and BSA (0.1%) 
 
Table 2.1.1.15: Media for MSC Culture 
Reagent Volume 
D-MEM Low Glucose + glutamax 440ml 
Hyclone FCS (10%) 50ml 
L-glutamine (100mM) 5ml 
Pen/Strep 5ml 
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Table 2.1.1.16: Media for Thawing Primary Samples 
Reagent Volume 
DNAse I (1mg/ml) 1ml 
ES FCS (20%)FBS  100ml  
Heparin (5000IU/ml) 4ml (20,000IU) 
IMDM (Iscoves) 390ml 
L-glutamine (200mM) 5ml 
Filter sterilized through 0.22µM syringe filter 
 
Table 2.1.1.17: Freezing media for Primary AML and MSC Samples 
Reagent Volume 
DMSO 10ml 
FBS 35ml 
Human albumin solution 5% 5ml 
 
Table 2.1.1.18: Reagents for CFC Assay 
Reagent Composition  Supplier  
MethocultTM H4034 IMDM, methylcellulose, BSA, 
FBS, 2-mercaptoethanol, 
rhSCF, rhGM-CSF, rhG-CSF, 
rhIL-3, rhEPO 
Stemcell Technologies, 
Grenoble, France 
Serum free media (SFM) with 
high growth factor cocktail 
IMDM, BIT, β-
mercaptoethanol, penicillin-
streptomycin, L-glutamine 
Flt3-L, SCF, IL-3, IL-6, G-CSF  
Made in house in Vacubottle 
and filter sterilised 
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Table 2.1.1.19: Serum free media (SFM) for primary cell culture  
Reagent  Volume  
IMDM 97.25ml 
BIT (BSA, insulin, transferrin) 25ml 
L-Glutamine 1.25ml 
Pen/Strep 1.25m 
β-Mercaptoethanol (200mM) 250µl (400µM) 
Filter sterilise through 0.22µm filter before use 
	
Table 2.1.1.20: SFM with high concentration growth factor cocktail	
Reagent Supplier Volume Final 
concentration 
SFM Made in house (2.1.1.18) 10mL - 
IL3 (10µg/mL) Stem Cell Technologies, 
Grenoble, France 
20µl 20ng/mL 
IL6 (10µg/mL) Stem Cell Technologies, 
Grenoble, France 
20µl 20ng/mL 
GCSF (10µg/mL) Chugai Pharma, London, UK 20µl 20ng/mL 
SCF (10µg/mL) Stem Cell Technologies, 
Grenoble, France 
100µl 100ng/mL 
Flt3L (10µg/mL) Stem Cell Technologies, 
Grenoble, France 
100µl 100ng/mL 
Filter sterilise through 0.22µm filter before use 
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Table 2.1.1.21: Drugs Tested and Suppliers 
Drug Mechanism of action Supplier 
Venetoclax (ABT-199; GDC-
0199) 559 
Bcl-2 selective inhibitor with 
no activity against Mcl-1 
Xcess Biosciences Inc, San 
Diego, USA 
Ara-C  Antimetabolic agent and DNA 
synthesis inhibitor 
Sigma-Aldrich, Dorset, UK 
Arsenic (III) oxide Causes degradation of PML-
RAR α 
Acts on the intracellular 
environment to influence 
apoptosis, differentiation, 
growth arrest, and 
angiogenesis - further research 
is required to determine the 
exact pathways through which 
the cytotoxic actions are 
mediated 
Sigma-Aldrich, Dorset, UK 
Cyclopamine (11-
Deoxojervine) 560 
Smo inhibitor Selleckchem.com, Suffolk, UK 
Elacridar hydrochloride (N-[4-
[2-(3,4-Dihydro-6,7-
dimethoxy-2(1H)-
isoquinolinyl)ethyl]phenyl]-
9,10-dihydro-5-methoxy-9-
oxo-4-acridinecarboxamide 
hydrochloride) 
P-gp/ABCG1 and BCRP/ABCG2 
inhibitor  
Tocris Bioscience, R&D 
systems, Abingdon, UK 
Glasdegib (PF-04449913)  Smo inhibitor  Selleckchem.com, Suffolk, UK 
HA14-1 (2-Amino-6-bromo-α-
cyano-3-(ethoxycarbonyl)-4H-
1-benzopyran-4-acetic acid 
ethyl ester) 
Bcl-2 inhibitor - binds to 
surface pocket; disrupts 
Bax/Bcl-2 interaction; binds 
Bcl-XL and Bcl-w 
Tocris Bioscience, R&D 
systems, Abingdon, UK 
Reversan (N-[3-(4-
Morpholinyl)propyl]-5,7-
diphenylpyrazolo[1,5-
a]pyrimidine-3-carboxamide) 
Selective inhibitor of MRP1 
and P-gp 
Does not sensitize MRP2, 
MRP3, MRP4 or MRP5 
transporters to known 
substrates 
Tocris Bioscience, R&D 
systems, Abingdon, UK 
Tomatidine hydrochloride (3β-
Hydroxy-5 α-tomatidane 
hydrochloride) 
Steriodal alkaloid structurally 
similar to Cyclopamine 
Santa Cruz, Texas, USA 
	 78	
TW37 (N-[[2-(1,1-
Dimethylethyl)phenyl]-2,3,4-
trihydroxy-5-[[2-(1-
methylethyl)phenyl]methyl]) 
Inhibits Bcl-2 and Bcl-XL  
Inhibits the activation of 
Notch-1 and Jagged-1  
Tocris Bioscience, R&D 
systems, Abingdon, UK 
Zosuquidar hydrochloride 
((αR)-4-[(1aα,6α,10bα)-1,1-
Difluoro-1,1a,6,10b-
tetrahydrodibenzo[a,e]cyclopr
opa[c]cyclohepten-6-yl]-α-[(5-
quinolinyloxy)methyl]-1-
piperazineethanol 
trihydrochloride) 
P-gp inhibitor  Tocris Bioscience, R&D 
systems, Abingdon, UK 
 
2.1.2 Molecular Studies: 
Table 2.1.2.1: Plastics for Molecular Studies and Suppliers 
Equipment Supplier 
Fluidigm dynamic Array integrated fluidic circuit      
(FLEXsix/48.48/96.96) 
Fluidigm, San Francisco, USA 
MicroAmp Optical Adhesive Film  Applied biosystems, Warrington, UK 
Nucleotide free tips, eppendorfs and PCR tubes Applied biosystems, Warrington, UK 
8/12-Cap MicroAmp Optical strips Applied biosystems, Warrington, UK 
96 and 384 MicroAmp Optical Well Plates Applied biosystems, Warrington, UK 
 
Table 2.1.2.2: Molecular Reagents and Suppliers 
Reagent Supplier 
3130 Pop-7 Polymer Life technologies, Paisley, UK 
5X Buffer Promega, Madison, USA 
Abi Prism Big Dye® V1.1  Thermo Fisher Scientific, 
Loughborough, UK 
Assay loading reagent (2x) Fluidigm, San Francisco, USA 
cDNA reverse transcription kit Applied Biosystems, Warrington, UK 
Diisopropylfluorophosphate (1mM)  Sigma-Aldrich, Dorset, UK 
DNA binding dye (20x) Fluidigm, San Francisco, USA 
DNAeasy Blood and Tissue Kit (69504) Qiagen, Crawley, UK 
DNAse I Qiagen, Crawley, UK 
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dNTP Sigma-Aldrich, Dorset, UK 
EDTA Running Buffer (10x) Life technologies, Paisley, UK 
Exonuclease I (E. coli) New England BioLabs, Hitchin, UK 
Exonuclease I reaction buffer New England BioLabs, Hitchin, UK 
Gene expression master mix Applied Biosystems, Warrington, UK 
GE Sample Loading Reagent (20x) Fluidigm, San Francisco, USA 
GoTaq Promega, Madison, USA 
Hi-Di Formamide Life technologies, Paisley, UK 
Illustra Exo-ProStar Thermo Scientific Nunc. Massachusetts, 
USA 
MgCl2 Promega, Madison, USA 
Molecular biology grade 100% Ethanol Qiagen, Crawley, UK 
Molecular biology grade water Qiagen, Crawley, UK 
Nuclease free water  Qiagen, Crawley, UK 
OligoDTs Qiagen, Crawley, UK 
PCR Master Mix (1.5mM MgCl2) Thermo Scientific Nunc. Massachusetts, 
USA 
Pre-amplification master mix Applied Biosystems, Warrington, UK 
Primers – see Table 2.1.2.7 Integrated DNA Technologies, Leuven, 
Belgium 
1X Quickstart Bradford Dye Reagent  Bio-Rad, Hertfordshire, UK 
RNeasy Plus Mini kit (74134) Qiagen, Crawley, UK 
RNaseOUT™ recombinant ribonuclease inhibitor Life technologies, Paisley, UK 
Sequencing Reaction Buffer  Thermo Fisher Scientific, 
Loughborough, UK 
SsoFast™ EvaGreen Supermix with low ROX Bio-Rad, Hertfordshire, UK 
Superscript® III reverse transcriptase Life technologies, Paisley, UK 
Taqman Gene Expression Assay (20x) Fluidigm, San Francisco, USA 
Taqman Probes – see Table 2.1.2.8 Applied Biosystems, Warrington, UK 
Taqman Universal PCR Master Mix (2x) Fluidigm, San Francisco, USA 
TE Buffer pH8.0 Applied Biosystems, Warrington, UK 
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Table 2.1.2.3: Molecular Equipment and Programmes and Suppliers 
Equipment Supplier 
Alamut Mutational Surveyor Interactive Biosoftware, Rouen,  
France 
Biomark Real-Time PCR Analysis Fluidigm, San Francisco, USA 
ChemiDocTM MP System Bio-Rad, Hertfordshire, UK 
Fluidigm Biomark Analyser Fluidigm, San Francisco, USA 
Nanodrop spectrophotometer 2100 Nanodrop technologies, Wilmington,  
USA 
Quantity-One 1-D Analysis Software Bio-Rad, Hertfordshire, UK 
Sorval Legend-T Centrifuge  DJB Labcare Ltd, Buckinghamshire, UK 
Taqman 7900 machine Applied biosystems, Warrington, UK 
Techne Thermal Cycler TC-412 Bibby Scientific Limited, Staffordshire,  
UK 
 
2.1.2.4 Reverse transcription 
Table 2.1.2.4.1: Reverse transcription master mix Step 1 
Reagent  Volume 
dNTPs 1µl 
Oligo dT 1µl 
RNA 500ng 
RNase free water 11µl – RNA volume 
 
Table 2.1.2.4.2: Reverse transcription master mix Step 2 
Reagent  Volume 
Reverse transcription master mix 1 13µl 
5x buffer 4µl 
DTT 1µl 
RNase 1µl 
Superscript III 1µl 
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Table 2.1.2.4.3:  Reverse Transcription Cycling Conditions 
 Step 1 Step 2 
Temperature (oC) 65 55 70 
Time  5mins 60mins 15mins 
 
2.1.2.5 Polymerase chain reactions 
Table 2.1.2.5.1: GoTaq® reverse transcription PCR (RT-PCR) mastermix 
Reagent  Volume 
cDNA 2µl 
dNTPs (10mM) 0.5µl 
Forward primer  0.2µl 
GoTaq® DNA polymerase 0.1µl 
Green GoTaq® Flexi Buffer (5X) 5µl 
MgCl2 (25MM) 3 µl 
Reverse primer 0.2µl 
RNAse free water 14µl 
 
Table 2.1.2.5.2: GoTaq® RT-PCR Mastermix Cycling Conditions 
 Stage 1: Initial 
denature 
Stage 2: Cycling conditions 30 cycles Stage 3: Final 
extension 
Hold 
Denaturing Annealing Extension 
Temperature 
(oC) 
95 95 60 72 72 4 
Time  2mins 30secs 60secs 60secs 5mins ∞ 
 
Table 2.1.2.6: Taqman® Probes  
Probe Life Technologies Identifier Probe Life Technologies Identifier 
ABCA2 Hs00242232_m1  ATP5B Hs00969569_m1  
ABCB1 Hs00184500_m1  ATR Hs00992123_m1  
ABCC1 Hs01561483_m1 AXIN1 Hs00394718_m1 
ABCC3 Hs00978452_m1  AXIN2 Hs00610344_m1  
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ABCG2 Hs01053790_m1  B2M Hs00984230_m1 
APC Hs01568269_m1  BAD Hs00188930_m1  
ATG5 Hs00169468_m1 BAK1 Hs00832876_g1 
ATG7 Hs00197348_m1 BAX Hs00180269_m1  
ATM Hs005892_m1  BBC3 Hs00248075_m1  
BCL2 Hs00608023_m1 DVL Hs00182896_m1  
BCL2A1 Hs00187845_m1  ENOX2 Hs00197268_m1 
BCL2L1 Hs00236329_m1  ETV6 Hs00231101_m1  
BCL2L10 Hs00368095_m1  FOS Hs00170630_m1 
BCL2L11 Hs00708019_s1 FOSL1 Hs00759776_s1 
BID Hs00609632_m1  FOXM1 Hs01073586_m1 
BIRC2 Hs01112284_m1  FOXN1 Hs00919266_m1  
BIRC5  Hs04194392_s1 FRZD Hs00201853_m1  
BMI1 Hs00995536_m1 GAPDH Hs02758991_g1 
BMP4 Hs00370078_m1 GLI1 Hs01110766_m1 
BRACHYURY Hs00610080_m1  GLI2 Hs01119974_m1 
CCND1 Hs00765553_m1 GLI3 Hs00609233_m1 
CCND2 Hs00153380_m1 GUSB Hs00939627_m1 
CD44 Hs01075864_m1  HES1 Hs00172878_m1  
CCDH1 Hs00765553_m1 HES5 Hs01387463_g1 
CCDH2 Hs00153380_m1 HHAT Hs00911326_m1  
CDX1 Hs00156451_m1 HHIP Hs01011015_m1 
CDX2 Hs01078080_m1  HOXA3 Hs00601076_m1 
CDX4 Hs00193194_m1  HOXA9 Hs00365956_m1 
C-JUN Hs01103582_s1 HOXB4 Hs00256884_m1  
CPA3 Hs00157019_m1 IGF1R Hs00609566_m1 
CXCR4 Hs0007978_s1 IHH Hs00745531_s1 
CXXC4 Hs00228693_m1  JAGGED Hs00171432_m1  
DHH Hs0036830_m1 KISS1 Hs00158486_m1 
DKK1 Hs00183740_m1  KIT Hs00174029_m1  
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DISP2 Hs00394338_m1  KLF4 Hs00358836_m1 
DMP1 Hs01009391_g1  KREMEN1 Hs00230750_m1 
DNMT1 Hs00945875_m1 LEF1 Hs01547250_m1 
DNMT3a Hs01027162_m1  LMO2 Hs00153473_m1  
DNMT3b Hs00171876_m1  MAML2 Hs00418423_m1  
MAML3 Hs00298519_s1 SFRP1 Hs00610060_m1  
MAP1LC3B Hs00797944_s1 SFRP2 Hs00293258_m1  
MCL1 Hs01050896_m1  SFRP4 Hs00180066_m1  
MECOM Hs00602795_m1 SHH Hs00179843_m1 
MEIS1 Hs00180020_m1  SMAD2 Hs00998186_m1 
MMP2 Hs01548727_m1  SMO Hs01090242_m1 
MMP3 Hs00968305_m1  SNAIL1 Hs00195591_m1 
MMP9 Hs00957562_m1  SNAIL2 Hs00161904_m1  
MMP13 Hs00942584_m1  SNAIL3 Hs01018996_m1  
MYB Hs00920556_m1  SOX2 Hs01053049_s1  
MYC Hs00153408_m1 SUFU Hs00960520_m1  
NANOG Hs02387400_g1 STIL Hs00161700_m1 
NLK Hs00939681_m1  TBP Hs99999910_m1 
NODAL Hs00415442_m1 TCF3 Hs00162613_m1 
NUMB Hs01105433_m1 TCF4 Hs00162613_m1  
P53 Hs01034249_m1  TCF7 Hs01556515_m1 
P73 Hs01056231_m1  TWIST1 Hs01675818_s1 
PARP1 Hs00242302_m1  TYW1 Hs00936867_m1 
PAX6 Hs01088114_m1  UBE2D2 Hs00366152_m1 
PBX1 Hs00231228_m1  VIMENTIN Hs00958111_m1  
PECAM1 Hs01065279_m1  WIF Hs00183662_m1  
PP2CA Hs01056778_g1 WNT4 Hs01573505_m1  
PPP2R1A Hs01026388_m1  WNT5a Hs00998537_m1 
PTCH1 Hs00181117_m1 YWHAE Hs00356749_g1 
PTCH2 Hs0018404_m1 XIAP Hs00745222_s1 
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ROR1 Hs00938677_m1 	 ZEB1 Hs01566408_m1 
ROR2 Hs00896176_m1	   
 
Table 2.1.2.7 Primers  
Primer Forward sequence Reverse sequence 
APAF-1  TCT CTG TGA GCC GGA AAC TT CGG GAA AGA TTC GTG ATG TT 
ATG5 GGC ACA CCA CTG AAA TGG C GAT GTT CCA AGG AAG AGC TGA AC 
ATG7 CTG ATG TTT GGA GAT TGG TTC C CAA CCC ATC AAC GTC CTA GC 
ATP5B TCC ATC CTG TCA GGG ACT ATG ATC AAA CTG GAC GTC CAC CAC 
B2M TTG TCT TTC AGC AAG GAC TGG  ATC CGG CAT CTT CAA ACC TCC  
BAD / BCL-XL AGC TCC GGA GGA TGA GTG AC CAC CAG GAC TGG AAG ACT CG 
BAK ACG CTA TGA CTC AGA GTT CC TGA TGC CAC TCT CAA ACA GG 
BAX GCT GAC ATG TTT TCT GAC GG  ATG ATG GTT CTG ATC AGT TCC 
BBC3 GAC CTC AAC GCA CAG TAC GA CTA ATT GGG CTC CAT CTC G 
BCL2 ATC GCC CTG TGG ATG ACT GAG T GCC AGG AGA AAT CAA ACA GAG GC 
BCL2L1 GCA TCG AAC AAC GAG AAT CA GCT GGT CTC CAG GTA ACG AA 
BCL-W / 
 BCL2L2 
AAG TGC AGG AGT GGA TGG TG GTC CTC ACT GAT GCC CAG TT 
BFK /  
BCL2L15 
TTC AAC GGA GAA TTG GAA GC AAT CCT GAG CAC ACC AGG TC 
BID GGA ACC GTT GTT GAC CTC AC GAG GAG CAC AGT GCG GAT 
BIK GAG GTT CTT GGC ATG ACT GAC CTG AGG CTC ACG TCC ATC TC 
BIM CAG CAC CCA TGA GTT GTG AC CTT GGG CGA TCC ATA TCT CT 
BMF GAA CCC CAG CGA CTC TTT TA TTT CGG GCA ATC TGT ACC TC 
BMP4 CAG CAC TGG TCT TGA GTA TCC T AGC AGA GTT TTC ACT GGT CCC 
BOK CAA GGT GGT GTC CCT GTA TG GCT GAC CAC ACA CTT GAG GA 
CASPASE 3 TGT GGA AGA ACT TAG GCA TC TTT GCT CAC ACT TTC TCT CA 
CASPASE 7 TCT TTT GTG CTG CTT CTT TG CCC ACT CCT ATC TTA CTC CA 
CASPASE 8 CTG GTC CCT GCT AAC ATT TG CTG GTC CCT GCT AAC ATT TG 
CASPASE 9 CCT GGA GTC TAG TTG GCT TCA TAT GGG GCC TGA ACA 
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CCNA1 CTC GTA GGA ACA GCA GCT ATG C GCT AGA ACT TTC AGA AGC AAG TGT  
TC 
CCNA2 ACC CTG GAA AGT CTT AAG CCT GTG TCT CTG GTG GGT TGA GG 
CCNB1 CAG CTC TTG GGG ACA TTG GTA AC ACT GGC ACC AGC ATA GGT ACC 
CCNC1 TTT GCT GAG CTT TCT GTG GA AAT GGT TGC CAT CTC TTT TCT C 
CCND1 TGC ATC TAC ACC GAC AAC TCC CGG ATG ATC TGT TTG TTC TCC G 
CCND2 CCG CAG TGC TCC TAC TTC AA GCC AAG AAA CGG TCC AGG TA 
CCND3 CCT CCT ACT TCC AGT GCG TG AGG CCA GGA AAT CAT GTG CA 
CCNE2 CAA GTT GAT GCT CTT AAA GAT GCT CC GCA GCA GTC AGT ATT CTG TAC TGG 
CFLAR CAC AGC TCA CCA TCC CTG TA GGC AGA AAC TCT GCT GTT CC 
CDH1 TTT GAC GCC GAG AGC TAC AC GTC CTT TGT CGA CCG GTG CA 
CDH2 CTG CTT CAG GCG TCT GTA GA GCC TGT CCT TCA TGC ACA TC 
CKIT GCA TTC AAG CAA ATG GCA C CCA ATC AGC AAA GGA GTG AA 
CXCR4 TTA CCA TGG AGG GGA TCA GT GTA GAT GGT GGG CAG GAA GA 
CYCTO - C ACT CTT ACA CAG CCG CCA AT CCT TCT TCT TAA TGC CGA CAA 
DIABLO AGA TGA AGT GTG GCA GGT GA GCT GCC ATC TCT GAA AGA CC 
FAS GGA TTG CTC AAC AAC CAT GC CCT CAA TTC CAA TCC CTT GG 
FASL1 GCA CAC AGC ATC ATC TTT GG CAT AGG TGT CTT CCC ATT CC 
ENOX2 GAG CTG GAG GGA ACC TGA TTT  CAC TGG CAC TAC CAA ACT GCA  
FOS AGG AGA ATC CGA AGG GAA AGG TAG TTG GTC TGT CTC CGC TTG 
FOXM1 TCA AAA CCG AAC TCC CCC TG GCA GCA CTG ATA AAC AAA GAA AGA 
GAPDH ACG GAT TTG GTC GTA TTG GG ATT TTG GAG GGA TCT GCT C 
GLI1 AGC CAA GCA CCA GAA TCG G TCT TGA CAT GTT TTC GCA GCG 
GLI2 CTC CTA TGG TCA CTT ATC TGC AAG T TGA ACC TAA GCT CTG TTG TCG G 
GLI3 TCC ATA CCT TGA CCA GCT TG  GCA GAT TGT CTC TGG ATC TC  
HHIP GCC ATT CAG TAA TGG TCC TTT GG CCA CTG CTT TGT CAC AGG AC 
HSP 60 AGT GGA AAT CAG GAG AGG TA AGA GGA GGA ATG AGA GAA GG 
HSP 70 ATG CCA TGT ACT TCT CTT GG ATA CAG AAC ATC TCC CAC CT 
HSP 90 CAC CAC CCC AAA TAT CTT CT TAG CTC CTC ACA GTT ATC CA 
IHH GGA CGC TAT GAA GGC AAG ATC G CAG CGA GTT CAG GCG GTC CTT 
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LC3B CGA TAC AAG GGT GAG AAG CA GCC TGA TTA GCA TTG AGC TG 
MCL1 CTT ACG ACG GGT TGG GGA TG TCC TGC CCC AGT TTG TTA CG 
MCM2 ACC CGA AGC TCA ACC AGA TG TGC GGA TCA TGG ACT CGA TG 
MCM3 GAA GTG ATG GAG CAG GGT CG CAG TGA GTC CTG TAG CCC AA 
MCM4 TGA CCG TTA CCC TGA CTC AA GGG AAT CAG CTG GGA TGT CC 
MCM5 CAT CTC TAT CCA GTG CCG CA GCA TTT GTC GGG CAT GAT GA 
MCM6 AAT TTG TCA GCT CCC ATC ATG T TGA ATG CAA ATC TAC TAT GCG CC 
MCM7 GCA TGA AAA TCC GGG GCA AC GTA AGC CCC ACT CCT GAG GA 
MCM8 GGA GGA AGC CAG AAA TAC GC CCA CAA ACA TAC ACG CCA CG 
MCM9 CCA GTC CCT TTC TCA GCC TG ACT TGT TCG AAT CAC TGT CCC A 
MCM10 TCT GGG GAA ACG ACT CAA CC TCG GCC GGT CAT TTT CTT GT 
MDM2 TGT TTG GCG TGC CAA GCT TCT C CACAGATGTACCTGAGTCCGATG 
MYC GAC TCT GAG GAG GAA CAA GA TTG GCA GCA GGA TAG TCC TT 
NUMB CCA AAC CAG TGA CAG TGG TGG C CCC AAG GGT TGG TTT CAC GC 
P53 CAG TCA GAT CCT AGC GTC GA TGT TCA ATA TCG TCC GGG GA 
PARP AGA AGT ACG TGC AAG GGG TG CCA GCG GTC AAT CAT GCC TA 
PMAIP AAG AAG GCG CGC AAG AAC TCA GGT TCC TGA GCA GAA GAG 
PTCH1 ACA TTT GTG TTA CAA ATC AGG AGA GC CTG TCC CAG ACT GTA ATT TCG C 
PTCH2 TGT GGT GGG AGG CTA TCT G GCA TGG TCA CAC AGG CAT AG 
RPA1 TGC GAA TCC TGA CAT CCC AG TGG TGT TAC TCC CTC CGA CT 
RPA2 CAG ACA TGT GTT TCA GCT GGT CAG GAA TGA GTG AAG CAG GGA 
SHH CGA GCG ATT TAA GGA ACT CAC C GCG TTC AAC TTG TCC TTA CAC C 
SMO CTG ACC GCT TCC CTG AAG G CGT CCT CGT ACC AGC TCT TGG 
STIL GAC ACA GTG CAA GCT GGA AGA C AGT CAG GCT CTT GAT CCT CAC C 
SUFU CTC CAG GTT ACC GCT ATC GTC A TGC TCA GGG ATG TTG GCA GAA G 
SURVIVIN TCC GCA GTT TCC TCA AAT TC GTT GCG CTT TCC TTT CTG TC 
TYW1 ATT GTC ATC AAG ACG CAG GGC  GTT GCG AAT CCC TTC GCT GTT  
UBE2D2 CCA TGG CTC TGA AGA GAA TCC  GATAGGGACTGTCATTTGGCC  
VIMENTIN GGA GAA ATT GCA GGA GGA GA TGC GTT CAA GGT CAA GAC GT 
XIAP AGA AAT CCA TCC ATG GCA GA CAG TTA GCC CTC CTC CAC AG 
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2.1.2.8 Fluidigm qRT-PCR 
Table 2.1.2.8.1: Pre-amplification mix - Primer 
Reagent  Volume 
Qiagen Multiplex PCR master mix 2.5µl 
Pooled assay Taqman mix (x2)  1.25µl 
RNase free water 1.5µl 
cDNA 1.25µl 
	
Table 2.1.2.8.2: Pre-amplification mix – Probe (Taqman®) 
Reagent  Volume 
Qiagen Multiplex PCR master mix 2.5µl 
Pooled primer mix 0.5µl 
RNase free water 0.75µl 
cDNA 1.25µl 
 
Table 2.1.2.8.3:  Pre-amplification Cycling Conditions  
 Stage 1: Initial 
denature 
Stage 2: Cycling conditions 14-18 cycles Stage 3: Final 
extension 
Hold 
Denaturing Annealing Extension 
Temperature 
(oC) 
94 94 60 72 72 4 
Time  15mins 30secs 60secs 40secs 5mins ∞ 
 
Table 2.1.2.8.4:  Exonuclease treatment mix for use after primer pre-
amplification  
Reagent  Volume 
RNase free water 1.4µl 
Exonuclease I reaction buffer 0.2µl 
Exonuclease I (E. coli) 0.4µl 
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Table 2.1.2.8.4.1 Exonuclease treatment Cycling Conditions 
Temperature 37˚C 80˚C 
Time 30mins 15mins 
 
Table 2.1.2.8.5 Assay mix for Fluidigm qRT PCR - Primer 
Reagent  Volume 
2x Assay loading reagent 3µl 
TE buffer 0.3µl 
Mixed forward and reverse primer 2.7µl 
 
Table 2.1.2.8.5.1: Sample mix for Fluidigm qRT PCR - Primer 
Reagent  Volume 
20x DNA binding dye 0.3µl 
SsoFast™ EvaGreen Supermix with low ROX 3µl 
Pre-amplified sample 2.7µl 
 
Table 2.1.2.8.6 Assay mix for Fluidigm qRT PCR - Probe 
Reagent  Volume 
2x Assay loading reagent 3µl 
Taqman probe 3µl 
 
Table 2.1.2.8.6.1: Sample mix for Fluidigm qRT PCR - Probe 
Reagent  Volume 
20x DNA binding dye 0.3µl 
SsoFast™ EvaGreen Supermix with low ROX 3µl 
Pre-amplified sample 2.7µl 
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Table 2.1.2.8.7: Fluidigm qRT PCR Cycling Conditions 
 Stage 1: Initial 
denature 
Stage 2: Cycling conditions 40 cycles Hold  
Denaturing  Annealing  
Temperature (oC) 95 95 60 4 
Time  60secs  5secs 20secs ∞ 
Melt curve when primers used: 60˚C to 95˚C with a 1˚C increase every 3 seconds 
 
2.1.2.9 Sanger Sequencing 
Table 2.1.2.9.1: SMO Primers 
Primer  Sequence  
Exon1F_1 GTAGCGCGACGGCCAGTCAACAAAGGAGCCGGGTC 
Exon1R_1                 CAGGGCGCAGCGATGACCCGCCAACTCAGCAAAAG 
Exon1F_2 GTAGCGCGACGGCCAGTCTGAGTTGGCGGGGTTGG 
Exon1R_2 CAGGGCGCAGCGATGACCCATCTTACCGCGGCAC 
Exon1F_3 GTAGCGCGACGGCCAGTGGATTCTCTGGGCGCACA 
Exon1R_3 CAGGGCGCAGCGATGACCAGGCACACGTTGTAGC 
Exon2F GTAGCGCGACGGCCAGTGAGGACAGGGGTGAAGCTG 
Exon2R CAGGGCGCAGCGATGACACTGGACCCTGCCCTATAC 
Exon3F GTAGCGCGACGGCCAGTCCCTGCCATGCTACCTAGAT 
Exon3R CAGGGCGCAGCGATGACTCTCTTCCCACGTTCCAGG 
Exon4F GTAGCGCGACGGCCAGTGGCTCAGTTAAGGGTGTCTG 
Exon4R CAGGGCGCAGCGATGATGCCCTGGATCTCGGTTTTA 
Exon5-6_1F GTAGCGCGACGGCCAGTGAACCTCCAGACCTCAGCAG 
Exon5-6_1R CAGGGCGCAGCGATGACTCACAGAGTCCCCATCCAC 
Exon5-6_2F GTAGCGCGACGGCCAGTTACTTCCACCTGCTCACCTG 
Exon5-6_2R CAGGGCGCAGCGATGATGGGGTTTCAGCATGGGG 
Exon7-8_1F GTAGCGCGACGGCCAGTTCCAGAGCCTTAGGACCCTC  
Exon7-8_1R CAGGGCGCAGCGATGAACTACCACCTACACACACCC 
Exon7-8_2F GTAGCGCGACGGCCAGTTGGGACAAGTTAGCCATAGGG 
Exon7-8_2R CAGGGCGCAGCGATGAGGTGGAGGTGGGTGTCTTTA 
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Exon7-8_3F GTAGCGCGACGGCCAGTGACTTCGGTCTGAGGTCCTG 
Exon7-8_3R CAGGGCGCAGCGATGAAGGAGAGAGTCTGCCCCACT 
Exon9F GTAGCGCGACGGCCAGTGGCCCTTCCCAAGATTTGAT 
Exon9R  CAGGGCGCAGCGATGACTGGGAGAGACTAGCACAT     
Exon10-11F GTAGCGCGACGGCCAGTCATCGCTCACACACCCATTC  
Exon10-11R CAGGGCGCAGCGATGATCCTTCCTCTTCCTCCTCCT 
Exon12_1F GTAGCGCGACGGCCAGTCAGGTTAAGTGCTCCCAGGG 
Exon12_1R CAGGGCGCAGCGATGACCCCATGGAGATGTTAGGCT 
Exon12_2F GTAGCGCGACGGCCAGTAGTTCTGGATGTCTGGCTCA 
Exon12_2R   CAGGGCGCAGCGATGAAGCTCTGGGTCCTCATCAAC 
Exon12_3F GTAGCGCGACGGCCAGTGGGGCCATGTCCTCTCTTAA 
Exon12_3R CAGGGCGCAGCGATGACTTGAACCCAGGAGACGGAG 
Universal forward tail: GTAGCGCGACGGCCAGT; Universal reverse tail: CAGGGCGCAGCGATGA 
 
Table 2.1.2.9.2: SMO RT-PCR Master mix 
Reagent  Volume 
DNA in a 20µl reaction. 1µl 
Forward primer (5pmol/µl) 0.5µl 
Reverse primer (5pmol/µl) 0.5µl 
PCR Master Mix (1.5mM) 18µl 
SMO PCR primers were diluted to 5µM (5pmol/µl) from 100µM stock 
 
Table 2.1.2.9.3: SMO RT-PCR  
 Stage 1: Initial 
denature 
Stage 2: Cycling conditions 35 cycles Stage 3: Final 
extension 
Hold 
Denaturing Annealing Extension 
Temperature 
(oC) 
95 94 56 72 72 4 
Time  2min 30secs 45secs 90secs 5mins ∞ 
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Table 2.1.2.9.4: SMO RT-PCR Product Clean Up 
 Step 1 Step 2 Step 4 
Temperature (oC) 37 80 4 
Time  15mins 15mins ∞ 
 
Table 2.1.2.9.5: SMO Sequencing Master mix 
Reagent  Volume 
Big Dye® Terminator  0.5µl 
Nuclease free water  7.5µl 
Sequencing forward OR reverse primer 1µl 
Sequencing Reaction Buffer 1µl 
Sequencing primers were diluted to 3.3µM (3.3pmol/µl) from 100µM stock 
 
Table 2.1.2.9.6: SMO Cycle Sequencing 
 Stage 1: Initial 
denature 
Stage 2: Cycling conditions 35 cycles Stage 3: Final 
extension 
Hold 
Denaturing Annealing Extension 
Temperature 
(oC) 
96 96 50 60 60 4 
Time  1min 10secs 5secs 4mins 4mins ∞ 
 
2.1.2.10 Next-generation Sequencing 
Table 2.1.2.10.1: Targets for Ion AmpliSeqTM Research genes panel 
Gene Target Gene Target 
ASXL1 Exon 12 IDH1 Exon 4 
BRAF COSMIC mutation, 
COSM476 
IDH2 Exon 4 
CBL Exon 8,9 JAKL2 Exon 14 
CEBPA All coding exons KIT Exons 8, 10, 11, 17 
DNMT3A All coding exons KRAS Exons 2, 3 
FLT3 Codons 676, 830-850 NPM1 Exon 12 
GATA2 All coding exons NRAS Exons 2, 3 
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PTPN11 Exons 3, 7, 8, 13 TP53 All coding exons 
RUNX1 Exons 3-8 WT1 Exons 7, 9 
TET2 All coding exons   
 
Table 2.1.2.10.1.1: Ion AmpliSeqTM Sequencing Conditions 
 Stage 1: Initial 
denature 
Stage 2: Cycling conditions 20 cycles Hold 
Denaturing Annealing & Extension 
Temperature (oC) 99 99 60 10 
Time  2 mins 15 secs 4 mins ∞ 
 
Table 2.1.2.10.2: Targets for Illumina TruSight® Myeloid Sequencing panel 
Gene Target Gene Target 
ABL1 Exons 4-6 IDH2 Exon 4 
ASXL1 Exon 12 IKZF1 Full  
ATRX Exons 8-10. 17-31 JAK2 Exons 12, 13 
BCOR Full JAK3 Exon 4 
BCORL1 Full KDM6A Full 
BRAF Exon 15 KIT Exons 2, 8-11, 13, 17 
CALR Exon 9 KRAS Exons 2, 3 
CBL Exon 8, 9 MLL Exons 5-8 
CBLB Exons 9, 10 MPL Exon 10 
CBLC Exons 9, 10 MYD88 Exons 3-5 
CDK2NA Full NOTCH1 Exons 26-28, 34 
CEBPA Full NPM1 Exon 12 
CSF3A Exons 14-17 NRAS Exons 2, 3 
CUX1 Full PDGFRA Exons 12, 14, 18 
DNMT3A Full PHF6 Full  
ETV6/TEL Full PTEN Exons 5,7  
EZH2 Full PTPN11 Exons 3, 13 
FBXW7 Exons 9, 10, 11 RAD21 Full  
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FLT3 Exons 14, 15, 20 RUNX1 Full  
GATA1 Exon 2 SETBP1 Exon 4 (partial) 
GATA2 Exons 2-6 SF3BP1 Exons 13-16 
GNaS Exons 8, 9 SMC1A Exons 2, 11, 16+17 
HRAS Exons 2, 3 SMC3 Exons 10, 13, 19, 23, 
25+28 
IDH1 Exon 4 SRSF2 Exon 1 
STAG2 Full  U2AFI Exons 2+6 
TET2 Exons 3-11 WT1 Exons 7, 9 
TP53 Exons 2-11 ZRSR2 Full  
 
Table 2.1.2.10.2.1: Illumina TruSight® Sequencing Conditions 
 Stage 1: Initial 
denature 
Stage 2: Cycling conditions 25 cycles Hold 
Denaturing Annealing Extension 
Temperature (oC) 95 95 66 72 72 10 
Time  3 mins 30 secs 30 secs 30 secs 5mins ∞ 
 
2.1.3 Protein expression  
Table 2.1.3.1: Reagents for Protein Preparation 
Reagent Supplier 
50mM Tris-HCL pH7.5 Made in house 
NaCl Sigma-Aldrich, Dorset, UK 
1% Nonidet p40 Sigma-Aldrich, Dorset, UK 
10% Glycerol Sigma-Aldrich, Dorset, UK 
5mM Ethylenediamine Tetraacetic acid (EDTA) Sigma-Aldrich, Dorset, UK 
1mM Sodium Orthovanadate  Sigma-Aldrich, Dorset, UK 
1mM Sodium Molybdate Sigma-Aldrich, Dorset, UK 
1mM Sodium Fluoride Sigma-Aldrich, Dorset, UK 
PMSF (stock – 80mg/ml in DMSO) Sigma-Aldrich, Dorset, UK 
Pepstatin A (stock – 1.4mg/ml in methanol) Sigma-Aldrich, Dorset, UK 
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Aprotinin (stock – 20mg/ml) Sigma-Aldrich, Dorset, UK 
Leupeptin (stock – 20mg/ml) Sigma-Aldrich, Dorset, UK 
Soyabean trypsin inhibitor (stock – 20mg/ml) Sigma-Aldrich, Dorset, UK 
 
Table 2.1.3.2: Solution for Protein Extraction 
 Protein Solubilisation Buffer Phosphatase and Protease Inhibitor 
Concentrations  
50mM Tris-HCL pH 7.5 1mM Sodium Orthovanadate 
150mM NaCl  1mM Sodium Molybdate 
1% Nonidet P40  1mM Sodium Fluoride 
10% Glycerol  4µg/mL Phenylmethylsulphonyl Fluoride 
 0.7µg/mL Pepstatin A 
10µg/mL Aprotinin 
10µg/mL Leupeptin 
10µg/mL Soybean trypsin inhibitor 
 
2.1.4 Western Blotting 
Table 2.1.4.1: Reagents and Suppliers 
Reagent Supplier 
Acrylamide Sigma-Aldrich, Dorset, UK 
APS  
APS (10%) - 0.1g APS in 1000µL MilliQ ultrapure water 
Sigma-Aldrich, Dorset, UK 
BSA Fraction V  Roche, West Sussex, UK 
Chemiluminescent HRP Substrate Millipore, Livingston, UK 
Glycine Sigma-Aldrich, Dorset, UK 
HCl In house 
2-ME Sigma-Aldrich, Dorset, UK 
MilliQ ultrapure water In house 
NaCl Sigma-Aldrich, Dorset, UK 
NP40  Sigma-Aldrich, Dorset, UK 
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NP40 (10%) - 25ml NP-40 in 250mL MilliQ ultrapure water 
Ovalbumin  Sigma-Aldrich, Dorset, UK 
PageRuler Plus Pre-stained Protein ladder Thermo Fisher Scientific, 
Loughborough, UK 
SDS  
SDS (10%) - 10g SDS in 91mL MilliQ ultrapure water 
Sigma-Aldrich, Dorset, UK 
Sodium azide Sigma-Aldrich, Dorset, UK 
TEMED Sigma-Aldrich, Dorset, UK 
Tris-HCl pH 6.8 
60.6g Trisma base in 500mL MilliQ ultrapure water, Hcl 
added dropwise to correct pH 
In house 
Tris-HCl pH 8.8 
60.6g Trisma base in 500mL MilliQ ultrapure water, NaOH 
added dropwise to correct pH 
In house 
Trizma base Sigma-Aldrich, Dorset, UK 
 
Table 2.1.4.2: Equipment and Suppliers 
Equipment Supplier 
Amersham Protran Premium 0.2 Nitrocellulose membranses Sigma-Aldrich, Dorset, UK 
Exposure cassette Carestream® Kodak® BioMax® Sigma-Aldrich, Dorset, UK 
Konica Minolta SRX-101A developer Konica Minolta, Sunderland, UK 
Mini-PROTEAN® System Glass Plates Bio-Rad, Hertfordshire, UK 
Mini-PROTEAN® Tetra Handcast Systems Bio-Rad, Hertfordshire, UK 
NanoDrop Spectrophotometer Thermo Fisher Scientific Nunc, 
Massachusetts, USA 
PowerPacTM Basic Power Supply Bio-Rad, Hertfordshire, UK 
Trans-Blot® SD Semi-Dry Transfer Cell Bio-Rad, Hertfordshire, UK 
 
 
 
 
 
	 96	
Table 2.1.4.3: 5% Sample Buffer  
Reagent Concentration 
β-Mercaptoethanol reducing agent (50µl/ml) 5% (v/v) 
Bromophenol blue Sigma-Aldrich, Dorset, UK 
MilliQ ultrapure water 10% (W/v) 
Glycerol 50% (v/v) 
SDS  10% (w/v) 
Tris-HCl pH 6.8  200mM 
 
Table 2.1.4.4: 10X TBS Buffer pH 7.5 
Reagent Volume / weight 
MilliQ ultrapure water 1000ml 
NaCl 87.6g 
Trizma base 24.2g 
 
Table 2.1.4.5: 1X TBS Buffer pH 7.5 
Reagent Concentration 
NaCl 150mM 
Tris-HCl pH 7.5 20mM 
100ml 10X TBS Buffer pH 7.5 in 900ml MilliQ ultrapure water 
 
Table 2.1.4.6: 1X TBSN Buffer  
Reagent Concentration 
NaCl 150mM 
NP40 0.05% (v/v) 
Tris-HCl pH 7.5 20mM 
100ml 10X TBS Buffer pH 7.5 in 900ml MilliQ ultrapure water with 4ml NP40 
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Table 2.1.4.7: 10X SDS Page Running Buffer 
Reagent Volume / Weight 
Glycine  149.2g 
MilliQ ultrapure water 1000ml 
SDS 0.1% (w/v)  
Trizma base  30g 
 
Table 2.1.4.8: 1X SDS Page Running Buffer 
Reagent Concentration 
Glycine  192mM 
SDS 10g  
Trizma base  25mM 
100ml 10x SDS Page Running Buffer in 900ml MilliQ ultrapure water 
 
Table 2.1.4.9: 10X Semi-Dry Transfer Buffer Stock 
Reagent Weight / Volume 
Glycine 29.3g 
MilliQ ultrapure water 1000ml 
SDS 3.75g  
Tris base  58.1g 
 
Table 2.1.4.10: 1X Semi-Dry Transfer Buffer 
Reagent Volume 
10X Semi-Dry Transfer Buffer 100ml 
Methanol (20%) 200ml  
MilliQ ultrapure water 1000ml 
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Table 2.1.4.11: Running Gel 
Reagent Volume  
7.5% 10% 15% 
Acrylamide (30%) 3.75ml 5ml 7.5ml 
APS (10%) 100µl 100µl 100µl 
MiliQ dH2O 5.6ml 4.35ml 1.85ml 
SDS (10%) 250µl 250µl 250µl 
TEMED 20µl 20µl 20µl 
Tris-HCl pH 8.8 5.6ml 5.6ml 5.6ml 
 
Table 2.1.4.12: 5% Stacking Gel  
Reagent Volume  
Acrylamide (30%) 1.67ml 
APS (10%) 50 µl 
MilliQ dH2O 6ml 
SDS (10%) 150µl 
TEMED 10 µl 
Tris-HCl pH 6.8 1.25ml 
 
Table 2.1.4.13: 5X BSA Blocking solution  
Reagent Concentration 
BSA  1% (w/v) 
Ovalbumin 1% (w/v) 
Sodium azide 0.01% (w/v) 
Dissolved in 1XTBS pH 7.5 
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Table 2.1.4.14: Antibody Conditions for Western blots 
Antibody Species  Dilution Diluent Manufacturer 
(Catalogue 
number) 
BCL-2  Rabbit 1/1000 1X BSA Cell signalling, 
MA, USA, (#2876) 
MCL-1 Rabbit 1/1000 1X BSA Cell signalling, 
MA, USA, (#4572) 
SMO Rabbit 1/1000 1X BSA Abcam, 
Cambridge, UK, 
(ab72130) 
 
2.1.5 Immunocytochemistry 
Table 2.1.5.1: Reagents and Suppliers for Immunocytochemistry 
Reagent Supplier 
Acetylated α-tubulin mouse monoclonal Sigma-Aldrich, Dorset, UK 
Alexa fluor 488-labelled goat anti-mouse IgG1  Life technologies, Paisley, UK 
Alexa fluor 568-labelled goat anti-mouse IgG2b  Life technologies, Paisley, UK 
BSA Sigma-Aldrich, Dorset, UK 
DAPI Invitrogen, Paisley, UK 
Ethanol 100% molecular grade Sigma-Aldrich, Dorset, UK 
Formaldehyde solution  Sigma-Aldrich, Dorset, UK 
Γ-tubulin mouse monoclonal  Sigma-Aldrich, Dorset, UK 
Nail polish Local pharmacy 
Normal Goat serum  Dako, Cambridgeshire, UK 
Ovalbumin Roche, West Sussex, USA 
Poly-L-Lysine (0.5mg/ml) Sigma-Aldrich, Dorset, UK 
PBS (w/o Ca2+ or Mg2+) (1X) In house 
100X Sodium Citrate Retrieval Buffer pH6 Thermo Fisher Scientific Nunc, 
Massachusetts, USA 
Sodium Tetraborate (100mM) Sigma-Aldrich, Dorset, UK 
TBS pH 7.5 (1X) In house 
Triton-X (0.2%) Sigma-Aldrich, Dorset, UK 
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Tween BDH Merck, Dorset, UK 
Xylene Ganta Medicals, York, UK 
 
Table 2.1.5.2: Equipment for Immunocytochemistry 
Equipment  Supplier  
Dako pen Dako, Cambridgeshire, UK 
10 well Multispot microscope slides Hendley, Essex, UK 
Pt Module  Thermo Fisher Scientific Nunc, 
Massachusetts, USA 
Tinfoil  Local supermarket  
 
Table 2.1.5.3: 5X Block 
Reagent Concentration 
BSA 5% 
Ovalbumin 1% 
Triton-X 0.2% 
Dissolved in 1X TBS pH 7.5 
 
Table 2.1.5.4: Antibody Conditions for Immunocytochemistry 
Antibody Species  Dilution Diluent Manufacturer 
(Catalogue number) 
Acetylated α-
tubulin  
Mouse 1/500 5% NGS in 1X PBS Sigma-Aldrich, Dorset, 
UK (T6793) 
DAPI  1/1000 5% NGS in 1X PBS Thermo Fisher Scientific 
Nunc, Massachusetts, 
USA (D1306) 
DHH  Goat 1/200 5% NGS in 1X PBS Santa Cruz, Texas, USA,  
(N-19; sc-1193) 
γ-tubulin  Mouse 1/100 5% NGS in 1X PBS Sigma-Aldrich, Dorset, 
UK (T5326) 
GLI-1  Rabbit 
Rabbit 
1/100 
1/100 
5% NGS in 1X PBS Cell Signalling, MA, USA, 
(25345) 
Abcam, Cambridge, UK 
(ab92611) 
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GLI-2 Rabbit 
Goat 
1/100 
1/100 
5% NGS in 1X PBS Santa Cruz, Texas, USA,  
(H-300; sc-28674) 
Santa Cruz (G-20; 
sc20291) 
GLI-3 Rabbit 1/100 5% NGS in 1X PBS Santa Cruz, Texas, USA, 
(H-280; sc-20688) 
IHH Rabbit 1/100 5% NGS in 1X PBS Abcam, Cambridge, UK 
(ab39634) 
PTCH-1 Rabbit 1/100 5% NGS in 1X PBS Santa Cruz, Texas, USA,  
(H-267; sc-9016) 
Acetylated α-
tubulin SHH 
Rabbit                         
Rabbit 
1/100 
1/100 
5% NGS in 1X PBS Millipore, Livingston, UK 
(06-1106).  
Santa Cruz, Texas, USA,  
(H-160; sc-9024) 
SMO Rabbit 1/100 5% NGS in 1X PBS Abcam, Cambridge, UK 
(ab72130) 
Secondary antibodies  
Alexa Fluor 
568-labelled 
anti-mouse 
IgG2b 
Goat anti-
mouse IgG1 
1/500 5% NGS in 1X PBS Life technologies, 
Paisley, UK, Invitrogen 
(A21144) 
Alexa Fluor 
488-labelled 
anti-mouse 
IgG1   
Goat  1/100 5% NGS in 1X PBS Life technologies, 
Paisley, UK, Invitrogen 
(A21121) 
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2.1.6 Immunohistochemistry 
Table 2.1.6.1: Reagents and suppliers for Immunohistochemistry 
Reagent Supplier  
Antibodies – see Table 2.1.5.3  
BOND Dewaxing agent  Leica Biosystems, Newcastle, UK 
(AR9222) 
BOND Polymer refine Detection kit  Leica Biosystems, Newcastle, UK 
(DS9800) 
BOND Primary Antibody Diluent  Leica Biosystems, Newcastle, UK 
(AR9352) 
BOND Wash Solution 10X Concentrate  Leica Biosystems, Newcastle, UK 
(AR9590) 
Epitope Retrieval 1 (ER1) solution  Leica Biosystems, Newcastle, UK 
(AR9961) 
Epitope Retrieval 2 (ER2) solution Leica Biosystems, Newcastle, UK 
(AR9640) 
 
Table 2.1.6.2: Equipment for Immunohistochemistry 
Equipment  Supplier  
Coverslips  Leica Biosystems, Newcastle, UK 
Leica Bond III Leica Biosystems, Newcastle, UK 
Microscope slides Leica Biosystems, Newcastle, UK 
 
Table 2.1.6.3: Antibody Conditions for Immunohistochemistry 
Antibody Control material Dilution Epitope retrieval  
(Time in mins) 
Supplier  
(Catalogue 
number) 
Anti-BCL-2  Tonsil 1:200 ER1 (20) Millipore, 
Livingston, UK, 
(05-729) 
Anti-BMP4  Colon cancer 1:100 ER2 (20) Millipore, 
Livingston, UK, 
(MAB1049) 
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Anti-CD44  Multi tissue control 
comprising tonsil, 
breast, small bowel 
and skin 
1:100  ER2 (20) Millipore, 
Livingston, UK, 
(04-1123) 
Anti-CCND1 Tonsil 1:80 ER1 (20) Millipore, 
Livingston, UK, 
(05-362) 
Anti-DHH  Testes 1:1000 EZ1 (10) Millipore, 
Livingston, UK, 
(04-967) 
Anti-GLI-1 Brain 1:100 ER1 (20) Abcam, 
Cambridge, UK, 
(ab92611) 
Anti-IHH  Colon cancer 1:1000 ER2 (20) Millipore, 
Livingston, UK, 
(MABF23) 
Anti-PTCH-1 Cardiac muscle 1:300 ER1 (30) Abcam, 
Cambridge, UK, 
(ab53715) 
Anti-SMO Kidney 1:200 ER2 (20) Abcam, 
Cambridge, UK, 
(ab72130) 
Anti-SHH  Colon cancer 1:100 ER1 (20) Millipore, 
Livingston, UK, 
(06-1106) 
Anti-WNT5a  Cardiac muscle 1:100 EZ1 (10) Millipore, 
Livingston, UK, 
(06-1058) 
Both ER1 and ER2 solutions are specific for heat-induced epitope retrieval; ER1 is optimal at pH 6, 
ER2 optimal at pH 9. EZ: enzyme retrieval. 
 
2.1.7 Flow cytometry  
Table 2.1.7.1: Plastics for Flow Cytometry 
Plastic Supplier  
FACS tubes  Greiner bio one, Gloucestershire, 
UK 
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Table 2.1.7.2: Equipment for Flow Cytometry 
Equipment Supplier  
BD FACSAriaTM III BD Biosciences, Oxford, UK 
BD FACSCantoTM II BD Biosciences, Oxford, UK 
BD FACSDivaTM Software BD Biosciences, Oxford, UK 
FlowJo Ashland, Oregon, USA 
 
Table 2.1.7.3: Reagents for Flow Cytometry 
Reagent Supplier  
Antibodies – see Table 2.1.7.7 BD Biosciences, Oxford, UK 
CellTrace Violet cell proliferation kit Life technologies, Paisley, UK 
CellTrace Carboxyfluorescein diacetate succinimidyl (CFSE) 
cell proliferation kit 
Life technologies, Paisley, UK 
Ethanol 100% molecular grade Sigma-Aldrich, Dorset, UK 
FACS flow solution BD Biosciences, Oxford, UK 
FACS clean solution BD Biosciences, Oxford, UK 
Fix & Perm cell fixation and permeabilisation kit Life technologies, Paisley, UK 
Foetal bovine serum (FBS) Life technologies, Paisley, UK 
Formaldehyde solution 36.5% Sigma-Aldrich, Dorset, UK 
Hank’s Balanced Salt Solution (HBSS) Life technologies, Paisley, UK 
1X PBS (w/o Ca2+ or Mg2+)  Life technologies, Paisley, UK 
Propidium iodide (PI) BD Biosciences, Oxford, UK 
Sodium azide Sigma-Aldrich, Dorset, UK 
 
Table 2.1.7.4: 1X HBSS 
Reagent Volume  
1X HBSS  5ml 
Sodium azide 0.01% (w/v) 
Sterile water 45ml 
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Table 2.1.7.5: FACS Buffer – FBS / 2% PBS 
Reagent Volume  
1X PBS 48ml 
FBS 2ml 
Sodium azide 0.01% (w/v) 
 
Table 2.1.7.6: Quenching solution for CFSE assay  
Reagent Volume 
1X PBS 40ml 
FBS 10ml 
Sodium azide 0.01% (w/v) 
 
Table 2.1.7.7: Antibodies for Flow Cytometry 
Primary antibody  Fluorochrome Catalogue reference 
BD Biosciences, Oxford, UK 
unless otherwise specified 
7AAD PerCP BD 559776 
Annexin V  FITC BD 556419 
CD3 PeCy5 
FITC 
BD 555341 
BD 555332 
CD4 PerCP-PeCy5 BD 560650 
CD8 PeCy7 BD 557750 
CD10 APC BD 655404 
CD11b FITC BD 562793 
CD11c FITC 
PE 
BD 555392 
Dako F0173 
CD14 PE 
PeCy7 
BD 555398 
Miltenyi Biotech, Surrey, UK 
130094364 
CD15 FITC BD 565236 
CD16 APC BD 561304 
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FITC 
V500 
BD 555406 
BD 561394 
CD20 APC 
BV421 
BD 559776 
BD 562873 
CD33 PeCy7  
PE 
PeCy5 
BD 333952 
BD 555450 
BD 551377 
CD34 PeCy5 
APC 
PeCy7 
BD 555823 
BD 555824 
BD 334881 
CD45 APC-Cy7 
PE 
V450 
BD 557833 
BD 555483 
BD 560367 
CD73 PE BD 550257 
CD90 PE 
PeCy7 
BD 555596 
BD 561558 
CD105 PerCP-cy5.5 BD 560819 
Lin- FITC BD 340546 
	
2.1.8 Electron microscopy 
Table 2.1.8.1: Equipment for Electron microscopy 
Equipment Supplier  
DIATOME diamond knife 45˚ Diatome, Hatfield, PA, USA 
Double sided conductive tape Agar Scientific, Essex, UK 
GATAN Micrograph Imaging software Gatan Inc., Pleasanton, CA, USA 
GATAN Multiscan camera 794 Gatan Inc., Pleasanton, CA, USA 
FEI Tecnai T20 TEM FEI, Oregon, USA 
Flat bed moulds  Agar Scientific ltd, Essex, UK 
100mesh formvar coated copper grids  Agar Scientific ltd, Essex, UK 
JEOL6400 SEM Jeol, Tokyo, Japan 
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LEICA Ultracut UCT Leica Microsystems, Milton 
Keynes, UK 
Olympus Scandium Universal SEM Imaging Platform Olympus Soft Imaging Solutions, 
Münster, Germany 
POLARON E3000 CPD Quorum Technologies, East 
Sussex, UK 
Quorum 150T High vacuum Sputter coating system Quorum Technologies, East 
Sussex, UK  
SEM support stubs Agar Scientific ltd, Essex, UK 
 
Table 2.1.8.2: Reagents for Electron microscopy 
Reagent Supplier  
Araldite/epon 812 resin     TAAB Laboratories Equipment 
Ltd., Berkshire, UK  
Distilled water  In house  
Ethanol (30%, 50%, 70%, 90% and 100%) VWR Chemicals, Leicestershire, 
UK 
Glutaraldehyde (2.5%)         Sigma-Aldrich, Dorset, UK 
Methanolic uranyl acetate (2%) -  2g Uranyl Acetate in 100ml 
Annalar Methanol  
Fisher Scientific, Leicestershire, 
UK 
Prepared in house  
Osmium Tetroxide (1%) Oxkem, Oxfordshire, UK 
Paraformaldehyde (2%)  Agar Scientific ltd, Essex, UK 
Propylene oxide     VWR Chemicals, Leicestershire, 
UK 
Reynolds lead citrate – Lead nitrate 1.33g, Sodium Citrate 
1.76g, 30ml distilled water 
 
Agar Scientific ltd, Essex, UK; 
Fisher Scientific, Leicestershire, 
UK 
Prepared in house 
Sodium Cacodylate (0.1M)  Agar Scientific ltd, Essex, UK 
Uranyl Acetate (0.5%) Agar Scientific ltd, Essex, UK 	
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2.2  Methods 
2.2.1  Tissue culture 
2.2.1.1 Drugs and reagents 
Details of all drugs used are described in Materials Table 2.1.1.13. 10mM stock solutions were 
prepared in DMSO and stored at -20oC. As2O3 was dissolved in 1M NaOH to a concentration of 
100mM. Dilutions of stock solutions were freshly prepared prior to each experiment in 
appropriate cell culture media. Growth factors were reconstituted according to manufacturer’s 
instructions and stored in single use aliquots at -80oC. 
 
2.2.1.2  Cell culture 
All cell culture experiments were performed using sterile technique in a laminar airflow hood. 
All cells were cultured in their specific culture media at 37oC in a humidified atmosphere with 5% 
CO2 (standard culture conditions).  
 
2.2.1.2.1 AML cell lines 
That AML is a heterogeneous, clonal disorder with a range of morphologic, immunophenotypic, 
cytogenetic, and molecular characteristics is reflected in the number of cell lines available; with 
over 50 available from one biological resource centre alone 561–564. A comprehensive 
understanding of the cell line studied being paramount to interpreting and translating results.  
Whilst the rationale for cell line choice will be discussed at the appropriate stage through this 
thesis; initially we sought to profile the Hh pathway and key downstream targets in a number of 
cell lines. These cell lines were chosen because they carry common mutations, represent a 
subtype for which there is a clinical need or which is easily definable, as our aim was for this 
work to carry from bench to bedside. In addition to clinical need, frequency and identifiability, 
publicly available datasets were mined to determine if any disease phenotypes had an 
association with deregulated Hh signalling or key downstream targets. The following publicly 
available datasets were analysed, Valk (GSE1159) 381, Mile (GSE13159) 565, and Stierwalt 
(GSE9476) 382.  
The following cell lines have been studied through this thesis: 
The OCI-AML3 cell line carries an NPM1 and DNMT3A R882C mutation, two of the more common 
mutations identified in AML. Further it belongs to the FAB M4 subgroup, myelomonocytic AML 
previously shown to respond to Hh inhibition and to potentially benefit from escalation of 
induction therapy 379,381. 
The Kasumi-1 cell line is a CD34+ expressing AML previously shown to respond to Hh inhibition 377.  
KG1a is a CD34-expressing selectively cultured variant of the KG1 cell line. KG1 was derived from 
a patient with erythroleukaemia in myeloblastic relapse. KG1a in contrast has lost the majority 
of its myeloid features, expressing only one myeloid antigen, instead expressing markers 
associated with T cells and T-ALL 548. Additionally, a study has shown, through ICC, that the 
CD34-expressing cell lines KG1 and its subline KG1a, possess primary cilia and therefore the 
potential for canonical Hh signalling to be active within the cells 566. 
Recent work has also shown the CD34+ cell lines, Kasumi-1 and KG1a, containing more CD34+ 
cells, to express higher levels of GLI-1. Further, inhibition of GLI-1 with GANT61 induced 
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apoptosis in the CD34+ KG1a and Kasumi-1 cell lines, whilst causing differentiation in the U937 
and NB4 cell lines, with a relative absence of CD34+ cells. A positive correlation between CD34 
and GLI-1 at a protein level was confirmed by immunohistochemistry (IHC) in primary AML MNCs, 
with GANT61 enhancing the cytotoxic effects of cytarabine in CD34+ primary AML cells 567.  
The MV4-11 and MOLM-13 cell lines express MLL and FLT3-ITD. FLT3-ITD being linked to aberrant 
Hh signalling and a poor prognosis 381,382. The MV4-11 cell line expresses the FLT3-ITD mutation at 
the gene and protein level whilst the MOLM-13 cell line carries the FLT3-ITD mutation but does 
not express the protein. 
The HL60 cell line is a promyelocytic cell line. Interestingly inhibition of the pathway through 
SMO antagonism has been shown not only to induce apoptosis but also induce monocytic 
differentiation 568. 
THP-1 is an acute monocytic cell line. Recent work has shown the clinical grade SMO inhibitors 
(vismodegib and sonidegib) to have moderate single agent activity on this cell line, and 
excitingly synergistic activity with a combination index (CI) value of 0.57 in combination with 
Azacitidine 413. 
The disease phenotype of each cell line studied is further defined in Materials: Table 2.1.1.5. 
For experiments, cells were seeded at 2x105/ml and harvested at various time points for 
functional assays, gene and protein analysis, dependent on experimental design.  
 
2.2.1.2.1.1 Cell line recovery post cryopreservation 
Cell lines were removed from liquid nitrogen and immediately thawed at 37oC in a water bath. 
Cells were added to a sterile 15ml falcon tube with a Pasteur pipette and slowly recovered by 
adding specific culture media drop-wise over 15mins at room temperature (RT) with constant 
agitation. Cells were centrifuged at 400xg for 5mins, the supernatant poured off, and the pellets 
resuspended in specific culture media. Following recovery, cell number and viability were 
assessed by trypan blue dye exclusion. Cells were seeded in standard tissue culture flasks at the 
appropriate density.  
 
2.2.1.2.1.2 Passaging AML cell lines  
AML cell lines were passaged every 2 days, with fresh warmed media, to maintain a cell density 
of between 1x105 – 1x106/ml. This enabled maintenance at optimal concentration according to 
ATCC or DSMZ instructions.  
Specific culture media is detailed in Materials: Table 2.1.1.7. 
 
2.2.1.2.2  Stromal cell lines  
The following stromal cell lines were used through this thesis – TM3 557, M210-B4 554, SL-SL 556 and 
HS-5 553.  
TM3(GLI-Luc) cells are murine Leydig tumour cells, stably transfected with a retroviral vector 
selectable by geneticin sensitivity, whereby luciferase expression is dependent on GLI activity.  
The M210-B4 and SL-SL cell lines, both murine bone marrow-derived stromal cell lines, were 
chosen as these are frequently used in LTC-IC assays. M210-B4 has been genetically engineered 
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to produce human IL-3 and G-CSF 554,555; SL/SL from the SL/SL mouse has been genetically 
engineered to produce human IL-3 and SCF 555,556. 
HS-5 stromal cells are human-derived, allowing comparison between a human and murine 
stromal environment. Furthermore, through this PhD, we derived a protocol utilising HS-5 
stromal cells and their conditioned media (CM) to support the recovery of primary AML cells on 
thawing. 
 
2.2.1.2.2.1    Passaging stromal cell lines 
Cells were cultured in 20ml specific culture media in a 75cm3 flask in standard culture 
conditions. Cells were passaged when approximately 85-90% confluent. Media was removed and 
cells washed in 1x PBS twice then detached with 5ml Trypsin/EDTA buffer (warmed to 37oC). 
Once detached, the reaction was neutralised with FBS. Cells were collected, centrifuged at 
400xg for 5mins and the supernatant discarded or filtered, aliquoted and frozen for future use. 
The pellet was resuspended in 10ml culture media, counted and 0.75x106 transferred to a 75cm3 
flask.  
200µl geneticin (1%) was added at each passage to the TM3 cells.  
 
SL-SL and M210-B4 cells were treated with geneticin and hygromycin B every 14 days at a final 
concentration of 400mg/ml, 62.5mg/ml and 800mg/ml, 125mg/ml respectively.  
 
Cell line characteristics are further defined in Materials: Table 2.1.1.5. 
 
Media conditions are outlined in Materials: Table 2.1.1.10-12. 
 
2.2.1.2.3  Cryopreservation of cell lines  
Cells were resuspended at a concentration of 4-6x106/2ml in freezing solution (Materials: Table 
2.1.1.13) and aliquoted into cryotubes. Cryotubes were placed in a 5100 Cryo -1oC freezing 
container to provide controlled temperature reduction at -1oC/min. Cells were stored at -80oC 
for short term use, and transferred to liquid nitrogen for long term storage at -185oC. 
  
2.2.1.2.4   Isolation of mononuclear cells (MNCs) 
All samples, PB and BM material, were obtained with informed consent, in accordance with the 
declaration of Helsinki, with Greater Glasgow and Clyde NHS Trust Ethics Committee approval 
from patients with newly diagnosed AML and normal healthy volunteers. See Appendix 1 for the 
biological characteristics of the patients from whom the samples were collected.  
All samples were brought to RT before processing. PB was diluted in a 1:1 ratio with sterile 1X 
PBS. 15ml of the diluted PB was carefully layered onto 10ml of Histopaque-1077 per 50ml Falcon 
tube and centrifuged at 400xg for 30mins at RT. After centrifugation, the opaque interface 
(containing the MNCs) was carefully aspirated using a pastette and transferred into a clean 15ml 
Falcon tube and the volume made up to 12ml using sterile 1X PBS. Following centrifugation at 
200xg for 10mins the supernatant was discarded. For the second and third washes the pellets 
were resuspended in 1X PBS to a total volume of 12ml, centrifuged at 400xg for 5mins and the 
supernatant discarded. Finally, the pellets were combined by resuspending in 10ml AML culture 
media (Materials: Table 2.1.1.14) and counted. 
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BM samples were first passed through a cell strainer to remove bone particles and then diluted in 
a 1:3 ratio with sterile 1X PBS. Processing was otherwise as described for PB. 
Cells used for deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and protein preparation were 
spun at 230xg for 5mins at RT, resuspended in 1ml 1X PBS containing diisopropyl 
fluorophosphates (DIFP) (1mM) and incubated on ice for 30mins.  
 
2.2.1.2.5   Primary cell recovery post cryopreservation 
50ml aliquots of thawing media (Materials: Table 2.1.1.16) were pre-warmed at 37oC prior to 
adding 1ml DNAse and filter sterilising (0.2µm single use filter unit). Primary AML cells were 
removed from liquid nitrogen and immediately thawed at 37oC and gently transferred to the 
bottom of a 50ml Falcon tube using a 3ml Pasteur pipette. 15mls of thawing media was added 
drop wise to the cells over a 20min period at RT to enhance the DNAse activity with constant, 
gentle agitation to prevent clumping. The cells were then passed through a 100µm sterile cell 
strainer, centrifuged at 200xg for 5mins and the media carefully poured off. The cells were 
gently resuspended and the remaining 35ml of thawing media added. Following 3hrs at RT, the 
cells were pelleted at 220xg for 15mins, and resuspended in primary AML culture media 
supplemented with 10% HS-5 CM at a concentration not greater than 1x106/ml.  The cells were 
then co-cultured on HS-5 cells (at approximately 80% confluence) overnight at 37oC. The flask 
was gently rocked to release AML cells from the stromal layer and the media containing the cells 
transferred into a 50ml Falcon tube. The flask was washed x3 using sterile 1X PBS to harvest the 
remaining AML cells. Cells were centrifuged at 200xg for 5mins, and pellets resuspended in AML 
culture media; cell number and viability was assessed by trypan blue dye exclusion. A recovery 
of 25-70% of the cryopreserved cell number was expected.   
 
2.2.1.2.6   Primary AML cell culture   
Cells were plated at 1-2x105/ml on a 24 well collagen coated plate pre-treated with 200µl 
fibronectin (15µl/ml/5µg/cm2). Cells were cultured in primary AML culture media (Materials 
Table 2.1.1.14) for various time periods, with and without defined drug treatments before being 
harvested for functional assays and gene and protein analysis, dependent on experimental 
design.  
 
2.2.1.2.7   MSCs derived from human BM samples 
MSCs can be isolated from various tissues including adipose, BM, umbilical cord and muscle, 
expanded in vitro and, due to their self-renewal potential passaged many times without 
significant alteration of their major properties. 
Cultured MSCs are defined by several characteristics. Morphologically they are fibroblast-like, 
they express a panel of markers: positive for Sca-1, CD105, CD90, CD73 and CD29, and negative 
for CD11b, CD31, CD34 and CD45 and they have the potential to differentiate into adipocytes, 
chondrocytes and osteoblasts 37. 
MSCs secrete molecules and extracellular vesicles with both local and distant effects. It is these 
secretions that are believed to be responsible for their anti-inflammatory, immune modulating, 
anti-tumour and regenerative properties 569–571. Both supernatant harvested from cultured MSCs 
and the MSCs themselves were therefore studied in a bid to determine whether there is a role 
for paracrine Hh signalling in both normal and malignant haematopoiesis.  
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2.2.1.2.7.1   Isolation of MSCs from human BM samples 
The plastic adherence method was used. Briefly, MSCs were derived from BM samples (BM was 
processed as per Methods; Table 2.2.1.4). 20x106 cells were resuspended in 8ml MSC culture 
media (Materials: Table 2.1.1.9). Suspended cells were transferred to a 25cm3 NUNC flask and 
cultured in standard culture conditions. Non-adherent cells were removed and media replaced 
after 72hrs. Fresh media was added every 3-4 days until cells reached approximately 80-90% 
confluency when they were passaged. 
 
2.2.1.2.7.2   Passage of MSCs 
Cells were passaged when approximately 80-90% confluent. Media was removed and cells washed 
in 1X PBS twice then detached with 5ml Trypsin/EDTA buffer (warmed to 37oC). Once detached, 
the reaction was neutralised with FBS. Cells were collected, centrifuged at 400xg for 5mins and 
the supernatant discarded or filtered, aliquoted and frozen for future use. The pellet was 
resuspended in 10ml culture media, counted and reseeded at a density of 1-2x103 cells/cm2. 
Fresh media was added every 3-4 days until further passage was required. Cells at passage 3 to 6 
were used for experiments.  
 
2.2.1.2.8  Cryopreservation of primary AML and MSCs 
Cells were resuspended at a concentration of 20x106/ml to 100x106/ml in freezing solution 
(Materials: Table 2.1.1.17) and aliquoted into cryotubes. Cryotubes were placed in a 5100 Cryo -
1oC freezing container at -80oC to provide controlled temperature reduction at -1oC/min and 
consequently better cell viability. Cells were cryopreserved in liquid nitrogen at -185oC until use.  
 
2.2.1.2.9 Processing of patient plasma  
Plasma was collected prior to processing samples for MNC isolation. All samples were collected in 
Ethylenediaminetetraacetic acid (EDTA) collector tubes. Samples were centrifuged at 400xg to 
preserve cell integrity whilst allowing collection of patient plasma. Plasma was snap frozen in 
liquid nitrogen before storing at -80˚C until use. Plasma samples were used to quantitatively 
measure human SHH in normal and AML patients. 
 
2.2.1.3   Resazurin reduction assay 
The resazurin (7-Hydroxy-3H-phenoxazin-3-one-10-oxide sodium salt) reduction assay is a method 
of measuring cell viability. It employs bio-reduction of the dye by metabolising cells to reduce 
the amount of the oxidized form, concomitantly increasing the fluorescent intermediate; 
fluorescence being proportional to the number of viable cells. The assay therefore allows the 
rapid assessment of cell viability to a wide range of drug concentrations.  
Briefly, cells (at a concentration of 1x104 cells per well) were cultured for 72hrs in 96 well plates 
in the presence of serially diluted concentration of each drug, allowing for 12 different 
concentrations of each drug. Following culture, 50µM resazurin was added to each well and 
incubated at 37oC for 4-6hrs. Plates were read at 535ex and 590em on a Spectramax M5 plate 
reader and analysed using SoftMax Pro software.  
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2.2.1.4  Luciferase assay  
The aim of this assay was to determine the degree of SMO inhibition by the test drug.  
TM3(GLI-Luc) cells were collected as described in Methods Table 2.1.1.12. Cells were then seeded 
at a concentration of 2x105/ml in the required number of wells of an opaque, white 96 well 
culture plate. Cells were left for 6hrs in standard culture conditions to allow adherence then 
incremental concentrations of the test drug resuspended in 5µl culture media added to make a 
final volume in each well of 100µl. Purmorphamine, a Smo agonist served as the positive control 
at a concentration of 5nM (previously determined optimal concentration by Dr D Irvine within the 
Copland laboratory as past of his thesis 572). Following 48hrs culture, 100µl luciferase was added 
per well and the degree of luminescence measured at 1500nm on a Spectramax M5 plate reader 
and analysed using SoftMax Pro software.  
Whilst it was quickly established that the IC50 of AML cells to Smo inhibitors was considerably 
higher than that of TM3(GLI-Luc) cells, this assay was utilised to ensure each new stock of the Smo 
inhibitors, cyclopamine, LDE225 and glasdegib, were comparable in efficacy, Figure 2.1.  
 
 
2.2.1.5   Cell counting and viability assessment  
Cell counts were performed using a haemocytometer; cell viability assessed by trypan blue 
exclusion. 10µl of trypan blue solution was added to 10µl of cells to give a 1:2 dilution from 
which 10µl was transferred to the haemocytometer. Cells were visualised with an inverted 
microscope using the x10 objective. Live and dead (blue) cells were counted allowing the 
absolute number of alive and dead cells per ml to be calculated. A minimum of 100 cells were 
counted per condition.   
Within the haemocytometer each 1mm2 square equates to a volume of 0.1µl. The absolute cell 
count per ml was therefore calculated by counting the number of live cells per mm2, dividing by 
the number of squares counted, multiplying by the trypan blue dilution factor (standardly 2) and 
then 104.   
 
Figure 2.1: Luciferase activity of the Gli-luciferase reporting TM3(GLI-Luc) cell line following culture 
with cyclopamine for 72hrs.  
Graph showing luciferase activity, as determined by luminescence, of the Gli-luciferase reporting 
TM3(GLI-Luc) cell line following culture with incremental concentrations of cyclopamine for 72hrs.  
Each point represents the mean of four independent experiment with the error bars indicating the 
standard deviation (SD). 
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2.2.1.7  Synergy studies 
Synergism is the process by which two or more drugs are used in combination to achieve an 
additional end effect, for example greater cell death. The drugs may target the same molecule 
or pathway through different mechanisms, or independent molecules or pathways. The end 
result, irrespective of drug mechanism of action, is greater efficacy. Further, drug synergism 
may allow for the use of lower doses of each drug within the combination, potentially reducing 
adverse reactions within the clinical setting.  
In order to determine synergism, the combination effect must be greater than that which is 
expected from the individual drug’s potencies. We used the Chou-Talalay method for drug 
combination, utilising computer software to analyse dose-effect. The formula is based on the 
median-effect equation, encompassing the Michaelis-Menten Hill, Henderson-Hasselbalch and 
Scatchard equations. The resulting combination index (CI) provides a quantitative definition for 
additive effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) in drug combinations 573.  
Cells were seeded in 96 well plates at 0.2x105/ml in media containing the test drug at varying 
concentrations. Two-fold serial dilutions were made with two concentration points above and 
below the IC50 value; a constant ratio was therefore maintained. Cells were cultured for varying 
times (24, 48 and 72hrs) then counted using a haemocytometer after being mixed in a 1:2 ratio 
with trypan blue solution. Biological duplicates were performed. Data analysis was performed 
with Compusyn software using the Chou-Talalay CI method 573. 
 
2.2.1.8   β-Galactosidase Cell staining 
The principle of this experiment was to determine cell senescence; senescent cells express 
increased levels of lysosomal β-galactosidase termed senescence-associated β-galactosidase.  
Cells were treated within the experimental arms then fixed and stained overnight according to 
manufacturer’s protocol. Briefly, cells (at a concentration of 1x104 cells per well) were cultured 
for 72hrs in 6 well plates in the presence or absence of the test drug. Following culture, cells 
were washed in 1X PBS before 1X fixative solution was added and the cells left for 15mins at RT. 
Cells were then washed twice with 1X PBS before adding β-galactosidase staining solution and 
incubating overnight at 37oC in a dry incubator (without CO2). This is a simple colorimetric assay, 
in the presence of increased levels of β-galactosidase, cells stain blue-green. Cells were scored 
under bright light microscopy. Alkali conditions (pH10) were used as a positive control.  
 
2.2.1.9 CFC assay 
The CFC assay is an in vitro assay designed to quantify haematopoietic progenitor cells. The 
assay is based on the ability of haematopoietic progenitor cells to proliferate and differentiate 
into colonies in semisolid media with adequate cytokine support. These colonies can be 
enumerated and characterised according to their unique morphology 574.  
Methylcellulose was thawed at 4oC overnight. For each experimental arm, a 3ml aliquot was 
placed into a sterile plastic vial using a 20ml syringe and brought to RT prior to use. Cell counts 
were performed to allow calculation of the volume of cell suspension required for 4x103 cells 
(primary samples) and 2x103 (cell lines) within each experimental arm. Cells were washed and 
resuspended in 200µl serum free media then pipetted onto the 3ml methylcellulose aliquot and 
thoroughly mixed. Due to the viscosity of the methylcellulose, to ensure equal division, 1.3ml 
was added to a 35mm tissue culture dish in duplicate. An additional 35mm culture dish 
containing sterile water was added to prevent culture plates from drying out. Samples were 
incubated for 10–14 days prior to characterising and counting the number of viable colonies.  
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The capacity of an individual colony to re-plate is used experimentally as a measure of the self-
renewal potential of the parent haematopoietic progenitor cell 575. Re-plating assays are 
therefore used to assess drug treatment effects specifically on self-renewal capacity of 
haematopoietic progenitors. 
For re-plates, 100µl of Methocult was added to each well of a 96-well plate, with the exception 
of the peripheral wells, which were filled with sterile water to prevent culture drying. 50 
colonies were then harvested from each experimental arm and resuspended in 10µl serum free 
media prior to being added to the Methocult and thoroughly mixed. Plates were cultured for a 
further 10-14 days prior to the number of viable colonies being counted. 
 
2.2.1.10   Cellular transfection 
A hairpin against human SMO in a PLKO.1 plasmid (Open Biosystems; 
TRCN0000014367:CGGCCTGACTGTGAGATCAAGAATCTCGAGATTCTTGATCTCACAGTCAGGTTTT) was 
previously validated within the Copland laboratory. The short hairpin RNA (shRNA) was cut using 
Ndel and SpeI restriction enzyme digestion and ligated into PLKO.1 with a green fluorescent 
protein (GFP) tag. PLKO.1 with a non-targeting hairpin sequence was used as a control. HEK293 
cells were transfected overnight at 37oC in T75cm3 flasks when approximately 75% confluent, 
using calcium chloride with HIV-1 and VSV-g as accessory plasmids. Virus was collected in DMEM 
supplemented with 20% FBS and the Kasumi-1 cell line was cultured in viral medium 
supplemented with 4mg/ml Polybrene. This was repeated every 3-4hrs. Following 48hrs of viral 
transduction the Kasumi-1 cells were washed and resuspended in normal media. After overnight 
culture, the GFP positive cells were sorted using the BD FacsAria for RNA and protein studies, 
and resuspended in fresh media allowing recovery for 24hrs before further experiments were 
undertaken.  
 
2.2.2  Molecular studies  
2.2.2.1  RNA extraction and quantification 
Cells were harvested, lysed and RNA extracted using the RNeasy RNA Plus Mini and Micro Kits as 
per manufacturer’s instructions.  
Briefly, cells were suspended in the recommended volume for cell number of guanidine-
thiocyanate-containing lysis buffer and homogenised using a 26G needle. The homogenised lysate 
was passed through a genomic DNA removal column to remove DNA contamination. Following 
ethanol precipitation, the sample was added to a silica spin column that selectively binds RNA 
prior to washing, with provided buffers to remove impurities. The column was then dried by 
centrifugation to remove ethanol and allow for a clean elute. RNAse-free water was used to 
elute the RNA.  
RNA concentration and quality were determined using a Nanodrop Spectrophotometer, using 2µl 
of the sample. 260nm quantifies nucleic acids. Absorbance was also recorded at 230nm and 
280nm to determine purity (as a ratio to 260nm). Contamination was primarily due to protein, 
phenol or carbohydrate contamination. Concentration was automatically calculated; pure RNA 
has an expected ratio of 2. RNA was stored at -80oC until required. 
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2.2.2.2  cDNA synthesis 
500ng of RNA was reverse transcribed to complementary DNA (cDNA) using the high fidelity 
reverse transcriptase Superscript III according to protocol as per manufacturer’s instructions.  
Briefly, this is a two-step reaction, as reverse transcriptase cannot initiate synthesis de novo. 
The first step enables oligo(dTs) to bind to the mRNA through the poly-A tail thus priming the 
DNA (Materials Table 2.1.2.4.1 Reverse transcription Mastermix Step 1; Materials Table 2.1.2.4.3 
Reverse transcription cycling conditions Step1). The second step involves second strand DNA 
synthesis. 7µl of reverse transcription mix 2 (Materials Table 2.1.2.4.2 Reverse transcription 
Mastermix Step 2) is added to each sample giving a total volume of 20µl and cycled as outlined in 
Materials Table 2.1.2.4.3 Reverse transcription cycling conditions Step 2. 
Oligo(dT) primers were used due to their specificity for mRNA and non-specific nature enabling 
different targets to be studied. The cDNA produced for each gene is therefore proportional to 
the mRNA from which it was produced. 
The integrity of cDNA was assessed by performing RT-PCR for GN2BL as a housekeeping gene 
using Promega GoTaq® DNA polymerase.  
 
2.2.2.3  Polymerase chain reaction (PCR) 
RT-PCR and qRT-PCR are methods to detect mRNA expression, with qRT-PCR able to quantify 
mRNA expression. The reactions can be performed using Taqman® probes or primers.  
Primers were designed in-house using National Center for Biotechnology Information (NCBI)/ 
Primer-Blast. Briefly, the cDNA sequences of each gene of interest were identified through a 
Pubmed search and used to design primers. We aimed to design primers of approximately 20 
base pairs with the forward and reverse primers having similar melting temperatures, ideally 
60oC. 
 
2.2.2.3.1  RT-PCR  
RT-PCR is a method to detect mRNA expression in a sample following its reverse transcription 
into cDNA. This is a qualitative analysis of expression. The method cannot quantify expression for 
a number of reasons: PCR products do not accurately reflect input cDNA since they are analysed 
following the exponential stage of amplification having reached a plateau, and ethidium bromide 
is a relatively insensitive stain. Gel electrophoresis separates products according to size. 
Briefly, the reaction involved mixing 2µl of the transcribed cDNA with the GoTaq® RT-PCR 
master mix (Materials Table 2.1.2.5.1). Cycling details are outlined in Table 2.1.2.5.2.  
PCRs were then run by gel electrophoresis using a 1.5% agarose gel. The gel was prepared with 
1.5g agarose powder in 100ml of 1X TBE buffer with ethidium bromide (10mg/ml). This was 
heated in a microwave until the agarose powder was fully dissolved, then poured into a casting 
tray with a comb to create the wells. The gel was left for approximately 30mins until fully set. 
12µl of PCR product was added to each well. 6µl of a 100bp DNA ladder was loaded into one lane 
of each gel for reference. PCR products were visualised due to the presence of ethidium bromide 
using the ChemiDoc MP System and analysed using the Quantity One 1-D Analysis Software.  
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2.2.2.3.2  Quantitative Real-Time PCR (qRT-PCR) by Fluidigm® 
Real-time quantitative PCR (qRT-PCR) enables relative and absolute quantitation of gene 
expression.  
Briefly the Taqman® assay uses oligonucleotide probes that are fluorescently labelled at their 5’ 
end, with a non-extendable 3' end containing a quencher dye. In the absence of the target 
sequence, the quencher dye neutralises the fluorescence emitted by the reporter dye. In the 
presence of the target sequence, the annealed probe is cleaved by Taq® DNA polymerase, 
separating the reporter dye from the quencher dye. With each cycle, additional reporter dye 
molecules are cleaved from their respective probes, resulting in an increase in fluorescence 
intensity proportional to the amount of amplicon produced. The same principle applied when 
primers were used, although in this instance Bio-Rad Ssofast Evagreen Supermix served as the 
fluorescent label.  
The abundance or frequency of a gene of interest is measured by setting a threshold level of 
fluorescence. When the signal emitted by the reporter dye molecules for each gene of interest 
cross this point a positive, or real, signal is recorded. This is termed the cycle threshold (CT). 
The CT therefore represents the stage within the PCR reaction when real signal is detected over 
a background level. High frequency genes which cross the threshold early (after a low number of 
PCR cycles) will have a low CT value, with the reverse being true for low copy number genes that 
therefore have a high CT value.  
Comparison between gene expression can be made, and statistical analysis performed, once 
variation in input cDNA is taken into account. Briefly, for each gene of interest, the DeltaCT 
(ΔCT) is calculated by subtracting the CT value of between 3 and 6 housekeeping (control) genes 
from the CT recorded the gene of interest. The 2-ΔΔCT method can then be used to show the 
relative expression of the gene of interest relative to control, where normal is expressed as 1 576. 
 
2.2.2.3.2.1 Pre-amplification 
Due to the low level expression of some target genes of interest, a pre-amplification step was 
carried out to increase the quantity of cDNA targets prior to gene expression analysis.  
Briefly cDNA was incubated with a pre-amplification mastermix, containing a pool of primers or 
probes specific to the cDNA of interest (Table 2.1.2.8.1 Primer Pre-amplification Mastermix; 
Table 2.1.2.8.2 Probe Pre-amplification Mastermix). Pre-amplification was performed for target 
and reference genes as per manufacturer’s instructions. Cycling conditions are detailed in Table 
2.1.2.8.3 The pre-amplified cDNA was then diluted 1:5 in Tris-EDTA (TE) buffer and stored at -
20oC until required.  
When primers were used, residual unused primers were removed using an exonuclease (Table 
2.1.2.8.4). Cycling conditions are detailed in Table 2.1.2.8.4.1. Exonuclease is used as it 
specifically digests single stranded DNA. 
 
2.2.2.3.2.2 qRT-PCR 
qRT-PCR was performed using Fluidigm® Biomark technology and data collected as per 
manufacturer’s instructions. The chip design was chosen dependent upon experiment design – 
those used were 48:48, 96:96 and FLEXsix Dynamic Array chips.  
Briefly, each sample was run in technical triplicate, and a no template control included with 
each chip. The chip was first primed with line control fluid before the assays (Tables 2.1.2.8.5 
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Primer & 2.1.2.8.6 Probe) and samples (Tables 2.1.2.8.5.1 Primer & 2.1.2.8.6.1 Probe) were 
loaded within 60mins. The FLEXsix has 6 12x12 partitions that can be run independently or 
simultaneously; this chip is only primed once, prior to the first run. Separate partitions can be 
used for up to 3 months following first use.  
Each chip is designed such that each sample is cycled with each probe/primer from loading into 
a single well. The FLEXsix generates 144 x 6 data points, the 48:48 chip 2304 data points and the 
96:96 chip 9216 data points. Internal sample control was ensured subtracting the average of 
selected housekeeping genes (ATP5S, B2M, ENOX2, GAPDH, GUSB, TYW1 and UBE2D2) from each 
gene of interests CT value. 
 
2.2.2.4 Gene expression array  
The purpose of this array was to evaluate changes within a large number of genes between the 
most primitive HSC compartment, and the early progenitor populations, MPP, CMP, GMP and 
MEP. The gene expression microarray (GSE 47927) was performed and analysed by the Copland 
laboratory prior to this study’s initiation 577.   
Briefly, patient samples were sorted using multi-parameter fluorescence-activated cell sorting 
(FACS). Samples were run on the Affymetrix GeneChip Human Gene 1.0ST array system, enabling 
28,869 transcript targets to be detected.  The annotated raw fluorescence intensity (.CEL) files 
were analysed using Partek Genomics Suite. Following log transformation, a one-way ANOVA was 
performed 578. 
 
2.2.2.5  DNA extraction and quantification 
Cells were harvested, lysed and DNA extracted using the DNAeasy Blood and Tissue Kit as per 
manufacturer’s instructions.  
Briefly, cells were directly lysed using Proteinase K before being passed through a silica spin 
column that selectively binds DNA, prior to washing with provided buffers to remove impurities. 
Buffer AE (a Tris-CL, EDTA, pH 9 buffer) was used to elute the RNA.  
DNA concentration was determined on a Nanodrop Spectrophotometer using 2µl of the sample, 
at 280nm. Absorbance was also recorded at 230nm and 260nm to determine purity (as a ratio to 
280nm). Impurities were primarily due to protein, phenol or carbohydrate contamination. 
Concentration was automatically calculated using a correction factor for differing base 
composition; pure DNA has an expected ratio of >1.8. DNA was stored at -80oC until required. 
 
2.2.2.6 Sequencing  
2.2.2.6.1 Sanger sequencing  
DNA polymerases synthesise DNA from deoxyribonucleotides. They can also incorporate 
analogues of nucleotide bases: dideoxyribonucleotides (ddNTPs). ddNTPs are perfectly 
functioning dNTPs, however once they are incorporated the DNA polymerase cannot progress any 
further since they lack the 3'-hydroxyl group. This is the basis of the Sanger sequencing method 
developed in 1977: the ddNTPs serving as specific chain-terminating inhibitors of DNA 
polymerase enabling the DNA sequence to be determined by reading the end ddNTP from each 
fragment generated by the sequencing cycle 579.  
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This process was further developed in the 1990s. Fluorescently based cycle sequencing labels 
each of the four ddNTPs with a different colour dye and the fragments are separated by capillary 
electrophoresis to determine the DNA sequence.  
Sanger sequencing was performed to determine the mutational status of SMO in an unselected 
primary patient cohort, SMO mutations being found in a number of solid malignancies 367,580–582. 
 
2.2.2.6.1.1 DNA template amplification and purification by PCR 
SMO PCR primers, detailed in Table 2.1.2.9.1, were diluted to 5µM (5pmol/µl) from 100µM stock 
with RNAse-free water before use. All SMO PCR primers where universally tailed.  
The SMO RT-PCR reaction was run using a mastermix as documented in Table 2.1.2.9.2, with a 
different reaction tube for each primer. 1µl DMSO was added to exon 1_1, 1_2 and 1_3 reactions 
as these regions are GC rich and therefore difficult to amplify. Cycling details are outlined in 
Table 2.1.2.9.3. To ensure clean sequencing 5µl of the sequencing PCR reaction was transferred 
to fresh tubes with 2µl of EXO-Star. Cycling details outlined in Table 2.1.2.9.4.  
 
2.2.2.6.1.2 Cycle sequencing 
A Big Dye® mastermix was prepared as documented in Table 2.1.2.9.5. 10µl was dispensed into 
each well then approximately 0.2µl of PCR product added. Sequencing primers were diluted to 
3.3µM (3.3pmol/µl) from 100µM stock. Cycling conditions are outlined in Table 2.1.2.9.6. 
 
2.2.2.6.1.3 Sequencing reaction purification by ethanol precipitation 
Following this, 2µl 3M sodium acetate and 28µl 100% ethanol was added to each well, the plate 
vortexed, mixed by inversion and spun at 3000xg for 30mins. The solution was then discarded. 
Complete removal of solution at each step was essential for good performance, so the plate was 
inverted and spun at 3000xg for 20secs. Then, 75µl of 70% ethanol was added to each well, the 
plate vortexed, mixed by inversion and spun at 3000xg for 10mins. At this stage, the plate was 
stored at -20 oC.  
 
2.2.2.6.1.4 Capillary electrophoresis  
Sequencing was performed on a Tetrad 3130/3130xl Genetic Analyser within NHS Lothian, 15µl of 
Hi-Di Formamide was added immediately before the plate was run. Analysis was performed using 
Alamut mutational surveyor.  
This work was accomplished in collaboration with NHS Lothian, in particular Dr Edwina Dobbin. I 
am indebted to her for her time, help and expertise.  
 
2.2.2.7.2 Next-generation Sequencing  
Non-random, clonal chromosome aberrations are detectable in approximately 55% of AML 
cases, and are important when considering disease classification and treatment algorithms; 
45% of cases however remain unclassified, leading to difficulties in risk stratification and 
treatment decisions 156,165.  
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In 2013, the Cancer Genome Atlas Research Network listed 23 significantly mutated genes in 
AML 583.	Following this, several AML research gene panels have been commercially developed, 
two have been used in this PhD. 
 
2.2.2.7.2.1  Ion AmpliSeq PGMTM 
The Ion AmpliSeqTM covers 19 genes, 14 described by the Cancer Genome Atlas Research Network 
583, Table 2.1.2.10.1.  
Ion semiconductor sequencing is a method of DNA sequencing based on the detection of 
hydrogen ions released during the polymerization of DNA. This is a method of sequencing by 
synthesis, a complementary strand being built on the sequence of a template strand. If the 
introduced dNTP is complementary to the leading template nucleotide, it is incorporated into 
the growing complementary strand. This causes the release of a hydrogen ion that triggers an 
ion-sensitive field-effect transistor ion sensor, in which the reaction is measured.  
The assay was performed as per manufacturer’s instructions, Table 2.1.2.10.1: Ion AmpliSeqTM 
Sequencing Conditions. 
This work was accomplished in collaboration with NHS Lothian, in particular Dr Edwina Dobbin 
and Dr Nicola Carroll. I am indebted for their time, help and expertise.  
 
2.2.2.7.2.2 Illumina TruSight® 
The Illumina TruSight® Myeloid panel covers 54 genes, 15 in their entirety and an additional 39 
targeted to cover oncogenic hotspots, Materials 2.1.2.10.2. 
Illumina dye sequencing also uses a sequence by synthesis approach.  
Briefly, purified dsDNA is cleaved by transposons generating random lengths of DNA. The cut 
ends are repaired and adapters, (indices which enable up to 96 samples to be run 
simultaneously), primer binding sites, and terminal sites (necessary for the DNA strand to attach 
to the flow cell) are added to each strand of DNA. The modified DNA is loaded onto a specialised 
chip, termed a flow cell, for amplification and sequencing. Hundreds of thousands of 
oligonucleotides are anchored to the bottom of the flow cell. These serve to bind DNA strands 
with complementary sequences.  
Once the fragments have attached, cluster generation begins through bridge amplification. This 
step makes approximately one thousand identical copies of each single template molecule in 
very close proximity, termed a cluster. Sequencing by synthesis is initiated using a sequencing 
primer; a single fluorescently tagged modified dNTP being added to the chain with each 
sequencing cycle. Each of these nucleotides has a reversible 3' terminator that acts as a 
terminator for polymerisation; ensuring only one nucleotide is added per cycle. After each round 
of synthesis, the base is determined by the wavelength of the fluorescent tag. Each of the four 
bases has a unique emission. This cycle is repeated 150 times until the full DNA molecule is 
sequenced. The purpose of the cluster is to ensure a strong fluorescence signal. The sequence 
data is analysed using the MiSeq reporter 584.  
The assay was performed as per manufacturer’s instructions, Materials 2.1.2.10.2.1: Illumina 
TruSight® Sequencing Conditions. 
This work was accomplished in collaboration with NHS Greater Glasgow and Clyde, in particular 
Dr Rachel Dakin. I am indebted for her time, help and expertise. 
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2.2.3  Protein studies 
2.2.3.1  Protein extraction and quantification 
1-5x106 cells were harvested and washed x3 in ice-cold 1X PBS without Ca2+ or Mg2+ and pelleted 
at 220xg. After the third wash, pellets were lysed in ice-cold solubilisation buffer containing 
phosphatase and protease inhibitors at a concentration of 2x106/10µl solubilisation buffer, Table 
2.1.3.2. This suspension was left on ice for 30mins then centrifuged at 20000xg for 10mins to 
pellet all cell debris. The supernatant was transferred to a fresh eppendorf and stored at -80oC.  
Protein concentration was quantified using the 1x Quick StartTM Bradford Dye Reagent and 
compared to a standard curve prepared using Quick StartTM Bovine Serum Albumin (BSA) protein. 
This is a colorimetric protein assay based on the binding of Coomassie Brilliant Blue G-250 dye to 
protein, and the associated colour change from brown to blue this causes. This can be measured 
by visual absorbance on the Spectramax M5 plate reader at 595nm using SoftMax Pro software. 
 
2.2.3.2  Sodium dodecyl sulfate polyacrylamide gel electrophoresis      
   Western blotting 
Gel solutions were prepared as per Tables 2.1.4.7 & 2.1.4.8. 10% gels were used to separate 
proteins smaller than 50kDa; 7.5% gels to separate those larger than 50kDa. All stacking gels 
were 5%.  
10-20µg of cell lysates were denatured at 100oC with Sodium dodecyl sulfate (SDS) and β-
mercaptoethanol for 5mins. Samples were run in 1x Running Buffer at 80Volts (V) for 15mins 
then 180V for 45mins. The semi-dry transfer method was used to transfer separated proteins to 
nitrocellulose membranes. Briefly, membranes and nitrocellulose were saturated in 1X semi-dry 
transfer buffer, the gel placed on top of the membrane and sandwiched between eight 9cm x 
6cm Whatman paper strips. Transfer was performed at 40mA/gel for 60mins and confirmed using 
Ponceau S Solution staining. Membranes were washed in 1X TBS to remove Ponceau S prior to 
blocking with 5% BSA for 1hr to prevent non-specific binding. Following blocking, the membrane 
was incubated in primary antibody and resuspended in 1X blocking solution overnight with gentle 
agitation on a rocker. Unbound antibody was washed with 1X TBS-N, pH 7.5, 4 times for 10mins 
per wash. Secondary antibodies, conjugated to horseradish peroxidise (HRP), were used at a 
dilution of 1:10,000 and incubated for 1hr. Secondary antibody was washed with 1X TBS-N 
followed by three 1X TBS washes, 10mins for each. Protein was visualised by placing membranes 
in 2ml chemiluminescent HRP substrate for 3mins, then placed in a cassette before being 
exposed to X-ray for varying time periods. X-ray film was developed using a Konica Minolta SRX-
101A developer in a dark room. 
 
2.2.3.3 Immunocytochemistry on cultured cells 
Immunocytochemistry (ICC) was performed on multispot polytetrafluoroethylene (PTFE) coated 
glass microscope slides if cells were non-adherent, and within 8-well Lab-Tek II chamber slides if 
adherent, allowing cellular morphology to be maintained. To ensure optimal fixing, the PTFE 
microscope slides were pre-coated with 5µg/ml Poly-L-Lysine in borate buffer. Cells were at a 
density of 6x104cells/well if non-adherent, and maintained at approximately 80% confluency if 
adherent. If non-adherent, cells were harvested at 3rd or 4th passage in optimal growing 
conditions (resuspended in fresh media 24hrs before harvesting at a density of 2-3x105/ml). Cells 
were washed once in 1X PBS, fixed for 10mins (non-adherent) or 30mins (adherent) with 4% 
paraformaldehyde, washed a further three times with 1X PBS then permeabilised over 15mins 
with 0.5% Triton-X100. Adherent cells were blocked in 5% normal goat serum (NGS) or 5% normal 
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rabbit serum (NRS) depending on which species the staining antibodies were raised in. Non-
adherent cells were blocked in 5% BSA/1% Ovalbumin in 1X PBS with 0.2% Triton-X100. Cells were 
blocked for a minimum of 30mins before the primary antibody was added and incubated 
overnight at 4oC; Table 2.1.4.10 shows primary antibody concentrations. 1:200 dilutions of 
appropriate secondary antibody (Alexa Fluor 488 or 594; mouse, goat or rabbit) were added after 
washing slides x3 in 1X PBS, and then incubated for 1hr at RT. Antibody master mixes were 
prepared for each experiment. 4',6-diamidino-2-phenylindole (DAPI) mounting solution was used 
to fix and seal the slides with cover slips. Negative (no primary antibody, NPA) controls were 
included with each experiment. For each antibody, microscope settings were kept constant 
between cell lines and samples. The slides were visualised on a Zeiss TS 100 inverted microscope 
and pictures taken using Axio-vision software. 
 
2.2.3.4 Immunocytochemistry on fresh frozen, paraffin-embedded,  
            EDTA-decalcified bone marrow trephines  
Whilst the protocol for identifying primary cilia in cultured cells is well recognised, there are no 
reports in the literature using fresh frozen, paraffin-embedded (FFPE) tissue.  
 
 
 
There are a number of well-recognised technical issues when performing ICC on FFPE, in 
particular auto fluorescence. The technique was therefore optimised on FFPE human BCC 
sections. These were chosen as BCC cells have been reported to have primary cilia 447, aberrant 
Hh pathway activity and, from a practical perspective, the tissue was easily accessible. The 
specificity of the antibodies was confirmed on mouse trachea sections, motile cilia being found 
on the surface of the trachea in large numbers, with both motile and primary cilia being 
composed of a microtubule-based cytoskeleton, Figure 2.2. 
 
Figure 2.2: Representative ICC cross sectional image, x40 magnification, depicting cilia on 
the mucosal surface of the trachea from a mouse.  
Tracheas were dissected, cut and mounted from sacrificed mice by Karen Dunn. Antibodies were 
added serially, at a range of concentrations. Images were visualised with a Zeiss TS100 inverted 
microscope. Respiratory cilia, composed of α-tubulin are stained with α-tubulin (red); γ-
tubulin, composing cell cytoskeleton is shown in green. Cell nuclei are stained with DAPI (blue). 
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BM trephine (BMT) sections were cut at 3-4µM, from embedded blocks, floated onto a warm 
(42°C) water bath then picked up onto Superfrost plus slides (performed by John O’Connor, NHS 
Lothian). To preserve antigenicity, sections were stored at 4oC. Prior to staining, sections were 
placed in a 60oC oven for 1hr, followed by 5mins in xylene to remove the paraffin. Sections were 
rehydrated with 2x 1min wash in 100% ethanol followed by a single 1min wash in 70% ethanol and 
finally 5mins in deionised water. Antigen retrieval was performed on the Thermo ScientificTM PT 
Module with pH6 sodium citrate retrieval buffer solution at 98oC for 25mins. Sections were 
subsequently washed in PBS/Tween (1:2000) twice (4mins each) before serially adding antibodies 
and incubating for an hour at RT or overnight at 4oC, (Table 2.1.5.4 Immunocytochemistry 
antibody details). Finally, sections were washed x2 in PBS/Tween, before DAPI at a 
concentration of 1:1000 was added, coverslip applied and fixed. Stained sections were visualised 
with a Zeiss 710 confocal scanning microscope with 60× oil immersion optics. Laser lines at 405, 
488 and 543 for excitation of DAPI, acetylated α-tubulin and γ-tubulin, respectively, were 
provided by an argon laser. Detection ranges were set to eliminate crosstalk between 
fluorophores. Positive (BCC cases) and NPA controls were included with each experiment; 
settings were adjusted between samples.  
 
2.2.3.5 Immunohistochemistry on FFPE BMTs 
This work was accomplished in collaboration with NHS Lothian, in particular John O’Connor, Tim 
Ingman and Dr John Goodlad. I am indebted for their time, help and expertise.  
Sections were cut at 3-4µM, from embedded blocks, floated onto a warm (42°C) water bath then 
picked up onto Superfrost plus slides (performed by John O’Connor, NHS Lothian). To preserve 
antigenicity sections were stored at 4oC. Sections were dewaxed prior to antigen retrieval using 
the proprietary antigen retrieval solutions ER1 and ER2 and the Leica Bond III platform. ER1 is a 
ready-to-use citrate-based pH6.0 solution; ER2 is a ready-to-use EDTA based pH 9.0 solution. 
Single antibody detection was accomplished using a Leica Bond III immunostainer (performed by 
Tim Ingman, NHS Lothian). All antibodies were optimised prior to use on control material as 
specified by product datasheet. Selected antibodies, optimal dilutions, control material and 
epitope retrieval method is documented in Table 2.1.6.3.  
Protein expression was estimated at x10 magnification by two investigators in a blinded fashion. 
A previously described score system with minor modifications was used 585. The staining intensity 
was semi-quantitatively classified as negative, weakly positive and over-expressed; staining was 
considered negative if <10% of cells were positive.   
 
2.2.3.6 Enzyme-linked immunosorbant assay  
A commercially developed enzyme-linked immunosorbant assay (ELISA) for SHH was used to 
quantitatively measure SHH expression; the assay employing an antibody specific for the N-
terminus of human SHH.  
To determine SHH ligand expression by various cell lines, conditioned media was collected, 
filtered using a 0.45µM filter and snap frozen. Plasma was collected from primary samples and 
processed as described in Section 2.2.1.2.9.  
The assay was performed as per manufacturer’s instructions. Briefly, the kit supplied a 96-well 
plate, pre-coated with an antibody specific for human SHH. Standards and samples were 
pipetted into wells and incubated for 2½hrs at RT. SHH present in a sample was consequently 
bound by the immobilised antibody. Wells were then washed x4 with 1X wash solution (provided 
in the kit and used throughout) and biotinylated anti-Human SHH antibody added and incubated 
with gentle agitation at RT for 1hr. Following further washes (x4) HRP-conjugated streptavidin 
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was added and the plate incubated at RT for 45mins. Following the final washes (x4) a TMB 
substrate solution was added to each well and the plate incubated at RT in the dark for 30mins. 
The reaction was stopped immediately by the addition of stop solution, colour being proportional 
to the amount of SHH bound. The reaction was quantified by absorbance measured at 450nm on 
a scanning plate reader immediately after the stop solution was added. The quantity of SHH 
present was determined from the standard curve. 
 
2.2.4  Flow cytometry 
Flow cytometry is a quantitative technique that enables characterisation of cells at a single cell 
level using fluorophore labelled antibodies and dyes. Simply, cells are suspended in a stream of 
fluid, passed through at least one laser exciting the fluorophore, causing the emission of light of 
a specific wavelength (colour). Each fluorophore has a different excitation and emission spectra. 
Multiple fluorophore-labelled antibodies can be used simultaneously provided they emit at 
different wavelengths (colours). The BD Biosciences FACSCanto™ II can detect up to 8 colours 
simultaneously using 3 lasers. 
All flow cytometry was performed on a FACSCanto™ II flow cytometer, data acquired using FACS 
Diva software and analysed using FlowJo software. Appropriate isotype controls, to determine 
the emission of non-specific binding, positive controls to offset spectral overlap between 
fluorophores, and an unstained sample were utilised to set voltages and compensation when 
required. Compensation was set using the linear-log scale for each antibody used. Viable cell 
populations, when required, were gated using FSC and SSC characteristics, with FSC measuring 
cell size, and SSC cytoplasmic granularity. A minimum of 10,000 events was collected for all 
experiments.  
 
2.2.4.1  Apoptosis assessment  
Apoptosis is a normal physiological process, essential for tissue homeostasis. It is characterised 
by certain features, including loss of membrane integrity, condensation of the cytoplasm and 
nucleus and inter-nucleosomal DNA cleavage.  
During the early stages of apoptosis there is loss of membrane asymmetry with phospholipid 
phosphatidylserine (PS) translocating from the inner to the outer leaflet of the plasma 
membrane. It is this feature by which Annexin V can identify apoptotic cells. Annexin V, a 
calcium dependent phospholipid-binding protein, has a high affinity for PS, binding to cells with 
exposed PS. When conjugated to fluorochromes, it can thereby identify cells undergoing 
apoptosis by flow cytometry.  
7-Amino-Actinomycin (7AAD) is a nucleic acid stain distinguishing between viable and dead cells 
on the basis of loss of membrane integrity, and is excluded from live cells. 
Tetramethylrhodamine, methyl ester (TMRM) is a cell-permeant fluorescent dye that is 
sequestered by active mitochondria. This stain therefore allows changes in mitochondrial 
membrane potential, an indirect consequence of MOMP, to be assessed.  
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2.2.4.1.1 Annexin / 7AAD staining 
The principle of this experiment was to quantitatively determine the percentage of viable, early 
apoptotic, late apoptotic and dead cells (Figure 2.3); cellular staining of Annexin V and 7AAD 
recording cell membrane integrity as a measure of cell viability. This assay is however unable to 
distinguish between necrotic and apoptotic cell death.   
Cells were harvested, washed twice with 1X HBSS (Table 2.1.7.4) and resuspended in 1X HBSS. 
Fluorophore-conjugated Annexin V and 7AAD were added (2µl of each per 100µl 1X HBSS) and 
mixed well prior to incubation for 15mins in the dark at RT. 300µl of 1X HBSS was then added 
and the samples analysed immediately. Analysis was performed using the BD FACSCanto II. 
Isotype controls and an unstained sample were utilised to set voltages and compensation. 
 
 
 
2.2.4.1.2 Tetramethylrhodamine methyl ester staining  
The principle of this was to quantitatively assess changes in mitochondrial membrane potential, 
an early feature of the apoptotic process. Cells were harvested, washed twice with FACS buffer 
(Table 2.1.7.5), resuspended in 1ml of 250nM TMRM in appropriate cell culture media and 
incubated for 30mins at 37°C. Cells were then washed twice with FACS buffer, and the samples 
analysed immediately using the BD FACSCanto II. Isotype controls and an unstained sample 
were utilised to set voltages. 
 
 
 
 
 
 
 
 
 
Figure 2.3:  Representative FSC / SSC and Annexin V / 7AAD plots for the OCI-AML3 cell line.  
OCI-AML3 cells were harvested, washed with 1X HBSS. Fluorophore-conjugated Annexin V and 7AAD 
were added prior to incubation for 15mins. 1X HBSS was then added and the samples analysed 
immediately. Analysis was performed using the BD FACSCanto II. (A) Representative FSC / SSC plot for 
the OCI-AML3 cell line; (A) Representative plot showing live / early apoptotic / late apoptotic and dead 
quadrants defined by Annexin V / 7AAD.    
(A) (B) 
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2.2.4.2 Proliferation studies  
The cell cycle is a complex series of events tightly governed within a cell leading to its division 
and duplication, ultimately resulting in two daughter cells 586.  
 
 
 
2.2.4.2.1 Propidium Iodide staining  
The principle of this experiment was to measure the proportion of cells progressing through the 
different stages of the cell cycle: Interphase (G1, S, G2) and Mitosis (M). Propidium iodide (PI) is 
an intercalating agent, binding double-stranded nucleic acids. PI is therefore capable of showing 
the increase in cellular DNA as the cell progresses through cell division prior to cell separation.  
Cells are fixed in ethanol prior to staining to permeabilise the cell and allow the PI to enter and 
bind the DNA. Cells were harvested, washed once with FACS buffer, fixed in 1ml 70% ice-cold 
ethanol whilst gently vortexing to prevent cell clumping, and stored for a minimum of 24hrs at -
20oC. Prior to analysis, cells were centrifuged at 400xg for 5mins, resuspended in 250µl PI/RNase 
staining buffer, vortexed for 30secs and incubated for 15mins at RT in the dark. Analysis was 
performed immediately using the BD FACSCanto II.  
When analysed a histogram, in linear scale, was used to visualise separate cells into G0-G1, S 
and G2-M phases of the cell cycle, according to the peaks and troughs seen in the control 
sample. In some experiments, there was not a clear peak for G2-M, in these instances cells were 
separated into G0-G1 and S-G2-M. The fluorescence of the G2-M peak should be approximately 
double that of the G0-G1 peak. To ensure accurate analysis for each experiment, this was 
confirmed using FlowJo software to calculate each peak’s mean fluorescence intensity (MFI). 
 
2.2.4.2.2 Carboxyfluorescein succinimidyl ester staining 
The principle of this experiment was to follow cell division. Carboxyfluorescein succinimidyl 
ester (CFSE) is an intracellular fluorescein-based dye that enables cell divisions to be tracked 587. 
CFSE fluorescence intensity progressively reduces with each cell division, due to the equal 
division of the fluorescent stain between daughter cells, allowing the number of divisions to be 
calculated relative to an undivided control population; Figure 2.5. 
M""
G2  
S  
G1  
M  
Figure 2.4: Diagrammatic representation of the cell cycle.   
M: Mitosis, G1: Growth, S: DNA synthesis and G2: Growth and preparation for mitosis.  
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Cells were harvested and washed twice with FACS buffer. At this stage, an aliquot was removed 
for the unstained untreated control (USUT). The remainder of the cells were resuspended in 5ml 
FACS buffer to which CFSE was added, to a final concentration of 1µM, and incubated in a 
waterbath at 37oC for exactly 10mins. CFSE uptake was stopped immediately by adding ice-cold 
quenching solution (Table 2.1.7.6) to the cells in a 10:1 ratio. Cells were then washed in FACS 
buffer before subsequent experiments were set up, and analysis performed at selected time 
points. For each experiment, an aliquot of CFSE+ cells were treated with 100ng/ml Colcemid, 
arresting cells in metaphase, serving to determine the position of CFSEmax cells.  
 
2.2.4.2.3  Cell TraceTM Violet staining 
The principle of this experiment was to follow cell division; Cell TraceTM Violet (CTV) 
fluorescence intensity progressively reducing with each cell division allowing number of divisions 
to be calculated relative to a non-dividing control population 588.  CTV was used in place of CFSE 
staining when studying cell division in the SMO knockdown model since these cells were labelled 
with GFP which is seen in the same channel (FITC) as CFSE.  
Cells were harvested and washed twice with FACS buffer. At this stage, an aliquot was removed 
for the UTUS control. The remainder of the cells were resuspended in 1ml FACS buffer to which 
2µL 5mM CTV stock solution in DMSO was added, to give a final concentration of 10µM, and 
incubated in a waterbath at 37oC for exactly 20mins. CTV uptake was stopped by adding 5x 
volume of cell-specific culture medium and incubating the cells for a further 5mins. Cells were 
then washed in FACS buffer before subsequent experiments were set up and analysis performed 
at selected time points.  
 
2.2.4.4   Detection of surface antigen expression  
The principle of this experiment was to determine the cellular phenotype. Expression and 
absence of a panel of CD markers by primary MSC cells being a key component to their validation 
37. Further, a change in CD markers expression is seen with cell differentiation. 
Briefly, cells were harvested, washed twice with 1x PBS and resuspended in FACS buffer. 
Fluorochrome-conjugated antibodies were added at specified concentrations (Table 2.1.7.7) and 
mixed well prior to incubation for 30mins in the dark at 4oC. Cells were the washed twice, re-
suspended in 400µl FACS buffer and the samples analysed immediately.  
Figure 2.5: Representative histogram showing a progressive reduction in CFSE fluorescence 
intensity with each successive cell division in the OCI-AML3 cell line. 
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2.2.4.5   Intracellular antibody staining  
Cells were harvested and washed twice with FACS Buffer. Fixation and permeabilisation was 
performed using FIX & PERM® Cell Fixation & Permeabilisation Kit as per manufacturer’s 
instructions, with the cells being fixed and stored to allow for intracellular staining at a later 
time.  
 
2.2.4.5.1 pBcl-2 
Briefly, to fix the cells, they were resuspended in 1ml 4% paraformaldehyde solution at 4oC and 
incubated for 20mins. Cells were then washed twice in FACS buffer and resuspended in 90% 
FBS/10% DMSO for storage at -80oC until required.  
Fixed cells were permeabilised prior to staining: cells were washed twice in FACS buffer to 
remove DMSO then resuspended in 1ml permeabilising agent (Perm/WashTM buffer, reagent B) for 
15mins. Fixed/permeabilised cells were thoroughly resuspended in 50µl Perm/WashTM buffer with 
2µl pBcl-2 and incubated at 4oC for 30mins. Cells were washed twice in Perm/WashTM buffer prior 
to being resuspended in 50µl Perm/WashTM buffer with 1µl FITC goat anti-rabbit IgG and 
incubated at 4oC for 15mins. This step was required since the pBCL-2 antibody was not 
conjugated to a fluorophore. Finally, cells were washed twice with 1ml Perm/WashTM buffer, 
resuspended in FACS buffer and analysis performed immediately.  
 
2.2.5  Electron microscopy 
Electron microscopy allows the ultrastructure of both tissues and cells to be studied and has 
classically been used to identify primary cilia within cells 416,428.  
Samples were stabilised (fixed), ensuring the ultrastructure of the BM was maintained. Fresh 
NOD-SCID mouse femurs were fractured and fixed in 2.5% Glutaraldehyde/ 2% 
Paraformaldehyde/ 0.1MSodium Cacodylate fixative buffer for one hour at RT.  Primary human 
BMT sections were dewaxed and rehydrated as described in 2.2.3.4, then fixed as for the murine 
bones. Samples were washed for 5mins in 0.1M Sodium Cacodylate buffer solution three times 
prior to secondary fixation in 1% Osmium Tetroxide/0.1M Buffer for one hour to add contrast. 
Sections were subsequently washed in distilled water three times (10mins each). Samples were 
then block stained in 0.5% Uranyl Acetate for one hour in the dark (light sensitive stain) to add 
contrast. Sections were dehydrated with serial 10min washes in ethanol at 30%, 50%, 70%, 90% 
and four 5min washes in 100% ethanol. Samples were further dehydrated through 4 washes in 
absolute ethanol (5mins each). Type 3A molecular sieves were used to dehydrate ethanol 
producing absolute ethanol – the ethanol must be anhydrous for resin embedding.  
For scanning electron microscopy (SEM), samples were delicately dried (referred to as critical 
point drying) ensuring preservation of the surface structure using a POLARON 3000 CPD to 
preserve morphology samples. Dried samples were mounted onto SEM support stubs using double-
sided conductive tape and silver paint and gold/palladium coated (20nm thickness) using a 
Quorum 150T High vacuum Sputter coating system. Imaging was performed on a JEOL6400 SEM 
running at 10kV. Tiff images were captured using Olympus Scandium Software.                         
For transmission electron microscopy (TEM), samples were washed in propylene oxide three 
times (5mins each) as this solvent mixes better with resin. Samples were then placed in 
propylene oxide:araldite/epon 812 (1:1) resin overnight. The propylene oxide evaporates off. 
The following day, samples were resuspended in pure araldite/epon 812 resin for three hours, 
the solution poured off and the process repeated twice, including a second overnight incubation. 
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The following day, samples were placed in fresh resin, embedded in flat bed moulds and 
polymerised for 48hrs at 60℃. 50-60nm thick ultrathin sections were produced using a LEICA 
Ultracut UCT and a DIATOME diamond knife at an angle of 6℃. Sections were picked up on 
100mesh formvar coated copper grids, then contrast stained with 2% methanolic uranyl acetate 
for 5mins and, subsequently, Reynolds lead citrate for 5mins. Samples were viewed on a FEI 
Tecnai T20 TEM running at 200kV. Images were captured using a GATAN Multiscan camera and 
GATAN Micrograph Imaging software. 
Margaret Mullin performed this work, I am grateful for her time, knowledge, perseverance and 
skill.  
 
2.2.6  Statistical analysis 
All statistical analyses were performed using Graphpad Prism 6. When two groups were compared 
the unequal variances t-test with Welch’s correction, Student’s t-test, Fisher’s exact test and 
the Chi-Squared test (dependent on experimental design) were used.  
Unless otherwise stated, all experiments were performed at least 3 times. Results are expressed 
as the mean +/- standard deviation (SD), or the median +/- range where appropriate. P ≤0.05 
was considered to be statistically significant. All results are expressed to the nearest three 
decimal places unless more significant, in these instances, results are expressed as p <0.001 or   
p <0.0001. 
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3  Hypothesis ‘The Hh pathway is deregulated in AML relative to normal 
haematopoiesis, this deregulation being associated with a poor prognosis 
and inferior clinical outcome.’  
 
3.1  To determine the activity of the Hh signalling pathway in select AML 
cell lines and an unselect cohort of primary human AML MNCs 
 
3.1.1 Introduction 
AML is a CSC disease, with the LSC believed to be responsible for treatment resistance, MRD and 
relapse. LSC behaviour is tightly controlled by a complex interplay between intrinsic and 
extrinsic signals with the Hh signalling pathway implicated as both an intrinsic and extrinsic 
mediator of CSC function.   
Whilst components of the Hh pathway have been shown to be expressed in select AML cell lines 
377,379,566 and primary AML MNCs, 378,379,381,382,565,566 no dataset has included all recognised 
components of the pathway. Further, the role of the Hh pathway in AML remains contentious. 
We therefore sought to confirm and then evaluate expression of the Hh signalling pathway in 
select, genetically diverse AML cell lines and within an unselected cohort of primary human AML 
patients.  
 
 3.1.2 Primary human AML MNCs differentially express components of the 
Hh pathway at the gene level 
To determine expression of members of the Hh signalling pathway MNCs from 76 newly diagnosed 
AML patients were studied. Sample characteristics are listed in Appendix 1. 
Whilst in diseases such as CML the LSC is well defined, in AML the phenotype of this primitive 
cell of origin remains to be determined 52,112,121,129, with recent work challenging previously 
accepted concepts 52. Gene expression was therefore performed on unselected PB MNCs 
(leukaemic blasts), and compared to unselected normal bulk MNCs (n=10) from a range of age 
groups (age range 22 – 73 years) comparable to our AML cohort. This is in keeping with published 
work 86,87. RNA was isolated from cells following culture for 24hrs. A standardised approach was 
adopted to minimise confounding factors.  
To account for input cDNA the ΔCT for each gene was calculated by subtracting the CT value of 6 
housekeeping (control) genes from the CT recorded for the gene of interest. ATP5S, β2M, ENOX2, 
GAPDH, TYW1 and UBE2D2 were selected as housekeeping genes, CT values ranged from 3 to 13. 
To ensure accuracy of our results samples were excluded where >2 genes failed due to technical 
reasons – poor technical triplicate, a signal was detected in the no template control (NTC) or the 
reaction failed by Fluidigm®. This stringency was applied to all gene expression analysis 
presented throughout this thesis. 	
Expression levels of the Hh ligands SHH, DHH and IHH, the receptors PTCH1 and SMO, the 
transcription factors GLI1-3, and the pathway modulators PTCH2, SUFU, HHIP, STIL, DISP2 and 
HHAT were quantified by qRT-PCR using Fluidigm® technology. Expression is presented as fold 
change (2-ΔΔCT) relative to our normal control cohort. Expression for DHH and GLI-2 are presented 
as 2-ΔCT as these genes were not expressed by our cohort of normal MNCs (n=10); Figure 3.1.2.1.  
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All three Hh ligands, SHH, IHH and DHH were expressed by our AML cohort. mRNA expression was 
demonstrated in 82.3% (42/51 samples), 83.6% (41/49 samples) and 69% (29/42 samples) for SHH, 
IHH and DHH, respectively, Figure 3.1.2.1. In contrast SHH and IHH were expressed in 6/10 
normal MNCs whilst DHH was not detected. Expression of the receptors SMO and PTCH1 was 
found in 84.2% (45/54 samples) and 78.9% (60/76 samples) of AML cases, respectively, whilst 
expression of GLI-1, GLI-2, and GLI-3 was detected in 52.6% (28/53 samples), 76.2% (32/42 
samples) and 65.8% (35/53 samples) respectively, Figure 3.1.2.1. Finally, PTCH2 was expressed 
in 84.2% of cases (64/76 samples), SUFU in 94.7% (72 samples), HHIP in 67.1% (51/76 samples), 
Figure 3.1.2.1: Variance in the baseline gene expression of members of the Hh signalling pathway 
in an unselected cohort of de novo primary human AML samples (n=76).  
RNA was extracted from cells harvested following culture for 24hrs. Expression levels were quantified 
by qRT-PCR using Fluidigm® technology with 6 housekeeping genes – ATP5S, B2M, ENOX2, GAPDH, TYWI 
and UBE2D2 serving as endogenous control; CT values for these genes ranged from 3 to 13. (A) mRNA 
expression levels are shown as the fold change (2-ΔΔCT) relative to the mean of 10 normal MNC samples. 
The median is presented with error bars showing interquartile range and demonstrating the variability 
in baseline expression between individual AML samples. Red lines highlight a 5-fold change taken as our 
threshold for significance. (B) mRNA expression for DHH and GLI-2 are shown as 2-ΔCT, these genes were 
not expressed by our cohort of 10 normal MNC samples. As in (A) the median is presented with error 
bars indicating the interquartile range. 
For each gene expression was evaluated in the following number of samples: SHH (51), IHH (49), DHH 
(42), SMO (54), PTCH1 (76), PTCH2 (76), GLI-1 (53), GLI-2 (42), GLI-3 (53), SUFU (76), HHIP (76), STIL 
(24), HHAT (22) and DISP2 (22); expression was not determined in all samples for STIL, HHAT and DISP2. 
Sample number otherwise varied for technical reasons – poor technical triplicates, signal detected in 
the no template control or failed reaction by Fluidigm®. Where the number of points on the graph does 
not total the number of samples in which gene expression was evaluated this is due to the gene not 
being expressed by that particular sample.  
SH
H IHH SM
O
PT
CH
1
PT
CH
2
GL
I1
GL
I3
SU
FU
HH
IP
ST
IL
HH
AT
DIS
P2
1×10-0 5
1×10-0 4
1×10-0 3
1×10-0 2
1×10-0 1
1×100 0
1×100 1
1×100 2
1×100 3
2-
Δ
C
T
DH
H
GL
I2
1×10-0 9
1×10-0 8
1×10-0 7
1×10-0 6
1×10-0 5
1×10-0 4
1×10-0 3
1×10-0 2
1×10-0 1
2-
Δ
C
T 
(A) 
(B) 
2-
Δ
Δ
C
T 
	 132	
STIL in 91.7% (70 /76 samples), DISP2 in 68.2% (15/22 samples) and HHAT in 27.6% (6/22 
samples), Figure 3.1.2.1.  
Strikingly, despite the heterogeneity of AML, analysis of an unselected cohort of de novo primary 
human AML samples (n=76) demonstrated deregulation of SMO when compared to normal MNCs 
(p<0.0001) with a significant >5-fold up-regulation demonstrated in 43.4% of cases (23/53 
samples) and a >5-fold down-regulation in 32.1% of cases (17/53 samples), Figure 3.1.2.1. In 
contrast PTCH1 was down-regulated (p=ns) with a >5-fold down-regulation in 39.5% (30/76 
samples), Figure 3.1.2.1. This data is particularly interesting given that PTCH1 has been shown 
to predict imatinib response and thus a promising molecular marker 251. Work in AML however has 
had focused on expression of the Gli transcription factors showing deregulation of the pathway. 
This data adds to that, providing a rationale for considering utilising the Smo inhibitors in AML.   
We acknowledge the Hh pathway is a self-renewal pathway, intrinsic to stem cell function. We 
therefore studied expression of components of the pathway in normal CD34+ selected cells (BM 
CD34+ cells were purchased from stem cell technologies; PB CD34+ cells were isolated from 
normal donors following G-CSF stimulation and apheresis) and normal bulk MNCs to determine if 
expression differed with cell maturity; Figure 3.1.2.2.  
 
 
Most striking was the homogeneity seen within the normal samples, the exception being on 
analysis of the receptors SMO and PTCH1 where a clear distinction between CD34 positive cells 
and MNCs was demonstrated, Figure 3.1.2.2.  
Figure 3.1.2.2: Variance in expression of components of the Hh pathway varied between normal 
bulk MNCs, CD34 select PB and CD34 select BM cells.  
PB CD34+ cells were harvested by G-CSF stimulated apheresis and CD34+ BM cells purchased from Stem 
Cell Technologies. RNA was extracted from recovered cells following culture for 24hrs. Expression levels 
were quantified by qRT-PCR using Fluidigm® technology. Expression levels are shown as 2-ΔCT, with 6 
housekeeping genes – ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2 serving as endogenous control. 
3-5 samples were analysed, where the number does not reach this data has been excluded for technical 
reasons to ensure accuracy. Error bars indicate SD.  
This graph clearly shows whilst there is a degree of variance expression is seen to cluster according to 
cell maturity. 
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Looking first at SMO, there was a statistically significant difference (p=0.019) in expression 
between the bulk MNC and CD34+ selected cells (both BM and PB derived), the populations being 
seen to cluster, with the CD34+ selected cells demonstrating a >10-fold increase in level of 
expression, Figure 3.1.2.2. Expression of PTCH1 differed markedly between the defined groups, 
with a statistically significant difference between CD34 select PB and BM cells (p=0.039), and 
CD34 select BM cells and bulk MNCs (p=0.016), statistical significance was not reached for CD34 
select PB cells relative to bulk MNCs (p=0.052) suggesting expression change on cell maturation, 
Figure 3.1.2.2.  
We questioned whether the differential expression of these regulating receptors correlated with 
pathway activity, hypothesising the pathway was down-regulated or ‘switched off’ with cell 
maturation. Interestingly however, expression of SMO and PTCH1 did not correlate with that of 
GLI-1, expression of GLI-1, the positive regulator, being relatively homogeneous across our 
normal cell populations, Figure 3.1.2.2. GLI-2 is not included within the figure since it was not 
reliably expressed in any of our normal samples. There was either (1) an absence of signal 
following 40 PCR cycles or (2) insufficiently robust data generated - poor technical triplicates 
(greater than 1.5CT difference). Importantly a signal was never detected below a CT of 37 
suggesting if the signal was real expression of GLI-2 in these isolated samples was at a very low 
level. This is particularly interesting considering its role as both a positive and negative 
regulator, and proposed close relationship between each of the transcriptional regulators.  
Considering the striking difference in SMO expression between the CD34 positive cells and bulk 
MNCs we considered our primary de novo AML expression data relative to a population of CD34 
positive cells, Figure 3.1.2.3.  
 
 
As expected, expression was seen to shift in accordance with the change in calibrator from bulk 
MNCs to CD34 positive cells. When CD34 positive normal cells (PB and BM) were used as the 
calibrator SMO expression was found to be down-regulated in 93.2% of AML cases, with 45.7% of 
cases demonstrating a >5-fold down-regulation relative to our cohort of normal CD34 positive 
cells. This marked difference in relative expression according to calibrator population is 
highlighted in Figure 3.1.2.4 with 32.1% showing a >5-fold down-regulation and 43.4% showing a 
>5-fold up-regulation when bulk normal MNCs were used as the calibrator. Recognising AML 
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Figure 3.1.2.3: SMO expression in an unselected cohort of de novo primary AML MNCs relative to 
normal CD34+ selected cells  
PB CD34+ cells were harvested by G-CSF stimulated apheresis and CD34+ BM cells purchased from Stem 
Cell Technologies. RNA was extracted from cells harvested following culture for 24hrs. Expression levels 
were quantified by qRT-PCR using Fluidigm® technology. mRNA expression levels are shown as the fold 
change (2-ΔΔCT) relative to the mean of 6 normal CD34+ select cell populations (PB and BM) with 6 
housekeeping genes – ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2 serving as endogenous control; CT 
values for these genes ranged from 3 to 13. The red line highlights a 5-fold change. 
The median is presented, showing SMO was universally, though variably, down-regulated in the AML 
bulk MNCs relative to normal CD34+ selected cells (BM and PB). Error bars indicate the interquartile 
range, demonstrating the degree of variance between samples.   
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arises from impairment in differentiation and a consequent accumulation of immature myeloid 
progenitor cells the differential expression of a targetable positive regulator with cell 
maturation makes Smo an interesting therapeutic target. Further, it could explain results from 
early phase clinical trials showing a reduction in disease burden with a relative sparing of normal 
haematopoiesis 407, standard therapeutic agents classically being associated with significant, and 
at times life threatening haematopoietic toxicity. An agent that spares an already compromised 
haematopoietic system is therefore very attractive in the clinical setting.  
 
 
Whilst we acknowledge leukaemic blasts are more primitive than mature MNCs arrested 
differentiation is fundamental to the pathogenesis of AML. To compare unselected AML MNCs 
with a selected more primitive normal CD34 expressing population has the potential to eliminate 
fundamental, potentially targetable, differences through population selection. We therefore 
consider it more accurate to compare AML MNCs, leukaemic blasts, to normal MNCs despite these 
marked differences. Gene expression of AML MNCs is thus compared with that in normal bulk 
MNCs throughout this thesis.  
 
3.1.3 SMO expression did not define an expression profile within the 
 Hh pathway 
Whilst deregulation of the Hh pathway has been reported within AML, no publicly 
available dataset has studied all components of the pathway. Further, there is no 
published data analysing the transcriptional relationship between family members 
within AML. We therefore sought to determine the impact of up-regulation of SMO at a 
transcriptional level on other family members. Expression levels were quantified by 
qRT-PCR using Fluidigm® technology as outlined above, 3.1.2. Samples were classified 
according to SMO expression, with high expressers defined as those with a ≥5-fold 
increase in SMO relative to normal MNCs. 26 of our cohort of 76 (34.2%) were stratified 
as high expressers of SMO. Gene expression within high expressers was compared to that 
in a cohort of AML samples demonstrating a <5-fold change in SMO relative to normal 
MNCs. Log transformation of the fold change was performed to analyse expression 
Figure 3.1.2.4: SMO expression in an unselected cohort of primary, de novo, AML MNC samples 
(n=76) relative to normal unselected MNCs and normal CD34+ selected cells. 
PB CD34+ cells were harvested by G-CSF stimulated apheresis and CD34+ BM cells purchased from Stem 
Cell Technologies. RNA was extracted from cells harvested following culture for 24hrs. Expression levels 
were quantified by qRT-PCR using Fluidigm® technology. 6 housekeeping genes – ATP5S, B2M, ENOX2, 
GAPDH, TYWI and UBE2D2 serving as endogenous control. (A) mRNA expression levels categorised 
according to fold change (2-ΔΔCT) relative to the mean of 10 normal bulk MNC samples. (B) mRNA 
expression levels categorised according to fold change (2-ΔΔCT) relative to the mean of 6 normal CD34+ 
select cell populations (PB and BM).  
A clear difference in relative expression, dependent upon comparator cell population, is demonstrated 
suggesting a down-regulation of SMO on cell maturation in normal haematopoiesis.  
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patterns within these defined cohorts according to the unsupervised Eisen approach 
using PermutMatrix software 589. Figure 3.1.3.1.  
 
 
The expression of components of the Hh pathway is shown for 53 of our 76 samples, with an 
equal proportion of samples demonstrating a ≥5-fold increase in SMO (classified as high 
expressers; n=26) and a <5-fold increase in SMO (n=27). 23 samples were excluded from this 
heatmap as the expression of ≥4 genes was not available / excluded. Expression values of 
excluded genes are marked in grey. Clustering was not performed due to missing data points. A 
heatmap was selected to represent this data since it enables comparison between cohorts and 
allows the reader to see the expression profile of individual samples and therefore appreciate 
the degree of heterogeneity.  
Figure 3.1.3.1: Heatmap showing expression of components of the Hh pathway in primary human 
AML MNCs according to SMO expression.  
RNA was extracted from cells harvested following culture for 24hrs. Expression levels were quantified by 
qRT-PCR using Fluidigm® technology. To account for input cDNA the ΔCT for each gene was calculated 
with 6 genes – ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2 serving as endogenous control. Technical 
triplicates were performed for each sample. Log transformation of the 2-ΔΔCT enabled graphical display of 
expression patterns according the unsupervised Eisen approach using PermutMatrix software 506, clearly 
showing expression of components of the Hh pathway to be heterogeneous, and not linked to SMO 
expression. 
≥ 
< 5-fold SMO 
5-fold SMO 
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Whilst a clear expression profile was not demonstrated within SMO high expressers, given the 
degree of heterogeneity and size of our cohort, this observation is not surprising. Interestingly, 
irrespective of SMO expression, SUFU and PTCH2 were shown to be up-regulated, whilst the 
ligands SHH and IHH are shown to be down-regulated relative to normal MNCs.  
 
3.1.4 Components of the Hh pathway are differentially expressed at a 
protein level in primary human AML 
The vast majority of work studying the Hh pathway looks at gene expression, excluding changes 
that may occur post transcription. We therefore sought to determine native protein expression 
of components of the Hh pathway and their relationship to each other and further to pathway 
activity, Gli-1 being recognised as a marker of pathway activity, in an unselected cohort of de 
novo primary human AML and normal subjects.  
Western blots were performed though are not presented due to the marked heterogeneity 
between experiments, raising concerns about the validity of the results, despite considerable 
time and effort optimising protocols. The quality of antibodies against components of the Hh 
signalling pathway is recognised by the scientific community to be an issue, protein data often 
not included in published works. The importance of the BM microenvironment in normal 
haematopoiesis and AML is also recognised. We had planned to evaluate and compare expression 
within the AML blast population, as determined by Western blotting, with that within the BM 
microenvironment, as determined by IHC.  
Following optimisation IHC enabled analysis of components of the Hh signalling pathway at the 
protein level within the BM microenvironment of human AML BMTs (n=37) compared to BMTs 
from normal age-matched controls (n=10). The expression of PTCH1, SMO, GLI-1 and all three Hh 
ligands were analysed. Ligand expression was included to determine whether autocrine or 
paracrine signalling existed in AML. Expression of SHH, DHH, IHH, SMO, PTCH1 and GLI-1 was 
estimated at x10 magnification by two investigators in a blinded fashion. In addition, a 
previously described scoring system was referenced 494 - samples were semi-quantitatively 
classified as positive (or ‘expressing’) if staining was identified in >10% and negative (or ‘non-
expressing) in those with expression below this threshold 494. This work was done with the 
assistance of Mr T Ingman and Dr J Goodlad. I am indebted for their time, skills and knowledge.  
Looking first at the Hh ligands. Expression of SHH was significantly down-regulated (p=0.002) 
within AML BMTs compared to normal BMTs, whilst there was no significant difference in 
expression of IHH or DHH between AML and normal subjects, Figure 3.1.4.1 (A,B&C). 
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Figure 3.1.4.1 A,B&C: : Expression of the Hh ligands in a cohort of primary, de novo AML samples as 
determined by IHC showing SHH to be significantly down-regulated in AML BMTs. 
IHC was performed on human AML BMTs (n=37) and compared to BMTs from normal controls (n=10). 
Expression of the ligands SHH, IHH and DHH was estimated at x10 magnification by two investigators in 
a blinded fashion. (A) Representative images at x10 (inlay x40) demonstrating staining patterns for 
each antibody. (B) Box and whisker plot showing percentage of positive cells per specimen, minimum 
and maximum values are depicted. (C) Pie charts showing the percentage of samples classified as 
negative, and the number classified as positive according to a recognised scoring system 494. by which 
staining intensity is semi-quantitatively classified as negative and positive (staining was considered 
negative if <10% of cells were positive).  
These graphs show SHH was significantly down-regulated (p=0.002) within AML BMTs compared to 
normal BMTs. There was no significant difference in expression of IHH or DHH between AML and normal 
subjects. Statistically significant results are highlighted with p value to the nearest 3 decimal places, 
those not highlighted are not significant (ns).  
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In addition, SHH was noted to demonstrate both nuclear and cytoplasmic expression within the 
AML BMTs but not the normal control BMTs, Figure 3.1.4.2 (B&C). Nuclear staining was seen with 
two different Shh antibodies, raised in different species. Within a BMT specimen, both nuclear 
(strong) and cytoplasmic (weak to moderate) staining was demonstrated implying differing levels 
of production, or reliance, dependent on cell lineage or cell maturity. Further cells within the 
same BMT specimen were seen to stain with differing intensities, implying variable antigen and 
therefore protein concentration. Erythroid cells were identified within erythroid islands as 
negative for SHH, whilst lymphoid cells were strongly positive for SHH.  
Interestingly, SHH showed both nuclear and cytoplasmic expression within the colon control, 
nuclear staining being identified within the colonic crypt bases where colonic SCs reside. Within 
the AML BMTs positive cells were scattered throughout the marrow, neither localising to the 
endosteal osteoblastic or peri-sinusoidal regions. This observation was investigated further, 
presented and discussed in section 3.1.5. 
 
 
Looking next at SMO, PTCH1 and GLI-1. Whilst a marked difference in the expression of PTCH1 
and GLI-1 was seen across both our normal control and AML cohort the difference was not 
significant due to the degree of variance, Figure 3.1.4.3 (A). Interestingly the mean expression 
for SMO was similar between our AML cohort and the normal controls.  
Figure 3.1.4.2: SHH in primary human (A) colon (control tissue) at x4 magnification, (B) normal 
BMT at x10 magnification and (C) AML BMT at x20 magnification showing cytoplasmic and nuclear 
expression. (Bi & Ci) are magnified images showing cytoplasmic (Bi) and nuclear and cytoplasmic 
staining (Ci). 
To determine native expression of SHH within the unique BM microenvironment IHC was performed on 
human AML BMTs (n=37) and compared to BMTs from normal controls (n=10). Each image is 
representative of those captured and studied for each population cohort, clearly demonstrating the 
staining pattern of SHH.  
The colon control SHH showed both nuclear and cytoplasmic expression, nuclear staining being 
identified within the colonic crypt bases where colonic SCs reside. Both nuclear and cytoplasmic 
expression was seen in AML BMTs whilst only cytoplasmic staining was demonstrated in the normalBMTs. 
(A) (B) (C) 
(Bi) (Ci) 
	 140	
Referencing the previously described scoring system 494 statistical significance was however seen. 
25% of our AML samples were classed as expressing GLI-1 according to this system as opposed to 
none of our normal controls (p<0.0001) whilst 85% of our AML samples expressed PTCH1 as 
opposed to 50% of our normal controls (p<0.0001), Figure 3.1.4.3 (B).  
Whilst the scoring system is recognised, and validated, within the scientific community for the 
purpose of this thesis we chose to present our data in two formats –unmanipulated, showing 
expression levels, and categorised, highlighting expression patterns, according to the validated 
scoring system 494.  
No relationship between expression levels of these proteins was demonstrated. It is important 
however, to consider the sensitivity of IHC. IHC does not differentiate between a membranous 
and cytoplasmic staining pattern and a purely cytoplasmic staining pattern. Classical, canonical 
signalling is controlled by the internalisation of Ptch1, removing its repression of Smo thereby 
allowing pathway activity. Whilst the lack of a relationship between SMO and PTCH1 is therefore 
potentially explained by the inability to determine functional from total protein levels the lack 
of a relationship between the receptors and GLI-1 raises the question of non-canonical signalling 
and pathway crosstalk, additional proteins determining GLI-1 expression.  
Our work clearly raises further questions: Is SMO an appropriate target given the relative 
similarity in its expression in normal and AML cases? Should we consider GLI-1 as our target when 
considering the Hh signalling pathway? Importantly however we have uniquely shown the Hh 
signalling pathway to be deregulated at a protein level as well as gene level in AML.  
This work does however suggest, as with other targeted therapies, that universal targeting of the 
Hh signalling pathway would not be appropriate, nor necessarily effective since GLI-1 was only 
expressed in a subset of cases (25%). Expression at a level of 25% in such a heterogeneous disease 
however is exciting and provides a clear rationale for considering this pathway as a potential 
therapeutic target. Finally, the marked difference in expression across our cohort of AML 
samples is also interesting. The phenotype and genotype of these patients in our opinion requires 
further evaluation in a bid to translate these results into the clinic.  
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Figure 3.1.4.3: Expression of PTCH1 and GLI-1 in a cohort of primary de novo AML BMTs relative to 
normal BMTs. 
IHC was performed on human AML BMTs (n=37) and compared to BMTs from normal controls (n=10). 
Expression of the receptors PTCH1 and SMO and the positive transcription regulator GLI-1 was estimated 
at x40 magnification by two investigators in a blinded fashion. (A) Box and whisker plot showing 
percentage of positive cells per specimen, minimum and maximum values are depicted. Expression of 
PTCH1, SMO or GLI-1 was not statistically significant due to variance. (B) Bar graph showing the 
percentage of samples classified as negative and positive according to a recognised scoring system 494 
by which staining intensity is semi-quantitatively classified (staining was considered negative if <10% of 
cells were positive). There was a statistically significant difference seen in the percentage of PTCH1 and 
GLI-1 positive cells (p<0.0001 by the Chi-Squared test). A relationship between the receptors PTCH1, 
SMO and GLI-1 was not apparent in the normal or AML BMTs.  
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3.1.5 Post-translational modification of SHH is impaired in AML  
As shown in Figure 3.1.4.2 IHC of primary de novo human AML BMTs had shown SHH expression to 
be cytoplasmic, as expected, and, interestingly, also nuclear. A nuclear expression pattern has 
previously been reported, and recognised in subsets of central nervous system cells 594. Nuclear 
staining was also identified within the colonic crypt bases, colon tissue serving as the positive 
control (Figure 3.1.4.2).  
Considering this further, colonic SCs reside within the crypt bases. As colonic SCs differentiate 
they lose their SC potential and move away from the crypt base towards the villous apex through 
the transit amplifying and differentiating zones. Additionally, SHH undergoes post-translational 
modification enhancing its activity and modifying its diffusion capacity.  
We hypothesised nuclear expression of SHH reflected attenuated post-translational modification 
within the SC population. ICC was performed on normal PB MNCs, obtained by G-CSF stimulation 
and apheresis or venepuncture, and sorted by FACS to allow analysis of patterns of SHH 
expression in defined cell populations. The following populations were sorted, stained and 
analysed: uncommitted early progenitor / SC (CD34+), myeloid - mature (CD11b+) and 
intermediate (CD33+). The pattern and intensity of SHH differed according to cell population. A 
nuclear location was exclusively seen in the normal HSC / progenitor populations (defined by 
their expression of CD34 or CD33). No detectable levels of SHH were demonstrated in mature 
neutrophils.  
Hhat is the sole acetyltransferase involved in SHH processing, we therefore sought to determine 
its expression within the HSC / progenitor populations, Figure 3.1.5.1. There was a 20-fold 
reduction in HHAT in normal HSCs (defined immunophenotypically as CD34+CD38-) compared to 
normal bulk MNCs (p=0.008). 
 
 
To verify our findings, we looked at microarray-based gene expression data previously generated 
within the Copland laboratory, GSE 47927. This enabled us to compare distinct populations 
within the haematopoietic hierarchy. Expression of HHAT was reduced in normal HSCs (defined 
immunophenotypically as CD34+CD38-CD90+D45RA-) compared to the more differentiated GMP 
and MEP populations (p=0.032 and p=0.001 respectively). Aside from normal subpopulations this 
array focused on CML, looking at expression levels in each sub-population within -CP, -AP and -
BC samples. We therefore studied HHAT in CML-BC, using this as a paradigm for AML. 
Interestingly there was a significant difference in expression between normal HSCs and CML-BC 
HSCs (p=0.001), with expression being lower within the CML-BC samples suggesting a down-
CD34 v MNC
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Figure 3.1.5.1: HHAT expression in HSCs relative to normal bulk MNCs.  
RNA was made from CD34+ selected cells (n=6) and MNCs (n=29). Expression levels were quantified by 
qRT-PCR using Fluidigm® technology. mRNA expression levels are shown as the fold change (2-ΔΔCT) 
relative to the mean of 6 normal CD34+ samples with 6 housekeeping genes – ATP5S, B2M, ENOX2, 
GAPDH, TYWI and UBE2D2.  
This data shows HHAT to be down-regulated in normal HSCs compared to normal bulk MNCs (p=0.008 
according to Fisher’s exact test).   
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regulation of autocrine Hh signalling. It is however important to acknowledge this microarray had 
analysed 2 myeloid BC-CML samples. Further, BC-CML is thought to arise due to continued BCR-
ABL activity and consequent increased genetic instability, with many patients carrying multiple 
mutations and chromosomal aberrations. Considering these factors it is important therefore not 
to overinterrept this result but rather view it with interest and recognise further work is required 
to confirm and validate this consideration.  
We had shown SHH to be differentially expressed by leukaemic blasts and normal MNCs, with 
SHH reduced at a protein level and evidence of impaired post-translational modification through 
down-regulation of HHAT in CD34+ cells relative to bulk MNCs. We had shown the positive 
regulator SMO to be up-regulated and the negative receptor PTCH1 to be repressed, with 
pathway activity evidenced by up-regulation of one of the prime transcriptional effectors GLI-2. 
We therefore sought to determine whether, as in B-cell lymphomas 364,595, the Hh pathway was 
activated in a paracrine fashion, through signals produced by neighbouring cells. Levels of the 
SHH ligand in the plasma of AML patients (n=11) and normal controls (n=6) was therefore 
measured by ELISA, Figure 3.1.5.2. 
 
 
In keeping with the disease, marked heterogeneity in the plasma concentration of SHH was 
demonstrated across our cohort of AML samples; the SD was 10-fold greater within the AML 
samples. Interestingly whilst the mean concentration of SHH in AML was 2-fold greater the 
median was comparable. These results suggest the SHH ligand is increased, indicating paracrine 
activity, in a subset of AML cases. Had time allowed we would have repeated the experiment to 
increase statistical power and sought to obtain paired samples enabling parallel measurement of 
circulating SHH, cellular SHH and gene expression data. 
 
There is already published evidence supporting a role for the Hh signalling pathway in AML - 
leukaemic cell lines and primary AML cells shown to express Gli-1 and Gli-2, indicative of 
active Hh signalling 69. Further, genetic and pharmacological inhibition of Gli-1 has been 
shown to have anti-leukaemic effects and to be capable of overcoming chemoresistance 
378,379. Through this section we have sought to further understand the role of the Hh 
signalling pathway in AML and normal haematopoietic cells.  
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Figure 3.1.5.2: SHH concentration within serum from primary, de novo AML and normal subjects by 
ELISA.  
The mean concentration of SHH was determined by ELISA, as described in methods 2.2.3.6, in AML was 
4304pg/ml (SD 6769pg/ml) compared to 2010pg/ml (619pg/ml) in normal samples though the results 
were not statistically significant.  
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Uniquely we have studied all components of the Hh signalling pathway at the gene level, 
interestingly showing SMO to cluster, with a cohort of both high and low expressers. 
Additionally whilst gene expression studies simply showed the genetic heterogeneity 
expected of AML when samples were classified according to SMO expression genes associated 
with poor prognosis and chemoresistance were found to be up-regulated in those samples 
demonstrating high levels of SMO. This is data we are still analysing, in particular referencing 
it to clinical data where available. We have looked at gene expression relative to both 
normal bulk MNCs and CD34+ select cells, our data mirroring published data, the results of 
which vary notably dependent on the comparator cell population and highlighting the 
difficulties faced when considering gene expression in AML. Additionally we have studied 
components of the pathway at a protein level, uniquely showing the location of SHH to differ 
according to cell maturity with HHAT, responsible for the post-translational modification of 
SHH and thus its cellular movement, found to be reduced in CD34+ select cells relative to 
mature MNCs.  
Having confirmed expression of components of the Hh signalling pathway in haematopoietic 
cells, with expression of GLI-1 serving as evidence of pathway activity, we sought to 
determine if haematopoietic cells possessed primary cilia, the machinery required to enable 
canonical Hh signalling and thus provide a rationale for the use of Smo inhibitors in AML.  
 
3.2 To determine whether haematopoietic cells, both normal and 
leukaemic, possess primary cilia.   
 
3.2.1 Introduction 
The strong connection between primary cilia and the Hh pathway was first reported in 2003 450. 
Following on from this, numerous other groups have demonstrated the relationship between 
components of the pathway and primary cilia 337,430,450–457. It is now widely accepted that 
vertebrate canonical Hh signalling requires primary cilia 417. Additionally, considering the ability 
of cilia to influence cell cycle and their involvement in signalling pathways, including Hh, Hippo 
and Wnt, a role for primary cilia in oncogenesis has begun to be hypothesised with early research 
supporting this theory 436–446.  
Haematopoietic cells have however, until recently, been considered to be among the few cells 
not to possess primary cilia 416,428. In 2013, the immunological synapse of T cells was shown to be 
highly dependent on IFT proteins and, therefore considered a functional homolog of the primary 
cilium 426. Whilst in 2014, work studying bone mechanotransduction in sheep identified primary 
cilia in 4% osteocytes, 4.6% bone lining cells, and in approximately 1% of cells within the BM 
(though these cells were not studied in greater depth) 610. Finally, in 2016, during the write up of 
this PhD, primary cilia were shown to be present on human PB and BM haematopoietic cells 
566,611. Further, these primary cilia were shown to be functional and to play a role in Hh 
signalling. Interestingly, analysis of AML cell lines (KG1, KG1a, and K562) demonstrated primary 
cilia to be less frequent and frequently dysmorphic 566,611. 
During the experimental phase of this PhD, we had questioned the conflicting results seen in 
vitro and in vivo with Smo antagonists. Further, whilst work had shown the Hh signalling pathway 
to be involved in cytotoxic T lymphocyte function, and the immunological synapse to potentially 
represent a modified cilium 426 whether a haematopoietic cell, normal or malignant possessed 
primary cilia remained unanswered. We therefore sought to determine whether primary human 
haematopoietic cells within the BM microenvironment or circulatory system, or AML cell lines 
possessed primary cilia, and therefore the machinery to enable canonical Hh signalling. We 
hypothesised HSPC would possess primary cilia within the BM but that these organelles would 
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become defunct on cell maturation and migration into the PB, this differential expression 
accounting for differences reported between in vitro and in vivo studies and the relative absence 
of haematopoietic toxicity following use of Smo antagonists in early phase clinical trials.  
 
3.2.2 Primary cilia were identified in haematopoietic cells within the bone 
marrow microenvironment 
ICC was performed to determine the presence or absence of primary cilia within the BM 
microenvironment. Briefly, FFPE BMT sections were deparaffinised and rehydrated prior to 
antigen retrieval. An unselected cohort of primary de novo human AML BMTs (n=25) and a cohort 
of normal control BMTs (n=10) were analysed. Within our AML cohort, the pathology report of 
80% reported sheets of blasts replacing or near replacing (>90%) the marrow space, enabling 
greater confidence in considering the identified primary cilia to arise within haematopoietic 
cells. Primary cilia were defined by co-localisation of acetylated α- and γ-tubulin, visualised 
using a Zeiss 710 confocal scanning microscope (60× oil immersion optics). Confocal microscopy 
enabled co-localisation of the two antibody signals and therefore proteins to be confirmed 
through z sections. Additionally, Image J enabled us to generate a model of fluorescence 
intensity mathematically confirming co-localistaion of the antibody signals 612, removing observer 
bias / interpretation. Cell morphology and cell location relative to sinusoids and bone trabeculae 
was recorded. Excitingly, primary cilia were identified in all AML (n=25), and 20% of normal 
(n=10)	BMTs by ICC, Figure 3.2.2.1. 
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Expression of primary cilia within our normal cohort was at a low frequency of <1% cells. In 
contrast the number of primary cilia identified in our AML cohort varied significantly in keeping 
with the disease’s heterogeneous nature. Whilst technical reasons precluded an accurate 
absolute number or percentage of cells expressing primary cilia within each specimen the 
percentage was approximated at <1% to 5% of cells. As an additional comparator we studied the 
expression of primary cilia within CML, a role for Hh signalling better established in this disease 
setting 249,251–253,412,613. In this setting, primary cilia were again identified in a cohort of ten CP-
CML BMTs. Expression was uniform, primary cilia being identified in approximately 1% of cells in 
all samples. The frequency of expression, even within AML, did not allow conclusions to be 
drawn regards cellular location within the BM – we had considered primary cilia, if limited to the 
HPSC, would be found preferentially within areas classically considered BM SC niche (in close 
vicinity to bony trabeculae or vascular sinusoids).  
The gold standard technique for identifying primary cilia is EM. Critical to EM is the fixation 
process, however, fresh human BMTs were not available. EM was therefore performed on human 
FFPE BMTs following deparaffinisation, rehydration and fixation in glutaraldehyde / 
paraformaldehyde. A cohort of 3 AML and 3 normal BMTs were studied. In addition, we analysed 
4 glutaraldehyde / paraformaldehyde fixed mice femurs. Mice femurs, fixed in optimal 
conditions for EM, were studied in parallel to the human BMTs since we had concerns tissue 
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Figure 3.2.2.1: Representative confocal images depicting primary cilia within normal human and 
primary, de novo human AML BMTs and a computer generated image depicting fluorescence signal. 
FFPE BMT sections were deparaffinised and rehydrated prior to antigen retrieval using the Thermo 
ScientificTM PT Module. Sections were stained for DAPI, acetylated α-tubulin and γ-tubulin prior to 
visualisation with a Zeiss 710 confocal scanning microscope (x60 oil immersion optics). Positive and no 
primary antigen controls were included with each experiment; settings were adjusted between 
samples.  
 (A, C & D) Representative confocal images from FFPE AML BMTs (n=25) and (B) normal (n=10) primary 
human BMTs clearly showing the presence of primary cilia. Primary cilia were defined by co-localisation 
of acetylated α and γ tubulin, (A) confirmed on z sections and through (E) computer generated models 
of fluorescence intensity. 
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architecture might be distorted during deparaffinisation and rehydration. Margaret Mullen, to 
whom I am indebted, largely performed this work.  
Primary cilia were identified in cells, which morphologically bared all the characteristics of 
haematopoietic progenitor cells by SEM and TEM 614–616, Figure 3.2.2.2.  Included in the figure are 
accepted and validated SEM and TEM primary cilia images for comparison 615,616.  
 
 
 
Finally, whilst primary cilia were identified on cells that, morphologically, were medium in size 
with a high nuclear to cytoplasmic ratio, we were unable to definitively label these cells 
haematopoietic in origin. In this respect, we tried staining our samples with additional primary 
antibodies (haematopoietic - CD45, CD34 and mesenchymal – CD44, CD90 and CD105) to confirm 
or refute their haematopoietic nature. This took considerable optimisation; the antigen retrieval 
process was felt to potentially damage the CD antigens and there was a need to carefully select 
our primary and secondary antibody cocktail to ensure specificity, minimise spectral overlap and 
be detectable using a Zeiss 710 confocal scanning microscope. An antibody cocktail containing 
acetylated α- and γ- tubulin, CD45 and a nuclear stain (DAPI) was optimised. Samples (human 
AML BMTs n=5 and normal human BMTs n=3) were mounted on coverslips (1cm in diameter) 
coated with carbon grids enabling each cell of interest to be ‘mapped’ for future identification 
and analysis of the cell’s ultrastructure by EM. This process was technically challenging and 
labour intensive. Difficulties included (1) cutting the sections sufficiently thin to enable EM to be 
performed, (2) mounting the sections on these small and delicate coverslips, (3) ensuring 
sections and carbon coating remained adherent to the coverslips during the antigen retrieval 
process, (4) ensuring optimal staining with four primary antibodies and three fluorochromes, and 
(5) visualising and mapping the desired cell. Primary cilia were identified within CD34+ cells in 
one sample, however, the sample was burnt during image capture, before the image had been 
sufficiently captured. In five samples, the process failed to produce an evaluable specimen 
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Figure 3.2.2.2: Representative SEM and TEM images depicting primary cilia within primary human 
de novo AML BMTs. 
EM was performed as described in methods 2.2.5. (A) Representative SEM image showing a cell 
independently identified as haematopoietic with a primary cilia and (Ai) SEM image of kidney primary 
cilium for comparison 614. (B) Representative TEM image showing  a cell independently identified as 
haematopoietic with a primary cilia and (Bi) cell and its primary cilium 615. 
(Ai) (Bi) 
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either due to distorted cell architecture (n=2), inadequate fixation - the sample therefore 
moving under the microscope precluding image capture (n=1) or poor staining quality / 
significant auto fluorescence (n=2). In two instances, no cilia were identified. For these reasons 
despite the process being performed on eight samples no images are available. 
We had shown primary cilia to be present within the BM, and satisfied ourselves they were 
present on haematopoietic cells. We therefore sought to determine whether they were present 
on haematopoietic cells within the circulatory system. ICC was performed on bulk AML MNCs 
(n=3), normal bulk PB MNCs (obtained by venepuncture (n=3)) and normal FACs sorted cell 
populations. The following populations were sorted, stained and analysed: uncommitted early 
progenitor / SC (CD34+, n=2), myeloid - intermediate (CD33+, n=2) and mature (CD11b+, n=3) 
and lymphoid - T (CD3+) and B (CD19+) (both n=3). In addition, ICC was performed on seven 
selected, genetically diverse AML cell lines including the KG1a cell line.  
Whilst the cytoskeleton was clearly and beautifully demonstrated, and in cases the centrosome 
and mitotic spindle, primary cilia were not identified within our AML cell lines, AML or normal 
MNCs or selected populations, Figure 3.2.2.3. The presence of primary cilia on haematopoietic 
cells within the BM microenvironment and absence on ‘circulating’ or ‘suspension’ cells suggests, 
as we had hypothesised, that primary cilia are lost once haematopoietic cells mature and 
migrate from the BM microenvironment. Excitingly, the absence of primary cilia, and thus the 
machinery to enable canonical Hh signalling, on mature / maturing haematopoietic cells 
potentially explains the differential results seen in vitro and in vivo, and further the relative 
sparing of haematopoietic toxicity in clinical trial.  
 
 
 
We acknowledge our data conflicts with that now published - Singh et al. reporting MNCs isolated 
from the PB and BM and AML cell lines (KG1, KG1a, and K562) possess primary cilia 566,611. It is 
important to note experimental techniques were different – Singh et al. analysed PB and BM 
MNCs directly after isolation without culture, in contrast our samples were cultured for 24hrs 
prior to analysis. Further, whilst the fluorescence intensity profiles show acetylated α- and γ-
tubulin to co-localise, it is important to note, as the authors do, the difference in the shape of 
the fluorescent signal of acetylated α-tubulin between the mouse embryonic fibroblasts (NIH3T3) 
used as a positive control and that demonstrated in the haematopoietic cells (PB and BM) and 
Figure 3.2.2.3: Representative ICC images at x100 magnification depicting an absence of primary 
cilia in circulating haematopoietic cells. 
ICC was performed on normal PB MNCs sorted by FACS (n=3), seven genetically diverse AML cell lines 
and 3 primary, de novo AML MNC samples. The normal and AML samples were sorted to enable analysis 
of the following populations: uncommitted early progenitor / SC (CD34+, n=2), myeloid - mature 
(CD11b+, n=3) and intermediate (CD33+, n=2) and lymphoid - T (CD3+) and B (CD19+) (both n=3) 
populations were selected. Cells were fixed, permeabilised and stained with α- and γ-tubulin. Nuclei 
were stained with DAPI. Images were visualised with a Zeiss TS100 inverted microscope.  
This representative image of mature CD11b+ myeloid cells clearly shows the absence of primary cilia. 
Primary cilia were absent from all of the sorted cell populations. 
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AML cell lines. Within the NIH3T3 cells, the acetylated α-tubulin was seen as a long, thin 
projection, arising from the basal body. In contrast, within the primary MNCs (PB and BM) and 
AML cell lines, the primary cilia were seen to be shorter, the signal from each antibody less 
distinct.  
Considering the identification of primary cilia within haematopoietic cells was challenging, we 
had determined strict criteria that needed to be fulfilled before we definitively recorded the 
signal as that of a primary cilium. Signal patterns as shown by Singh et al. would not, according 
to our criteria, derived following extensive review of published images, have been classified as 
primary cilia. On close inspection of the acetylated α-tubulin images for the PB MNCs the signal 
is composed of two distinct dots rather than a single tubular projection, the images being more 
consistent with those of a centrosome. Further, looking at the images for BM MNCs, whilst the 
acetylated α-tubulin signal appears as a single dot the images for γ-tubulin are significantly 
impaired by the degree of background signal. Considering the numerous roles acetylated α- and 
γ-tubulin play within the cell, it is important to establish whether these signals represent true 
primary cilia or, as shown in cytotoxic T lymphocytes 426, a modified cilium. Our discounted 
images were not dissimilar to those published by Singh et al. Interestingly however, whether true 
or modified, these organelles are shown to be functional, and haematopoietic cells utilising them 
to facilitate canonical (ligand-mediated) Hh signalling and pathway activity. Finally, the authors 
report the presence of primary cilia on virtually all PB and BM MNCs. This conflicts with work 
published in 2014 identifying primary cilia in approximately 1% of cells within the BM (though 
these cells were not studied in greater depth, and the work was performed in sheep) 610. This 
frequency data is however, more in line with our data. Considering their, and our functional data 
presented in Chapter 4, perhaps these organelles do represent modified primary cilium and 
therefore an ongoing ability to respond to Smo inhibition, irrespective of stage of maturation / 
microenvironment.  Whether primary cilia are, with time, accepted to be present on 
haematopoietic cells, and further those in the circulation or simply those within the BM niche is 
hugely exciting and remains to be determined.  
 
3.3 To determine whether increased Hh activity resulted from activating 
mutations within Smo 
 
3.3.1 Introduction 
We had shown deregulated mRNA expression of components of the Hh pathway, with pathway 
activity evidenced by GLI-2 expression. In addition, we had demonstrated the Hh pathway to be 
deregulated at a protein level, GLI-1 being up-regulated within the BM microenvironment 
relative to normal controls in keeping with increased pathway activity. In addition, circulating 
SHH was demonstrated following analysis of serum from a cohort of AML subjects. Whilst the 
median concentration was comparable to that demonstrated in normal control subjects, marked 
variation was observed within the AML cohort indicating an importance, possibly reliance, in a 
subset of AML cases. These results do not, however, account for the increased Hh activity 
observed at both a gene and protein level. Constitutive pathway activation through gain-of-
function mutations and epigenetic changes in the positive regulator Smo have been observed in a 
number of solid malignancies 370,371. Whilst epigenetic modifications have been observed in a 
cohort of paediatric AML patients, correlating with disease status 372 mutations have not been 
identified in haematological malignancies 378. Pathogenic missense mutations in exon 9 and 10 of 
the SMO gene have been demonstrated in BCCs 367. Further an insertion mutation in exon 1 and 
missense mutations in exons 9 and 12 of the SMO gene have been found in gastric tumours, 
though these do not appear to be driver mutations 617. We therefore sought to determine if a 
mutation or mutations within SMO could be responsible for our findings. 
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3.3.2 Sanger sequencing did not identify a mutation in SMO to account for 
the increased activity in this cohort 
Our data, as discussed in the preceding sections, and that published by others 378,381,382,618, clearly 
shows the Hh pathway to be deregulated in AML. We therefore considered whether a gain-of-
function mutation within Smo might account for the increased activity. No mutations had been 
identified in haematological malignancies, we therefore chose to sequence each of the twelve 
exons rather than adopt a targeted approach. Once optimised Sanger sequencing was performed 
on an unselect cohort of primary de novo human AML samples (n=36). This work was performed 
in collaboration with Dr E Dobbin to whom I am indebted for her time, knowledge and expertise.  
 
 
Figure 3.3.2.1 A: Representative Sanger sequencing chromatographs.  
Sanger sequencing was performed on an unselected cohort of primary, de novo human AML samples 
(n=36). Each of the twelve exons of SMO were sequenced. Select chromatographs are shown, in each 
case the wild-type sequence (wt) is depicted at the top. 
(A) No abnormality, (B) 920+79C>T Intron 4 dbSNP rs2075778 Reference 1000 Genomes Project, clean 
preparation, (C) 921-84 T>C Intron 4 dbSNP T>C rs2075779 Reference 1000 Genomes Project, poor 
preparation but still analysable. 
(C) 
(A) 
(B) 
	 151	
 
 
We did not identify a somatic mutation in SMO using the COSMIC database as mutation reference 
in our cohort by Sanger sequencing, Figures 3.3.2.1A&B. In keeping with the genetic instability 
and heterogeneity of AML, a number of silent and missense mutations were identified (mean 1; 
range 1-3). All samples were shown to contain single nucleotide polymorphisms (SNPs) (mean 4; 
range 3-8), though the effects of these SNPs are unknown and deserve further consideration. 
Whilst we are reluctant to conclude an absence of mutations within SMO in AML due to our 
cohort size we also recognise mutations, albeit at a low level, were identified in a cohort of 39 
histologically variable gastric tumors 617. Additionally, paired RNA / protein and DNA samles were 
not available precluding correlation with Smo expression and pathway deregulation, this is an 
area we believe worthy of further investigation – ‘is SMO the driver of Hh deregulation?’ 
Looking at those malignancies within which SMO mutations have been identified, it is important 
to recognise the frequency is low in most – within a carefully defined subset of 
medulloblastomas, recognised to have aberrant Hh activity termed ‘sonic-hedgehog-driven 
medulloblastoma’, mutations average approximately 15% 619 whilst the frequency within gastric 
malignancies is reported as approximately 5% 617. Further, whilst the frequency within BCC has 
been reported at up to 50%, this is in those cases demonstrating resistance to Smo inhibitors 620, 
thereby considered a selected population. It is important therefore to consider our study may 
have been insufficiently powered to detect a mutation considering the intrinsic heterogeneity of 
AML 
 
 
 
 
Figure 3.3.2.1 B: Schematic highlighting the type and position of genetic abnormalities in SMO in 
an unselected cohort of primary, de novo human AML samples (n=36). 
Sanger sequencing was performed to obtain full length coding sequences in a cohort of 36 de novo 
primary human AML samples. The COSMIC database served as mutation reference. Data is 
diagrammatically represented showing type, position and frequency of genetic abnormalities. The 
missense mutation was classed as C0 by Align GV, and predicted to be tolerated with a score of 0.81; 
substitution mutations were synonymous variants.  
A mutation was not identified however in keeping with the genetic instability and heterogeneity of AML 
all samples contained single nucleotide polymorphisms (SNPs) with an average of 4 SNPs detected per 
sample (range 1-7); the effects of these variants are unknown.  
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3.4 To determine the association of the Hh pathway on prognosis in AML 
 
3.4.1 Introduction 
We had shown components of the Hh pathway to be deregulated at a gene level, in keeping with 
published data 378,381,382,618, and at a protein level; with pathway activity again demonstrated at 
both a gene and protein level. In addition, we had shown haematopoietic cells possess primary 
cilia, enabling canonical Hh signalling within the BM microenvironment. We therefore questioned 
whether deregulation of components of this pathway had prognostic implications. A number of 
groups have published on the negative impact of GLI-2, and to a lesser extent GLI-1 378,381,382; 
with a significant association being reported between GLI-2 and the poor prognostic marker 
FLT3-ITD 325,378,382. The impact of other members of the pathway remains to be determined, 
though co-expression of SMO (p=ns) and GLI-1 (p=0.002) has been shown in GLI-2 expressers 
suggestive of canonical pathway activation 378. The influence of Hh signalling on disease 
phenotype and, consequently clinical outcome, however remains to be determined. We 
therefore sought to correlate our expression data with patients' baseline characteristics and 
clinical outcome.  
 
3.4.2 Genes associated with a poor prognosis were up-regulated in our 
cohort of samples with high expression of SMO  
We considered whether, on considering the wide range of downstream targets of the Hh 
signalling pathway, we could identify a gene expression profile specific to those samples with up-
regulated SMO. In this respect, whilst there is considerable evidence to support the role of the 
Hh signalling pathway in AML 69, and its correlation with the FAB classification M4 phenotype 379 
and FLT3-ITD mutation 325,378,382 the impact of pathway deregulation on downstream targets and 
other SC pathways is unknown. A >100-gene signature encompassing a wide range of downstream 
targets was therefore studied. We selected members of the self-renewal pathways and key 
downstream targets following a literature review inclusive of both solid and haematological 
malignancies. Genes selected included the ABC transporters, those involved in ‘intrinsic’ cell 
death, cell cycle regulators, components of the BMP, EMT, Notch, TGFβ and Wnt pathways, DNA 
methyltransferases, pluripotency regulators, proteases, transcription factors and tyrosine 
kinases. Expression was calculated as 2-ΔΔCT, allowing comparison of levels of mRNA expression 
between primary AML samples. Samples were classified according to SMO expression (high 
expressers defined as those with a ≥5-fold increase in SMO relative to normal MNCs). Gene 
expression within this cohort was compared to that demonstrated in those AML samples 
demonstrating a <5-fold change in SMO relative to normal MNCs (n=50); Figure 3.4.2.1. We 
required a gene to be expressed in > 10 samples within each cohort to be considered in our 
analysis. Expression values were excluded if there was a greater than 1.5CT difference between 
technical triplicates or two of the technical triplicates failed in either the AML or comparator 
(normal) sample.  
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There was a >5-fold up-regulation of genes associated with chemoresistance and poor survival in 
both high and low SMO expressing patients relative to our normal cohort. These genes included 
ABCC1, CD44, DNMT3B, ETV6, FOXM1, KIT, MECOM, MMP2, MYB, SNAIL1 and ZEB1. Further, there 
was a 4-5-fold reduction in the pro-apoptotic genes BAK, BAX and BAD. These genes are 
associated with (1) determining cell behaviour / fate (FOXM1, KIT, MECOM and ZEB1) (2) 
chemoresistance (ABCC1, DNMT3B, KIT, MMP2, SNAIL1 and ZEB1) and (3) poor prognosis (CD44 
and ZEB1). There was a statistically significant difference in the expression of ABCC1 (p=0.011), 
using the unpaired t-test with Welch’s correction, between the two cohorts with expression 
greater in the SMO high expressers. Interestingly patients with high levels of SMO expression also 
demonstrated higher levels of CD44, ZEB1 and SNAIL1 when compared to the low SMO expressing 
patients. CD44, ZEB1 and SNAIL1 are linked to EMT transition, with high CD44 expression 
correlating to lower overall survival in AML 590. The absence of a statistical significance was 
considered to reflect the degree of variance between samples, and sample size.  
It is important to consider a couple of noteworthy observations in greater detail. Published data 
has shown NUMB to be increased in the absence of Smo and, to show an upward trend following 
pharmacological inhibition of Smo 252. Our data shows NUMB to be decreased in AML relative to 
our normal cohort. Further there was a difference though this was not statistically significant 
between our two cohorts of AML with a 2-fold reduction in NUMB in patients with high levels of 
SMO expression and a 4-fold reduction in the low SMO expressing patients, Figure 3.4.2.2.  
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Figure 3.4.2.1: Expression of genes associated with chemoresistance, and poor survival, according 
to SMO expression.  
RNA was made from cells harvested following culture for 24hrs. Expression levels were quantified by 
qRT-PCR using Fluidigm® technology. mRNA expression levels are shown as the fold change (2-ΔΔCT) 
relative to the mean of 10 normal MNC samples with 6 housekeeping genes – ATP5S, B2M, ENOX2, 
GAPDH, TYWI and UBE2D2 serving as endogenous control. A ≥ 5-fold change relative to normal MNCs 
(n=10) was categorised as high SMO expression. The red lines indicate a 5-fold change. Results are 
depicted in a box and whisker plot showing median, min and max values.  
In addition to the up-regulation of these genes in AML relative to normal MNCs this graph shows the 
median expression of CD44, DNMT3B, FOXM1, KIT, MECOM1, MMP2, SNAIL1 and BAD to be increased in 
SMO high expressers compared to those demonstrating a <5-fold change in SMO relative to normal 
MNCs. The unpaired t test with Welch’s correction demonstrated a statistical significant difference in 
the expression of ABCC1 (p=0.011).  
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Additionally, HOXA3 and HOXA9 were up-regulated within patients with high levels of SMO 
expression relative to the low SMO expressing patients though this was not significant, Figure 
3.4.2.3. The HOX genes are recognised to play a significant role in haematopoiesis 591, with 
aberrant expression extensively reported in AML and implicated in the process of malignant 
transformation 592. Further, an association between the Hox genes and Hh signalling pathway has 
been reported 593, both involved in the process of development and cellular patterning. Whilst an 
association between aberrant Hh signalling and members of the Hox family might therefore be 
anticipated, it is interesting to consider the role of these expression changes in the malignant 
transformation process. 
 
 
 
Figure 3.4.2.2: Expression of NUMB according to SMO expression.  
RNA was made from cells harvested following culture for 24hrs. Expression levels were quantified by qRT-PCR using 
Fluidigm® technology. mRNA expression levels are shown as the fold change (2-ΔΔCT) relative to the mean of 10 
normal MNC samples with 6 housekeeping genes – ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2 serving as 
endogenous control. A > 5-fold change relative to normal MNCs (n=10) was categorised as high SMO expression. The 
red lines indicate a 5-fold change. Results are depicted in a box and whisker plot showing median, min and max 
values showing NUMB was increased in high SMO expressers though this was not significant.  
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Figure 3.4.2.3: Expression of HOXA3 and HOXA9 according to SMO expression.  
RNA was made from cells harvested following culture for 24hrs. Expression levels were quantified by qRT-PCR using 
Fluidigm® technology. mRNA expression levels are shown as the fold change (2-ΔΔCT) relative to the mean of 10 
normal MNC samples with 6 housekeeping genes – ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2 serving as 
endogenous control. A > 5-fold change relative to normal MNCs (n=10) was categorised as high SMO expression. The 
red lines indicate a 5-fold change. Results are depicted in a box and whisker plot showing median, min and max 
values showing HOXA3 and HOXA9 to be up-regulated in SMO high expressers relative to those with a <5-fold 
increase in SMO relative to our normal cohort, though the result was not significant.  
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3.4.3 Increased SMO correlated with an increase in high-risk stratification 
and poor prognostic features 
Caldicott approval was obtained prior to hospital records being accessed. Patient demographics, 
baseline disease characteristics, treatment and clinical outcomes, where available, were 
recorded for each AML sample analysed, Appendix 1. Of the 76 samples we studied, clinical data 
was available for 56 samples (73.7%). Samples were classified according to SMO expression, with 
high expressers defined as those with a ≥5-fold increase in SMO relative to normal MNCs. 26 of 
our cohort of 76 (34.2%) were stratified as high expressers. Clinical data within this cohort was 
compared to the cohort of AML samples demonstrating a <5-fold change in SMO.  
There was no significant difference between patient demographics (sex and age at diagnosis) 
between the two cohorts. Considering published data, we considered the FLT3-ITD mutation 
status of our cohort of SMO high expressers. The FLT3-ITD mutation was reported in 5 SMO high 
expresser samples (19.2%), and 7 demonstrating a <5-fold change in SMO (26.7%). Whilst these 
results are in keeping with published data, FLT3-ITD mutations being reported in 15-36% of cases 
depending on AML subtype 180,188,195,621–623 the result was not as we had expected. We had 
hypothesised FLT3-ITD would be present at a higher frequency in SMO high expressers 
considering FLT3-ITD has been linked to aberrant Hh signalling 381,382. Interestingly however, 
there was an increase in the percentage of patients classified as Internediate-2 (high risk) 
according to the ELN Prognostic scoring system 1, Figure 3.4.3.1 
 
 
3.4.4 Next-generation sequencing confirmed an aggressive phenotype in 
those classified as SMO high expressers 
Next-generation DNA sequencing has shown AML to be associated with, on average, five somatic 
mutations in recurrently mutated genes. Further, non-random, clonal chromosome aberrations 
are detectable in approximately 55% of AML cases, contributing to disease classification and 
treatment algorithms. 45% of cases however remain unclassified, leading to difficulties in risk 
stratification and treatment decisions 156,165. In 2013, the Cancer Genome Atlas Research Network 
listed 23 significantly mutated genes in AML 583.	Following this a number of AML research gene 
panels have been commercially developed, two were used for this section of work: the Ion 
AmpliSeqTM and the Illumina TruSight® Myeloid panels. Different panels were used as this work 
was performed in conjunction with the development and evaluation of sequencing services 
within haematological malignancies within NHS Lothian (Ion AmpliSeqTM) and NHS Greater 
Glasgow and Clyde (Illumina TruSight®).  
 
Figure 3.4.3.1: ‘Risk’, according to the ELN Prognostic system 1, according to SMO expression. 
≥ 5-fold SMO < 5-fold SMO 
Intermediate-1 
Intermediate-2 
Adverse 
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The Ion AmpliSeqTM covers 19 genes, 14 described by the Cancer Genome Atlas Research Network 
583. In contrast, the Illumina TruSight® Myeloid panel covers 54 genes, 15 in their entirety and an 
additional 39 targeted to cover oncogenic hotspots. Analysis was performed using Alamut, a 
software application designed to interpret medical genetic variants. This system integrates data 
(protein annotations, mutations, polymorphisms and conservation information) from public 
sources enabling users to study the effects of genetic variants on transcription, splicing and 
translation. 47 samples were sequenced, 30 by Ion AmpliSeqTM. 18 of the 47 samples (38.3%) 
were classified as SMO high expressers, 15/47 (31.9%) demonstrated a <5-fold increase in SMO 
relative to normal MNCs. Gene expression was not available for 14 of the 47 samples (29.8%).  
In keeping with AML, marked genetic heterogeneity was demonstrated, with a mean of 4.7 
publically documented pathogenic mutations detected by the Illumina TruSight® Myeloid panel 
(range 1 to 8), and a mean of 1.7 detected by Ion AmpliSeqTM (range 0 to 4). Mutations, and the 
number of samples within which they were detected are depicted in Figure 3.4.4.1. Those genes 
/ oncogenic hotspots in which no abnormality was found are not shown.  
 
 
All 47 samples were shown to contain SNPs with a mean of 8.2 SNPs detected by the Illumina 
TruSight® Myeloid panel (range 5 to 13), and a mean of 10.2 detected by Ion AmpliSeqTM (range 7 
to 17), Figure 3.4.4.2. The marked difference in mutation frequency is explained by the variant 
number of targets of each panel; whilst the variance in SNP concordance also reflects analytical 
differences including read depth and frequency parameters and filters such as the inclusion / 
exclusion of synonymous and intronic SNPs.  
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Figure 3.4.4.1: Spectrum, and absolute number, of pathological somatic mutations in a cohort of 
primary, de novo AML samples according to sequencing panel. 
Ion	AmpliSeqTM	covers	19	genes,	14	described	by	the	Cancer	Genome	Atlas	Research	Network	582.	In	contrast	the	
Illumina	TruSight®	Myeloid	panel	covers	54	genes,	15	in	their	enJrety	and	an	addiJonal	39	targeted	to	cover	
oncogenic	hotspots.	Analysis	was	performed	using	Alamut.	47	samples	were	sequenced,	30	by	Ion	AmpliSeqTM.	In	
keeping	with	AML	marked	geneJc	heterogeneity	was	demonstrated,	with	a	mean	of	4.7	pathogenic	mutaJons	
detected	by	the	Illumina	TruSight®	Myeloid	panel	(range	1	to	8),	and	a	mean	of	1.7	detected	by	Ion	AmpliSeqTM	
(range	0	to	4).	 
Ion AmpliSeqTM Illumina TruSight® 
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Considering those in which SMO expression data was available, marked genetic heterogeneity 
was demonstrated, Figure 3.4.4.3. Whilst a genetic pattern was not demonstrated we found 
DNMT3A, associated with an inferior outcome 320,624, to be present in 25% (4/16) of SMO high 
expressers compared to 6.7% (1/15) in those with a <5-fold increase in SMO relative to normal 
MNCs (p=0.0006). This is particularly interesting considering research showing synergy between 
sonidegib and vismodegib and azacitidine, and an RNA interference screen which identified 
several HDAC sensitiser genes including components of the Hh pathway 413. Additionally, EZH2, 
FLT3, GATA2, IDH2, MFSD11, NPM1, NRAS, RUNX1, SRSF2, TET2, TP53 and WT1 mutations were 
more frequent in SMO high expressers, expression patterns were statistically significant for 
EZH2, NPM1, NRAS, TP53 (all p<0.0001) and TET2 p=0.015. Statistical analysis was performed 
using the Chi-Squared test. 
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Figure 3.4.4.2: Spectrum, and absolute number, of SNPs and percentage of cases expressing SNPs 
according to sequencing panel.  
Ion	AmpliSeqTM	covers	19	genes,	14	described	by	the	Cancer	Genome	Atlas	Research	Network	582,	the	Illumina	
TruSight®	Myeloid	panel	covers	54	genes,	15	in	their	enIrety	and	an	addiIonal	39	targeted	to	cover	oncogenic	
hotspots.	Analysis	was	performed	using	Alamut.	47	samples	were	sequenced.	In	keeping	with	AML	marked	geneIc	
heterogeneity	was	demonstrated.	All	47	samples	were	shown	to	contain	SNPs	with	a	mean	of	8.2	SNPs	detected	by	
the	Illumina	TruSight®	Myeloid	panel	(range	5	to	13),	and	a	mean	of	10.2	detected	by	Ion	AmpliSeqTM	(range	7	to	
17).	The	marked	diﬀerence	in	mutaIon	frequency	is	explained	by	the	variant	number	of	targets	of	each	panel;	
whilst	the	variance	in	SNP	concordance	also	reﬂects	analyIcal	diﬀerences	including	read	depth	and	frequency	
parameters	and	ﬁlters	such	as	the	inclusion	/	exclusion	of	synonymous	and	intronic	SNPs.	 
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3.5 Discussion  
AML encompasses a group of aggressive haematological neoplasms. It is a clinically, 
morphologically and genetically heterogeneous disease involving one or all of the myeloid 
lineages 150. Within this heterogeneous disease genetic and morphological subtypes have been 
demonstrated. Published data has linked the Hh pathway both to those carrying the FLT3-ITD 
mutation and, interestingly, those classified morphologically as M4/5 according to the FAB 
classification system 381. These associations are interesting in their clinical utility, being readily 
defined / detected, and further in their poor prognostic association, our increasing knowledge 
and understanding of AML suggesting the need for targeted therapies.     
We have uniquely shown the Hh pathway to be deregulated at a gene and protein level, pathway 
activity evidenced by GLI-1 activity. Interestingly, we did not demonstrate a clear relationship 
between SMO, PTCH1 or the positive regulator GLI-1. It is important however to note that whilst 
we had analysed expression of GLI-1, we did not assess the expression of GLI-2 or GLI-3, an 
intricate relationship existing between these transcription factors and pathway activity. The 
expression of each transcription factor and their relationship with other components of the Hh 
pathway in our opinion deserves further evaluation. Further we recognise crosstalk exists 
between the self-renewal pathways, and whilst we had studied the expression of notable 
downstream targets, key upstream molecules such as members of the Ras/Raf/Mek pathway 
were not studied.  
Figure 3.4.4.3: Spectrum, and absolute number, of mutations categorised according to SMO 
expression.  
Samples were sequenced using the Ion AmpliSeqTM and the Illumina TruSight® Myeloid panel with 
analysis performed using Alamut. 47 samples were sequenced. Samples were categorised according to 
SMO expression. 16 were SMO high expressers and 15 demonstrated a <5-fold increase in SMO relative 
to normal MNCs. Gene expression was not available for 16 samples.  
This graph shows the sequencing results for those in which SMO expression data was available. DNMT3a 
was present in 25% (4/16) of SMO high expressers compared to 6.7% (1/15) in those not classed as SMO 
high expressers (p=0.0006). EZH2, FLT3, GATA2, IDH2, MFSD11, NPM1, NRAS, RUNX1, SRSF2, TET2, TP53 
and WT1 mutations were more frequent in SMO high expressers, expression patterns were statistically 
significant for EZH2, NPM1, NRAS, TP53 (all p<0.0001) and TET2 p=0.015 by the Chi-Squared test. 
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The lack of a relationship between a key regulator of pathway activity and the receptors SMO 
and PTCH1 caused us to question whether primary human haematopoietic cells within the BM 
microenvironment or circulatory system, or AML cell lines possessed primary cilia, and therefore 
the machinery to enable canonical Hh signalling. Whilst it is widely accepted that vertebrate 
canonical Hh signalling requires primary cilia 417 until recently haematopoietic cells have been 
considered to be among the few cells not to possess primary cilia 416,428. Interestingly in 2013, 
emphasising the importance of a microtubular structure in enabling canonical Hh signalling, in 
the absence of a primary cilium the immunological synapse of T cells was shown to serve as a 
functional homolog of the primary cilium 426. We hypothesised HSPCs possess primary cilia within 
the BM but that these organelles become defunct on cell maturation and migration into the PB. 
During the write up of this PhD, Singh et al. reported MNCs isolated from the PB and BM and AML 
cell lines (KG1, KG1a, and K562) posses primary cilia 566,611; primary cilia were less frequent and 
often dysmorphic in the AML cell lines (KG1, KG1a, and K562) 566,611. Importantly, these primary 
cilia were shown to be functional and play a role in Hh signalling. We too identified primary cilia 
in both normal and AML BMTs by ICC, further confirming the primary cilia structure through EM. 
In contrast however we did not identify primary cilia in PB AML or normal MNCs or AML cell lines. 
Whilst we have reservations regarding the images, questioning whether they might represent 
centrosomes rather than primary cilia, the evidence to show these structures are functional, 
involved in Hh signalling is hugely exciting. Whether primary cilia are, with time, accepted to be 
present on haematopoietic cells, and further those in the circulation or simply those within the 
BM niche remains to be determined.  
Having shown deregulation of the Hh signalling pathway in AML, and the presence of primary 
cilia enabling canonical signalling in haematopoietic cells within the BM we considered the role 
of the Hh ligands. We found SHH to be significantly down-regulated in AML BMTs relative to 
normal BMTs. We considered whether the expression differences between AML and normal BMTs 
reflected different cellular composition. Whilst we acknowledge lymphocytes may comprise up 
to 20% of the normal BM population, with a marked reduction classically seen in AML due to the 
variable replacement of the normal BM population by blast cells we considered this part of the 
disease process and therefore important to include in our comparisons.  
Considering the differential expression of SHH we analysed HHAT, the acetyltransferase 
responsible for post-translational modification of SHH, finding it to be significantly down-
regulated in AML MNCs compared to normal MNCs. Within normal haematopoiesis HHAT 
expression increased with cell maturation, being lowest in HSCs. Further, we noted SHH to be 
located within the cytoplasm and nuclei of AML blast cells and interestingly, cells located within 
the colonic crypt bases, colonic tissue being our control material. This was particularly 
interesting since nuclear expression was not seen in normal BMTs, nor in colonic cells once they 
had migrated from the crypt base. Considering this data we hypothesised HHAT, and therefore 
SHH activity, was tightly regulated by SCs, potentially controlling canonical signalling and thus 
pathway activity. We sought to validate this hypothesis by analysing HHAT in colonic crypt bases 
relative to its expression in colonic villi apices, the crypt bases containing colon SCs, and the 
apices mature, differentiated daughter cells. Whilst the SC niche within the BM 
microenvironment is recognised it is not so clearly defined, nor identifiable within tissue. We 
therefore planned to use colon tissue, with its anatomically defined cell maturation as a model 
for pathway modulating processes within haematopoiesis. Ethical consent was obtained. Six 
frozen human colon sections were laser dissected. Four colonic crypt bases, and four colonic 
crypt apices were captured and processed for RNA. Unfortunately samples were destroyed prior 
to analysis. We plan to repeat this technically very interesting and challenging work in the 
future.  
Pathway activity in the absence of ligand expression within the AML blast cell population led us 
to consider paracrine activity. Paracrine activity has been shown to determine pathway activity 
in mature B cell malignancies 364. Whilst variation might be expected within a heterogeneous 
disease such as AML the concentration range was particularly interesting. The majority of AML 
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cases showed a similar expression pattern to our normal age matched control cohort; two 
samples were shown to be 4- and 10-fold greater. It is tempting to consider whether these 
results suggest a differential dependence and response, emphasising the importance of sample 
and subtype selection however this would need to be verified in a larger cohort. The results 
certainly raise interesting questions however. How does the serum concentration of SHH affect 
pathway activity? Can serum SHH be used as a biomarker for those cases with increased Smo and 
or Hh signalling, or to identify the cases most suited to the small molecule Smo antagonists. 
Particularly interesting is the question of how the serum SHH concentration correlates with SHH 
with the BM microenvironment given we had shown a statistically significant down-regulation of 
SHH within AML BMTs. Further if this data is considered in parallel to preliminary data showing 
stromal cell sensitivity to Smo antagonism to vary depending upon confluence discussed in 
section 6 could the hypercellular nature of AML inhibit stromal Hh activity? In an attempt to 
answer this we have begun work harvesting media from MSCs at varying confluence alone and 
following culture with cyclopamine to determine the impact on levels of secreted SHH. Further, 
we acknowledge this was a small cohort and plan to increase our numbers, and consequently the 
study power in the future. We would seek to perform paired analysis enabling correlation of SHH 
expression in AML BMTs and serum and SHH expression with pathway activity in our blast 
population.  
The absence of a clear relationship between components of the Hh pathway and pathway 
activity led us to question whether, as in solid malignancies a gain-of-function mutation within 
Smo might account for the increased activity. An extensive literature search did not find any 
reports on mutational status within haematological malignancies. However, whilst a number of 
silent and missense mutations were identified a somatic mutation in SMO was not identified. 
Interestingly a number of SNPs were identified throughout SMO though the effects of these are 
unknown although one could speculate that given the number observed per sample that these 
might in some way influence protein stability. In the future we would seek to determine if a loss-
of-function in PTCH1 might explain the lack of a relationship between the receptors and pathway 
activity.   
Finally whilst a correlation between SMO, clinical characteristics and prognosis was not 
identified we plan to look at the impact of other components. Interestingly PTCH1 has been 
shown to confer a poor outcome in CML. It would therefore be interesting to look at the 
expression of PTCH1 in BC-CML and further to contrast this to expression within primary de novo 
AML cases.  
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4 Hypothesis ‘The Hedgehog signalling pathway represents a viable 
therapeutic target in AML’ 
 
4.1 To determine the effect of the Smo inhibitors, cyclopamine, sonidegib 
and glasdegib, on a diverse array of AML cell lines and primary AML 
MNCs in vitro 
 
4.1.1 Introduction 
Hh signalling is vital in the maintenance and expansion of the LSC in myeloid malignancies; 
serving either as a survival and proliferation signal or through direction of the LSC fate 252,344,375–
377.  
Work by the Copland group has already shown the Hh pathway to be deregulated in CML stem 
and progenitor cells. Further, using the clinical grade Smo inhibitor, LDE225 (sonidegib; Novartis 
Pharma) in combination with nilotinib (second generation TKI; Novartis Pharma), they were able 
to effectively eliminate CML stem and progenitor cells both in vitro and in vivo 254,412.  
We have shown the Hh signalling pathway to be deregulated in an unselected cohort of primary 
de novo AML samples (Chapter 3) in keeping with published data 378,379,625. However whilst the 
evidence of pathway deregulation is increasing, with aberrant signalling linked to drug resistance 
349,377 and high levels of the transcription factors GLI-1 and GLI-2 shown to confer a poor 
prognosis 378,379,381,382 the relationship between the Hh pathway and AML, and further its role in 
disease pathogenesis, is not yet fully understood.  
We sought to determine the effect of Smo inhibition in AML. We recognised the morphological, 
immunophenotypic, cytogenetic, and molecular heterogeneity of AML. We therefore selected 
seven, genetically diverse, AML cell lines (HL60, Kasumi-1, KG1a, MOLM-13, MV4-11, OCI-AML3 
and THP-1). These cell lines were specifically chosen because they (1) carry high prevalence 
mutations, (2) are easily definable, (3) carry poor risk features or (4) published data indicated a 
link between characteristics of the chosen cell line and the Hh pathway. The following publically 
available datasets were analysed: GSE1159 381, GSE13159 565 and GSE9476 382. These datasets 
were selected because of the (1) number of samples analysed and, (2) cell populations studied. 
GSE1159 contains data from 285 AML patients, with data for 13,000 genes derived from PB or BM. 
Work published using this dataset identified 16 groups of patients on the basis of molecular 
signatures through unsupervised cluster analyses, GLI-1 shown to associate with FLT3-ITD and the 
FAB M4 phenotype 381. GSE13159 presents whole-genome data from 2,096 PB or BM samples 565. 
This work was undertaken to assess the clinical utility of gene expression profiling in the 
diagnosis and classification of myeloid and lymphoid malignancies. Referencing conventional 
classification definitions investigators reported an accuracy of 92% (median specificity 99.7%), 
confirmed using a prospective cohort of 1152 (95.6% median sensitivity, 99.8% median 
specificity) 626. GSE9476 compares gene expression profiles between normal haematopoietic cells 
isolated from 38 healthy volunteers - CD34+ selected (n = 18), unselected BM (n = 10) and 
unselected PB (n = 10) and unselected blast cells from 26 AML patients 382. Twenty genes were 
differentially expressed in AML relative to normal haematopoietic cells; expression changes for 
13 of the 20 genes were confirmed using the GSE1159 dataset 382.  
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4.1.2 Components of the Hh signalling pathway are expressed in select 
AML cell lines and primary AML cells at both a gene and protein level 
Components of the Hh pathway have been shown to be expressed in select AML cell lines, yet not 
in others 377,379,566. We therefore first screened our chosen AML cell lines. Expression levels of the 
receptors PTCH1 and SMO, the transcription factors GLI1-3, and the pathway modulators PTCH2, 
SUFU and HHIP were quantified by qRT-PCR using Fluidigm® technology. RNA was extracted from 
cells harvested in optimal growing conditions (resuspended in fresh media 24hrs before 
harvesting at a density of 2-3x105/ml). To account for input cDNA the ΔCT for each gene was 
calculated by subtracting the CT value of 6 housekeeping (control) genes from the CT recorded 
for the gene of interest. ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2 were selected as 
housekeeping genes, CT values ranged from 3 to 13. To ensure accuracy of our results, samples 
were excluded where >2 genes failed due to technical reasons – poor technical triplicate, a signal 
was detected in the no template control (NTC) or the reaction failed by Fluidigm®. This 
stringency was applied to all gene expression analyses presented throughout this chapter. 
Expression is presented as 2-ΔCT, allowing comparison of levels of mRNA expression between each 
cell line; Figure 4.1.2.1.  
 
 
 
 
 
Our chosen cell lines all had complex karyotypes. By FAB classification, four were 
myelomonocytic (MOLM-13, MV4-11, OCI-AML3 and THP-1). Additionally, two were CD34 
expressing (Kasumi-1 and KG1a) and two carried the FLT3-ITD mutation (MOLM-13 and MV4-11). 
Despite these shared characteristics, striking differences were demonstrated. Of the components 
analysed; SMO, PTCH1, GLI-1, STIL and SUFU were expressed by all of our selected cell lines. 
Figure 4.1.2.1: Variance in the mRNA expression of components of the Hh pathway in seven 
genetically diverse AML cell lines.  
RNA was extracted from cells harvested in optimal growing conditions. Expression levels were 
quantified by qRT-PCR using Fluidigm® technology. Expression levels are shown as 2-ΔCT, with 6 
housekeeping genes –ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2 serving as endogenous control; CT 
values for these genes ranged from 3 to 13. The mean of 3-5 samples are presented clearly 
demonstrating the variability in baseline expression between the cell lines. Error bars indicate SD.  
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GLI-2 was universally not expressed. GLI-3 was expressed by Kasumi-1, MOLM-13, MV4-11 and 
OCI-AML3; HHIP was expressed by Kasumi-1, KG1a and MOLM-13. It is interesting to note the 
presence of GLI-3 in CD34+ Kasumi-1, yet its absence in the CD34+ KG1a cell line, and the 
expression of HHIP by the FLT3-ITD+ MOLM-13 cell line yet its absence in FLT3-ITD+ MV4-11 cell 
line indicating there is not a simplistic relationship between cell maturity or mutational status 
and the Hh pathway.  
A notable difference in the expression of SMO was demonstrated between cell lines, with OCI-
AML3 the highest expresser and MV4-11 the lowest. A less pronounced difference in the 
expression of PTCH1 was demonstrated between cell lines, with KG1a the highest expresser and 
Kasumi-1 the lowest. All cell lines showed evidence of pathway activity with expression of GLI-1, 
though heterogeneity persisted with differences in expression seen between THP-1, the highest 
expresser, and Kasumi-1, the lowest. The absence of GLI-2 is particularly interesting, if not 
perplexing, considering GLI-1 and -3 and other key members of the pathway were expressed. It 
would be interesting to investigate this further, to evaluate the presence or absence of GLI-2 in 
our selected AML cells lines. Interestingly, there was minimal variance, across all cell lines, in 
the expression of STIL and SUFU, components functioning to determine pathway activity through 
their interactions with GLI-1. These results emphasise the need to carefully select potential 
subtypes of AML for targeted therapies and, when analysing and interpreting results, the 
importance of correlating functional responses to phenotype and genotype. 
Cell lines serve as experimental models, enabling investigation and analysis of primary processes 
and the effect of manipulating molecular pathways. It is, however, well recognised that cell 
lines may not always behave in the same manner as, and not always accurately represent, 
primary cells 627. Primary cell experiments are therefore required to validate cell line data. In 
this respect, we studied the expression of components of the pathway in normal CD34+ selected 
cells (BM CD34+ cells were purchased from stem cell technologies; PB CD34+ cells were isolated 
from normal donors following G-CSF stimulation and apheresis), normal bulk MNCs and an 
unselected cohort of 76 primary AML cases. Whilst expression in our normal and primary de novo 
AML cohorts are presented in section 3.1.2 here we consider the differential expression between 
these cohorts and our selected AML cell lines. RNA was extracted from cells harvested following 
culture for 24hrs; a standardised approach was adopted to minimise confounding factors. 
Expression is presented as 2-ΔCT, enabling comparison of expression levels; Figure 4.1.2.2.  
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Looking first at the mRNA expression within our normal cohorts and selected AML cell lines there 
were notable differences. Expression within the AML cell lines was more heterogeneous. GLI-1 
showed a trend towards up-regulation in our AML cell lines compared to normal cells, 
irrespective of CD34 status (p=ns). STIL and HHIP were universally down-regulated in normal cells 
(p=ns) relative to our selected AML cell lines. Interestingly, expression patterns for the CD34+ 
AML cell lines did not mirror those of our CD34+ normal cohorts (PB or BM). Irrespective of CD34 
status, expression of SMO within our selected cell lines was comparable to that of the CD34+ PB 
and BM normal samples. Whilst expression of PTCH1 was rather distinct it was closer to that 
demonstrated in bulk MNCs. This data suggests a differential expression of components of the Hh 
pathway in normal and malignant progenitor cell populations, accepting the limitations of 
comparing immortalised cell lines with primary patient samples.  
 
 
 
 
Figure 4.1.2.2: Variance in the mRNA expression of components of the Hh pathway between 
normal bulk MNCs, CD34+ selected PB and CD34+ selected BM cells.  
PB CD34+ cells were harvested by G-CSF stimulated apheresis and CD34+ BM cells purchased from Stem 
Cell Technologies. RNA was extracted from cells harvested following culture for 24hrs. Expression levels 
were quantified by qRT-PCR using Fluidigm® technology. Expression levels are shown as 2-ΔCT, with 6 
housekeeping genes – ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2 serving as endogenous control. 
3-5 samples were analysed, where the number does not reach this data has been excluded for technical 
reasons to ensure accuracy. Error bars indicate SD.  
This graph clearly shows expression to differ between normal cell populations and AML cell lines for 
select genes. Interestingly, irrespective of CD34 status, expression of SMO within the AML cell lines is 
comparable to that of the CD34+ PB and BM normal samples whilst expression of PTCH1 is closer to that 
seen in bulk MNCs and markedly different from expression within the CD34+ select cell populations.   
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A standardised approach was adopted since earlier experiments had shown marked variation in 
the mRNA expression of SMO, Figure 4.1.2.3. We considered a number of potential factors - 
passage number, cell density and time relative to media change. We therefore sought to remove 
any potential confounding factor bias from our results by controlling for these variables. The 
observed mRNA expression variance fits with the recognised synergistic relationship between the 
Hh pathway and cell cycle regulators and other pathways including the Notch pathway, which is 
subject to cis-inhibitory interactions 628. It would be interesting to consider this in further detail 
in the future.  
 
 
 
4.1.3 Manipulation of the Hh pathway by Smo inhibition with cyclopamine 
alters cell proliferation in select cell lines 
Cyclopamine is a steroidal alkaloid, isolated from the American corn lily 629,630. Its effects are 
caused by inhibition of the Hh pathway through direct inhibition of Smo. Whilst its poor 
solubility, stability, and moderate activity 631 has impeded its clinical development, a number of 
analogues have been developed which have progressed to clinical trial as discussed in section 
1.4.5. Despite its limitations, however, it continues to be used in research to evaluate the effect 
of Hh pathway inhibition. Tomatidine, a steroidal alkaloid with structural similarity to 
cyclopamine, though unable to inhibit Smo, is used experimentally as a negative control 263, 
serving to give greater confidence that results generated are due to Smo inhibition rather than 
off-target effects.  
 
 
 
Figure 4.1.2.3: Expression of SMO in seven genetically diverse AML cell lines according to 
harvesting conditions.  
RNA was extracted from cells harvested at variable density (2x105-1x106/ml), passage number (P2-7) 
and growing conditions (24-48hrs post media change). Expression levels were quantified by qRT-PCR 
using Fluidigm® technology. Expression levels are shown as 2-ΔCT with 6 housekeeping genes serving as 
endogenous control - ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2. Each data point represents the 
mean of a technical triplicate. The mean of 5-7 samples are presented with error bars indicating SD 
clearly demonstrating the variability in baseline expression both within and between the cell lines.  
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We utilised the resazurin assay to determine the effect of a wide range of concentrations of 
cyclopamine on cell viability following culture for 72hrs for each of our chosen cell lines; Figure 
4.1.3.1. A 72hr time point was chosen to allow sufficient time for an effect to be demonstrated, 
whilst minimising the risk of confounding factors such as nutrient exhaustion, altered 
environment (pH, electrolyte balance) due to apoptosing cells and cis- and trans- interactions 
due to increased cell density.  
A 50% reduction in luminescence, taken as a crude measure of the half maximal inhibitory 
concentration (IC50), was universally not seen at doses below 10µM, Figure 4.1.3.1. This is 
notably higher than that demonstrated following culture of the Gli-luciferase reporting TM3(GLI-
Luc) cell line with cyclopamine for 72hrs, the IC50 falling between 5µM and 10µM (Figure 2.1).  
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Figure 4.1.3.1: Metabolic activity as a measure of cell viability in seven genetically diverse AML 
cell lines following culture with incremental doses of cyclopamine (µM) as determined by the 
resazurin assay.  
Cells, at a concentration of 1x105/ml, were exposed to incremental doses of cyclopamine and cultured for 
72hrs. Cell viability was determined using the resazurin assay. Results are expressed as the mean 
luminescence (n=4) with error bars indicating SD. Luminescence in the presence 20µM tomatidine is 
highlighted in red, serving as the NDC. Luminescence in the presence of tomatidine was comparable to 
that with media only. Notably, luminescence following culture of the Gli-luciferase reporting TM3(GLI-Luc) cell 
line with cyclopamine for 72hrs demonstrated a 50% reduction in luminescence between 5µM and 10µM.   
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Whilst Graphpad software can enable accurate calculation of the IC50, we chose to record a 
‘rough range’ for the IC50 for each cell line, Table 4.1.3.1. This approach was taken considering 
experimental design - the shape of the curves and limited data points above a concentration of 
6.25µM calling into question the accuracy of the Graphpad extrapolated IC50 values. Expression 
of SMO did not affect cell response to cyclopamine. 
Table 4.1.3.1 Cyclopamine IC50 values for our selected AML cell lines as determined by the 
resazurin assay 
Cell line IC50 
HL60 >12.5µM, <25µM 
Kasumi-1 >25µM 
KG1a >25µM 
MOLM-13 >12.5µM, <25µM 
MV4-11 >25µM 
OCI-AML3 >25µM 
THP-1 >12.5µM, <25µM 
 
Although no significant effect on cell viability was seen below 10µM we acknowledge the 
limitations of the resazurin assay in assessing the IC50. We therefore elected to perform cell 
counts and assess cell viability by trypan blue dye exclusion at 24hrs, 48hrs and 72hrs in the 
genetically diverse Kasumi-1 and OCI-AML3 cell lines using a range of doses including those 
significantly below the approximated IC50: NDC, 100nM, 1µM, 5µM, 10µM and 20µM to determine 
if cyclopamine had a time- or concentration-dependent effect on cell kinetics; Figure 4.1.3.2. 
20µM as the maximum dose is in keeping with published work in haematological disease 377. 
Further, work looking at dose- and route-dependent toxicity and pharmacokinetic profiles using 
naive female C57BL/6J mice at 12–16 weeks of age reported cyclopamine toxicity to be 
independent of Cmax or area under curve (AUC) values, with a Cmax of 19.9µM ± 3.15µM, and 
AUC of 59.6µM ± 4.4µM 631. Lower doses were included given the self-renewal nature of the Hh 
signalling pathway, inhibition therefore not necessarily expected to result in apoptosis. These 
doses were determined by referencing the Gli-luciferase reporting TM3(GLI-Luc) cell line (Methods 
2.2.1.4).  
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In the OCI-AML3 cell line there was no difference in cell counts between the NDC and all 
concentrations of cyclopamine at 24hrs. At 48hrs there was a trend towards a reduction in the 
number of live cells following culture with 5µM, 10µM and 20µM, reaching statistical significance 
following culture with 10µM (p=0.006) and 20µM (p=0.038). At 72hrs a statistically significant 
reduction in live cells was seen following culture with 5µM (p=0.012), 10µM (p<0.001) and 20µM 
(p=0.003).  
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Figure 4.1.3.2: Cell viability, as determined by the trypan blue dye exclusion assay, in the OCI-
AML3 and Kasumi-1 cell lines following culture with cyclopamine at increasing concentrations.  
OCI-AML3 and Kasumi-1 cells were seeded at a concentration of 2x105/ml, exposed to incremental 
doses of cyclopamine and cultured for 24hrs, 48hrs and 72hrs. Cell counts, live and dead, were 
determined using the trypan blue dye exclusion assay. Each bar represents the mean cell number x 104 
from four independent experiments with error bars indicating SD showing culture with cyclopamine 
caused a time and concentration dependent reduction in cell viability in the OCI-AML3 and Kasumi-1 
cell lines. All statistically significant results are highlighted with p value to the nearest 4 decimal 
places, those not highlighted are not significant (ns).   
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In the Kasumi-1 cell line there was a statistically significant difference in the number of live cells 
following culture with 20µM at 24hrs and 48hrs (p=0.043 and p=0.035 respectively) relative to 
the NDC. At 72hrs there was a trend towards a reduction in the number of live cells following 
culture with 1µM, reaching statistical significance following culture with 5µM (p<0.001), 10µM 
(p<0.0001) and 20µM (p<0.0001).  
The range for all future experiments was therefore narrowed to: NDC, 5µM, 10µM and 20µM. In 
each experiment tomatidine at a maximum dose of 20µM and DMSO at a volume of 1.25µl/ml 
(volume equivalent to maximum dose of cyclopamine) were used as negative controls (NDC). 
In the HL60, KG1a, MV4-11, OCI-AML3 and THP-1 cell lines, cell number by trypan blue dye 
exclusion showed a statistically significant reduction in live cell number with increasing doses of 
cyclopamine (statistics following culture with the maximum concentration of 20µM cyclopamine: 
p=0.008, p=0.006, p=0.006, p=0.047 and p=0.010 respectively). This was not seen in the negative 
control arms. The total number of dead cells however remained relatively constant (all p=ns). 
This was confirmed by Annexin V / 7AAD staining which demonstrated no significant change in 
viable, early apoptotic, late apoptotic or dead cells, suggesting an alteration in cell cycle 
kinetics rather than apoptosis; Figure 4.1.3.3.  
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In contrast, apoptosis was seen in two genetically diverse AML cell lines: the CD34+ hypo-diploid 
Kasumi-1 cell line expressing the AML-ETO fusion gene and KIT mutation and the hyper-diploid, 
myelomonocytic MOLM-13 cell line carrying the FLT3-ITD and CBL mutants and the MLL-AF9 
fusion gene; Figure 4.1.3.4. Previous research has indicated an association between FLT3-ITD 
mutational status and Hh pathway activity 381,382, potentially explaining the increased sensitivity 
of the MOLM-13 cell line to Smo inhibition. Apoptosis was not seen in other myelomonocytic cell 
lines: MV4-11, OCI-AML3 and THP-1. This is particularly interesting considering both the MV4-11 
and MOLM-13 cell lines carry the FLT3-ITD and MLL mutants, and are derived from paediatric 
patients. MOLM-13 cells, however, carry the additional genetic abnormality, CBL, and 
interestingly, do not express FLT3-ITD at the protein level. Further, we demonstrated differing 
results in our two selected CD34-expressing cell lines: Kasumi-1 and KG1a. Whilst increased 
activity has been shown in more primitive CD34+ AML cells 618 our results highlight the 
heterogeneity intrinsic to AML. A common phenotypic or genotypic trait to explain the increased 
sensitivity of the Kasumi-1 and MOLM-13 cell lines could not be identified. 
 
 
 
Figure 4.1.3.3: Proliferation, as determined by the trypan blue dye exclusion assay, and apoptosis, 
as determined by Annexin V / 7AAD staining, in the Kasumi-1 and MOLM-13 cell lines following 
culture with cyclopamine (5µM, 10µM and 20µM).  
Cells from each of the AML cell lines were seeded at a concentration of 2x105/ml, exposed to 
incremental doses of cyclopamine and cultured for 72hrs. (A) These graphs show cell viability as 
determined by trypan blue exclusion for each of the AML cell lines. Each bar represents the mean cell 
number x104/ml from four independent experiments with error bars indicating SD. (B) These graphs 
indicate the proportion of cells which are viable, in early apoptosis, in late apoptosis or dead as 
determined by Annexin V / 7AAD staining, and analysis by flow cytometry. The percentages shown 
indicate the proportion of total events within each of the respective categories as gated on the flow 
cytometry plots (see Figure 2.3 for gating strategy). Each bar represents the mean percentage from 
four independent experiments with error bars indicating SD showing cyclopamine caused a statistically 
significant, though variable, reduction in proliferation not explained by apoptosis in select, genetically 
diverse, AML cell lines. All statistically significant results are highlighted with p value to the nearest 3 
decimal places, those not highlighted are not significant (ns). 
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For the purpose of further understanding the effect of Smo inhibition, we focused on two 
cell lines, the Kasumi-1 cell line in which apoptosis was demonstrated, and the OCI-AML3 cell 
line in which altered cell kinetics in the absence of apoptosis was observed. Reference is 
however made to other cells lines where informative results are available.   
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Figure 4.1.3.4: Proliferation, as determined by the trypan blue dye exclusion assay, and apoptosis, 
as determined by Annexin V / 7AAD staining, in select, genetically diverse, AML cell lines following 
culture with cyclopamine (5µM, 10µM and 20µM).  
Cells from each of the AML cell lines were seeded at a concentration of 2x105/ml, exposed to 
incremental doses of cyclopamine and cultured for 72hrs. (A) These graphs show cell viability as 
determined by trypan blue exclusion for each of the AML cell lines. Each bar represents the mean cell 
number x 104 from four independent experiments with error bars indicating SD. (B) These graphs 
indicate the proportion of cells which are viable, in early apoptosis, in late apoptosis or dead as 
determined by Annexin V / 7AAD staining, and analysis by flow cytometry. The percentages shown 
indicate the proportion of total events within each of the respective categories as gated on the flow 
cytometry plots (see Figure 2.3 for gating strategy). Each bar represents the mean percentage from 
four independent experiments with error bars indicating SD; graphs showing cyclopamine caused 
apoptosis in select, genetically diverse, AML cell lines. All statistically significant results are highlighted 
with p value to the nearest 3 decimal places, those not highlighted are not significant (ns).  
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4.1.4 Manipulation of the Hh pathway by Smo inhibition with cyclopamine 
alters cell cycle kinetics in select AML cell lines 
We clearly demonstrated reduced proliferation in the absence of apoptosis in genetically distinct 
cells lines: HL60, KG1a, MV4-11, OCI-AML3 and THP-1. We therefore sought to determine the 
underlying mechanism. Cell cycle kinetics were studied by two methods: PI (to enable analysis of 
cell cycle status) and CFSE (to enable analysis of cellular proliferation). In addition, these assays 
were performed in the Kasumi-1 cell line, in which cyclopamine had resulted in apoptosis, to 
enable us to compare and contrast cellular responses.  
In the OCI-AML3 cell line, cell cycle arrest was demonstrated with a clear increase in the 
percentage of inactive, non-cycling cells (G0-G1) (p=0.011) and reduction in the dividing cell 
fractionss (S-G2-M) compared to the NDC by PI (p=0.009), Figure 4.1.4.1. Considering this further 
we used CFSE, an intracellular fluorescein-based dye, that enables cell divisions to be analysed 
587; CFSE fluorescence intensity progressively reduces with each cell division, due to the equal 
division of the fluorescent stain between daughter cells, allowing the number of divisions to be 
calculated relative to an undivided control population. This data supported that seen with PI, 
CFSE clearly showing a reduction in cell division with increasing doses of cyclopamine compared 
to the NDC; Figure 4.1.4.2.  
 
Figure 4.1.4.1: Percentage of inactive, non-cycling (G0-G1) OCI-AML3 cells by PI staining following 
culture with cyclopamine (10µM and 20µM) for 72hrs. 
OCI-AML3 cells were seeded at a concentration of 2x105/ml, exposed to incremental doses of 
cyclopamine, cultured for 72hrs then harvested and stained with PI prior to analysis by flow cytometry. 
(A) Representative flow cytometry plots, and gating strategy, following PI staining of OCI-AML3 cells 
following culture with select doses of cyclopamine for 72hrs. Each plot is representative of data from 
one experiment of four with similar results. (B) Bar graph indicating the proportion of cells within 
determined cell cycle phase (G0-G1and S-G2-M) as determined by PI, and analysis by flow cytometry. 
Each bar represents the mean percentage from four independent experiments with error bars 
indicating SD. Statistically significant results are highlighted with p value to the nearest 3 decimal 
places. This figure clearly shows culture of OCI-AML3 cells with cyclopamine for 72hrs to increase the 
percentage of inactive, non-cycling (G0-G1) cells.  
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Figure 4.1.4.2: Cellular proliferation, as determined by CFSE in OCI-AML3 cells following culture 
with cyclopamine (10µM and 20mM) for 72hrs.  
OCI-AML3 cells were seeded at a concentration of 2x105/ml, exposed to incremental doses of 
cyclopamine, cultured for 72hrs then harvested and stained with CFSE prior to analysis by flow 
cytometry. (A) Representative flow cytometry plots (i) Cell population, (ii) Histogram showing colcemid 
control (green) relative to CFSE stained population, (iii) Staggered histogram showing NDC, 10µM 
cyclopamine and 20µM cyclopamine, (iv) Histograms with gating strategy following CFSE staining of 
OCI-AML3 cells following culture with select doses of cyclopamine for 72hrs. Each plot is representative 
of data from one experiment of four with similar results. (B) This graph indicates the proportion of 
cells within each cell division as determined by CFSE and analysis by flow cytometry clearly 
demonstrating a block in cell proliferation following culture with 20µM cyclopamine for 72hrs. (C) 
Graph showing the average MFI for each experimental arm showing a progressive increase in the MFI, 
consistent with reduced proliferation and cell division, following culture with increasing doses of 
cyclopamine for 72hrs. 
Each bar represents the mean percentage from four independent experiments with error bars 
indicating SD. All statistically significant results are highlighted with p value to the nearest 3 decimal 
places, those not highlighted are not significant (ns). 
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In contrast, in keeping with the apoptosis demonstrated by Annexin V / 7AAD, cell cycle analysis 
by PI in the Kasumi-1 cell line demonstrated a statistically significant reduction in cells 
undergoing interphase and mitosis, the dividing cell fraction (S-G2-M) (p=0.015), with a 
concomitant modest increase in dying (sub G0) cells though this was not significant, Figure 
4.1.4.3. CFSE demonstrated no significant difference in the rate of proliferation between the 
NDC and all doses of cyclopamine up to and including 20µM, Figure 4.1.4.4.  
 
 
 
Figure 4.1.4.3: Percentage of inactive, non-cycling (G0-G1) Kasumi-1 cells by PI staining following 
culture with cyclopamine (10µM and 20µM) for 72hrs.  
Kasumi-1 cells were seeded at a concentration of 2x105/ml, exposed to incremental doses of 
cyclopamine, cultured for 72hrs then harvested and stained with PI prior to analysis by flow cytometry. 
(A) Representative flow cytometry plots, and gating strategy, following PI staining of Kasumi-1 cells 
following culture with select doses of cyclopamine for 72hrs. Each plot is representative of data from 
one experiment of four with similar results. (B) This graph indicates the proportion of cells within 
determined cell cycle phases (G0-G and, S-G2-M) as determined by PI, and analysis by flow cytometry. 
Each bar represents the mean percentage from four independent experiments with error bars 
indicating SD. Statistically significant results are highlighted with p value to the nearest 3 decimal 
places, those not highlighted are not significant (ns).  
This data clearly shows culture of Kasumi-1 cells with cyclopamine for 72hrs resulted in a reduction in 
proliferating cells, with a concomitant increase in dying cells.  
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Whilst the cell kinetic data was in keeping with reduced proliferation in the OCI-AML3 cell line, 
the mechanism remained unclear. We therefore considered whether culture with cyclopamine 
resulted in cellular senescence or differentiation in the OCI-AML3 cell line, discussed in the 
following sections.  
 
 
4.1.5 Manipulation of the Hh pathway by Smo inhibition with cyclopamine 
did not induce cellular senescence in select AML cell lines 
Cell senescence, as a possible mechanism to explain the altered cell kinetics seen in the OCI-
AML3 cell line was determined through measurement of β-galactosidase activity. β-galactosidase 
activity was also measured in the HL60, Kasumi-1, KG1a and MV4-11 cell lines. The Kasumi-1 cell 
line was included as a comparator given the differing effect Smo inhibition had.  
 
 
Figure 4.1.4.4: Cellular proliferation, as determined by CFSE in Kasumi-1 cells following culture 
with cyclopamine (10µM and 20µM) for 72hrs.  
Kasumi-1 cells were stained with CFSE, seeded at a concentration of 2x105/ml, exposed to incremental 
doses of cyclopamine and cultured for 72hrs prior to analysis by flow cytometry. (A) Representative 
flow cytometry plots, and gating strategy, of CFSE stained Kasumi-1 cells following culture with select 
doses of cyclopamine for 72hrs. Each plot is representative of data from one experiment of three with 
similar results. (B) This graph indicates the proportion of cells within each cell division as determined 
by CFSE, and analysis by flow cytometry, clearly showing culture of Kasumi-1 cells with cyclopamine for 
72hrs did not affect cell division by CFSE staining. Each bar represents the mean percentage from three 
independent experiments with error bars indicating SD. All statistically significant results are 
highlighted with p value to the nearest 3 decimal places, those not highlighted are not significant (ns).   
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β-galactosidase activity was measured in each of the cell lines following culture for 72hrs with 
cyclopamine at a dose of 10µM and 20µM, tomatidine at a dose of 20µM and DMSO at a volume of 
1.25µl/ml; Figure 4.1.5.1. No evidence of cellular senescence was demonstrated either in the 
presence of cyclopamine or the negative controls, the positive control confirmed the assay had 
worked (development of blue colouration) on each occasion (n=3).  
 
 
 
4.1.6 Manipulation of the Hh pathway by Smo inhibition with cyclopamine 
induced differentiation in select AML cell lines 
We considered whether cell differentiation could explain the altered cell kinetics demonstrated 
in previous assays, we had observed a morphological change in cells whilst performing trypan 
blue dye exclusion cell counts. We therefore studied our flow cytometry plots, specifically 
looking at the FSC / SSC plots for each experimental condition and each cell line. There was a 
striking, statistically significant increase in SSC within the HL60, MV4-11, OCI-AML3 and THP-1 
cell lines, with cells clearly becoming more granular when cultured for 72hrs with 20µM of 
cyclopamine when compared to the NDC. A similar, though less significant effect, was seen at 
10µM. Interestingly, no morphological change was demonstrated within either of the CD34-
expressing cell lines, Kasumi-1 and KG1a; Figure 4.1.6.1.  
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Figure 4.1.5.1: β-glactosidase activity in select, genetically diverse, AML cell lines following 
culture with 20mM cyclopamine for 72hrs.  
β-galactosidase activity, a characteristic of senescent cells not found in other cell states eg. quiescent 
cells was assessed in HL6o, Kasumi-1, KG1a, Mv4-11 and OCI-AML3 cells following culture for 72hrs with 
cyclopamine at a dose of 10µM and 20µM, tomatidine at a dose of 20µM and DMSO at a volume of 
1.25ml/ml. The percentage of senescent cells (staining blue-green) for each of our selected cell lines 
following culture with cyclopamine 20µM, the negative and positive control is shown. A minimum of 100 
cells were counted for each experimental arm. Alkali conditions (pH10) were used as a positive control, 
all cells within the positive control stained blue-green. There was no evidence of cellular senescence in 
any of the cell lines across all the experimental arms, with cells remaining colourless (n=3).  
	 178	
 
 
 
Analysis of the MOLM-13 cell line showed two different effects within the same cell population; 
Figure 4.1.6.2. As expected there was a population of cells that underwent apoptosis 
(highlighted in green). However, when these were gated out as shown in Figure 4.1.6.2 (B) two 
distinct populations of live cells remained (live by Annexin V / 7AAD). These cell populations 
were distinguishable by their FSC / SSC properties. One population demonstrated no change, 
plotting in the same region as those from the NDC whilst, interestingly, a second, smaller 
population showed an increase in SSC in keeping with increased granularity, as seen in the HL60, 
MV4-11, OCI-AML3 and THP-1 cell lines.  
Figure 4.1.6.1: Representative FSC / SSC plots from select, genetically diverse AML cell lines 
following culture with 20µM cyclopamine for 72hrs.  
Cells from each of our seven selected, genetically diverse AML cell lines were seeded at a 
concentration of 2x105/ml, exposed to incremental doses of cyclopamine and cultured for 72hrs prior 
to analysis by flow cytometry. Representative FSC / SSC flow cytometry plots are shown. Each plot is 
representative of data from one experiment of three with similar results and demonstrates the striking 
increase in SSC (reflecting cell granularity) in the HL60, MV4-11, OCI-AML3 and THP-1 cell lines relative 
to the NDC; whilst no change is seen in the Kasumi-1 or KG1a cell lines. FSC, forward scatter; SSC, side 
scatter. 
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We recognise the data obtained from the FACs scatter plots was observational. We therefore 
sought to validate our observations. Cells were therefore visualised by light microscopy with Diff-
Quik® staining. The OCI-AML3 cell line was shown to clearly have a more mature monocytoid 
appearance with increased cytoplasm, cytoplasmic vacuoles and granules and loss of cytoplasmic 
basophilia and nucleoli, supporting our observation of a change in cell morphology, Figure 
4.1.6.3. All slides were blindly reported and independently verified by Dr M Leach, Consultant 
Haematologist, NHS Greater Glasgow and Clyde to whom I am indebted for time and expertise. 
Morphological changes were not seen in the presence of 20µM tomatidine. 
Figure 4.1.6.2: Representative FSC / SSC plots from the MOLM-13 cell line following culture with 
20µM cyclopamine for 72hrs.  
MOLM-13 cells were seeded at a concentration of 2x105/ml, exposed to incremental doses of 
cyclopamine and cultured for 72hrs prior to analysis by flow cytometry. Representative FSC / SSC flow 
cytometry plots are shown. Each plot is representative of data from one experiment of three with 
similar results. (A) Shows the FSC / SSC plot for the total number of events recorded; Green highlights 
those events considered as dead / dying cells and cell debris. (B) Shows the FSC / SSC plot following 
exclusion of the apoptosing cell population clearly showing a smaller but distinct population of cells 
with increased granularity relative to the NDC. FSC, forward scatter; SSC, side scatter. 
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Differentiation was confirmed by CD marker expression in the OCI-AML3 cell line following 
culture with cyclopamine at concentrations of 10µM and 20µM for 72hrs. A statistically 
significant increase in the expression of CD11b (p<0.0001) and CD11c (p=0.008), in keeping with 
a more mature phenotype was demonstrated following culture with cyclopamine 20µM for 72hrs 
when compared to the NDC arm; Figure 4.1.6.4. No difference in expression was seen in the 
following myeloid markers: CD14, CD15, CD16, CD33, CD34 and CD68 (data not shown). CD 
marker analysis at 24hrs and 48hrs showed a progressive change with time. The effect therefore 
did not occur on exposure to cyclopamine but rather the progressive morphological change 
implies a shift in cell division towards differentiation rather than proliferation.  
Figure 4.1.6.3: Representative images following Diff-Quik® staining of OCI-AML3 cells following 
culture with 20mM cyclopamine for 72hrs.  
OCI-AML3 cells were seeded at a concentration of 2x105/ml, exposed to incremental doses of 
cyclopamine and cultured for 72hrs. Freshly harvested cells were spun onto a microscope slide by the 
use of a cytocentrifuge then stained with Diff-Quik® to enable analysis of cell morphology. 
Representative images are shown. Each plot is representative of data from one experiment of four with 
similar results. Following culture with 20µM cyclopamine the OCI-AML3 cells can be seen to have 
increased cytoplasm, cytoplasmic vacuoles and granules compared to the NDC with their higher nuclear 
to cytoplasmic ratio, visible nucleoli and basophilic cytoplasm. (A) NDC x60 magnification, (B) NDC 
x100 magnification, (C-D) Cyclopamine 20µM x100 magnification, showing range of morphological 
features displayed by the more mature monocytoid cells. 
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Gene expression analysis sought to determine a mechanism for cell differentiation. Key genes 
involved in myelomonocytic and granulocytic regulation and differentiation were studied, levels 
quantified by qRT-PCR using Fluidigm® technology. Genes were chosen on the basis of their role 
within early haematopoiesis and myeloid maturation. To account for input cDNA the ΔCT for 
each gene was calculated by subtracting the CT value of 2 housekeeping (control) genes, ENOX2 
and UBE2D2, from the CT of the gene of interest. The 2-ΔΔCT method was used to show expression 
of the gene of interest relative to the NDC, which was expressed as 1.  
There was a reduction in the expression of the early lineage markers: NAB2, GATA1, EGR2, SCL, 
IRF8 and EGR1 (p=ns) and an increase in expression seen in genes involved in differentiation and 
maturation, PU1, GCSF and MPO (p=ns); Figure 4.1.6.5. Whilst the results support our functional 
data we had expected the changes to be statistically significant. It is important however, to note 
that all early haematopoiesis markers were down-regulated and those involved in maturation up-
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Figure 4.1.6.4: CD marker expression profile on OCI-AML3 cells following with cyclopamine 20µM 
for 72hrs.  
OCI-AML3 cells were seeded at a concentration of 2x105, exposed to incremental doses of cyclopamine 
and cultured for 72hrs. Freshly harvested cells were stained with an antibody cocktail containing 
CD11b, CD11c, CD14, CD15, CD16, CD33, CD34 and CD68 prior to analysis by flow cytometry. (A) 
Representative flow cytometry plots. Each plot is representative of data from one experiment of four 
with similar results. (B) Graphs show the mean fluorescence intensity (MFI) of the CD markers (CD11b 
(i) and CD11c (ii)) as determined by flow cytometry showing culture with cyclopamine for 72hrs led to 
a change in cell CD marker expression profile of OCI-AML3 cells. Each bar represents the mean 
percentage from four independent experiments with error bars indicating SD. All statistically significant 
results are highlighted with p value to the nearest 3 decimal places. Unstained untreated (grey dotted 
line); NDC (blue); 20µM cyclopamine (red). 
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regulated. To postulate significance might be seen at a later time point does not fit with our 
functional data showing clear differentiation by 72hrs. We did not study all genes involved in 
early haematopoiesis and myeloid maturation and may therefore have missed those in which a 
significant change has occurred. On reflection, however, we propose these relatively minor shifts 
in gene expression in key behaviour and lineage determinant genes are sufficient to significantly 
affect cell phenotype, to alter the balance between self-renewal and differentiation, as 
demonstrated by our functional assays. 
 
 
Finally, CFC assays were performed to determine the ability of the OCI-AML3 cells to proliferate, 
and differentiate, into colonies. The CFC assay is an in vitro assay based on the ability of 
haematopoietic progenitor cells to proliferate and differentiate into colonies in semisolid media 
with adequate cytokine support. These colonies can be enumerated and characterised according 
to their unique morphology, providing information about differentiation and proliferative 
qualities 574,632.  
We hypothesised culture with cyclopamine, through its ability to cause cell differentiation, 
would result in fewer colonies by CFC assay. In contrast to our hypothesis, there was no 
significant difference between absolute colony number across all experimental arms. Further, 
the absolute colony numbers challenged our previous results, showing no significant difference 
between total colony numbers, and therefore proliferative capabilities, across each of the 
experimental arms. When we considered the predominant character of the colonies, as defined 
by morphology, within each of the experimental arms however an extremely interesting 
observation was made. Initial culture with 20µM cyclopamine for 72hrs resulted in a statistically 
significant reduction in the more pluripotent CFU-GM (p=0.006) colonies and an increase in 
omnipotent CFU-G (p=0.013) colonies at day 12 compared to the 20µM tomatidine control. Whilst 
CFU-M colonies were reduced 2-fold following drug treatment the result was not significant; 
Figure 4.1.6.6. Replates were performed though <3 secondary colonies grew in each of the 
experimental arms (n=2). We consider this difference in colony morphology to indicate a shift 
Figure 4.1.6.5: Culture of OCI-AML3 cells with cyclopamine for 72hrs resulted in a change in the 
mRNA expression of early lineage genes and those intrinsically involved in cellular maturation. 
OCI-AML3 cells were seeded at a concentration of 2x105/ml, exposed to incremental doses of 
cyclopamine and cultured for 72hrs. RNA was extracted from freshly harvested cells. A reduction in 
early lineage markers and an increase in genes involved in differentiation and maturation Is clearly 
demonstrated though these results were not statistically significant. Expression levels are shown as the 
fold change (2-ΔΔCT) relative to NDC with 2 housekeeping genes (ENOX2 and UBE2D2) serving as 
endogenous control. Each bar represents the mean fold change from three independent experiments 
with error bars indicating SD. 
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towards differentiation but not a fully differentiated state, the cells retaining the property of 
self-renewal. Excitingly these results correlate, and thus strengthen, our in vitro functional 
assays and gene expression data.  
 
 
Whilst the CFC assay is a recognised and accepted assay for studying cell behaviour, colony 
morphology and number enabling analysis of a cell’s ability to proliferate and / or differentiate, 
we sought to validate our findings, recognising that this data is observational and thus could be 
subject to observer bias. We therefore sought to analyse the expression of select CD markers by 
cells within our colonies using flow cytometry.  
Briefly, at day 12, colonies were counted and characterised before being harvested, washed and 
stained prior to flow cytometry analysis. Expression of CD11b and CD11c were studied as these 
CD markers had shown significant up-regulation following liquid culture of the OCI-AML3 cells. No 
difference in expression was seen (n=2; data not shown). It is important however to consider 
these results in experimental context. Methocult contains a cocktail of growth factors, designed 
to support the growth and differentiation of HPCs. It would be interesting therefore to study a 
broader range of CD markers, the mature markers - CD14, CD15, CD16 and CD68, and the more 
immature markers - CD33 and CD34. In addition, experimental design precluded analysis of 
individual colonies; if expression changes were not universal they may therefore not have been 
detected.  
Whilst we had demonstrated a statistically significant difference in colony character, suggesting 
modified differentiation abilities we considered whether this was a reversible phenotype shift. In 
vivo studies have shown rapid clearance of cyclopamine, with serum drug concentrations 
approaching, or below, the lower limit of quantification 24hrs following bolus administration 631. 
Figure 4.1.6.6: Colony morphology and number at day 12 following culture of OCI-AML3 cells with 
cyclopamine (10µM and 20µM) for 72hrs.  
OCI-AML3 cells were seeded at a concentration of 2x105/ml, exposed to incremental doses of 
cyclopamine and cultured for 72hrs. Cells, from each experimental arm, at a concentration of 4x103/
ml, were suspended in serum free media (supplemented with a growth factor cocktail), added to 
methylcellulose media, thoroughly mixed then divided between two 35mm culture dish before being 
cultured for a further 12 days. (A) Representative images of colonies at day 12 (i) CFU-GM, (ii) CFU-G 
(B) Graphs show the absolute number of each type of colony showing culture of OCI-AML3 cells with 
cyclopamine for 72hrs resulted in a change in colony morphology but not the absolute colony number at 
day 12. Each bar represents the mean percentage from four independent experiments with error bars 
indicating SD. All statistically significant results are highlighted with p value to the nearest 3 decimal 
places. CFU-, colony forming unit; GM, granulocyte, macrophage; G, granulocyte; M, macrophage. 
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‘Washout’ experiments were therefore performed. Briefly OCI-AML3 cells were cultured for 72hrs 
with 10µM and 20µM cyclopamine as described previously, washed twice in fresh media prior to 
resuspending the cells in fresh media and culturing for a further 72hrs in the absence of 
cyclopamine. Analysis showed loss of cell cycle arrest by PI and a striking and complete reversion 
of FSC / SSC parameters; Figure 4.1.6.7.  
 
 
It would be interesting to determine if increased Smo inhibition, through prolonged culture or 
the addition of fresh drug every 24hrs, equating to a daily or continuous administration within 
the clinical setting, would cause irreversible differentiation, or go further to modify the cells 
proliferative abilities.  
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Figure 4.1.6.7: SSC profile of OCI-AML3 cells following culture with 20µM cyclopamine for 72hrs 
and after a ‘wash-out’ and further 72hrs in fresh media.  
OCI-AML3 cells were seeded at a concentration of 2x105/ml, exposed to incremental doses of 
cyclopamine and cultured for 72hrs. Cells were then harvested, washed twice in fresh media prior to 
being resuspended in fresh media and cultured for a further 72hrs in the absence of cyclopamine. (A) Bar 
graph showing the SSC MFI, reflecting changes in cell granularity, at baseline and following culture with 
and subsequently without cyclopamine, clearly showing culture of OCI-AML3 cells with cyclopamine 
induced a reversible change in cell granularity as determined by the SSC profile. Each bar represents 
the mean percentage from three independent experiments with error bars indicating SD, clearly 
demonstrating the marked increase in cell granularity following culture with cyclopamine and the 
subsequent reversal back to baseline following its removal. (B) Representative flow cytometry plots 
from each experimental stage. Each plot is representative of data from one experiment of three with 
similar results. Statistically significant results are highlighted with p value to the nearest 3 decimal 
places, those not highlighted are not significant (ns).                                                                    
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4.1.7 Gene interference using a SMO siRNA in the Kasumi-1 cell line generated 
differing functional results dependent upon the degree of knockdown achieved (n=2 
with technical duplicates) 
Whilst tomatidine was used as a negative control to ensure the effects seen with cyclopamine 
were due to Smo inhibition, we sought to clarify this further. A shRNA against human SMO in a 
PLKO.1 plasmid (Methods 2.2.1.10) was therefore used to generate a Kasumi-1 SMO knockdown 
(KD). The Kasumi-1 cell line was selected since pharmacological inhibition had resulted in 
apoptosis whilst other cell lines had shown differentiation. We therefore questioned whether 
apoptosis was an off-target effect or a reflection of sensitivity to cyclopamine.  
In parallel to functional assays, the KD efficiency was analysed by RT-qPCR analysis. Compared 
with the scrambled (SCR) control, the remaining SMO expression ranged from 20% to 50%. For 
clarity, the average and individual results are shown, Figure 4.1.7.1. This experiment was 
performed twice. For the purpose of my thesis, I have addressed each of the biological replicates 
in succession as each supports a different hypothesis. I acknowledge this experiment needs to be 
repeated to achieve at least n=3 not least due to the differing results obtained. 
 
 
 
In the 50% SMO KD model at 72hrs (Figure 4.1.7.1c) there was a 1.5-fold increase in the total 
number of live cells relative to input number by trypan blue dye exclusion compared to a 2.5-
fold increase in the SCR control (Figure 4.1.7.2). Accounting for differences in the input cell 
number for each of the experimental arms at the 72hr time point, there was 1.8-fold greater 
number of live cells in the SCR control compared to SMO KD. In contrast to the results we had 
seen following pharmacological Smo inhibition, there was no difference in the number of dead 
cells by trypan blue dye exclusion between the SMO KD and SCR control. We therefore had 
evidence of reduced proliferation in the 50% SMO KD which was not explained by apoptosis.  
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Figure 4.1.7.1: Knockdown efficiency of a shRNA against human SMO in Kasumi-1 cells.  
Kasumi-1 cells were virally transfected with a GFP tagged shRNA, cultured for 24hrs then harvested, 
RNA extracted and qRT-PCR performed to assess knockdown efficiency. Expression levels are shown as 
the fold change (2-ΔΔCT) relative to NDC with 2 housekeeping genes (ENOX2 and UBE2D2) serving as 
endogenous control showing variable knockdown of SMO. (A) Each bar represents the fold change from 
two independent experiments with error bars indicating SD; (B&C) Each graph shows fold change from 
each individual experiment highlighting the variance in knockdown efficiency.  SCR, Scrambled; KD, 
SMO knockdown.  
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Considering this finding cell proliferation was studied by FACs using CTV to follow cell 
division; CTV fluorescence intensity progressively reducing with each cell division 
allowing number of divisions to be calculated relative to a non-dividing control 
population 588.  CTV was used rather than CFSE as our cells were labelled with GFP, seen in 
the same channel (FITC) as CFSE.  
Interestingly, a reduction in cell proliferation was demonstrated by CTV showing a >2-fold 
reduction (0.45-fold change) in the MFI at 24hrs in the SCR control compared to a <2-fold 
reduction (0.67-fold change) in the SMO KD, Figure 4.1.7.3. Analysis beyond this time point was 
limited by the low input numbers and auto-fluorescence generated by the GFP tagged plasmid.  
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Figure 4.1.7.2: Cell viability, as determined by trypan blue dye exclusion, in a 50% SMO KD 
in the Kasumi-1 cell line.  
Kasumi-1 cells were virally transfected with a GFP tagged shRNA. mRNA expression by qRT-PCR 
demonstrated 50% efficiency. (A) Levels of SMO expression following viral transfection expressed 
as the fold change (2-ΔΔCT) relative to SCR control with 2 housekeeping genes (ENOX2 and UBE2D2) 
serving as endogenous control. (B) Cell number by trypan blue dye exclusion in the SMO KD and 
SCR control. (C) Percentage live and dead cells by trypan blue dye exclusion in the SMO KD and 
SCR control.  
Reduced proliferation is demonstrated in the 50% KD compared to the SCR control by trypan blue 
dye exclusion, with no difference in the percentage of dead cells.  
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Figure 4.1.7.3: Proliferation, as determined by CTV staining, in a 50% SMO KD in the Kasumi-1 cell 
line.  
Kasumi-1 cells were virally transfected with a GFP tagged shRNA. qRT-PCR demonstrated 50% 
efficiency. Reduced proliferation was demonstrated in the 50% KD compared to the SCR control by CTV 
staining and flow cytometry analysis. (A) FACS plot showing all events, with the live cell population 
gating strategy. (B) FACS plot showing GFP status of the live cell population with gating strategy. (C) 
FACS plot showing baseline (0hrs) CTV staining profile for the SMO KD (orange line) and SCR control 
(grey line). (D) FACS plot showing CTV staining profile following 24hrs culture profile for the SCR 
control (grey line) relative to baseline (blue line). (E) FACS plot showing CTV staining profile following 
24hrs culture for the SMO KD (orange line) relative to baseline (blue line). (F) Graph showing the MFI of 
CTV staining at successive time points (24, 48 and 72hrs) in the SMO KD and SCR control clearly showing 
a reduction in proliferation at 24hrs in the 50% SMO KD relative to the SCR control. 
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Interestingly, as with the OCI-AML3 cell line in which altered cell kinetics were clearly 
demonstrated, a difference in cell morphology as determined by FSC / SSC parameters was also 
demonstrated suggesting a partial reduction in SMO leads to cell differentiation, Figure 4.1.7.4.  
 
 
In contrast, in the 80% SMO KD model there was a 25% reduction in the total number of live cells, 
and a doubling in the number of dead cells by trypan blue dye exclusion compared to the SCR 
control at 72hrs. A difference in cell viability between the SMO KD and SCR control at 24hrs, 
48hrs and 72hrs was confirmed by 7AAD with an increase in dead cells seen in the SMO KD 
relative to SCR control at each time point, Figure 4.1.7.5. Further, in contrast to the results seen 
with the 50% KD there was no difference in the FSC / SSC parameters between the SMO KD and 
SCR control arm, Figure 4.1.7.6.  
Figure 4.1.7.4: SSC profile of a 50% SMO KD in the Kasumi-1 cell line. 
Kasumi-1 cells were virally transfected with a GFP tagged shRNA. qRT-PCR demonstrated 50% 
efficiency. Flow cytometry demonstrated an increase in SSC (reflecting granularity) in the 50% SMO KD 
compared to the SCR control following culture for 24hrs.  
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Figure 4.1.7.5: Cell viability, as determined by trypan blue dye exclusion, in an 80% SMO KD 
in the Kasumi-1 cell line.  
Kasumi-1 cells were virally transfected with a GFP tagged shRNA. mRNA expression by qRT-PCR 
demonstrated 80% efficiency. (A) Levels of SMO expression following viral transfection expressed 
as the fold change (2-ΔΔCT) relative to SCR control with 2 housekeeping genes (ENOX2 and UBE2D2) 
serving as endogenous control. (B) Percentage live and dead cells by trypan blue dye exclusion in 
the SMO KD and SCR control. (C) The SMO KD showed a progressive reduction in the number of 
live cells, with an accompanying increase in dead cells by 7AAD.  
An increase in cell death was demonstrated in the 80% KD compared to the SCR control by trypan 
blue dye exclusion and FACs analysis using 7AAD. 
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Figure 4.1.7.6: SSC profile of an 80% SMO KD in the Kasumi-1 cell line.  
Kasumi-1 cells were virally transfected with a GFP tagged shRNA. qRT-PCR demonstrated 80% 
efficiency. Flow cytometry demonstrated no change in FSC / SSC parameters in the SMO KD compared 
to the SCR control following culture for 24hrs.  
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Whilst we acknowledge our knockdown model needs to be repeated, it is tempting to compare 
the contrasting results in our two KD experiments with the differing effects seen between the 
cell lines dependent upon their IC50. This raises an interesting hypothesis, with exciting 
translational opportunities - could partial Smo inhibition force the cells to differentiate, whilst 
complete, or near complete, inhibition cause apoptosis? In the future we plan to validate this 
hypothesis by repeating the experiment to ensure n≥3 for both the partial SMO KD model, and 
near complete SMO KD model, evaluating key members of the Hh signalling pathway and 
downstream targets at both the gene and protein level. Further, it would be interesting to 
analyse the cells at a morphological level for evidence of differentiation and also apoptosis - 
hallmarks of cell apoptosis being cell shrinkage, nuclear DNA fragmentation and membrane 
blebbing 633. In addition, it would be very interesting to perform a KD in the OCI-AML3 cell line 
given the contrasting response to cyclopamine.  
There was insufficient material from the limited experiments performed to allow protein analysis 
by Western blotting. Interestingly, despite the functional changes demonstrated, ICC showed no 
significant difference in SMO expression between the SMO KD and SCR control at 72hrs, This may 
however reflect basal protein expression, before changes in transcription could be translated to 
the protein level, the presence of the protein reflecting the rate of protein degradation rather 
than changes in protein synthesis 634. Further, Smo is cycled between the membrane and 
cytoplasm depending on pathway activity. The antibody however cannot discriminate between 
available (membrane bound) and unavailable (cytoplasmic) protein. Had time allowed, we would 
have repeated the experiment, performing ICC on cells harvested at both earlier and later time 
points, to determine the timing and degree of change in SMO protein expression.  
 
4.1.8 Smo inhibition with cyclopamine led to the down-regulation of GLI-1, a 
marker of pathway activity, in select, genetically diverse AML cell 
lines.  
As discussed in Background 1.4.2, whilst classically the Hh pathway was believed to be ligand-
dependent, more recent work has considered the notion of non-canonical signalling 349,350,374. 
Further, both positive and negative feedback is understood to regulate pathway activity 
331,340,345,635,636. We therefore sought to determine the effects of cyclopamine on the transcription 
of components of the Hh pathway. RNA was extracted from an aliquot of cells harvested 
following culture with increasing doses of cyclopamine for 72hrs. The remainder of the cells 
were used for various functional assays to minimise confounding effects and to ensure gene 
changes could be accurately correlated with functional change. The 2-ΔΔCT method was used to 
show expression of the gene of interest relative to the NDC, expressed as 1, Figure 4.1.8.1.  
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Figure 4.1.8.1: Variance in the mRNA expression of components of the Hh pathway in seven 
genetically diverse AML cell lines following culture with cyclopamine (10µM and 20µM) for 72hrs. 
RNA was extracted from an aliquot of cells harvested following culture with cyclopamine at a dose of 
10µM and 20µM for 72hrs. Expression levels were quantified by qRT-PCR using Fluidigm® technology. 
Expression levels are shown as 2-ΔΔCT, with 6 housekeeping genes genes – ATP5S, B2M, ENOX2, GAPDH, 
TYWI and UBE2D2 serving as endogenous control; CT values for these genes ranged from 3 to 13. The 
mean of 3 biological replicates, each performed in technical duplicate, are shown with error bars 
indicating the SD clearly showing a marked variance in the mRNA expression of components of the Hh 
pathway in our selected AML cell lines.  
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There was no significant change in the expression of SMO in each of our selected cell lines 
following culture with cyclopamine (10µM and 20µM). PTCH1 was down-regulated in the 
genetically diverse Kasumi-1, MOLM-13 and MV4-11 cell lines following culture with 20µM 
cyclopamine though not 10µM; apoptosis was seen in the Kasumi-1 and MOLM-13 cell lines though 
not the MV4-11 cell line following culture with cyclopamine. GLI-1 was down-regulated in the 
MOLM-13 cell line and, to a lesser degree the Kasumi-1 cell line; it was marginally up-regulated 
in the MV4-11 cell line. GLI-2, previously shown to be absent when cells were harvested 
following culture for 24hrs at optimal cell density was not detected in any cell line, irrespective 
of experimental condition. Interestingly, the transcriptional repressor, GLI-3, was variably down-
regulated in all cell lines, with the effect greater following culture with 20µM cyclopamine. 
There was minimal change identified in the other negative regulators HHIP, STIL and SUFU 
following culture of each of our selected, genetically diverse cell lines with both 10µM and 20µM 
cyclopamine.  
 
4.1.9 Manipulation of the Hh pathway by Smo inhibition with cyclopamine 
affects expression of genes involved in apoptosis and autophagy in a 
cell line-specific manner 
We recognise the degree of cross talk between the self-renewal pathways, and the potential for 
redundancy of individual components, and therefore the limitations of interpreting expression of 
components of the Hh pathway in isolation. We therefore sought to analyse expression of key 
downstream targets. Acknowledging the vast array of targets of the pathway, Figure 1.8, we 
selected key targets and pathways (1) known to be affected by conventional treatment 
(considering our ultimate objective to evaluate the potential of these small molecule inhibitors 
in the clinical setting) and (2) in accordance with our functional data. 
First line treatment for AML standardly uses Ara-C combined with an anthracycline 201,202. 
Research has shown clinical response to Ara-C to depend upon genes including deoxycytidine 
kinase, cytidine deaminase, cytosolic 5’-nucleotidases, DNA polymerases, topoisomerases, BCL-2 
and TP53 533. However, the exact mechanism, and the pathways involved remain to be 
determined. Considering the complexity of AML, and the evidence to support pathway 
redundancy, it is not surprising that small molecule inhibitors, as single agents, have had limited 
effects. Our functional data, supported by others 377,379, has shown Smo inhibition to result in 
apoptosis in select cell lines. However, in contrast to these results, reduced proliferation in the 
absence of apoptosis was demonstrated in other cell lines. This is again supported by research 
showing the Hh pathway to regulate the cell cycle 362,637. Additionally, autophagy is a highly 
controlled proteolytic process that can be induced by cellular stress 638,639, with recent work 
demonstrating its involvement in oncogenesis, disease progression, treatment resistance and 
relapse 640. Interestingly, recent work has shown the Hh pathway to regulate autophagy, though 
results are conflicting with the Hh pathway being shown to both inhibit and induce autophagy 
613,641,642. Our results had shown evidence of both altered cell cycle kinetics and apoptosis. We 
therefore sought to determine the effect of cyclopamine at a gene level on apoptosis, autophagy 
and the cell cycle.  
RNA was extracted from cells following culture with cyclopamine at a concentration of 5µM, 
10µM and 20µM for 72hrs. 5µM was selected to evaluate whether gene expression was affected 
by a concentration not shown to affect cell proliferation or cell death by trypan blue dye 
exclusion. Technical triplicates were performed for each sample. The 2-ΔΔCT method was used to 
show expression of the gene of interest relative to the NDC. Log transformation of the fold 
change enabled graphical display of expression patterns according to the unsupervised Eisen 
approach using PermutMatrix software 589; Figure 4.1.9.1.		
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Figure 4.1.9.1: Gene expression profiles for genes involved in apoptosis, autophagy and cell cycle, 
following culture with cyclopamine (5µM, 10µM and 20µM) for 72hrs.  
RNA was extracted from an aliquot of cells harvested following culture with increasing doses of 
cyclopamine for 72hrs. Expression levels were quantified by qRT-PCR using Fluidigm® technology. To 
account for input cDNA the ΔCT for each gene was calculated by subtracting the CT value of 6 
housekeeping (control) genes (ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2) from the CT recorded the 
gene of interest. Technical triplicates were performed for each sample. Log transformation of the 2-ΔΔCT 
enabled graphical display of expression patterns according the unsupervised Eisen approach using 
PermutMatrix software 506. Complete-linkage clustering of our selected genes and all experimental 
conditions are shown. The expression changes and consequent clustering of Kasumi-1 and MOLM-13 
following culture with cyclopamine 20µM is highlighted in blue. MV4-11 and THP-1 are also seen to 
cluster irrespective of cyclopamine concentration, highlighted in orange.  
K
as
um
i-1
 &
 
M
O
LM
-1
3 
20
µ
M
 
M
V4
-1
1 
&
 T
H
P-
1 
 
10
 / 
20
µ
M
 
H
L6
0,
 K
G
1a
, 
O
C
I-A
M
L3
,  
10
 / 
20
µ
M
 
H
L6
0 
	 194	
The results generated by PermutMatrix are striking. Complete linkage clustering found marked 
similarity between the Kasumi-1 and MOLM-13 cell lines (highlighted in blue) suggesting a 
dependence upon Smo or the Hh pathway or a shared characteristic influenced by the Hh 
pathway despite their genetic diversity. Interestingly, this similarity in gene expression was 
restricted to culture with 20µM cyclopamine; expression patterns following culture with 
cyclopamine at 5µM and 10µM were scattered throughout the heatmap suggesting a threshold 
effect. It is important however, to consider whether the expression changes within the Kasumi-1 
and MOLM-13 cell lines reflect cellular stress, and the apoptotic process, or whether it is these 
expression changes which result in apoptosis. To investigate this further we would analyse gene 
expression at successive time points, correlating it with functional data. As striking as this 
clustering, or similarity, is, is the disparity in the expression patterns of the CD34 positive cell 
lines: Kasumi-1 and KG1a, and the FLT3-ITD expressing cell lines: MV4-11 and MOLM-13. In our 
opinion, these varied expression changes highlight the complexity, and to a degree our yet 
superficial understanding and characterisation, of AML.  
A number of findings are now highlighted and discussed in further detail. LC3B was up-regulated 
in the Kasumi-1 and MOLM-13 cell lines following culture with cyclopamine at a concentration of 
20µM; Figure 4.1.9.2. This is particularly interesting considering the dual role LC3B plays in 
regulating autophagy and microtubule assembly 643, microtubules being vital in forming primary 
cilia and thereby enabling canonical Hh signalling 429,431,454,641. Apoptosis was observed following 
culture of the Kasumi-1 and MOLM-13 cell lines with cyclopamine (10µM and 20µM). Interestingly 
expression changes were not seen following culture of the Kasumi-1 and MOLM-13 cell lines with 
10µM cyclopamine. ULK1, ATG5 and ATG7 were not significantly affected, remaining relatively 
uniformly expressed following culture with cyclopamine, at a concentration of 10µM and 20µM, 
relative to the NDC in all cell lines. 
 
 
Figure 4.1.9.2: Expression of genes involved in autophagy in seven genetically diverse, AML cell 
lines, following culture with cyclopamine (10µM and 20µM) for 72hrs.  
RNA was extracted from an aliquot of cells harvested following culture with increasing doses of 
cyclopamine for 72hrs. Expression levels were quantified by qRT-PCR using Fluidigm® technology. 
Expression levels are shown as 2-ΔΔCT, with 6 housekeeping genes genes – ATP5S, B2M, ENOX2, GAPDH, 
TYWI and UBE2D2 serving as endogenous control; CT values for these genes ranged from 3 to 13. The 
mean of 3 biological replicates are shown, each performed in technical duplicate, with error bars 
indicate SD. With the exception of LC3B genes involved in autophagy were uniformly expressed by our 
selected genetically diverse AML cell lines, irrespective of the concentration of cyclopamine with which 
they were cultured.  
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Within the anti-apoptotic genes we had selected, minimal change was seen following culture 
with cyclopamine (10µM and 20µM) relative to the NDC in all cell lines with a couple of notable 
exceptions; Figure 4.1.9.3. BCL-W was down-regulated in the genetically diverse HL60 and 
MOLM-13 cell lines (>10-fold), in which our functional data had shown differing results; it was 
relatively unchanged in the Kasumi-1, KG1a, MV4-11 and OCI-AML3 cell lines. MCL-1 was 
consistently up-regulated by MV4-11 following culture with cyclopamine (both 10µM and 20µM; 3-
fold and 2.3-fold, respectively) though this was not significant. This is particularly interesting 
since recent work analysing Bcl-2 inhibitors has highlighted the intricate relationship between 
Mcl-1 and Bcl-2, either seemingly able to ‘rescue’ the cell from apoptosis if up-regulated in the 
absence of the other 232. We postulate that up-regulation of MCL-1 might explain the differential 
results, both functional and at a gene level, seen following culture of our two FLT3-ITD positive 
cell lines MOLM-13 and MV4-11 with cyclopamine.  
 
 
 
Minimal change was seen within our selected pro-apoptotic genes following culture with 
cyclopamine relative to the NDC in all cell lines (Figure 4.1.9.4); notable exceptions require 
further discussion. APAF-1, BBC3 and BID were down-regulated in the Kasumi-1 cell line while 
TP53 was down-regulated in the HL60 cell line following culture with cyclopamine.  
Considering our functional data, the gene expression profiles we observed were not expected - 
we had anticipated an expression shift in favour of apoptosis in the Kasumi-1 and MOLM-13 cell 
lines. We propose a number of potential explanations, which, would be interesting to consider in 
the future: (1) changes occurred at a protein rather than gene level, (2) slight changes in 
expression of these powerful genes were sufficient to push cells towards apoptosis, (3) caspase-
independent pathways were involved, the tumour necrosis factor (TNF) receptor, c-Jun N-
terminal kinase (JNK), NF-κB and mitogen-activated protein kinase (MAPK) / ERK 645,646. It would 
be interesting to study expression of these genes.  
Figure 4.1.9.3: mRNA expression of the anti-apoptotic members of the Bcl-2 family in seven 
genetically diverse, AML cell lines, following culture with cyclopamine (10µM and 20µM) for 72hrs. 
RNA was extracted from an aliquot of cells harvested following culture with increasing doses of 
cyclopamine for 72hrs. Expression levels were quantified by qRT-PCR using Fluidigm® technology. 
Expression levels are shown as 2-ΔΔCT, with 6 housekeeping genes genes – ATP5S, B2M, ENOX2, GAPDH, 
TYWI and UBE2D2 serving as endogenous control; CT values for these genes ranged from 3 to 13. The 
mean of 3 biological replicates, each performed in technical duplicate, are shown with error bars 
indicate SD. mRNA expression of the anti-apoptotic members of the Bcl-2 family were tightly regulated 
with the exception of BCL-W in seven genetically diverse AML cell lines following culture with 
cyclopamine for 72hrs.  
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Within regulators of cell cycle, CCND1, required for progression through the G1 phase of the cell 
cycle, was down-regulated in the Kasumi-1 and MOLM-13 cell lines following culture with 20µM 
cyclopamine, Figure 4.1.9.5. The uniform up-regulation of PARP1 is interesting considering its 
role in differentiation, proliferation and perhaps, more importantly in this context, DNA repair. 
Further, PARP1 has been shown to be up-regulated in haematological malignancies, with clinical 
grade PARP inhibitors in early clinical trial in solid and haematological malignancies; the PARP 
inhibitor Olaparib was approved by the EMA and FDA in 2014 647–653 for relapsed ovarian cancer. 
As we have discussed earlier, the use of small molecule inhibitors in isolation is unlikely to 
change the trajectory of these highly complex and diverse malignancies. Could Smo inhibition 
induce a stress response thus sensitising AML cells to standard chemotherapeutic agents or other 
small molecule inhibitors? 
 
Figure 4.1.9.4: mRNA expression of pro-apoptotic members of the Bcl-2 family in seven genetically 
diverse AML cell lines, following culture with cyclopamine (10µM and 20µM) for 72hrs.  
RNA was extracted from an aliquot of cells harvested following culture with increasing doses of 
cyclopamine for 72hrs. Expression levels were quantified by qRT-PCR using Fluidigm® technology. 
Expression levels are shown as 2-ΔΔCT, with 6 housekeeping genes genes – ATP5S, B2M, ENOX2, GAPDH, 
TYWI and UBE2D2 serving as endogenous control; CT values for these genes ranged from 3 to 13. The 
mean of 3 biological replicates, performed in technical duplicate, are shown with error bars indicate 
SD. Expression of pro-apoptotic genes was tightly regulated, and largely unchanged following culture 
with cyclopamine across each of our selected AML cell lines. 
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4.1.10 Manipulation of the Hh pathway with glasdegib, a clinical grade SMO 
inhibitor alters cell proliferation 
APML is the success story of AML, a model for precision medicine. In APML ATRA forces the 
leukaemic blast cells to differentiate, rendering them more susceptible to cytotoxic agents. 
Evidence of differentiation in select, genetically definable, AML cell lines in vitro was, 
therefore, hugely exciting, suggesting a potential mechanism, and thus role, for Smo antagonism 
in the clinical management of AML. We hypothesised Smo inhibition would drive a subset of AML 
cases to differentiate, rendering them more sensitive to cytotoxic therapy. Further, evidence of 
apoptosis in other, genetically distinct, AML cell lines suggests Smo antagonists have the 
potential to prove beneficial though perhaps through different mechanisms dependent upon 
genotype. Considering this and recognising cyclopamine is not suitable for clinical use we studied 
several clinical grade drugs: Erivedge® (vismodegib, Genentech), Glasdegib® (PF-04449913, 
Pfizer) and Odomzo® (sonidegib, Novartis), discussed in greater depth in Background 1.4.5.1. 
The results of our work looking at glasdegib are presented here. The OCI-AML3 cell line was 
selected to determine whether cellular differentiation was specific to Smo inhibition with 
cyclopamine or seen in the presence of other, clinical grade, Smo antagonists. In addition, 
another myelomonocytic cell line, MOLM-13, was studied. MOLM-13 carries the FLT3-ITD 
mutation, found in approximately 30% of all cases of AML, with published data linking the FLT3-
ITD mutation with deregulated Hh signalling, in particular in those historically classed as FAB M4 
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Figure 4.1.9.5: mRNA expression of genes involved in cell cycle regulation and differentiation in 
seven genetically diverse AML cell lines, following culture with cyclopamine (10µM and 20µM) for 
72hrs. 
RNA was extracted from an aliquot of cells harvested following culture with increasing doses of 
cyclopamine for 72hrs. Expression levels were quantified by qRT-PCR using Fluidigm® technology. 
Expression levels are shown as 2-ΔΔCT, with 6 housekeeping genes genes – ATP5S, B2M, ENOX2, GAPDH, 
TYWI and UBE2D2 serving as endogenous control; CT values for these genes ranged from 3 to 13. The 
mean of 3 biological replicates, performed in technical duplicate, are shown with error bars indicate 
SD. PARP was universally up-regulated following culture with cyclopamine. The cell cycle regulators 
were otherwise not significantly affected by culture with cyclopamine, irrespective of concentration 
with the exception of CCND1 and CCND2 which were down-regulated following culture of the Kasumi-1 
and MOLM-13 cell lines.  
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379,381. Further, our functional data had shown evidence of apoptosis, with gene expression 
studies consistent with cellular stress, following culture with cyclopamine.  
We utilised the resazurin assay to determine the effect of a wide range of concentrations of 
glasdegib on cell viability following culture for 72hrs for each of our chosen cell lines; Figure 
4.1.10.1.    
 
 
Using the resazurin assay, no significant change in metabolic activity was seen with doses below 
25µM in the OCI-AML3 cell line, with no change in metabolic activity across all doses in the 
MOLM-13 cell line. These results are consistent with those reported showing no notable change 
following in vitro short term culture of the AML cell line Marimo 383 and comparable to results 
obtained following culture of these cell lines with cyclopamine (section 4.1.3). These results 
contrasted with those reported following long-term in vitro culture and murine studies 383.  
We recognise the limitations of the resazurin assay. Further, this assay had suggested minimal 
effect on metabolic activity following culture of these cell lines with cyclopamine at 
concentrations below 25µM; whilst trypan blue dye exclusion had demonstrated a statistically 
significant reduction in the number of live cells following culture with cyclopamine at a 
concentration of10µM and 20µM. Considering our aim was to compare the effects of the in vitro 
culture of genetically diverse AML cell lines with cyclopamine to those with a clinical grade Smo 
antagonist we referenced a phase 1 safety and pharmacokinetics study published in 2015 407 to 
determine appropriate drug concentrations. Objective responses, suggestive of biological 
activity, were demonstrated across a range of doses, with the maximum tolerated dose for 
continuous treatment reported to be 400mg OD 407. The recommended phase two dose was 
determined to be ≤200mg OD. No off-target effects were identified. We therefore looked at the 
median pharmacokinetic area under the plasma concentration-time curve at 0hrs following the 
administration of 180mg, 270mg and 400mg. Converting ng/ml to µM we determined a dose 
range of 2.67µM to 10.68µM. A glasdegib concentration of 2.67µM, 5.34µM and 10.68µM was 
therefore used for all future experiments; we wished to determine the effects of a clinical grade 
drug at clinically compatible concentrations. Considering our results following culture with 
cyclopamine we initially performed the following functional assays:  
 
 
Figure 4.1.10.1: Metabolic activity, as a measure of cell viability, in the MOLM-13 and OCI-AML3 
cell lines following culture with incremental doses of glasdegib (µM) for 72hrs, as determined by 
the resazurin assay.  
Cells, at a concentration of 1x105/ml, were exposed to incremental doses of glasdegib (µM) and cultured 
for 72hrs. Cell viability was determined using the resazurin assay. Results are expressed as the mean 
luminescence (n=8) with error bars indicating SD. NDC is highlighted in red. Whilst a reduction in 
luminescence was demonstrated following culture of the OCI-AML3 cell line at concentrations of >25mM 
no change was seen within the MOLM-13 cell line across all concentrations.  
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1) Trypan blue dye exclusion (as a measure of cell proliferation and death),  
2) Annexin V / 7AAD staining with flow cytometry analysis (to accurately study the process 
of apoptosis),  
3) PI staining with flow cytometry analysis (to analyse cell cycle kinetics) and 
4) Analysis of FSC / SSC flow cytometry plots (to assess morphological change). 
There was a consistent downward trend in the number of live cells by trypan blue dye exclusion 
following culture of OCI-AML3 cells with increasing concentrations of glasdegib; with a 
statistically significant reduction demonstrated following culture with glasdegib at a 
concentration of 10.68µM (p=0.049). There was no change in the number of dead cells by trypan 
blue dye exclusion, and no evidence of apoptosis by Annexin V / 7AAD. In contrast to results 
obtained following culture with cyclopamine there was no change in cell cycle kinetics by PI, 
Figure 4.1.10.2.   
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Figure 4.1.10.2: Cell viability and cell cycle kinetics following culture of the OCI-AML3 cell line 
with glasdegib (2.67µM, 5.34µM and 10.68µM; clinically achievable concentrations) for 72hrs. 
OCI-AML3 cells were seeded at a concentration of 2x105/ml, exposed to incremental doses of 
glasdegib, cultured for 72hrs then harvested and stained with trypan blue dye exclusion, Annexin V / 
7AAD or PI prior to analysis. (A) Bar graph showing cell viability as determined by trypan blue dye 
exclusion. Each bar represents the mean cell number x104/ml from four independent experiments with 
error bars indicating SD. (B) Bar graph showing the proportion of cells which are viable, in early 
apoptosis, in late apoptosis or dead as determined by Annexin V / 7AAD staining, and analysis by flow 
cytometry. The percentages shown indicate the proportion of total events within each of the 
respective categories as gated on the flow cytometry plots (see Figure 2.3 for gating strategy). Each 
bar represents the mean percentage from four independent experiments with error bars indicating SD. 
(Ci) Bar graph indicating the proportion of cells within each cell cycle phase (G0-G1, S, G2-M and Sub 
G0) as determined by PI staining, and analysis by flow cytometry. Each bar represents the mean 
percentage from four independent experiments with error bars indicating SD. (Cii) Representative flow 
cytometry plots, and gating strategy, following PI staining. Each plot is representative of data from 
one experiment of four with similar results. All statistically significant results are highlighted with p 
value to the nearest 3 decimal places, those not highlighted are not significant. These graphs showing 
culture of the OCI-AML3 cell line with glasdegib caused a statistically significant reduction in 
proliferation not explained by apoptosis or altered cell kinetics.  
C
el
l c
ou
nt
s 
x1
04
 
(A) 
1 2 3 4
0
20
40
60
80
100
2.67µM 5.34µM 10.68µM NDC %
 to
ta
l e
ve
nt
s 
co
un
te
d 
 
(Ci) 
Pe
rc
en
ta
ge
 to
ta
l e
ve
nt
s 
co
un
te
d 
 
PE 
(Cii) 
NDC 
10.68µM 
1 2 3 4
0
50
100
150
200
* p=0.049
2.67µM 5.34µM 10.68µM NDC 
* p=0.049 
Alive 
Dead 
%
 to
ta
l e
ve
nt
s 
co
un
te
d 
 
1 2 3 4
0
2
4
6
8
10
20
40
60
80
100
2.67µM 5.34µM 10.68µM NDC 
(B) 
  Live 
  Early apoptosis 
  Late apoptosis 
  Dead 
  G0-G1 
  S 
  G2-M 
  Sub G0 
	 201	
 
 
Analysis of the FSC / SSC plots following culture of the OCI-AML3 cell line with glasdegib for 
72hrs, whilst not as striking as following culture with cyclopamine, showed a statistically 
significant increase in the SSC parameter in keeping with increased granularity, Figure 4.1.10.3. 
This was confirmed when cells were visualised by light microscopy - cells were seen to have a 
more mature phenotype with cytoplasmic vacuoles and granules and loss of nucleoli. Slides were 
blindly reported and independently verified by Dr M Leach, Consultant Haematologist, NHS 
Greater Glasgow and Clyde to whom I am indebted for time and expertise.  
Within the MOLM-13 cell line, there was a reduction in the total number of live cells by trypan 
blue dye exclusion following culture with increasing doses of glasdegib, though this was not 
significant. In contrast to results following culture with cyclopamine, there was no change in the 
total number of dead cells by trypan blue dye exclusion, and no evidence of apoptosis by 
Annexin V / 7AAD staining. It must, however, be acknowledged that whilst a reduction in live 
cells was seen with increasing concentrations of cyclopamine apoptosis was only apparent 
following culture with 20µM. Interestingly, PI staining demonstrated cell cycle arrest with a 
statistically significant increase in the percentage of inactive, non-cycling cells (G0-G1) following 
culture with glasdegib, 5.35µM (p=0.029) and 10.68µM (p=0.035), compared to the NDC; Figure 
4.1.10.4. Further work is required to determine the mechanism of cell cycle arrest. There was 
no evidence of cellular senescence as determined by measuring β-galactosidase activity and, 
there was no change in FSC / SSC parameters seen between the NDC and all concentrations of 
glasdegib, Figure 4.1.10.5.  
Figure 4.1.10.3: SSC MFI, and representative FACS plot, following culture of the OCI-AML3 cell line 
with glasdegib (2.67µM, 5.34µM and 10.68µM; clinically achievable concentrations) for 72hrs. 
OCI-AML3 cells were seeded at a concentration of 2x105/ml, exposed to incremental doses of 
glasdegib, cultured for 72hrs then harvested prior to analysis by flow cytometry. (A) Representative 
FSC / SSC flow cytometry plot from one experiment of four with similar results. This demonstrates the 
increase in SSC (reflecting cell granularity) in OCI-AML3 cell line relative to the NDC. (B) Bar graph 
showing the MFI of SSC. Each bar represents the mean MFI from four independent experiments with 
error bars indicating SD. All statistically significant results are highlighted with p value to the nearest 3 
decimal places, those not highlighted are not significant. The FACS plot, and bar graph, clearly showing 
culture of the OCI-AML3 cell line with glasdegib caused a statistically significant increase in the SSC 
parameter, reflecting increased granularity.  
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Figure 4.1.10.4: Cell viability and cell cycle kinetics following culture of the MOLM-13 cell line 
with glasdegib (2.67µM, 5.34µM and 10.68µM; clinically achievable concentrations) for 72hrs.  
MOLM-13 cells were seeded at a concentration of 2x105/ml, exposed to incremental doses of glasdegib 
and cultured for 72hrs then harvested and stained with trypan blue dye exclusion, Annexin V / 7AAD or 
PI prior to analysis. (A) Bar graph showing cell viability as determined by trypan blue dye exclusion. 
Each bar represents the mean cell number x104/ml from four independent experiments with error bars 
indicating SD. (B) Bar graph showing the proportion of cells which are viable, in early apoptosis, in late 
apoptosis or dead as determined by Annexin V / 7AAD staining, and analysis by flow cytometry. The 
percentages shown indicate the proportion of total events within each of the respective categories as 
gated on the flow cytometry plots (see Figure 2.3 for gating strategy). Each bar represents the mean 
percentage from four independent experiments with error bars indicating SD. (Ci) Bar graph indicating 
the proportion of cells within each cell cycle phase (G0-G1, S, G2-M and Sub G0) as determined by PI 
staining, and analysis by flow cytometry. Each bar represents the mean percentage from four 
independent experiments with error bars indicating SD. (Cii) Representative flow cytometry plots, and 
gating strategy, following PI staining. Each plot is representative of data from one experiment of four 
with similar results. All statistically significant results are highlighted with p value to the nearest 3 
decimal places, those not highlighted are not significant. This figure clearly showing culture of the 
MOLM-13 cell line with glasdegib caused a statistically significant increase in inactive, non-cycling cells 
(G0-G1) by PI staining.  
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4.1.11 Manipulation of the Hh pathway with glasdegib affected genes 
involved in apoptosis, autophagy and cell cycle, with a striking 
difference seen between two myelomonocytic AML cell lines 
Expression of genes involved in apoptosis, autophagy and cell cycle were analysed in the MOLM-
13 and OCI-AML3 cell lines following culture with glasdegib. These cell behaviour pathways were 
selected considering published data linking the Hh pathway to apoptosis, autophagy 613,641,642 and 
cell cycle regulation to determine if glasdegib might render cells more sensitive to treatment 
with standard agents such as Ara-C. Further these genes had been studied following culture with 
cyclopamine, enabling us to compare and contrast the effects of different Smo antagonists. RNA 
was extracted from an aliquot of cells harvested following culture with glasdegib at a 
concentration of 2.67µM, 5.34µM and 10.68µM for 72hrs. To account for input cDNA the ΔCT for 
each gene was calculated by subtracting the CT value of 6 housekeeping (control) genes from the 
CT recorded for the gene of interest. ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2 were 
selected as housekeeping genes, CT values ranged from 3 to 13. Technical triplicates were 
performed for each sample. The 2-ΔΔCT method was used to show expression of the gene of 
interest relative to the NDC. Log transformation of the fold change enabled graphical display of 
expression patterns according to the unsupervised Eisen approach using PermutMatrix software 
589; Figure 4.1.11.1.  
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Figure 4.1.10.5: SSC MFI, and representative FACS plot, following culture of the MOLM-13 cell line 
with glasdegib (2.67µM, 5.34µM and 10.68µM; clinically achievable concentrations) for 72hrs. 
MOLM-13 cells were seeded at a concentration of 2x105/ml, exposed to incremental doses of glasdegib, 
cultured for 72hrs then harvested prior to analysis by flow cytometry. (A) Representative FSC / SSC flow 
cytometry plot from one experiment of four with similar results. This demonstrates no change in the 
FSC / SSC parameters in the MOLM-13 cell line relative to the NDC. (B) Bar graph showing the MFI of 
SSC. Each bar represents the mean MFI from four independent experiments with error bars indicating 
SD. All statistically significant results are highlighted with p value to the nearest 3 decimal places, 
those not highlighted are not significant. The FACS plot, and bar graph, clearly showing culture of the 
MOLM-13 cell line with glasdegib did not affect the cells FSC / SSC parameters. 
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Figure 4.1.11.1: Gene expression profiles for genes involved in apoptosis, autophagy and cell 
cycle, following culture of the MOLM-13 and OCI-AML3 cell lines with glasdegib (2.67µM, 5.34µM 
and 10.68µM) for 72hrs. 
RNA was extracted from an aliquot of cells harvested following culture with increasing doses of glasdegib 
for 72hrs. Expression levels were quantified by qRT-PCR using Fluidigm® technology. To account for input 
cDNA the ΔCT for each gene was calculated by subtracting the CT value of 6 housekeeping (control) 
genes from the CT recorded for the gene of interest. Technical triplicates were performed for each 
sample. Log transformation of the 2-ΔΔCT enabled graphical display of expression patterns according the 
unsupervised Eisen approach using PermutMatrix software 506. Complete-linkage clustering of our 
selected genes, and all experimental conditions, are shown highlighting the strikingly different 
expression patterns of our selected genes in these two myelomonocytic cell lines.  
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The difference in gene expression between the two cell lines is striking though interestingly the 
concentration of glasdegib with which the cells were cultured was not a significant variable. 
Expression of select genes is discussed in further detail. Numb, an evolutionally conserved cell 
fate determinant, has been shown to be increased in the absence of Smo in CML 252. We 
demonstrate NUMB to be up-regulated following culture of both cell lines with glasdegib, at all 
concentrations. In contrast to results following culture with cyclopamine CCNDI was progressively 
down-regulated in the OCI-AML3 cell line following culture with increasing doses of glasdegib 
(2.5-fold reduction); no change was seen in the MOLM-13 cell line. There was no change in LC3B 
in either cell line following culture with glasdegib (at 2.67µM, 5.34µM and 10.68µM) relative to 
the NDC; there was a progressive down-regulation of ATG7 in the MOLM-13 cell line with 
increasing concentrations of glasdegib (2-fold reduction following culture with 10.68µM). Whilst 
the majority of the Bcl-2 family were largely unchanged, of the pro-apoptotic genes NOXA was 
progressively up-regulated whilst BID was progressively down-regulated in the OCI-AML3 cell line 
following culture with increasing concentrations of glasdegib. BCL-2 and BCL2L1 were down-
regulated following culture of the MOLM-13 cell line with glasdegib at all concentrations; BBC3 
was up-regulated whilst BAX, BIM, BMF, BIK and Cytochrome C were down-regulated. These 
results highlight the complexity involved when interpreting mRNA expression data and the need 
to correlate results with functional data, and where appropriate determine protein expression. 
Further, it suggests subgroup analysis, and perhaps even selection, should be considered when 
considering trial data and the clinical application of Smo antagonists.  
 
4.1.12 Combination treatment with glasdegib and Ara-C showed synergism 
in both the MOLM-13 and OCI-AML3 cell lines 
We had shown glasdegib, at clinically tolerated doses, to cause changes in SSC in OCI-AML3 cells, 
and to alter cell cycle kinetics in MOLM-13 cells. Whilst subtle, these changes were significant. 
Further, we had shown, irrespective of concentration, glasdegib resulted in changes in genes 
involved in apoptosis and the cell cycle. Whilst these expression changes were not reflected in 
our functional data, we questioned whether glasdegib induced a stress response in AML cells, 
potentially making them more sensitive to standard chemotherapeutic agents. First line 
treatment for AML standardly uses Ara-C combined with an anthracycline 201,202 with clinical 
response dependent upon genes including BCL-2 and TP53 533. Work has also linked the Hh 
signalling pathway to the methyltransferases, reports showing inhibition of the Hh pathway to 
enhance the effects of the HMAs, whilst silencing of SHH, SMO and GLI-3 sensitised cells to the 
HMAs 413. Additionally, at the time of this PhD, Pfizer were running an early phase clinical trial 
looking at glasdegib in combination with Ara-C, presented at ASH 2016 654. We therefore elected 
to determine whether the combination of Ara-C and glasdegib was synergistic in vitro. The 
CompuSyn computer programme employing the Chou-Talalay method (discussed in section 
2.2.1.7) was used to quantify synergy between Ara-C and glasdegib in the MOLM-13 and OCI-AML3 
cell lines. Briefly cell counts as determined by the trypan blue dye exclusion assay were 
recorded following culture of the MOLM-13 and OCI-AML3 cell lines with glasdegib, Ara-C and the 
combination of glasdegib and Ara-C at a range of concentrations for 24hrs, 48hrs and 72hrs. The 
concentrations and combinations are depicted in Figure 4.1.12.1. We had determined the IC50 for 
each drug initially using the resazurin assay, recognising its limitations but acknowledging it 
allowed for the rapid evaluation of cell metabolic activity following culture with a wide range of 
drug concentrations. The trypan blue dye exclusion assay was used to confirm accuracy of this 
calculated IC50 and published work was referenced. 
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The CI was seen to range from 1.779 to 0.0095 and 2.750 to 0.188 in the MOLM-13 and OCI-AML3 
cell lines respectively with synergism CI < 1, antagonism CI > 1 and an additive effect CI = 1, 
Figure 4.1.12.2. However it is important to consider the drug concentrations at which synergism 
was seen. Within the MOLM-13 cell line interestingly antagonism with a CI ≥1 was demonstrated 
following culture with Ara-C at ¼ the predetermined IC50 irrespective of the concentration of 
glasdegib. Synergism was seen following culture within all other concentration combinations. The 
CI for clinically compatible drug concentrations was clearly synergistic ranging from 0.307 to 
0.779 (mean 0.545). Within the OCI-AML3 cell line, antagonism, with a CI ≥1 was seen when the 
concentration of Ara-C was below the calculated IC50 irrespective of the concentration of 
glasdegib. Importantly however, whilst less powerful, synergism was seen at clinically 
compatible drug concentrations, the CI ranging from 0.683 to 0.821 (mean 0.764). Whilst it must 
be noted that the drug concentrations differed between the two cell line it is exciting to 
consider a synergistic effect was seen in these two genetically diverse AML cell lines, Figure 
4.1.12.3.  
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Figure 6.3.4.1: Schematic of the experimental layout used to to#quan(fy#synergy#between#ABT4199#and#
Ara4C#in#the#MOLM413#and#OCI4AML3#cell#lines#using#the#Chou4Talalay#method.#
MOLM-13 and OCI-AML3 cells were seeded at a density of 2x105/ml and cultured with specific 
concentrations of each drug as outlined above for 24hrs, 48hrs and 72hrs. Trypan blue exclusion was 
performed to determine the number of live and dead cells for each experimental condition. Technical 
duplicates were performed, and the experiment performed three times.  
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Figure 4.1.12.1: Schematic of the exp rimental layout used to determine the rela ionship between 
glasdegib and Ara-C in the MOLM-13 and OCI-AML3 cell lines using the Chou-Talalay method. 
MOLM-13 and OCI-AML3 cells were seeded at a density of 2x105/ml, cultured with specific 
concentrations of each drug as outlined above for 24hrs, 48hrs and 72hrs. Trypan blue dye exclusion 
was performed to determine the number of live and dead cells for each experimental condition. 
Technical duplicates were performed, and the experiment performed three times. 
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Figure 4.1.12.2: Combination indices for the OCI-AML3 and MOLM-13 cell lines according to 
experimental conditions according to the Chou-Talalay method. 
OCI-AML3 and MOLM-13 cells were seeded at a density of 2x105/ml, and cultured with specific 
concentrations of each drug as outlined in Figure 4.1.12.1 for 24, 48 and 72hrs. Trypan blue dye 
exclusion was performed to determine the number of live and dead cells for each experimental 
condition. Technical duplicates were performed, and the experiment performed three times.  
CompuSyn software was used. CI<1 = synergism (red), CI=1 = additive effect, CI>1 = antagonism 
(blue).  
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4.1.13 Manipulation of the Hh pathway by Smo inhibition in unselected 
primary AML samples produced differing results  
Whilst cell lines, as experimental models, enable the investigation and analysis of primary 
processes and the effect of manipulating these, it is well recognised that cell lines may not 
always behave in the same manner as, and therefore not always accurately represent, primary 
cells 627. We therefore sought to determine the effect of Smo inhibition in a cohort of primary 
AML samples, initially focusing on cyclopamine, then the clinical grade Smo inhibitors glasdegib 
Ara-C Combination Glasdegib 
OCI-AML3 MOLM-13 
(A) 
(B) 
(Ci) 
Figure 4.1.12.3: Representative plots generated according to the Chou-Talalay method following 
culture of the OCI-AML3 and MOLM-13 cell lines with specific concentrations of glasdegib and Ara-C 
for 72hrs. 
OCI-AML3 and MOLM13 cells were seeded at a density of 2x105/ml and cultured with specific 
concentrations of each drug as outlined in Figure 4.1.12.1 for 24hrs, 48hrs and 72hrs. Trypan blue dye 
exclusion was performed to determine the number of live and dead cells for each experimental 
condition. Technical duplicates were performed, and the experiment performed three times. Data for 
the 72hr time point are shown. (A) Dose-Effect curve, (B) Median-Effect plot and (C) DRI and CI plots 
for OCI-AML3 and MOLM-13 cells.  
These plots clearly show wide variation in effect dependent upon drug concentration. While minimal 
effect on cell viability was seen with glasdegib alone, in both cell lines the combination of glasdegib 
and Ara-C, at select doses, was synergistic.   
(A) 
(B) 
(Ci) (Ci) (Cii) 
	 209	
and sonidegib, alone and in combination with Ara-C. We sought to determine the effect of 
combination therapy in primary samples considering we had demonstrated evidence of synergism 
in genetically diverse AML cell lines.  
Primary AML MNCs were isolated from whole PB and BM samples, recovered and cultured as 
detailed in Methods 2.2.1.2.4-6. An unmanipulated recovered cell population was used.  
Considering first cyclopamine, whilst its pharmacokinetics and moderate activity have impeded 
its clinical development, it continues to be used in research to evaluate the effect of Smo 
inhibition 631. Further, these experiments enabled us to compare the results generated by 
primary AML cells with those from immortalised AML cell lines, the concern being through the 
process of generating a cell line these cells undergo genotypic and / or phenotypic change. Cells, 
seeded at a density of 1.5x105/ml, were cultured as NDC and with cyclopamine at the following 
concentrations - 100nM, 1µM, 5µM, 10µM and 20µM; 20µM tomatidine was used as an additional 
control as described in Methods 2.2.1.2.6. A broad range of concentrations was used to ensure an 
effect was not missed. Cell counts and the assessment of cell viability were performed by trypan 
blue dye exclusion at 24, 48 and 72hrs in technical triplicates using one sample (AML 022) 
initially, Figure 4.1.13.1. Doses and time points were selected to determine if cyclopamine had a 
time- or concentration-dependent effect on cell viability and kinetics.  
 
 
There was no difference in cell viability between the NDC and all concentrations of cyclopamine 
at 24hrs. At 48hrs there was a reduction in the number of live cells following culture with 10µM 
and 20µM with a further reduction demonstrated at 72hrs. The range was therefore narrowed to: 
5µM, 10µM and 20µM with a single time point of 72hrs selected for additional primary samples 
(AML1002, AML 017 and AML 005), Figure 4.1.13.2.  
Figure 4.1.13.1: Cell viability, as determined by trypan blue dye exclusion, in one primary AML 
sample following culture with select concentrations of cyclopamine for 72hrs. 
The primary sample AML 022 was recovered as described in Methods 2.2.1.2.5. Recovered cells were 
seeded at a concentration of 1.5x105/ml, exposed to incremental doses of cyclopamine and cultured 
for 72hrs as described in Methods 2.2.1.2.6. Each bar represents the mean cell number x 104/ml from 
technical triplicates. 
There was no difference in cell count between the NDC and all concentrations of cyclopamine at 24hrs. At 
48hrs there was a reduction in the number of live cells following culture with 10µM and 20µM cyclopamine 
with the effect increased at 72hrs. Statistical analysis was not performed since this graph represents data 
from n=1.  
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Whilst statistical significance was not demonstrated there was a trend towards a reduction in the 
number of live cells following culture with 10µM, (p=0.065) and 20µM (p0.051). No significant 
difference in the number of dead cells was seen between the NDC and all concentrations of 
cyclopamine.  
Acknowledging the altered biological properties of primary AML cells and AML cell lines, it is 
reassuring that a similar trend was seen in both the cell lines and primary samples analysed, with 
no change in viability seen at 24hrs whilst a reduction was seen at 48hrs, increasing at 72hrs 
following culture with cyclopamine at concentrations of ≥10µM. Additionally, we had questioned 
whether an effect might be lost due to the genetic heterogeneity of primary AML cells; this data 
discounted this. It would be interesting to assess the effect of cyclopamine in defined subtypes 
of AML. Would statistical significance be reached? Having demonstrated an effect with 
cyclopamine, recognising its limitations in the clinical setting and the value of our primary AML 
cell bank as a resource, we sought to determine the effect of two clinical grade Smo antagonists 
– glasdegib and sonidegib, alone and in combination with Ara-C.  
Primary AML samples were seeded at a density of 1.5x105/ml and cultured with sonidegib at the 
following concentrations - 25nM, 100nM and 500nM alone and in combination with Ara-C 250nM 
and 500nM as described in Methods 2.2.1.2.6. Sonidegib concentrations were selected following 
review of data published by the Copland group studying sonidegib in CML 412. A concentration of 
500nM for Ara-C equates to the maximum clinically tolerated. Cell counts and the assessment of 
cell viability was performed by trypan blue dye exclusion at 72hrs in four samples (AML 018, AML 
020, AML 036 and AML 037), Figure 4.1.13.3.  
Figure 4.1.13.2: Cell viability, as determined by trypan blue dye exclusion, in primary, de novo, 
AML MNCs (n=4) following culture with select concentrations of cyclopamine for 72hrs.  
The primary samples AML 1002, AML 022, AML 017 and AML 005 were recovered as described in Methods 
2.2.1.2.5. Recovered cells were seeded at a concentration of 1.5x105/ml, exposed to incremental 
doses of cyclopamine and cultured for 72hrs as described in Methods 2.2.1.2.6. Each bar represents the 
mean cell number x 104/ml with error bars indicating SD. 
There was a trend towards a reduction in the number of live cells following culture with 10µM and 20µM 
cyclopamine though this was not significant. The number of dead cells did not differ between the NDC 
and all concentrations of cyclopamine.  
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As expected, there was a reduction in cell viability following culture with Ara-C 250nM and 
500nM. Interestingly there was no significant difference between the effect of Ara-C at a 
concentration of 250nM and 500nM with both reducing cell viability more than 2-fold. There was 
no change in cell viability following culture with sonidegib. The addition of sonidegib did not 
enhance the effect of Ara-C. Results following the assessment of apoptosis mirrored the results 
for cell viability - Annexin V / 7AAD staining and flow cytometry analysis showing a reduction in 
the live cell population with an increase in early apoptosis following culture with Ara-C alone, 
and in combination with sonidegib. The addition of sonidegib did not enhance the effect of Ara-C 
in these short-term assays, Figure 4.1.13.4. Considering the absence of an effect, albeit we had 
only assessed proliferation and apoptosis in short-term assays, and the concomitant release of 
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Figure 4.1.13.3: Cell viability, as determined by trypan blue dye exclusion, in primary, de novo, 
AML MNCs (n=4) following culture with sonidegib (25nM, 100nM and 500nM) alone, Ara-C (250nM 
and 500nM) alone, and the combination of sonidegib 500nM with Ara-C (250nM and 500nM) for 
72hrs. 
The primary samples AML 018, AML 020, AML 036 and AML 037 were recovered as described in Methods 
2.2.1.2.5. Recovered cells were seeded at a concentration of 1.5x105/ml, exposed to incremental 
concentrations of sonidegib alone and in combination with Ara-C 250nM and 500nM and cultured for 
72hrs as described in Methods 2.2.1.2.6. (A) Graph showing the mean cell number x104/ml with error 
bars indicating SD in each of the experimental arms. (B) Graph illustrating the variance between 
samples. 
There was no change in cell viability following culture with sonidegib alone. There was a reduction in 
cell viability following culture with Ara-C 250nM and 500nM. Interestingly there was no difference 
between the results obtained from these two concentrations. The addition of sonidegib did not 
enhance the effect of Ara-C.  
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data from the NCT01826214 study evaluating the efficacy and safety of LDE225 (sonidegib) in 
patients with R/R acute leukaemia 655, we decided not to continue investigating sonidegib.  
 
 
Considering glasdegib, we sought to determine its effect on primary cells in liquid culture using 
clinically achievable concentrations. We accept the limitations of this approach in an in vitro 
system. These concentrations were however selected to enable comparison between primary 
cells and cell lines and, recognising the degree of crosstalk between pathways, by tailoring our 
drug concentrations, we sought to limit off-target and supra-therapeutic ‘toxic’ effects leading 
to false conclusions. Additionally, considering our data showing a marked reduction in cell 
viability, explained by apoptosis in primary cells following culture with Ara-C at a concentration 
of 250nM and 500nM, we choose a concentration of 100nM. We wanted to determine if inhibition 
of the Hh pathway conferred an additive effect, and ensure an effect was not masked by 
another, more powerful drug effect. A concentration of 100nM is supported by data studying the 
IC50 for single agent Ara-C in expanded primary AML cells in liquid culture 
656 and concentrations 
utilised in other published primary AML cell in vitro studies 657. Cells were seeded at a density of 
1.5x105/ml and cultured as either the NDC or with glasdegib 2.67µM, Ara-C 100nM, glasdegib 
2.67µM and Ara-C 100nM or cyclopamine 20µM as described in Methods 2.2.1.2.6. Five primary 
samples (AML 1002, AML 053, AML019, AML018 and AML 013) with variable SMO expression 
relative to normal MNCs were selected (2-ΔΔCT range 0.626 – 28.700). One sample was excluded 
from analysis due to poor recovery: AML 019 – this sample was an APML, recovery potentially 
therefore reflecting cell biology, these blasts classically being hypergranular. Cell counts and the 
assessment of cell viability was performed by trypan blue dye exclusion at 72hrs in technical 
duplicate, Figure 4.1.13.5.  
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Figure 4.1.13.4: Cell viability, as determined by Annexin V / 7AAD staining, in primary, de novo, 
AML MNCs (n=4) following culture with sonidegib (25nM, 100nM and 500nM) alone, Ara-C (250nM 
and 500nM) alone and the combination of sonidegib 500nM with Ara-C (250nM and 500nM) for 
72hrs. 
The primary samples AML 018, AML 020, AML 036 and AML 037 were recovered as described in Methods 
2.2.1.2.5. Recovered cells were seeded at a concentration of 1.5x105/ml, exposed to incremental 
concentrations of sonidegib alone and in combination with Ara-C 250nM and 500nM and cultured for 
72hrs as described in Methods 2.2.1.2.6. Apoptosis was assessed by Annexin V / 7AAD staining and 
analysis by flow cytometry. The proportion of viable, early apoptosis, late apoptosis and dead cells are 
shown. Each bar represents the mean total number of events from four independent experiments with 
error bars indicating SD.  
A reduction in the proportion of live cells with a consequent increase in early apoptosis was seen 
following culture with Ara-C alone, and in combination with sonidegib. Statistical significance was not 
reached. The addition of sonidegib did not enhance the effect of Ara-C.  
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There was a reduction in cell viability by trypan blue dye exclusion following culture with Ara-C 
100nM alone and in combination with glasdegib 2.67µM though this was not significant (p=0.074 
and p=0.089 respectively). As previous experiments had shown, represented in Figures 
4.1.13.1&2, there was a reduction in cell viability following culture with cyclopamine, but again, 
this was not significant (p=0.081). There was no difference in the number of dead cells by trypan 
blue dye exclusion across all experimental arms relative to the NDC.  
We sought to evaluate whether the reduction in cell proliferation was due to cell apoptosis, 
acknowledging no difference in cell death had been demonstrated. Annexin V / 7AAD staining 
and flow cytometry analysis showed an increase in apoptosis (early and late) following culture 
with Ara-C alone though this was not significant (p=0.054). The addition of glasdegib did not 
enhance this effect.  
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Figure 4.1.13.5: Cell viability, as determined by trypan blue dye exclusion, following culture with 
glasdegib alone and in combination with Ara-C, in primary, de novo, AML MNCs (n=4) for 72hrs. 
The primary samples AML 1002, AML 053, AML 019, AML 018 and AML 013 were recovered as described in 
Methods 2.2.1.2.5. AML 019 was excluded due to poor recovery. Recovered cells were seeded at a 
concentration of 1.5x105/ml, exposed to glasdegib 2.67µM alone and in combination with Ara-C 100nM 
and cyclopamine 20µM and cultured for 72hrs as described in Methods 2.2.1.2.6. Cell counts, live and 
dead, were determined by trypan blue dye exclusion. Each bar represents the mean cell number x 104/
ml with error bars indicating SD. 
There was no change in cell viability following culture with glasdegib alone. There was a reduction in 
cell viability following culture with Ara-C 100nM alone and in combination with glasdegib 2.67µM 
though these results were not significant. The addition of glasdegib to Ara-C did not increase the effect 
of Ara-C.  
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The reduction in total cell number by trypan blue dye exclusion in the absence of apoptosis is 
interesting however. Considering previous results demonstrating cyclopamine to induce 
differentiation we considered whether this reduction in cellular proliferation was as a 
consequence of altered cell cycle kinetics. No change in cell cycle kinetics, by PI staining, was 
seen across all experimental arms relative to the NDC, Figure 4.1.10.7.  
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Figure 4.1.13.6: Cell viability, as determined by Annexin V / 7AAD staining, in primary, de novo 
AML MNCs (n=4) following culture with Ara-C (100nM), cyclopamine (20µM), glasdegib (2.67µM) and 
the combination of Ara-C (100nM) and glasdegib (2.67µM) for 72hrs.  
The primary samples AML 1002, AML 053, AML 019, AML 018 and AML 013 were recovered as described in 
Methods 2.2.1.2.5. AML 019 was excluded due to poor recovery. Recovered cells were seeded at a 
concentration of 1.5x105/ml, exposed to glasdegib 2.67µM alone and in combination with Ara-C 100nM 
and cyclopamine 20µM and cultured for 72hrs as described in Methods 2.2.1.2.6. Apoptosis was 
assessed by Annexin V / 7AAD staining and analysis by flow cytometry. The proportion of viable, 
apoptotic and dead cells are shown. Each bar represents the mean total number of events from four 
independent experiments with error bars indicating SD.  
There was no significant difference between each of the experimental arms. Considering the high 
degree of variance between each of the samples we considered the data on an individual basis – a 
trend towards apoptosis was not apparent across all experimental arms.  
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Whilst there was no evidence of a change in cell cycle kinetics we accept the limitations of our 
selected assay. In particular we were not able to differentiate between G0 and G1. We therefore 
performed CFSE analyses on three primary samples (AML 1002, AML 018 and AML 013) to 
determine if cell division was affected. For technical reasons, primarily the number of cells 
available for analysis, the results were inconclusive and are not shown.  
Finally, the Hh signalling pathway is a self-renewal pathway, involved in aspects of tissue 
maintenance and regeneration - proliferation, apoptosis, chromatin modelling, and self-renewal 
257. We recognise we had not studied self-renewal activity in our liquid assays. Whilst, possibly, 
the most robust assessment of self-renewal activity is through limited dilution xenograft 
transplantation, in vitro assays, as an experimental model, are frequently used. Further these 
assays have a potential benefit in non-immortalised cells since these cells may only be capable 
of a limited number of divisions. We therefore sought to perform re-plating of colonies derived 
from CFC assays. 
CFC assays were undertaken on four samples (AML 1002, AML 053, AML 018, AML 013), with a 
view to perform a re-plate assay to assess self-renewal potential. We plated 4x103/ml, 4x104/ml 
and 1x105/ml cells following culture with glasdegib 2.67µM alone and in combination with Ara-C 
100nM, Ara-C 100nM alone and cyclopamine 20µM. No samples suffered contamination. 
Irrespective of plating density three samples were not suitable for analysis because (1) an 
insufficient number of colonies grew (≤2 within the NDC) and / or (2) cell ‘clusters’ contained 
insufficient cell numbers to be counted as a colony 658. The results of one sample are presented, 
Figure 4.1.13.8.  
Figure 4.1.13.7: Cell cycle kinetics, as determined by PI staining, in primary, de novo AML MNCs 
(n=4) following culture with Ara-C (100nM), cyclopamine (20µM), glasdegib (2.67µM) and the 
combination of Ara-C (100nM) and glasdegib (2.67µM)for 72hrs. 
The primary samples AML 1002, AML 053, AML 019, AML 018 and AML 013 were recovered as described in 
Methods 2.2.1.2.5. AML 019 was excluded due to poor recovery. Recovered cells were seeded at a 
concentration of 1.5x105/ml, exposed to glasdegib 2.67µM alone and in combination with Ara-C 100nM 
and cyclopamine 20µM and cultured for 72hrs as described in Methods 2.2.1.2.6 before being harvested 
and stained with PI prior to analysis by flow cytometry. The graph shows the proportion of cells within 
each cell cycle phase (G0-G1, S, G2-M and Sub G0) as gated on the flow cytometry plots. Each bar 
represents the mean percentage from four independent experiments with error bars indicating SD.  
There was considerable variance between these primary samples, as demonstrated by the error bars. 
Individually, and collectively however, no significant difference in cell cycle kinetics was seen between 
each of the experimental arms.  
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Ara-C reduced colony formation as expected; published data showing Ara-C to target committed 
progenitor cells 659. Interestingly, cyclopamine and, to a lesser degree glasdegib reduced colony 
formation suggesting Smo antagonists influence the behaviour of the more mature, committed 
progenitor cells. The combination of Ara-C and glasdegib did not further reduce colony forming 
potential. No colonies grew within the NDC arm of our secondary re-plates preventing further 
analysis.  
Referencing literature recommended cell numbers per 35mm plate varied markedly; for CD34+ 
enriched cells a cell density of 5.0x102/ml– 2.0x103/ml is recommended, for BM 1.0x104/ml – 
5.0x104/ml and for PB 1x105/ml – 2x105/ml. Further we had shown colonies with a cell density of 
4.0x104. We therefore do not consider our selected cell densities to be the cause of CFC failure. 
Work in AML, both expression and functional studies, classically uses bulk AML MNCs, does this 
approach need to be reconsidered when considering the self-renewal pathways? Published work 
has however shown bulk primary AML MNCs to be capable of forming colonies, though 
interestingly, cells were either added to MethoCult immediately following thawing, or after a 
significantly shorter in vitro culture period of 24hrs 618,660. It would be interesting to replicate 
these experimental designs. Had we simply been unlucky in selecting samples with a low 
percentage of HSPCs or in which the HSPCs had not survived cryopreservation and storage? 
Considering experimental design, it would be interesting to compare colony forming potential 
following culture with supportive stromal cells. Would supportive stromal cells protect the 
colony forming potential of HSPCs? There is work currently ongoing within the Copland group 
seeking to optimise our CFC and serial re-plate protocol for primary AML samples to allow 
evaluation of these small molecule inhibitors on their colony-forming ability and subsequently 
their self-renewal capacity.  
Figure 4.1.13.8: Total number of colonies, normalised to the NDC, at day 14 following culture of a 
primary, de novo, AML MNC sample (n=1) with Ara-C (100nM), cyclopamine (20µM), glasdegib 
(2.67µM)and the combination of Ara-C (100nM) and glasdegib (2.67µM). 
The primary sample AML 1002 was recovered as described in Methods 2.2.1.2.5. Recovered cells were 
seeded at a concentration of 1.5x105/ml, exposed to glasdegib 2.67µM alone and in combination with 
Ara-C 100nM and cyclopamine 20µM and cultured for 72hrs as described in Methods 2.2.1.2.6. Cells 
were subsequently harvested, washed and resuspended in fresh SFM. 4x104 cells were inoculated into 
Methocult as described in Methods 2.2.1.9. Colonies were counted after 14 days. Colony number is 
shown normalised to the NDC.  
The graph indicates Ara-C, and cyclopamine reduce colony formation and, to a lesser degree glasdegib. 
The combination of Ara-C and glasdegib did not further reduce colony forming potential. Statistics are 
not presented as this graph represents n=1. 
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4.1.12 Discussion  
AML is characterised by a number of functional changes, including increased proliferation, 
differentiation block, inhibition of apoptosis and altered cell adhesion and stromal interactions. 
Pharmacological inhibition of Smo with cyclopamine or glasdegib (PF-04449913) has been shown 
to abrogate chemoresistance 377–379,618. Previous work with the Kasumi-1 cell line has shown 
cyclopamine to induce apoptosis 73. Uniquely we have shown Smo inhibition with cyclopamine 
allows cellular differentiation in select, genetically diverse, AML cell lines whilst higher doses 
induces apoptosis in other genetically diverse AML cell lines, indicating that partial and total 
inhibition of the pathway may potentiate different responses in AML. Further, we have shown 
cyclopamine to reduce proliferation in the absence of cell death in a limited unselected cohort 
of primary AML samples.  
Considering the clinical grade Smo antagonists we referenced published work. We demonstrated 
an absence of effect on proliferative abilities and apoptosis following short-term in vitro culture 
of primary AML cells with sonidegib. A comprehensive exposure-response analysis was recently 
published reporting pharmacokinetic characteristics of sonidegib within clinical trial 661. This 
study reported the Cmin to range from 680.9ng/ml to 1089ng/ml depending upon time point. 
Converting ng/ml to µM provides a dose range of 1.402µM to 2.243µM. Further daily dosing, as in 
the clinical trials, led to a log-fold increase in plasma concentration. An absence of effect may 
therefore reflect our experimental design and selected concentrations. Unfortunately the 
NCT01826214 study, evaluating the efficacy and safety of LDE225 (sonidegib) in patients with 
R/R acute leukaemia, returned disappointing results with no CRs and one CRi in the 69 
participants treated. Subsequent to this data release Novartis determined it would not pursue 
LDE225 as a therapy in haematological malignancies.  
During the write up of this PhD glasdegib was shown to reduce proliferation in the absence of 
cell death in vitro in the Marimo cell line 618. The Marimo cell line was developed from a 68 year 
old female following treatment for essential thrombocythaemia, a MPN, representing a t-AML, 
with a complex karyotype 662. This work used a maximum concentration of 5µM of glasdegib 618, 
comparable to the median concentration used in our work. How the drug was administered was 
not addressed, however, the time points studied differed from ours - the majority of work 
focused on a 48hr time point, though the MTT assay was extended to 6 days 618. As with our data 
in genetically diverse cell lines, 5µM induced minimal cell death. Interestingly, and in contrast to 
our work, this study demonstrated a reduction in the quiescent G0 population by Hoechst-
33343low/Pyronin-Ylow and flow cytometry analysis. Hoechst-33343low/Pyronin-Ylow is capable of 
separating G0 and G1 since Hoechst-33343low is an exclusive DNA dye while Pyronin-Ylow reacts 
with both DNA and RNA 663. This shift towards cell proliferation was supported by their MTT assay 
results showing a relative increase in the number of viable cells when cells were cultured with 
5µM glasdegib for up to, and including, three days. Interestingly, however, there was a relative 
reduction in the viable cell number beyond this time point, though the mechanism was not 
discussed in the paper. Whilst no comment on cell morphology was made, a comprehensive 
screen of cell surface markers, including CD markers and adherent surface molecules, using the 
BD Biosciences human cell surface marker screening panel, only recorded a substantial reduction 
in the expression of CD164, a potent negative regulator of haematopoiesis 664, the significance of 
which was not discussed. Whether non-significant changes were observed was also not discussed.		
The shift in cell proliferation is particularly interesting, though not fully developed. These 
results contrast with ours in which reduced proliferation was demonstrated. Whilst experimental 
design differed, and may account for some of these differences, it is interesting to consider the 
different genetics of the cell lines studied; in particular the Marimo cell line carrying the 
calreticulin mutation. Whilst recent work has suggested this cell line is not dependent on 
JAK/STAT signalling 665, a relationship between the STAT and Hh pathways is well recognised. 
Could a shift in balance between these two pathways account for the relative increase in early 
proliferation? Was the loss of effect with time due to drug metabolism or a change in cellular 
behaviour? Does a more complex relationship exist? It would be interesting to replicate thei 
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experimental design using our selected cell lines, and further to perform our selected assays on 
the Marimo cell line in order to determine if the reported effects are due to experimental design 
or cell line specific - particularly important when seeking to translate results into the clinic.  
Our data extends on this published data. Whilst we have also shown reduced proliferation by 
trypan blue dye exclusion and apoptosis by Annexin V / 7AAD our KD model adds complexity to 
the picture. Our KD model suggests cellular response to Smo antagonism is dependent upon the 
degree of Smo inhibition achieved. Whilst we acknowledge the genetic diversity of our selected 
AML cell lines it is interesting to consider the varied expression of SMO within each of these cell 
lines, and therefore degree of inhibition following exposure to the Smo antagonists, as a 
determining factor in cellular response. We acknowledge our KD models need to be repeated 
and, further studies are required to validate this hypothesis. 
If we consider these results in parallel to those seen with the clinical grade Smo antagonist 
glasdegib the therapeutic possibilities become even more exciting. We demonstrated a 
statistically significant increase in SSC properties in select AML cell lines following culture with 
glasdegib. Further, a synergistic relationship between glasdegib and Ara-C in select AML cell lines 
was shown. These results are especially interesting considering the recently presented Phase II 
NCT01546038 trial, reporting an improved OS in AML, and high-risk MDS patients treated with PF-
04449913 (glasdegib) and LDAC compared with LDAC alone 618.  
It is not possible to hypothesise that Smo inhibition causes, or allows, cellular differentiation 
without considering, and learning, from the success story of APML. ATRA is able to induce CR in 
>90% of patients with APML through in vivo differentiation of the blast population. In 
combination with an anthracycline ATRA results in cure, with relatively mild toxicity, in >90%; in 
combination with arsenic trioxide cure rates have been shown to reach 100% 164. The ability of 
Smo antagonists to allow cellular differentiation in the DNMT3a carrying OCI-AML3 cell line is 
therefore particularly exciting, especially since a RNA interference screen 413 had shown a 
number of the Hh family members, including SMO, to potentially sensitise cells to the effects of 
azacitidine. Will detection of the DNMT3a mutation, or those with chromosome 5 or 7 
abnormalities, classify a subpopulation of AML which, in the future we will treat differently, with 
improved outcomes much as detection of PML-RARA determines a subgroup of AML with a 
significantly better prognosis. This is particularly important as HDAC inhibitors afford a viable 
treatment option for those less fit patients for whom the outlook is otherwise bleak. Had time 
allowed we would have sought to determine the functional effect of glasdegib and the HDAC 
inhibitors on our genetically diverse AML cells lines. It will be interesting therefore to see the 
results of the NCT02367456 trial, a combination study of glasdegib (PF-04449913) and azacitidine 
as a first line therapy in patients with MDS, AML and CMML which is currently underway.  
Published data however is conflicting, with the variation in results itself a particularly 
interesting finding. A number of groups have reported a limited effect following short-term in 
vitro culture with the Smo antagonists, whilst also demonstrating changes in long-term culture 
and murine models 618. Further, early phase human clinical trials of AML have recently reported 
promising results 618. This is not simply explained by the genetic diversity of AML. Considering 
CML, a genetically homogeneous disease characterised by the t(9;22) chromosomal translocation, 
the Copland group has previously reported no evidence of effect following short-term culture of 
CD34+ CP-CML cells with sonidegib, alone and in combination with the TKI nilotinib. Long-term 
culture-initiating cell assays (LTC-ICs) and replates however showed the number and self-renewal 
capacity of CML LSCs to be reduced following Smo inhibition and, the combination of sonidegib 
and nilotinib to reduce CD34+ CP-CML cell engraftment in NOD/SCID/Gamma (NSG) mice 412. We 
therefore considered a number of variables, which might contribute to the discrepant results 
seen following Smo antagonism in vitro (short and long-term assays) and in vivo: 
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(1) Genetic heterogeneity  
Published data has shown a correlation between the Hh pathway and FLT3-ITD mutational status 
and those cases with a monocytic phenotype, M4 and M5 according to the FAB classification 381. 
Even within these defined groups marked variation is seen; studies therefore require large 
numbers to ensure sufficient power. An absence of effect may therefore simply reflect sample or 
cell line selection.  
(2) Cell phenotype  
There are two important considerations under this category: cell lines versus primary cells and, 
bulk versus defined populations.  
Cell lines serve as experimental models enabling investigation and analysis of primary processes 
and the effect of manipulating these processes. Cell lines are however immortalised, may not 
always behave in the same manner as, and therefore not always accurately represent, primary 
cells 627. Primary cell experiments are therefore required to validate cell line data. When 
interpreting primary cell work, it is however important to remember these cells have also been 
manipulated – they have been harvested, isolated and, in many instances, cryopreserved before 
utilisation. What is the effect of cryopreserving and thawing these cells? Does this process select 
specific cell populations, and therefore influence the results generated?  
Considering next the cell population being analysed. If we consider CML, work within this disease 
is able to focus on the more primitive stem and progenitor populations, understood to lead to 
treatment resistance and disease relapse, and which, within the context of CML are well 
defined. Within AML however the stem cell phenotype remains to be fully defined. Initially 
defined as CD34+CD38− further work phenotypically defining the human AML LSC as 
CD34+CD38−CD90−IL−3R+CD71−HLA−DR−CD117− 112,130–133, with evidence the LSC population 
resembles, and derives from, HPCs 113,131,133–137,149. The majority of work within AML uses bulk 
MNCs derived from the PB or BM. Considering the Hh pathway is defined as a stem cell self-
renewal pathway, we consider the cell population to be an important variable in determining 
response. Indeed the Hh signalling pathway has been shown to be more active in CD34+ primary 
AML cells than in CD34- primary AML cells 618. Results must therefore be carefully interpreted for 
the population in which they have been derived.  
(3) Primary cilia 
The relationship between primary cilia and the Hh pathway was first reported in 2003 450. It is 
now widely accepted that vertebrate canonical Hh signalling requires primary cilia 337,417,430,450–457. 
Haematopoietic cells have however, until recently, been considered to be among the few cells 
not to possess primary cilia 416,428,566,611. This data and ours suggests haematopoietic cells possess 
primary cilia and therefore the machinery to enable canonical Hh signalling though response may 
differ depending upon cell phenotype; discussed in greater depth in section 3.2. 
(4) Influence of the microenvironment 
The intricate relationship between the BM microenvironment and HSCs, both normal and 
malignant, is well established. Recent evidence highlights the importance of the SC niche in 
governing SC behaviour. Considering experimental design, supportive stromal cells are absent 
from CFCs and liquid culture. Published data has shown colony growth to occur in >50% of 
samples though cells were plated either immediately after thawing or following culture for 
24hrs. Colonies grew 25% of our samples (1/4). This work is insufficiently powered to consider 
whether insufficient colonies reflect experimental design or sample selection; it does however 
raise an interesting question about AML progenitor cell behaviour in vitro. When an AML stem 
cell phenotype is defined it would be fascinating to track this cell and it’s behaviour following in 
vitro liquid culture at various time points, would we see a shift towards a more mature, and thus 
differentiated, phenotype? Considering our in vitro data we hypothesise manipulation of the Hh 
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signalling pathway through Smo antagonism influences leukaemic cell behaviour, encouraging 
both apoptosis and differentiation, effect potentially dependent upon both intrinsic and extrinsic 
factors.  
The evidence in favour of the use of small molecule Smo inhibitors appears to be ever increasing, 
the recently presented Phase II NCT01546038 trial particularly encouraging, demonstrating an 
effect in an unselected cohort of AML and high-risk MDS patients treated with PF-04449913 
(glasdegib) and LDAC compared with LDAC alone 618. Whether Smo antagonists will have a role 
clinically outwith the trial setting however remains to be determined. Further, whether these 
drugs, as with other small molecule inhibitors will find their niche, demonstrating increased 
efficacy in a select subtype or subtypes is an area of great interest. 
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5 ‘Key downstream targets of the hedgehog pathway represent 
therapeutic targets.’ 
 
5.1  Introduction 
There is considerable data showing the Hh signalling pathway to be intrinsically linked to 
numerous pathways and downstream targets, both in solid tumours and haematological 
malignancies, Figure 5.1.1. 
 
 
5.1.1 Primary human AML MNCs differentially express key downstream 
components of the Hh pathway at a gene level 
Considering the degree of cross talk between the self-renewal pathways – BMP, Hippo, Notch, 
TGFβ and Wnt, and the vast array of downstream targets, as depicted in Figure 1.10, we studied 
the expression of >100 genes (outlined in 3.4.2) within an unselected cohort of MNCs from 
primary de novo AML samples (n=76). Sample characteristics are listed in Appendix 1. Expression 
was compared to an unselected cohort of normal bulk MNCs (n=10) for reasons previously 
discussed (section 3.1.2), and in keeping with published work. Expression levels were quantified 
by qRT-PCR using Fluidigm® technology. To account for input cDNA the ΔCT for each gene was 
calculated by subtracting the CT value of 6 housekeeping (control) genes (ATP5S, β2M, ENOX2, 
GAPDH, TYW1 and UBE2D2) from the CT recorded for the gene of interest. Expression is 
presented as 2-ΔΔCT, allowing comparison of levels of mRNA expression between each AML sample; 
Figure 5.1.1.1.  
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Figure 5.1.1: Schematic depicting recognised interactions between the self-renewal pathways. 
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Whilst the heterogeneity of AML is demonstrated no gene expression patterns were identified - 
expression was studied both within and across AML subtypes and according to SMO expression.   
Genes were found to be up- and down-regulated relative to normal MNCs and to not be 
expressed. Further, within individual genes expression varied markedly (fold change difference 
across an individual gene ranging from 100 to 10,000). Despite this heterogeneity, considering 
those genes expressed, interesting trends were noted within our unselected cohort of primary de 
novo human AML samples. Up-regulation of CDX2, DNMT1, DNMT3B, ETV6, FOXM1, HOXA9, KIT, 
MECOM, MMP2, MYB, SNAIL1, SNAIL3, TCF3, TCF4, TWIST1 and Vimentin was demonstrated 
whilst down-regulation was seen in BMI1, CXXC4, FOXN1, LEF1, LEFTY1, LMO2, MAML3, MMP9, 
NANOG, NUMB, PBX1, PECAM1, POU5F1, ROR1, SFRP, SFRP1 and SOX2. Interestingly, there was 
no significant difference between AML and normal MNCs in the following genes: CDK2, CPA3, 
DKK3, DKK4, DNMT3A, FOSL1, HES1, KLF4, NLK, PP2CA and WNT4.  
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Figure 5.1.1.1: Variance in mRNA expression both within, and between, select genes in an 
unselected cohort of bulk primary AML MNCs.  
RNA was extracted from cells harvested following culture for 24hrs. Expression levels were quantified 
by qRT-PCR using Fluidigm® technology. mRNA expression levels are shown as the fold change (2-ΔΔCT) 
relative to the mean of 10 normal MNC samples with 6 housekeeping genes – ATP5S, B2M, ENOX2, 
GAPDH, TYWI and UBE2D2 serving as endogenous control. The median is presented with error bars 
indicating the interquartile range. Red lines indicate a 5-fold change. A total of 76 primary samples 
were screened though not for all genes, sample number variance reflects technical issues – poor 
technical triplicates, signal detected in the no template control or failed reaction by Fluidigm®.  
(A, B & C) Genes were chosen due to their association with myeloid malignancies and / or the Hh 
signalling pathway and from self-renewal pathways with which Hh is known to cross-talk in myeloid 
malignancies. 
(C) 
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5.1.2 Key downstream targets of the Hh pathway are differentially 
expressed at a protein level in primary human AML 
The BM niche is a highly dynamic system which serves to regulate and support haematopoiesis 
14,44,45. Deregulated interactions have been shown to be fundamental in disease pathogenesis 11,15–
17.; within AML interactions between the leukaemic cell and those of the BM are thought to be 
involved in chemoresistance 596,597. We sought to determine native protein expression of key 
downstream targets of the Hh pathway within this unique, highly specialised environment.  
IHC was performed on an unselected cohort of de novo primary human AML BMTs (n=37) and 
compared to BMTs from normal controls (n=10). Targets were selected following review of the 
literature and our gene expression data. Expression of BCL-2, BMP4, CD44, CCND1, Vimentin, and 
Wnt5a were analysed. GLI-1 and -3 have been shown to transcriptionally regulate BCL-2 in BCC.  
BCCs are known to express high levels of BCL-2 with deregulated Hh signalling, mediated through 
SHH, thought to contribute to the up-regulation in BCL-2 598. The Gli proteins have been shown to 
induce BMP expression, specifically BMP-4, during normal bone formation 599, though their 
relationship in malignancies remains to be determined. CD44 is extensively expressed within the 
adult BM, shown to play an important role in adult haematopoietic regulation with research 
showing a number of cell surface ligands including CD44 to be preferentially expressed on the 
AML LSC compared to the normal HSC 600. Further, CD44 is recognised to be active alongside the 
Hh signalling pathway 248; work showing the GLI transcriptional regulators and CD44 serve as 
important biomarkers for aggressiveness, survival and recurrence in gastric cancers 601. A close 
relationship is also recognised between the Hh signalling pathway and cell cycle regulators, in 
health 602 and disease 603. The EMT pathway and its regulation is far less understood, a complex 
interplay between the Hh, WNT and TGFβ signalling pathways presently considered to be key 
factors in determining this process 604. Additionally, the Wnt5a ligand is expressed in HSPCs, 
lymphocytes and stromal cells within the BM 605,606; Wnt5a being shown to maintain HSCs in a 
quiescent state, suppressing their proliferation 607.	Expression of these targets is shown in Figure 
5.1.2.1. 
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As expected there was marked variation in the expression of these targets within our AML 
cohort, and to a lesser degree our normal cohort. Statistics were performed using Fisher’s exact 
test. Looking first at BCL-2, there was a significant up-regulation within our AML cohort relative 
to normal controls (p<0.0001).  
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Figure 5.1.2.1 A&B: IHC on a cohort of AML BMTs (n=) demonstrated marked variation in key 
downstream targets of the Hh signalling pathway; with BCL-2 significantly up-regulated and BMP4 
significantly down-regulated in AML. 
IHC was performed on human AML BMTs (n=37) and compared to BMTs from normal controls (n=10).  
Expression was estimated at x10 magnification by two investigators in a blinded fashion.  
(A) Representative images at x10 demonstrating staining patterns for each antibody. (B) Box and 
whisker plot showing percentage of positive cells per specimen, minimum and maximum values are 
depicted.  
There was marked variance in expression within our AML cohort. BCL-2 and CCND1 were significantly 
up-regulated (p<0.0001 and p<0.001 respectively) whilst BMP4, CD44 and WNT5a were significantly 
down-regulated (p=0.007, p=0.025 and p=0.027 respectively) in AML BMTs relative to normal BMTs. 
Statistics were performed using Fisher’s exact test and are highlighted with p values to the nearest 3 
decimal places.  
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Considering the clinical phenotype of AML, published data and the results of early phase clinical 
trials targeting Bcl-2 in AML, up-regulation of BCL-2 was expected. It is however, interesting to 
consider it in parallel with our gene expression data showing BCL-2 to be deregulated in AML, 
with an equal percentage of samples demonstrating up- and down-regulation of BCL-2 relative to 
our normal cohort, presented in section 5.3.1. BCL-2 however was significantly up-regulated with 
no overlap between the expression values within our AML and normal cohorts.  
BMP4, interestingly, was down-regulated in AML relative to our normal cohort (p<0.001). If we 
consider this alongside our gene expression data we had shown BMP4 and SMAD2 to be down-
regulated relative to normal MNCs (both the mean and median fold change), and published data 
reporting AML cells to induce osteogenic differentiation and acquire a growth advantage through 
BMP-connective tissue growth factor (CTGF) signalling 608. Interestingly, considering other 
myeloid malignancies, work in CML has shown the BMP pathway to be deregulated in all 
subpopulations of CML from immature CD34 positive cells through to mature neutrophils 
(CD14+/CD15+), lymphocytes (CD3+ and CD19+) and erythroid cells (glycophorin +); high levels of 
BMP receptor Type 1a&b (BMPRIa and BMPRIb) and low expression SMAD1 shown to differentiate 
between normal and malignant immature cells 609. Further, BMP4 has been shown to be down-
regulated in CML CD34+ cells and up-regulated in MNCs 609. It would therefore be particularly 
interesting to study expression of soluble BMP4 and further of the receptor BMPR1a&b at both 
the gene and protein level in our AML cohort.   
CCND1 was shown to be up-regulated at the protein level though expression was consistently 
≤10% in both the normal and AML samples; none of the normal control showed expression of >1%, 
one AML sample was positive for CCND1 in 10% of cells. Interestingly our gene expression data 
had shown CNND1 to be both up- and down-regulated relative to normal MNCs (fold change 0.057 
to 100.349), Figure 5.1.1.1, suggesting a complex network of interactions regulate protein 
expression and, further, cell behaviour.  
CD44 was down regulated in AML cell relative to our normal cohort though there was marked 
variance. This result contrasts with what we had expected, CD44 expression linked to a poor 
prognosis 590, targeting of CD44 with a monoclonal antibody shown to eradicate human AML SCs 
in a NOD SCID mouse model 600. Interestingly, however there are a number of variants of CD44, 
with differential expression seen on progenitor and mature haematopoietic cells and further, 
some but not all linked with inferior prognosis 590.  The datasheet does not specify which variants 
are identified by our selected antibody, it would therefore be extremely interesting to repeat 
IHC on the same samples using antibodies specific to variants associated with AML – CD44v6, and 
those linked to other haematological malignancies – CD44v9 and CD44v10 590.   
Finally, WNT5a was highly expressed in both the normal and AML BMTs. Interestingly however 
there was a statistically significant difference in expression; WNT5a was down-regulated in our 
AML cohort (p=0.027). Whilst Wnt5a is classically considered to activate non-canonical signalling 
it is also recognised to inhibit canonical signalling. It would be interesting to assess expression of 
the Wnt family receptors downstream targets.  
Statistical significance remained for BCL-2 (p=0.001) and BMP4 (p=0.029) when samples were 
categorised according to a previously published semi-quantitative scoring system 494 with 
statistics performed using Fisher’s exact test, Figure 5.1.2.1. Importantly statistical significance 
was lost for CCND1/2, CD44 and WNT5a when this scoring system was applied.  
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This data highlights the importance of analysing downstream targets at a protein level, to 
consider both translational and post-translational modifiers in determining protein synthesis, and 
further, the intricate relationship between family members in determining protein expression 
and ultimately cell fate.  
 
This data combined with our functional data, presented in chapter 4, demonstrating altered cell 
cycle kinetics, differentiation and apoptosis following Smo inhibition led us to consider the 
relationship between cell cycle regulators and components of the Bcl-2 family with the Hh 
signalling pathway. Log transformation of the fold change was performed to enable graphical 
analysis of our dataset according to the unsupervised Eisen approach using PermutMatrix 
software 589. Complete linkage analysis, an agglomerative method of hierarchical clustering 
found key members of the Bcl-2 family and cell cycle regulators to cluster with components of 
the Hh signalling pathway, Figure 5.1.2.3. We therefore sought to determine whether Bcl-2 and / 
or select ABC transporters could be therapeutically targeted in select AML cell lines and primary 
samples. 
Figure 5.1.2.2: BCL-2 was significantly elevated whilst BMP4 was significantly down-regulated in 
primary human AML irrespective of subtype. 
IHC was performed to assess the expression of (A) BCL-2 and (B) BMP-4 within the BM microenvironment 
in a cohort of primary human de novo AML BMTs (n=37) and compared to expression in BMTs from 
normal controls (n=10). Protein expression was estimated at x40 magnification by two investigators in a 
blinded fashion. The staining intensity was semi-quantitatively classified as negative and positive; 
staining was considered negative if <10% of cells were positive 489.  
BCL-2 was significantly up-regulated (p=0.001) whilst BMP4 was significantly down-regulated (p<=.029). 
Statistics were performed using the Fisher’s exact test and are shown to the nearest three decimal 
places. 
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Figure 5.1.2.3: Heatmap showing expression of members of the Bcl-2 family, cell cycle regulators, 
select ABC transporters and components of the Hh signalling pathway, clustering highlighted by 
complete linkage analysis in an unselected cohort of primary, de novo, human AML samples (n=28).  
RNA was made from a cohort of 28 de novo primary human AML samples relative to normal bulk MNCs 
(n=10). AML MNCs were derived from PB and BM; the use of AML MNCs is in keeping with published work 
86,87.  MNCs were harvested following culture at a density of 1.5x105/ml for 24hrs. To account for input 
cDNA the ΔCT for each gene was calculated by subtracting the CT value of 6 housekeeping (control) 
genes from the CT recorded for the gene of interest. ATP5S, β2M, ENOX2, GAPDH, TYW1 and UBE2D2 
were selected as housekeeping genes. Expression levels were quantified by qRT-PCR using Fluidigm® 
technology. Log transformation of the 2-ΔΔCT enabled graphical display of expression patterns according 
to the unsupervised Eisen approach using PermutMatrix software 588. Complete linkage analysis finding 
key members of the Bcl-2 family, cell cycle regulators and ABC transporters to cluster with components 
of the Hh signalling pathway. 
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5.2 ABC transporters in AML 
 
5.2.1 Introduction 
The ABC family consists of 48 functionally distinct transmembrane proteins subdivided across 
seven subfamilies (ABCA through ABCG) 526. They play an important role in normal physiology, 
being present in virtually all cells, responsible for the transport, or efflux, of a huge variety of 
compounds, across plasma and intracellular membranes. In addition, they have been linked to a 
number of disorders including AML, in which they have been demonstrated at diagnosis, arising 
during treatment and presenting on relapse, conferring an inferior outcome.  
Chemoresistance is considered one of the main causes of treatment resistance and disease 
relapse. Cells exposed to cytotoxic agents have been shown to develop chemoresistance through 
a number of mechanisms, including deregulated ABC transporter expression. To date increased 
expression of thirteen of the ABC transporters (ABCA2, ABCB1, ABCB4, ABCB11, ABCC1–6 
ABCC10, ABCC11 and ABCG2) have been linked to chemoresistance. ABC transporters serving to 
protect the CSC from a broad range of cytotoxic agents 539,540,666,667, and to confer a survival 
advantage through altered cholesterol metabolism in AML 668–670. We therefore studied expression 
of the ABC transporters ABCA2, ABCB1, ABCC1, ABCC2 and ABCG2 in a cohort of de novo primary 
human AML samples relative to normal bulk MNCs (n=10). AML MNCs (leukaemic blasts) were 
derived from PB and BM; the use of AML MNCs is in keeping with published work 86,87. RNA was 
isolated from cells following culture for 24hrs. To account for input cDNA the ΔCT for each gene 
was calculated by subtracting the CT value of 6 housekeeping (control) genes from the CT 
recorded for the gene of interest. ATP5S, β2M, ENOX2, GAPDH, TYW1 and UBE2D2 were selected 
as housekeeping genes. Expression was quantified by qRT-PCR using Fluidigm® technology. 
Expression is presented as fold change (2-ΔΔCT) relative to our normal control cohort with marked 
variance between AML samples, seen within each of the ABC transporters and up-regulation of 
ABCA2, ABCC1, ABCG2 and to a lesser degree ABCC3; Figure 5.2.1.1. We therefore sought to 
study the expression of select ABC transporters within our cell lines and, to determine whether 
these ABC transporters represented therapeutic targets.   
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5.2.2 The ABC transporters are heterogeneously expressed in AML cell 
lines  
qRT-PCR using Fluidigm® technology was used to determine the baseline mRNA expression of a 
number of ABC transporters - ABCA2, ABCB1, ABCC1, ABCC3 and ABCG2; selected following a 
literature search showing them to be linked to chemoresistance in AML. RNA was extracted from 
cells harvested in optimal growing conditions (resuspended in fresh media 24hrs before 
harvesting at a density of 2-3x105/ml). To account for input cDNA, the ΔCT for each gene was 
calculated by subtracting the CT value of 6 housekeeping (control) genes from the CT recorded 
for the gene of interest. ATP5S, β2M, ENOX2, GAPDH, TYW1 and UBE2D2 were selected as 
housekeeping genes. Expression is presented as 2-ΔCT, allowing comparison of levels of mRNA 
expression between each cell line, Figure 5.2.2.1.  
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Figure 5.2.1.1: mRNA expression of select ABC transporters in an unselected cohort of primary, de 
novo, human AML MNC samples (n=76) relative to a normal control (n=10). 
RNA was made from cells harvested following culture for 24hrs. Expression levels were quantified by 
qRT-PCR using Fluidigm® technology. Expression levels are shown as 2-ΔΔCT, with 6 housekeeping genes –
ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2 serving as endogenous control; CT values for these 
genes ranged from 3 to 13. Red lines indicate a 5-fold change. The median is presented, error bars 
show the SD and demonstrate (1) the variability in baseline expression between individual AML samples, 
(2) the variance between each of the ABC transporters and, (3) the up-regulation of ABCA2, ABCC1, 
ABCG2 and to a lesser degree ABCC3.   
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Genetic heterogeneity is clearly demonstrated. ABCA2 and ABCC1 were expressed by all of our 
selected cell lines. A >100-fold difference in the expression of ABCA2 was demonstrated between 
cell lines; THP-1 cells demonstrated the highest expression and Kasumi-1 cells the lowest. A 
>100-fold difference in the expression of ABCC1 was also demonstrated between cell lines; OCI-
AML3 cells had the lowest expression whilst THP-1 cells were again shown to have the highest 
expression. This is particularly interesting considering we had shown THP-1 cells to be less 
sensitive to Ara-C, the IC50 by rezarurin assay being > 4-fold higher, than our other selected cell 
lines (Figure 5.2.3.2). ABCB1 was detected in the Kasumi-1, KG1a and MOLM-13 cell lines. ABCC3 
was only expressed within the MV4-11 cell line whilst ABCG2 was expressed by the HL60 and 
KG1a cell lines. Previous work has shown 22 ABC transporters, including ABCB1 and ABCC1, to be 
predominantly expressed in CD34+CD38− cells and, to be subsequently down-regulated upon 
differentiation into the CD34+CD38+ cells 545; four of our selected ABC transporters were 
expressed by the CD34+ KG1a cell line, and three by the Kasumi-1 cell line. Interestingly 
however, whilst the CD34+ cell lines (Kasumi-1 and KG1a) expressed a number of the studied ABC 
transporters the CD34- cell lines, MOLM-13, MV4-11 and THP-1, were shown to express these 
genes at significantly higher levels. Both FLT3-ITD+ cell lines, MOLM-13 and MV4-11, expressed 
three of our selected ABC transporters; this is particularly interesting since FLT3-ITD is 
associated with a poor prognosis. 
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Figure 5.2.2.1: Variance in the expression of ABCA2, ABCB1 and ABCC1 in seven, genetically 
diverse, AML cell lines. 
RNA was made from cells harvested in optimal growing conditions. To account for input cDNA the ΔCT 
for each gene was calculated by subtracting the CT value of 6 housekeeping (control) genes from the 
CT recorded for the gene of interest. ATP5S, β2M, ENOX2, GAPDH, TYW1 and UBE2D2 were selected as 
housekeeping genes. Expression levels were quantified by qRT-PCR using Fluidigm® technology and are 
shown as 2-ΔCT. The mean of 3 biological replicates samples are shown with error bars indicating SD. A 
marked variance in the mRNA expression of ABCA2, ABCB1 and ABCC1 was demonstrated in seven, 
genetically diverse AML cell lines.  
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5.2.3 The ABC transporters elacridar, reversan and zosuquidar confer no 
additional benefit to Ara-C in select AML cell lines 
The ABC inhibitors serve as bio-enhancers, designed to block transport mediated drug efflux. 
Deregulated ABC transporter expression is well recognised in AML, with chemoresistance a 
powerful and difficult clinical issue. Despite research into ABC transporters generating exciting 
hypotheses, clinical trials studying the first (verapamil, quinidine and cyclosporine A) and second 
(PSC-833 (Valspodar)) generation inhibitors, with and without chemotherapy, showed little 
clinical benefit. Interestingly, RNA expression indicates high redundancy between the ABC 
transporters. Further, functional studies appear to suggest a ‘rescue effect’ from alternative 
non-targeted transporters in these early studies. The absence of toxicity when these small 
molecule inhibitors are used clinically, and the high frequency of their expression in AML, does 
however mean they remain interesting therapeutic targets. We therefore sought to study a 
number of multifunctional modulators in seven genetically diverse, AML cell lines.  
Three ABC transporter drugs were chosen: elacridar which inhibits ABCG1 and ABCG2, reversan 
which inhibits ABCC1 and ABCG1 and zosuquidar which inhibits ABCG1. We selected these 
inhibitors for a number of reasons. The roles for ABCG2 and ABCC1 are well established, both up-
regulated in our cohort of de novo primary human AML samples 667,670. ABCC1 and ABCG2 were 
differentially expressed in our cell lines enabling us to contrast each cell line’s response to the 
different inhibitors – in order to demonstrate an effect should these inhibitors be used in a 
selected, targeted manner? Whilst we did not screen our cells lines for expression of ABCG1, and 
its direct involvement in chemoresistance has not yet been demonstrated, this is one of six ABC 
transporters predominantly expressed by immature haematopoietic cells and associated with a 
chemoresistant phenotype 534; ABCG1 expression shown to be >1000-fold greater in HSCs 
compared to non-HSCs 531. We therefore questioned whether this represented a new target.  
All inhibitors were tested on KG1a, OCI-AML3 and THP-1 cells alone, and in combination, with 
100nM and 500nM Ara-C for 72hrs to ensure time to enable an effect to be measurable yet avoid 
confounding factors such as nutrient exhaustion, or increased apoptosis due to surrounding cell 
death and the consequent environment change. A concentration of 500nM Ara-C was selected as 
this is the maximally tolerated clinical dose; 100nM was selected to assess whether the addition 
of an ABC transport inhibitor would allow a dose reduction in Ara-C without loss of effect. 100nM 
is consistent with published work studying the effect of Ara-C in AML in vitro 656,657. Cell lines 
were chosen according to their phenotype and ABC transporter expression. KG1a is a CD34+ cell 
line expressing ABCC3 and ABCG2, OCI-AML3 a myelomonocytic cell line expressing neither of our 
targeted ABC transporters though a number of others, and THP-1, a myelomonocytic cell line 
with the highest expression of ABCC1. Metabolic activity, as a measure of cell viability, was 
measured using the resazurin assay.  
The ABC transport inhibitors were not expected to result in cell death alone. However a 
reduction in luminescence, reflective of a fall in metabolic activity was demonstrated following 
culture of the KG1a cell line with increasing concentrations of all three ABC transporter 
inhibitors. Considering the OCI-AML3 cell line, a progressive decline in metabolic activity was 
seen following culture with reversan and zosuquidar whilst a marked reduction in viabilty was 
seen following culture with elacridar at a concentration of greater than 5µM. Finally, looking at 
the THP-1 cell line, no effect was seen following culture with reversan at all concentrations or 
zosuquidar until the concentration exceeded 25µM whilst a gradual decline was seen following 
culture with elacridar. Figure 5.2.3.1. As expected culture of each of these cell lines with 
increasing concentrations of Ara-C for 72hrs led to a progressive reduction in cell viability; Figure 
5.2.3.2.  
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Figure 5.2.3.1: Metabolic activity, as a measure of cell viability, in three genetically diverse AML 
cell lines following culture with incremental concentrations of select ABC transport inhibitors (µM).  
Cells, at a concentration of 1x105/ml, were cultured with incremental doses of elacridar, reversan and 
zosuquidar for 72hrs. Cell viability was determined using the resazurin assay. Results are expressed as 
the mean luminescence (n=4) with error bars indicating SD. The NDC is highlighted in red.  
The ABC transporters had a variable effect on metabolic activity within the selected AML cell lines, this 
did not appear to reflect ABC transporter expression. 
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The addition of our selected ABC transport inhibitors did not enhance the reduction in cell 
viability seen following culture with Ara-C at both 100nM and 500nM as measured by the 
resazurin assay. The shape of the graphs, and thus change in metabolic activity, mirrored that 
seen following culture with the ABC transport inhibitors as single agents, Figure 5.2.3.3. Further, 
a variable effect, not reflective of ABC transporter expression was demonstrated. There was a 
progressive decline in metabolic activity following culture of the KG1a cell line with increasing 
concentrations of all three ABC transporter inhibitors; with no difference in effect was seen 
between elacridar, targeting ABCG1 and ABCG2, and the other ABC transporter inhibitors. The 
KG1a cell line expresses ABCG2 suggesting a degree of redundancy of the ABC transporters. 
Figure 5.2.3.3.  
Despite published work in solid malignancies showing limited clinical impact we had hoped a 
more targeted approach would enable us to identify a therapeutic window. In light of these 
findings however the role of ABC transport inhibitors in the treatment of AML was not pursued 
further during my PhD. 
Figure 5.2.3.2: Metabolic activity, as a measure of cell viability, in three genetically diverse AML 
cell lines following culture with incremental concentrations of Ara-C. 
Cells, at a concentration of 1x105/ml, were cultured with incremental concentrations Ara-C for 72hrs.  
Cell viability was determined using the resazurin assay. Results are expressed as the mean 
luminescence (n=4) with error bars indicating SD. NDC is highlighted in red. Culture of each of these 
cell lines with increasing concentrations of Ara-C for 72hrs led to a progressive reduction in metabolic 
activity. 
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Figure 5.2.3.3: Metabolic activity, as a measure of cell viability, in three genetically diverse AML 
cell lines following culture with incremental concentrations of select ABC transport inhibitors (µM) 
and Ara-C 500nM.  
Cells, at a concentration of 1x105/ml, were cultured with incremental doses of elacridar, reversan and 
zosuquidar and Ara-C at a concentration of 500nM for 72hrs. Cell viability was determined using the 
resazurin assay. Results are expressed as the mean luminescence (n=4) with error bars indicating SD. 
Highlighted in red is the luminescence (viability) following culture with Ara-C 500nM as a single agent 
for comparison.  
An additive effect between the ABC transport inhibitors and Ara-C was not evident in our selected AML 
cell lines.  
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5.3 Bcl-2 inhibition in AML 
 
5.3.1 Introduction 
An association between AML and Bcl-2 family has long been recognised, with high Bcl-2 being 
demonstrated to be an independent prognostic factor and predictor of remission 517. Further, 
more recent work analysing expression within sorted populations has shown, in contrast to their 
normal counterparts, quiescent CD34+CD33-CD13- AML cells highly express Bcl-2 519,520. It is these 
primitive cells, which are believed to be responsible for MRD, and relapsed disease. The 
increased functional reliance of leukaemic cells upon Bcl-2 in comparison to normal 
haematopoietic cells makes it an exciting therapeutic target.  
We therefore studied expression of the Bcl-2 family in a cohort of de novo primary human AML 
samples relative to normal bulk MNCs (n=10); experimental design as described in section 5.2.1. 
Expression is presented as fold change (2-ΔΔCT) relative to our normal control cohort with 
members of the Bcl-2 family deregulated in AML compared to normal and interestingly, almost 
universally down-regulated; Figure 5.3.1.1. We therefore sought to (1) study the expression of 
the Bcl-2 family within our cell lines, (2) determine whether inhibition of Bcl-2 represented a 
viable therapeutic and, (3) if cell death was demonstrated to determine the underlying 
mechanism.   
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Figure 5.3.1.1: mRNA expression of the Bcl-2 family in an unselected cohort of primary, de novo, 
human AML MNC samples (n=76) relative to our normal cohort (n=10). 
RNA was made from cells harvested following culture for 24hrs. Expression levels were quantified by 
qRT-PCR using Fluidigm® technology. Expression levels are shown as 2-ΔΔCT, with 6 housekeeping genes –
ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D serving as endogenous control; CT values for these genes 
ranged from 3 to 13. Red lines indicate a 5-fold change. Pro-apoptotic family members are highlighted 
in green, anti-apoptotic family members in blue. The median is presented, error bars show the SD and 
demonstrate the variability in baseline expression between individual AML samples; pro-apoptosis genes  
shown to be down-regulated, with the greatest variance seen in the expression of BCL-2.  
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5.3.2 The Bcl-2 family are heterogeneously expressed in AML cell lines  
qRT-PCR using Fluidigm® technology was used to determine the baseline mRNA expression of 
components of the Bcl-2 family, expressed as 2-(DCT), with experimental design as described in 
section 5.2.2. Genetic heterogeneity is clearly demonstrated, Figure 5.3.2.1. Both pro- and anti-
apoptotic family members were deregulated. Despite the phenotypic heterogeneity of our cell 
lines, expression patterns were relatively homogeneous. Interestingly, both pro- and anti-
apoptotic components of the Bcl-2 family were up- and down-regulated, suggesting a complex 
network of interactions regulate the apoptotic process.  
Looking at select genes in more detail, the anti-apoptotic member MCL-1, essential for the 
survival of HSCs 671 and involved in delayed cell cycle progression through interactions with the 
checkpoint inhibitors and cyclin dependent kinases 672,673 was consistently, and homogeneously, 
highly expressed in all cell lines suggesting a dependence upon this molecule. BCL-2 was also up-
regulated, though expression was more heterogeneous, the OCI-AML3 and THP-1 cell lines 
showing consistently lower levels of expression relative to the other cell lines. Of the pro-
apoptotic members the expression of BAK and BAX, the gate-keepers for cytochrome c release, 
was particularly interesting - BAK was shown to be down-regulated whilst BAX was up-regulated. 
Expression of BAX was approximately 10-fold greater than that for BAK. This divergent expression 
pattern is particularly interesting considering activation of these proteins is required for 
mitochondrial driven apoptosis, their activity precisely controlled by the same pathways.  
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Figure 5.3.2.1: Baseline gene expression of members of the Bcl-2 family in seven, genetically 
diverse, AML cell lines. 
RNA was made from cells harvested in optimal growing conditions. Expression levels were quantified by 
qRT-PCR using Fluidigm® technology. Expression levels are shown as 2-ΔCT, with 6 housekeeping genes –
ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2 serving as endogenous control. The mean of 3 samples 
are presented, with error bars showing the SD. Pro-apoptotic family members are highlighted in green, 
anti-apoptotic family members in blue. Both pro- and anti-apoptotic components of the Bcl-2 family 
are shown to be up- and down-regulated. MCL-1 is consistently, and homogeneously, highly expressed in 
all cell lines. BCL-2 is also up-regulated, though expression is more heterogeneous. Of the pro-
apoptotic members BAK is shown to be down-regulated whilst BAX is up-regulated. 
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Previous work has shown the ratio of BAX and / or BAK to BCL-2, rather than expression of BAK, 
BAX and BCL-2, to have prognostic and predictive significance in colon and bladder cancer 674,675. 
We therefore evaluated the BAX/BCL-2 and BAK/BCL-2 expression ratios for each cell line, Table 
5.3.2.1.  
Table 5.3.2.1: BAX/BCL-2 and BAK/BCL-2 expression ratios in seven, genetically diverse, AML 
cell lines 
Cell line BAK/BCL-2 expression ratio BAX/BCL-2 expression ratio 
HL60 0.179157 0.461673 
Kasumi-1 0.240589 1.60712 
KG1a 0.0807 1.250073 
MOLM-13 0.044261 1.301589 
MV4-11 0.188073 1.34105 
OCI-AML3 0.044461 0.432757 
THP-1 0.494037 2.630983 
 
This table demonstrates that whilst BAX is seen to be up-regulated at a gene level the balance of 
pro- and anti-apoptotic gene expression favours anti-apoptosis in the majority of cell lines. In 
those cell lines in which the ratio favours apoptosis – Kasumi-1, KG1a, MOLM-13, MV4-11 and 
THP-1, with the exception of the THP-1 cell line, this appears to be counteracted by the marked 
shift in favour of anti-apoptosis when looking at the BAK/BCL-2 expression ratios. It is important 
to consider however that these ratios do not account for the other family members, or 
interacting genes, a complex network of interactions determining cell fate – morphologically and 
functionally these cells were healthy, maintaining their predetermined rate of cell division. 
Further, gene expression does not necessarily correlate with functional activity, as it does not 
account for post-transcriptional regulation. For example, although transcriptional control of BCL-
2 by NFκβ and SHH has been reported 598,676, evidence suggests post-transcriptional regulation to 
be fundamental to its function 677. We therefore sought to determine the baseline expression of 
BCL-2 in each of our selected cell lines by western blotting, with SHP2 serving as an endogenous 
control (n=2), Figure 5.3.2.2.  
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BCL-2 was present in the HL60, KG1a, MOLM-13, OCI-AML3 and THP-1 cell lines, and absent from 
Kasumi-1, K562 and MV4-11. K562 was established from a 53 year old female with BC-CML, with 
studies determining it to be an erythroleukaemia. U937 was derived from a 37 year old male with 
histiocytic lymphoma, used to study monocyte behaviour. Both were included for interest to 
consider expression of BCL-2 in other haemaopoeitic cell lineages.  
Accounting for the endogenous control the HL60, OCI-AML3 and THP-1 cell lines had the highest 
amount of protein whilst the KG1a and MOLM-13 had the least. This is particularly interesting as 
it contrasts with our BCL-2 expression data, with the OCI-AML3 and THP-1 showing the lowest 
levels of BCL-2 and HL60 and MV4-11 showing the highest. This difference could be explained by 
a number of factors including protein stability, processes involved between transcription and 
translation and the complex network involved in the apoptotic process. This is in keeping with 
other published work which analysed the correlation between gene and protein expression, 
finding it to be as low as 40% depending upon the system 678. It does however highlight the 
importance of assessing, and measuring, expression of the target when considering the use of 
small molecule inhibitors. 
 
5.3.3 Targeting Bcl-2 with ABT-199, HA14-1 and TW37 has a variable effect 
within select, genetically diverse AML cell lines 
ABT-199 is a second generation BH3 mimetic, gaining FDA approval for the treatment of 
relapsed, refractory CLL with 17p deletion in 2016 522. HA14-1 and TW37 are small molecule 
inhibitors of Bcl-2 which also inhibit other Bcl-2-like family members Bcl-XL and Bcl-W 679, and 
Bcl-W 680,681 respectively. Considering HA14-1, previous work has highlighted the importance of 
Bcl-XL in platelet survival 232. Treatment with the first generation BH3-mimetic ABT-263 
complicated by dose-limiting severe thrombocytopenia, an issue which led to the development of 
ABT-199. This is an important consideration given patients with AML frequently present with 
thrombocytopenia. All drugs were tested on KG1a, MOLM-13, MV4-11, OCI-AML3, and THP-1 cells 
for 72hrs to enable an effect to be measurable yet avoid confounding factors such as nutrient 
exhaustion. Cell metabolic activity was measured using the resazurin assay, Figure 5.3.3.1 and 
Table 5.3.3.1. 
 
Figure 5.3.2.2: Representative Western blot showing expression of BCL-2 in select, genetically diverse 
AML cell lines, a glioblastoma cell line and erythroid BC-CML cell line. 
Protein was extracted from cells harvested in optimal growing conditions as described in section 2.2.3.1. 
Western blotting, as described in section 2.2.3.2, enabled quantitative analysis of BCL-2. Representative 
western blot of two with similar results showing variance in the expression of BCL-2. SHP2 served as an 
endogenous control. The THP1cell line was run twice for internal control THP1a shows results for 10µg 
protein, THP1b for 20µg protein. 
GBM, glioblastoma multiforme cell line; K562, erythroid CML-BC cell line; U937, monocyte lymphoma cell 
line.  
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Table 5.3.3.1: IC50 values for ABT-199, HA14-1 and TW37 (select BH3 mimetics) in five 
genetically diverse, AML cell lines as determined by the resazurin assay 
Cell line IC50(µM) 
ABT-199 HA14-1 TW37 
KG1a 0.1-0.2 12.5-25 0.05-0.1 
MOLM-13 <0.05 >25 0.39 
MV4-11 <0.05 12.5-25 0.2-0.39 
OCI-AML3 >25 >25 0.2-0.39 
THP-1 12.5-25 >25 0.1-0.2 
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The heterogeneous response both between, and within, our selected cell lines following culture 
with each of the three Bcl-2 inhibitors is clearly demonstrated by the dose response curves, 
Figure 5.3.3.1, and confirmed when looking across the IC50 values shown in Table 5.3.3.1. All cell 
lines were resistant to HA14-1 with no effect seen following culture at concentrations below 
6.25µM, an effect only demonstrated following culture at concentrations greater than 25µM in 
the OCI-AML3 and THP-1 cell lines. Intermediate sensitivity to TW37 was seen in all cell lines, 
with the IC50 ranging between 100nM and 1µM. Two cell lines were sensitive to ABT-199 induced 
apoptosis, MOLM-13 and MV4-11, with an IC50 <50nM, whilst three were highly resistant with an 
IC50 >10µM. As a comparator ABT-199 has been shown to have an inhibitory constant of <0.1nM in 
CLL. The marked variation in response between each cell line is not unexpected considering the 
notable differences in Bcl-2 expression at baseline, in addition to the different genetic 
signatures, and likely differing drug pharmacodynamic profiles. Considering all three compounds 
are small molecule BH3 mimetics, preventing heterodimerisation, and consequently inactivation, 
of pro-apoptotic molecules the variable effect is interesting, seemingly pointing to small but 
fundamental differences in their pharmacological properties. ABT-199 was in early phase clinical 
trials within AML, we therefore elected to investigate the mechanisms underlying treatment 
resistance and sensitivity. Further, and rather interestingly, whilst preclinical ex vivo data 
suggested AML cell lines, primary patient samples, and murine primary xenografts are very 
sensitive to single-agent venetoclax 682 a subsequent early phase clinical trial evaluating 
venetoclax as a single agent in patients with R/R AML demonstrated responses (CR/CRi) of 19% 
(6/32 patients) 524. In contrast in elderly patients with untreated AML venetoclax, in combination 
with LDAC or HDMAs, showed a response rate of 44% and 76% respectively 523,683. Whilst these 
conflicting results may simply reflect eligibility criteria and single versus combination therapy it 
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Figure 5.3.3.1: Metabolic activity, as a measure of cell viability, in five genetically diverse AML cell 
lines following culture with incremental doses of select BH3 mimetics / Bcl-2 inhibitors (µM).  
Cells, at a concentration of 1x105/ml, were cultured with incremental concentrations of select Bcl-2 
inhibitors (HA14-1, TW27 and ABT-199) and cultured for 72hrs. Cell viability was determined using the 
resazurin assay. Results are expressed as the mean luminescence (n=4) with error bars indicating SD. 
NDC is highlighted in red. The heterogeneous response both between, and within, our selected cell 
lines following culture with each of the three Bcl-2 inhibitors is clearly shown. 
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may also reflect up-regulation of Bcl-XL and Mcl-1 in AML, particularly in relapsed disease 684. 
High BCL-2 correlates with venetoclax sensitivity in CLL 559,685; with cell line work and xenograft 
models in CLL and NHL cells suggesting sensitivity to the BH3 mimetics can be predicted by the 
ratio of anti-apoptotic to pro-apoptotic family members 686,687. Whether this can be translated 
into the clinic, and further whether this will be seen in acute or myeloid malignancies remains to 
be determined. We therefore selected the sensitive MOLM-13 and highly resistant OCI-AML3 cell 
lines for further analysis. Had time allowed we would have sought to understand the mechanism 
underpinning the different responses seen across the different BH3 mimetics.   
 
5.3.4 Combination treatment with ABT-199 and Ara-C showed a highly 
synergistic effect on cell death in MOLM-13 cells 
The development and introduction of small molecule inhibitors into the treatment armoury of 
AML is hugely exciting. In vitro and in vivo work has however shown these agents to have limited 
effect in isolation. Recognising this, the majority of current clinical trials are using these new, 
experimental, small molecule inhibitors in conjunction with established chemotherapeutic 
agents such as Ara-C and decitabine.  We therefore sought to determine if the combination of 
Ara-C and ABT-199 was synergistic. The Chou-Talalay method (discussed in section 2.2.1.7) was 
used to quantify synergy between ABT-199 and Ara-C in the MOLM-13 and OCI-AML3 cell lines. 
Briefly cell counts were performed by trypan blue dye exclusion following culture for 24, 48 and 
72hrs. The concentrations and combinations are depicted in Figure 5.3.4.1.  
 
 
 
Tables 5.3.4.1A&B show the predetermined IC50 for each drug as single agents, and the ED50 
calculated by the Chou-Talalay method for each drug when used in combination at 24, 48 and 
72hrs. Synergism, with a CI<0.47 (range 0.13-0.47) and DRI>2 (range 2-70) for all dose 
combinations was seen in the MOLM-13 cell line. It is interesting to note the calculated ED50 for 
ABT-199 in MOLM-13 cells was >100-fold greater than that determined for CLL cells for which 
venetoclax (ABT-199) is clinically approved and licensed. Weak synergism was seen in the OCI-
AML3 cell line, Figure 5.3.4.2. However this was using a clinically toxic concentration of ABT-
199. All subsequent experiments performed on the OCI-AML3 cell line used the maximum 
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Figure 6.3.4.1: Schematic of the experimental layout used to to#quan(fy#synergy#between#ABT4199#and#
Ara4C#in#the#MOLM413#and#OCI4AML3#cell#lines#using#the#Chou4Talalay#method.#
MOLM-13 and OCI-AML3 cells were seeded at a density of 2x105/ml and cultured with specific 
concentrations of each drug as outlined above for 24hrs, 48hrs and 72hrs. Trypan blue exclusion was 
performed to determine the number of live and dead cells for each experimental condition. Technical 
duplicates were performed, and the experiment performed three times.  
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Figure 5.3.4.1: Schematic of the exp rim ntal layout used to determi e the relationship betwee  
ABT-199 and Ara-C in the MOLM-13 and OCI-AML3 cell lines using the Chou-Talalay method.  
MOLM-13 and OCI-AML3 cells were seeded at a density of 2x105/ml and cultured with specific 
concentrations of each drug as outlined above for 24, 48 and 72hrs. Trypan blue dye exclusion was 
performed to determine the number of live and dead cells for each experimental condition. Technical 
duplicates were performed, and the experiment performed three times. 
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clinically tolerated concentration of 1.15µM for ABT-199 and 500nM Ara-C. The calculated ED50 
for both ABT-199 and Ara-C was used for all further experiments with the MOLM-13 cell line. All 
experiments were terminated at 72hrs. Had time allowed, in addition to using the maximum 
clinically tolerated dose, we would have performed all experiments on the OCI-AML3 cell line 
using the same concentrations as for the MOLM-13 cell line. This would enable comparison to be 
made between a sensitive and resistant cell line at both a functional and molecular level.  
Tables 5.3.4.1A&B: IC50, and ED50, for ABT-199 and Ara-C in the MOLM-13 and OCI-AML3 cell 
lines following culture for 72hrs 
(A) 
Cell line ABT-199 Ara-C 
IC50 
MOLM-13 50nM 150nM 
OCI-AML3 10µM 0.5µM 
	
(B)	
Cell line ABT-199 Ara-C 
ED50 at 24hrs 
MOLM-13 114.2nM 896.6nM 
OCI-AML3 18.770µM 1.334µM 
ED50 at 48hrs 
MOLM-13 31.7nM 85.1nM 
OCI-AML3 18.454µM 211nM 
ED50 at 72hrs 
MOLM-13 19.562nM 34.487nM 
OCI-AML3 7.854µM 77nM 
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Figure 5.3.4.2: Representative plots generated according to the Chou-Talalay method following 
culture of the OCI-AML3 and MOLM-13 cell lines with specific concentrations of ABT-199 and Ara-C 
for 72hrs. 
MOLM-13 and OCI-AML3 cells were seeded at a density of 2x105/ml, and cultured with specific 
concentrations of each drug as outlined in Figure 5.3.4.1 for 24, 48 and 72hrs. Trypan blue dye 
exclusion was performed to determine the number of live and dead cells for each experimental 
condition. Technical duplicates were performed, and the experiment performed three times. (A) Dose-
Effect curve,  (B) Median-Effect plot, (C) CI plot, and (D) Normalised isobologram for OCI-AML3 and 
MOLM-13 cells. These plots clearly demonstrate strong synergism in the MOLM-13 cell line. Whilst 
synergism is also seen within the OCI-AML3 cell line this is at clinically toxic concentrations of ABT-199.  
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5.3.5 Inhibition of Bcl-2 using the BH3 mimetic ABT-199 alters cell 
proliferation in select AML cell lines 
Using the resazurin assay, we had demonstrated OCI-AML3 to be resistant to ABT-199 whilst 
MOLM-13 was relatively sensitive. The Chou-Talalay method had demonstrated synergism 
between Ara-C and ABT-199 in the MOLM-13 cell line, and whilst also demonstrating weak 
synergism in the OCI-AML3 cell line this was at clinically toxic concentrations of ABT-199. We 
therefore sought to further analyse the effect of ABT-199, Ara-C and the combination of ABT-199 
and Ara-C on our selected cell lines.  
First we assessed cell proliferation and viability by trypan blue dye exclusion at 72hrs. With the 
OCI-AML3 cell line, culture for 72hrs with 500nM Ara-C led to a statistically significant decrease 
in the total number of live cells by trypan blue dye exclusion (p=0.007); culture with 1.15µM 
ABT-199 did not statistically affect the total number of live cells. There was a further decrease 
in the total number of live cells by trypan blue dye exclusion when cells were cultured with the 
combination of 500nM Ara-C and 1.15µM ABT-199 (p=0.003). There was no statistical difference 
between the total number of live cells in the Ara-C and ABT-199 arms, however a significant 
difference was shown between ABT-199 and the combination arm (p=0.004). Whilst the number 
of dead cells by trypan blue dye exclusion was increased in the Ara-C and combination arms this 
was not significant. Annexin V / 7AAD staining and flow cytometry analysis demonstrated a 
statistically significant increase in early apoptosis with the Ara-C and combination arms (p=0.013 
and p=0.045 respectively); whilst the total number of live cells counted was lowest in the 
combination arm, this was not significant due to variance, it was significant in the Ara-C arm 
(p=0.030), Figure 5.3.5.1.  
Culture of the MOLM-13 cell line with both 19.5nM ABT-199 and 34.5nM Ara-C as single agents 
showed a statistically significant decrease in total number of live cells by trypan blue dye 
exclusion (p=0.0003 and p=0.001 respectively). This was significantly enhanced when cells were 
cultured with the combination of 19.5nM ABT-199 and 34.5nM Ara-C (p<0.0001). Additionally 
there was a statistical difference in the number of live cells when comparing ABT-199 and Ara-C 
(p=0.013) and both ABT-199 and Ara-C and the combination arm (both p<0.0001). There was an 
accompanying statistically significant increase in dead cells by trypan blue dye exclusion in the 
ABT-199 arm (p=0.002), further enhanced in the combination arm (p=0.0006). A statistical 
difference in the number of dead cells was demonstrated between ABT-199 and Ara-C (p=0.002) 
and ABT-199 and the combination arm (p=0.009). Annexin V / 7AAD staining and flow cytometry 
analysis supported these results showing a statistically significant reduction in the percentage of 
live cells following culture with ABT-199 (p=0.001), Ara-C (p=0.006) with increased significance 
in the combination arm (p=0.005). Early and late apoptosis were increased in all treatment arms 
(ABT-199, p=0.001; Ara-C p=0.009; combination p=0.0008). Late apoptosis was increased 
following culture with ABT-199 (p=0.006) and the combination (p=0.007); Figure 5.3.5.1.  
	 247	
 
 
%
 to
ta
l e
ve
nt
s 
co
un
te
d 
1 2 3 4
0
20
40
60
80
100 * p=0.045
* p=0.013
NDC ABT-199 Ara-C ABT-199 
Ara-C 
C
el
l c
ou
nt
s 
x1
04
/m
l 
(A) 
1 2 3 4
0
20
40
60
80
100
** p=0.003
** p=0.004
** p=0.007
NDC ABT-199 Ara-C ABT-199 
Ara-C 
Figure 5.3.5.1: Proliferation and apoptosis, as determined by trypan blue dye exclusion and 
Annexin V / 7AAD staining, following culture of the OCI-AML3 and MOLM-13 cell lines with ABT-199 
(1.15µM and 19.5nM respectively) and Ara-C (34.5nM and 500nM respectively) for 72hrs.  
OCI-AML3 cells were seeded at a concentration of 2x105/ml, exposed to ABT-199 (1.15µM), Ara-C 
(500nM) and ABT-199 (1.15µM) and Ara-C (500nM) in combination and cultured for 72hrs. MOLM-13 cells 
were seeded at a concentration of 2x105/ml, exposed to ABT-199 (19.5nM), Ara-C (34.5nM) and ABT-199 
(19.5nM) and Ara-C (34.5nM) in combination and cultured for 72hrs. (A) These graphs show cell viability 
as determined by trypan blue dye exclusion. Each bar represents the mean cell number x 104 /ml from 
four (OCI-AML3) and nine (MOLM-13) independent experiments with error bars indicating SD. (B) These 
graphs indicate the proportion of cells which are viable, in early apoptosis, in late apoptosis or dead as 
determined by Annexin V / 7AAD staining, and analysis by flow cytometry (see Figure 2.3 for gating 
strategy). Each bar represents the mean percentage from four (OCI-AML3) and nine (MOLM-13) 
independent experiments with error bars indicating SD. All statistically significant results are 
highlighted with p value to the nearest 3 decimal places, those not highlighted are not significant (ns). 
Within the MOLM-13 cell line a statistically significant reduction in live cells, explained by apoptosis, 
was seen following culture with ABT-199 and Ara-C, with the significance increased further in the 
combination arm consistent with drug synergism. ABT-199 did not reduce proliferation, or induce 
apoptosis, and there was no evidence of synergism in the OCI-AML3 cell line.  
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5.3.6 Inhibition of Bcl-2 using the BH3 mimetic ABT-199 alter cell cycle 
kinetics in select AML cell lines 
Changes in cell viability following culture of MOLM-13 cells with ABT-199 alone, and in 
combination with Ara-C, had been shown by trypan blue dye exclusion; with an absence of effect 
seen in the OCI-AML3 cell line. Ara-C is the backbone of current AML treatment. We therefore 
sought to determine if, and how, ABT-199 and Ara-C alone, and in combination, affected cell 
cycle in our selected AML cell lines by PI staining and flow cytometry analysis.  
A statistically significant reduction in the percentage of OCI-AML3 cells in G0-G1 was 
demonstrated following culture with the combination of Ara-C and ABT-199 (p=0.019). The shape 
of the histograms generated following PI staining (n=6) precluded separation of the S and G2-M 
phases. No statistically significant change in cell cycle kinetics was seen following culture with 
ABT-199 or Ara-C alone; though Ara-C as a single agent was demonstrated to affect cell cycle 
kinetics in a manner very similar to the combination arm, lack of statistical significance was 
attributed to variance in the results, Figure 5.3.6.1.  
A statistically significant reduction in the percentage of MOLM-13 cells in the G0-G1 fraction was 
demonstrated when cultured with ABT-199 alone (p=0.043) and in combination with Ara-C 
(p=0.049). The percentage of cells within the G0-G1 fraction following culture with Ara-C alone 
was reduced, though this was not significant. A statistical difference between ABT-199 and the 
combination of ABT-199 and Ara-C was demonstrated (p=0.038). A statistically significant 
increase in the percentage of cells in the sub G0 fraction was seen following culture with Ara-C 
alone (p=0.011) and in combination with ABT-199 (p=0.043). Whilst the percentage of events 
gated within the sub G0 fraction was 1.5-fold greater in the combination arm relative to ABT-199 
this was not statistically significant. There was no significant difference in the percentage of 
cells within the S or G2-M phases between any of the experimental arms, Figure 5.3.6.1. It would 
be interesting to analsye cell cycle kinetics at earlier time points, the cells appearing to arrest in 
G0-G1 and subsequently enter sub G0. It would be interesting to utilise agents such as Hoechst-
33343low/Pyronin-Ylow to separate the G0 and G1 stages to determine the effect ABT-199 had 
within this fraction of cells. This data suggests ABT-199 does not affect the cell cycle in the 
MOLM-13 cell line. Whilst Ara-C has been shown to result in cell cycle inhibition 533 this was not 
demonstrated in our hands. This may be due to the drug concentrations selected for the purpose 
of our experiments.  
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Figure 5.3.6.1: Cell cycle kinetics, as determined by PI staining, following culture of the OCI-AML3 
and MOLM-13 cell lines with select, and differing, concentrations of ABT-199 and Ara-C for 72hrs.  
OCI-AML3 and MOLM-13 cells were seeded at a concentration of 2x105/ml, exposed to ABT-199 (1.15µM 
and 19.5nM respectively), Ara-C (500nM and 34.5nM respectively) or the combination, cultured for 
72hrs then harvested and stained with PI prior to analysis by flow cytometry. (A) Representative 
staggered histograms showing the PI staining pattern generated with FlowJo software. Each plot is 
representative of data from one experiment of four with similar results. (B) These graphs indicate the 
proportion of cells within each cell cycle phase as determined by PI staining, and analysis by flow 
cytometry. Each bar represents the mean percentage from four independent experiments with error 
bars indicating SD. All statistically significant results are highlighted with p value to the nearest 3 
decimal places, those not highlighted are not significant. ABT-199 is shown to significantly reduce the 
number of cycling MOLM-13 cells, the addition of Ara-C increasing this effect; ABT-199 did not affect 
cell cycle kinetics in OCI-AML3.  
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5.3.7 Inhibition of Bcl-2 using the BH3 mimetic ABT-199 induces apoptosis 
via the ‘intrinsic’ cell death pathway 
We had shown ABT-199 to induce apoptosis in the MOLM-13 cell line. We sought to determine if 
this was, as expected, through the ‘intrinsic’ cell death pathway by affecting mitochondrial 
membrane integrity, and further, the effect of Ara-C on this process. TMRM is a cell permeant 
fluorescent dye readily sequestered by active mitochondria. This stain therefore enables the 
assessment of mitochondrial membrane potential. Loss of mitochondrial membrane potential is 
an indirect consequence of MOMP, whereby the mitochondrial membrane becomes permeable, 
with the consequent leakage of intermembrane proteins including cytochrome c, indicative of 
apoptosis by the ‘intrinsic’ pathway. When mitochondrial membrane integrity is lost the 
mitochondria are no longer able to retain TMRM, the dye is therefore redistributed throughout 
the cell’s cytoplasm. This results in a clear fall in fluorescence intensity quantified by flow 
cytometry.  
Mitochondrial membrane potential, using the TMRM stain and flow cytometry analysis, was 
measured following culture with ABT-199, Ara-C and the combination of ABT-199 and Ara-C for 
72hrs, Figure 5.3.7.1. No significant difference in the mitochondrial membrane potential was 
seen in OCI-AML3 cell line across all treatment arms. Interestingly, considering the absence of 
effect when OCI-AML3 cells were cultured with ABT-199 and Ara-C as single agents a 25% 
reduction in mitochondrial membrane potential and 20% increase in cells gated as Annexin V 
positive was however demonstrated in the combination arm. Whilst this was not significant it 
does hint at a beneficial effect existing between Ara-C and ABT-199 in this resistant cell line.  
There was a statistically significant decrease in mitochondrial membrane potential when MOLM-
13 cells were treated with ABT-199 alone (p=0.033) with statistical significance increased in the 
combination arm (p=0.002). In addition there was an increase in early apoptosis - the percentage 
of cells gating as Annexin V positive increasing from 40% in the ABT-199 arm to 50% following 
culture with both Ara-C and ABT-199, Figure 5.3.7.1.  
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The loss of membrane potential is in keeping with the known mechanism of action of ABT-199, a 
BH3 mimetic, by binding to the hydrophobic groove of multiple anti-apoptotic members of the 
Bcl-2 family this molecule inhibits the anti-apoptotic function of these proteins enabling 
apoptosis through the pro-apoptotic family members, Bak and Bax. We consider this balance 
shift, sensitising cells to cellular stress as the mechanism for the synergism seen between ABT-
199 and Ara-C in MOLM-13 cells. Further, it suggests that whilst synergism was not seen in the 
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Figure 5.3.7.1: Mitochondrial membrane potential, as measured by TMRM, following culture of the 
OCI-AML3 and MOLM-13 cell lines with select, and differing, concentrations of ABT-199 and Ara-C 
for 72hrs. 
OCI-AML3 and MOLM-13 cells were seeded at a concentration of 2x105/ml, exposed to ABT-199 (1.15µM 
and 19.5nM respectively), Ara-C (500nM and 34.5nM) or the combination, cultured for 72hrs then 
harvested and stained with TMRM and Annexin V prior to analysis by flow cytometry. (A) Representative 
flow cytometry plots following TMRM / Annexin V staining. Each plot is representative of data from one 
experiment of four with similar results. (B) Representative staggered histograms showing the TMRM 
staining pattern, generated using FlowJo software. Each histogram is representative of data from one 
experiment of four with similar results. (C) These graphs indicate the proportion of cells with 
preserved membrane potential, gated as TMRM positive by flow cytometry. Each bar represents the 
mean percentage from four independent experiments with error bars indicating SD. All statistically 
significant results are highlighted with p value to the nearest 3 decimal places, those not highlighted 
are not significant.   
These figures demonstrate the significant reduction in TMRM (in keeping with loss of mitochondrial 
membrane integrity) following culture of the MOLM-13 cell line with ABT-199, with the effect 
strengthened by the addition of Ara-C. Whilst a similar change was seen on culturing OCI-AML3 cells the 
results were not significant. 
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resistant OCI-AML3 cell line, the addition of ABT-199 to conventional chemotherapy in an 
unselected patient cohort may still show clinical benefits.  
We had shown loss of mitochondrial membrane potential, recognised to be a consequence of Bak 
and Bax activity. We therefore sought to confirm activation of the pro-apoptotic Bax protein. 
Analysis of the conformational change of Bax however, was unsuccessful (n=6). A fluorochrome 
conjugated antibody is no longer available. Despite trialling a number of primary anti-Bax 
antibodies (manufactured by the same company against the same epitope and sourced from 
other companies) a consistent and reliable result could not be obtained precluding accurate 
interpretation. Had time allowed we would have continued to optimise this experiment to 
enable the direct measurement of ‘intrinsic’ pathway activity.  
Bcl-2 contains a BH3 motif, the target for ABT-199. We therefore sought to quantify BCL-2 
following culture with ABT-199, Ara-C and the combination relative to the NDC. Protein was 
quantified by western blotting (n=2), with SHP2 serving as an endogenous control, Figure 5.3.7.2.  
BCL-2 was shown to be reduced in MOLM-13 cells following culture with ABT-199 and Ara-C in 
combination for 72hrs. Considering its mechanism of action we would not expect it to affect 
protein levels. Whilst we considered if this result reflected transcriptional and translational 
effects of Ara-C, known to target BCL-2 533, the absence of this effect following culture with Ara-
C alone, does not support this hypothesis. The result may reflect the degree of cellular stress, 
with a ‘switching off’ of pro-survival proteins, and shift towards apoptosis in these cells, 
however this cannot be conclusively determined with this data. In this respect it would be 
interesting to measure BCL-2 levels at progressive time points, correlating BCL-2 with functional 
data.  
Accounting for endogenous control within the OCI-AML3 cell line, BCL-2 was reduced in all 
treatment arms. This data is perhaps harder to explain – our functional data showing no evidence 
of apoptosis following culture with ABT-199 precluding apoptosis as an explanation, and ABT-199 
not affecting protein levels, rather disabling the function of BCL-2. In the future we plan to 
repeat this experiment, to improve statistical power and determine actual protein levels using 
mass spectrometry.  
 
 
 
 
 
Figure 5.3.7.2: Representative Western blot showing BCL-2 expression following culture of the 
OCI-AML3 and MOLM-13 cell lines with select concentrations of ABT-199 and Ara-C for 72hrs. 
OCI-AML3 and MOLM-13 cell lines were seeded at a density of 2x105/ml, exposed to ABT-199 (1.15µM 
and 19.5nM respectively), Ara-C (19.5nM and 500nM respectively) and the combination of ABT-199 and 
Ara-C (using the respective concentrations), cultured for 72hrs then harvested. Protein was extracted 
as described in section 2.2.3.1. Western blotting, as described in section 2.2.3.2, enabled quantitative 
analysis of BCL-2 within each experimental arm. Representative western blot of two with similar results 
is shown demonstrating a reduction in BCL-2 following culture of MOLM-13 cells for 72hrs with Ara-C 
and ABT-199 in combination. SHP2 served as an endogenous control. 
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Post-translational phosphorylation of BCL-2 is known to regulate its anti-apoptotic function 
688,689. Importantly, phosphorylation of BCL-2 has been shown to induce a structural alteration in 
the BH3-binding groove 690, with recent work showing this to confer resistance to BH3 mimetics 
in CLL cells by impeding direct binding 690,691. pBCL-2 was therefore measured by flow cytometry 
(n=2). We considered whether a lack of apoptosis within the OCI-AML3 cell line in the presence 
of a BH3 mimetic could be, in part, due to increased pBCL-2. pBCL-2 is an intracellular protein, 
therefore cells were fixed and permeabilised prior to staining. Baseline levels of pBCL-2 were 
first determined. Subsequent to this pBCL-2 levels were measured following culture of MOLM-13 
and OCI-AML3 cell lines with ABT-199, Ara-C and the combination of ABT-199 and Ara-C, with 
results compared to the NDC, Figure 5.3.7.3.  
 
Figure: 5.3.7.3: pBCL-2 expression, as determined by flow cytometry, following culture of the OCI-
AML3 and MOLM-13 cell lines with select, and differing, concentrations of ABT-199 and Ara-C for 
72hrs. 
OCI-AML3 and MOLM-13 cells were seeded at a concentration of 2x105/ml, exposed to ABT-199 (1.15µM 
and 19.5nM respectively), Ara-C (500nM and 34.5nM) or the combination, cultured for 72hrs then 
harvested and stained with pBCL-2 prior to analysis by flow cytometry. (A) Representative overlain 
histograms showing the pBCL-2 staining pattern. Each is representative of data from one experiment of 
three with similar results. (B) These graphs show the MFI of pBCL-2 within each treatment arm by flow 
cytometry. Each bar represents the mean percentage from three independent experiments with error 
bars indicating SD. All statistically significant results are highlighted with p values to the nearest 3 
decimal places, those not highlighted are not significant.  
A statistically significant decrease in pBCL-2 following culture of OCI-AML3 cells with Ara-C is shown. 
The addition of ABT-199 did not increase this effect. Whilst a reduction in p-BCL2 is shown following 
culture of the MOLM-13 cell line with ABT-199 and, further so with the combination of ABT-199 and Ara-
C, this was not significant.  
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The MFI of pBCL-2 was 1.5-fold greater in the OCI-AML3 cells compared to the MOLM-13 cells at 
baseline, and within the NDC. This may serve as one potential explanation for the marked 
difference in sensitivity between the two cell lines to ABT-199. Looking within our experimental 
arms: OCI-AML3 cells demonstrated a statistically significant reduction in p-BCL-2 following 
culture with Ara-C (p=0.002) and the combination (p=0.005) relative to the NDC. In addition a 
statistical reduction in pBCL-2 was seen following culture with Ara-C (p=0.007) and the 
combination (p=0.005) relative to culture with ABT-199 alone. An absence of effect following 
culture with ABT-199 would support the hypothesis that BH3 mimetic activity is prevented in the 
presence of pBCL-2. As stated previously, cellular response to Ara-C is dependent upon a number 
of genes including BCL-2 533. An extensive literature search did not find work reporting on the 
effect of the BH3 mimetics on pBCL-2. Considering the greatest experience of ABT-199 is in CLL, 
it would be interesting to assess both total BCL-2 and pBCL-2 following culture of CLL cells with 
ABT-199. Additionally, considering venetoclax has received FDA approval for the treatment of 
both CLL (those who have received at least one prior therapy and carry the TP53 mutation) and 
AML (those who are not eligible for standard high dose treatment in combination with HMAs) it 
would be particularly interesting to compare and contrast protein responses in these two very 
different haematological malignancies.  
The MOLM-13 cell line expressed lower levels of pBCL-2 relative to the OCI-AML3 cell line. This 
indicates the numerous and complex mechanisms involved in determining cell response to Ara-C. 
If p-BCL2 levels alone were sufficient to sensitise cells to Ara-C we would expect the IC50 for OCI-
AML3 cells to be lower than that demonstrated in MOLM-13 cells. It is not possible to contrast 
the differing effects on pBCL-2 levels between the two cell lines following culture with Ara-C 
since OCI-AML3 cells were exposed to the IC50 of Ara-C (500nM), whilst MOLM-13 cells were 
exposed to 37.5nM as determined by the Chou-Talalay method for drug synergy, a concentration 
23% of the IC50. As expected no significant change in levels of pBCL-2 was seen following culture 
with ABT-199. The reduction in pBCL-2 following culture with ABT-199 and Ara-C is however 
interesting, though not easily explained. One hypothesis is Ara-C effects the transcription and 
translation of BCL-2, resulting in less BCL-2, whist targeting existing pBCL-2 and ABT-199 binds to 
the hydrophobic groove within BCL-2, inhibiting phosphorylation of newly translated BCL-2. An 
alternative explanation is this result reflects the degree of cellular stress, with a shutting down 
of survival processes and shift towards apoptosis.  
 
5.3.8 Sensitivity to ABT-199 is not solely dependent on the expression of 
Bcl-2, rather a complex interplay between the pro-apoptotic and anti-
apoptotic family members 
Whilst we had shown differences in the baseline expression of Bcl-2 at a gene and protein level, 
and also in the expression of pBCL-2 in the genetically diverse OCI-AML3 and MOLM-13 cell lines 
we questioned whether other factors contributed to cell sensitivity to the BH3 mimetics. We 
considered whether the differential response demonstrated arose from (1) a lack of dependence 
upon the Bcl-2 family, (2) an up-regulation of other anti-apoptotic family members or, (3) 
recruitment of other survival molecules. In this respect the MCL-1 / BCL-2 ratio has been shown 
to predict sensitivity of CLL cells to the BH3 mimetics, higher ratios predictive of resistance 690. 
We therefore sought to determine levels of MCL-1 at baseline and following culture within each 
of our experimental arms.  
Accounting for endogenous control, no change in MCL-1 was seen across all experimental arms, 
in both the MOLM-13 and OCI-AML3 cell lines, Figure 5.3.8.1. Whilst a reduction in MCL-1 
following culture of the MOLM-13 cell line with ABT-199 and Ara-C could be considered the 
endogenous control was not sufficiently clean to allow enable conculsions to be drawn. An 
absence of change was not surprising however. Considering its mechanism of action we did not 
expect ABT-199 to affect levels of MCL-1. MCL-1 activity has been shown to be largely 
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determined at a transcriptional level by extrinsic (growth factors 692–694) and intrinsic (notably 
transcription factors belonging to the STAT family 695) signals; whilst the STAT family has clearly 
been linked with AML, work to date has not shown this family to be a target for Ara-C. Instead, 
research has looked at the JAK/STAT pathway as a potential molecular target, utilising JAK2 
inhibitors alone and with conventional chemotherapy 696. The currently recruiting NCT02257138 
trial is composed of two parts. Part one is designed to determine the maximally tolerated dose 
of decitabine in combination with the JAK2 inhibitor ruxolitinib in patients with AML. Considering 
the concept of personalised, or tailored medicine, part two will seek to determine if this 
combination is clinically beneficial in post myeloproliferative neoplasm AML; the presence of the 
JAK2 V617F mutation, resulting in constitutive activation of the JAK/STAT pathway, is 
considered the most important criterion in the diagnosis of BCR-ABL MPNs according to the WHO 
classification.  
 
In the future it would be interesting to quantitate the level of MCL-1 relative to both BCL-2 and 
pBCL-2, and further to quantify levels of BAK and BAX and the ratio of these pro-apoptotic 
proteins to their anti-apoptotic family members.  
 
5.3.9 The BH3 mimetic ABT-199 affects genes involved in apoptosis in a cell 
line-specific manner 
There is extensive work published on the effect of baseline protein levels on the sensitivity and 
resistance of cells to the BH3 mimetic, ABT-199 559,685,687, and further the effect of the BH3 
mimetics on Bcl-2 family members at a protein level. There is however, little data on the effect 
of these small molecules at a gene level. We therefore sought to determine gene expression 
changes of members of the Bcl-2 family, other cell death and apoptosis regulators and the Hh 
signalling pathway. The 2-ΔΔCT method was used to show expression relative to the NDC, with 
experimental design as described in section 5.2.2. 
The difference in gene expression is striking, Figure 5.3.9.1. Considering the OCI-AML3 cell line, 
we had shown an absence of cell death following culture with ABT-199. At the gene level 
however both pro- and anti-apoptotic genes were up-regulated suggesting a cellular stress 
response despite an absence of functional effect. In contrast, culture of the OCI-AML3 cell line, 
with Ara-C alone, and in combination with ABT-199, resulted in apoptosis; addition of ABT-199 
Figure 5.3.8.1: Representative Western blot showing MCL-1 expression following culture of the 
OCI-AML3 and MOLM-13 cell lines with select concentrations of ABT-199 and Ara-C for 72hrs.  
OCI-AML3 and MOLM-13 cell lines were seeded at a density of 2x105/ml, exposed to ABT-199 (1.15µM 
and 19.5nM respectively), Ara-C (500nM and 34.5nM) and the combination, cultured for 72hrs then 
harvested. Protein was extracted as described in section 2.2.3.1. Western blotting, as described in 
section 2.2.3.2, enabled quantitative analysis of MCL-1 within each experimental arm. GAPDH served as 
an endogenous control.  
Representative western blots of two with similar results are shown demonstrating no change in the 
quantity of MCL-1, accounting for endogenous control, across all experimental arms, and within both 
cell lines.  
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had not enhanced the apoptotic effect demonstrated following culture with Ara-C alone. At a 
gene level culture with Ara-C in combination with ABT-199 led to a statistically significant up-
regulation of BAK (p=0.004) whilst culture with Ara-C alone led to a significant up-regulation of 
BAX (p=0.043). Interestingly, the anti-apoptotic genes, BCL-2 and MCL-1, were also up-regulated 
though the results were not significant. In contrast a universal down-regulation of selected pro- 
and anti-apoptotic genes was seem in the MOLM-13 cell line, across all experimental arms. BCL-2 
was statistically significantly down-regulated following culture with ABT-199 (p=0.011). 
Statistical significance was not demonstrated following culture with ABT-199 and Ara-C, this was 
considered to be due to the high variance in expression.  
 
 
 
The ratio of BAK and /or BAX to BCL-2 rather than the expression of these genes in isolation is 
predictive of cell behaviour in solid malignancies 674,675. We therefore considered the BAX/BCL-2 
and BAK/BCL-2 expression ratios, Table 5.3.9.1.  
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Figure 5.3.9.1: Expression of members of the Bcl-2 family following culture of the OCI-AML3 and 
MOLM-13 cell lines with select concentrations of ABT-199 and Ara-C for 72hrs.  
OCI-AML3 and MOLM-13 cells were seeded at a concentration of 2x105/ml and exposed to ABT-199 
(1.15µM and 19.5nM respectively), Ara-C (500nM and 34.5nM respectively) or the combination. Cells 
were cultured for 72hrs then harvested and RNA extracted. Expression levels were quantified by qRT-
PCR using Fluidigm® technology. Expression levels are shown as 2-ΔΔCT, with 6 housekeeping genes – 
ATP5S, B2M, ENOX2, GAPDH, TYWI and UBE2D2 serving as endogenous control. The mean of 3 biological 
replicates, performed in technical duplicate, are shown. Error bars indicate SD.  
Both pro- and anti-apoptotic genes were up-regulated in the OCI-AML3 cell line whilst they were down-
regulated in the MOLM-13 cell line across all experimental arms suggesting a complex network is 
involved in determining cell fate. 
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Table 5.3.9.1: BAX/BCL-2 and BAK/BCL-2 expression ratios following culture of the MOLM-13 
and OCI-AML3 cell lines with ABT-199, Ara-C and the combination of ABT-199 and Ara-C for 
72hrs 
Experimental arm BAK/BCL-2 expression ratio BAX/BCL-2 expression ratio 
OCI-AML3 
ABT-199 0.101 0.025 
Ara-C 0.301 0.226 
ABT-199 & Ara-C 0.087 0.029 
MOLM-13 
ABT-199 63.780 39.139 
Ara-C 6.364 10.329 
ABT-199 & Ara-C 180.158 30.345 
 
Interestingly within the OCI-AML3 cell line these expression ratios suggested a shift in expression 
to support apoptosis across all experimental arms, most notably the combination arm. Whilst in 
stark contrast results within the MOLM-13 cell line suggested the balance of these pro- and anti-
apoptotic genes to favour anti-apoptosis. The differential gene expression between experimental 
arms is interesting considering ABT-199 inhibits anti-apoptotic protein activity through the 
competitive, and irreversible, binding of the BH3 domain. Whether these genetic changes 
translate to the protein level would be an interesting angle to pursue and an interesting concept 
to consider when investigating drug resistance, especially resistance acquired during therapy. 
Considering cell physiology we had expected expression of anti-apoptotic genes to increase in 
the presence of cellular stress such as culture with cytotoxic agents, with a subsequent increase 
in pro-apoptotic genes when irreversible cell damage was recognised by the cell. This expression 
data conflicts with our functional data suggesting a complex, tightly regulated, process involved 
in determining cell behaviour and fate. It would be interesting to assess genetic changes over a 
time period to determine if these changes were time-dependent. The up-regulation of BAK and 
BAX in the resistant OCI-AML3 cell line is however hugely exciting, suggesting a potential role for 
the BH3 mimetics in combination with standard chemotherapeutics agents such as Ara-C in AML. 
 
 
5.3.10 The BH3 mimetic ABT-199 resulted in apoptosis in unselected primary 
AML samples, with the addition of Ara-C showing an additive effect 
We have previously acknowledged the limitations of cell lines as experimental models 627, 
discussed further in 5.3.11. We therefore sought to determine the effect of the BH3 mimetic 
ABT-199 in a cohort of primary de novo human AML samples, alone and in combination with Ara-
C.  
Primary AML MNCs were isolated from whole PB and BM samples, recovered and cultured as 
detailed in Methods 2.2.1.2.4-6. An un-manipulated recovered cell population was used. Four 
samples were seeded at a density of 1.5x105/ml and cultured with ABT-199 at 19.5nM and 
1.15µM, alone and in combination with Ara-C 100nM as described in Methods 2.2.1.2.6. 19.5nM 
was the IC50 for MOLM-13 cells, our ABT-199 sensitive AML cell line; 1.15µM is the maximally 
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tolerated clinical dose. Cell counts and the assessment of cell viability was performed by trypan 
blue dye exclusion at 72hrs in three primary AML samples (AML 1002, AML 013 and AML 022) with 
technical triplicates, Figure 5.3.10.1. 
 
 
 
There was a statistically significant reduction in cell viability following culture with ABT-199 at a 
concentration of 1.15µM and Ara-C (p=0.025), with a statistically significant increase in the 
number of dead cells normalised to the NDC (p=0.005). ABT-199 alone, at both 19.5nM and 
1.15mM, also caused a statistically significant increase in the number of dead cells when results 
were normalised to the NDC (p=0.043 and p=0.048 respectively). Whilst a reduction in live cells 
and increase in dead cells was demonstrated following culture with Ara-C alone, and in 
combination with ABT-199 at a concentration of 19.5nM, the results were not significant.  
In keeping with absolute cell numbers as defined by trypan blue dye exclusion apoptosis was 
evidenced by Annexin V / 7AAD staining and flow cytometry analysis; Figure 5.3.10.2. There was 
a statistically significant reduction in the proportion of live cells following culture with Ara-C in 
combination with ABT-199 at 19.5nM (p=0.020), with an accompanying increase in apoptosis 
(p=0.025). There was an increase in apoptosis relative to the NDC following culture with Ara-C 
(100nM) and ABT-199 (19.5nM) as single agents though this was not significant (p=0.054 and 
p=0.051 respectively). A statistically significant difference in the proportion of apoptotic cells 
Figure 5.3.10.1: Proliferation, as determined by the trypan blue dye exclusion, following culture 
of an unselected cohort of primary de novo AML MNCs (n=3) with ABT-199 (19.5nM and 1.15µM) 
and Ara-C (100nM) alone, and in combination for 72hrs.  
The primary samples AML 1002, AML 013 and AML 022 were recovered as described in Methods 
2.2.1.2.5. Recovered cells were seeded at a concentration of 1.5x105/ml then cultured for 72hrs with 
ABT-199 (19.5nM and 1.15µM), alone and in combination with Ara-C (100nM) as described in Methods 
2.2.1.2.6. Each bar represents the mean cell number x104/ml (alive and dead) as determined by trypan 
blue dye exclusion with error bars indicating the SD. All statistically significant results are highlighted 
with p value to the nearest 3 decimal places, those not highlighted are not significant (ns).  
ABT-199 alone (at both concentrations - 19.5nM and 1.15µM) caused an increase in the number of dead 
cells when results were normalised to the NDC (p=0.043 and p=0.048 respectively). There was no 
significant difference in the number of live cells. ABT-199 at a concentration of 1.15µM, in combination 
with Ara-C, caused a statistically significant reduction in live cells (p=0.025), with an increase in dead 
cells (p=0.005).   
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was not reached following culture with ABT-199 at a concentration of 1.15µM alone, and in 
combination with Ara-C 100nM; this was considered due to significant variance between samples.  
 
 
 
We also considered cell cycle kinetics assessed by PI staining and flow cytometry. ABT-199 at a 
concentration of 19.5nM and 1.15µM in combination with Ara-C led to a greater reduction in the 
proportion of quiescent ‘resting’ cells and increase in dying / dead cells compared to the effect 
seen following culture with Ara-C as a single agent. Statistical significance was reached following 
culture with ABT-199 (1.15µM) and Ara-C in combination with a reduction in the proportion of 
G0-G1 (p=0.025) and M (p=0.007) fractions and an increase in the Sub G0 fraction (p=0.021). 
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Figure 5.3.10.2: Apoptosis, as determined by Annexin V / 7AAD staining, following culture of an 
unselected cohort of primary de novo AML MNCs (n=3) with ABT-199 (19.5nM and 1.15µM) and Ara-
C (100nM) alone, and in combination for 72hrs.  
The primary samples AML 1002, AML 013 and AML 022 were recovered as described in Methods 
2.2.1.2.5.Recovered cells were seeded at a concentration of 1.5x105/ml, exposed to ABT-199 (19.5nM 
and 1.15µM), alone and in combination with Ara-C (100nM) and cultured for 72hrs, as described in 
Methods 2.2.1.2.6, prior to being stained with Annexin V / 7AAD and analysis by flow cytometry. The 
percentages shown indicate the proportion of total events gated as viable, apoptotic (early and late) 
and dead. Each bar represents the mean percentage from three independent experiments with error 
bars indicating SD. All statistically significant results are highlighted with p value to the nearest 3 
decimal places, those not highlighted are not significant (ns). 
A statistically significant reduction in live cells (p=0.02) with an increase in apoptosis was seen 
following culture with Ara-C in combination with ABT-199 at a concentration of 19.5nM (p=0.025). 
There was an increase in apoptosis relative to the NDC following culture with Ara-C (100nM) and 
ABT-199 (19.5nM) as single agents though this was not significant. Statistical significance was not 
reached following culture with ABT-199 (1.15µM alone and in combination with Ara-C 100nM) due to 
variance.  
*p=0.020 
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5.3.11 There was no evidence of synergism between glasdegib, at a     
 concentration of 2.67µM and ABT-199 at a concentration of 19.5nM 
Bcl-2 is a recognised downstream target of the Hh signalling pathway. We therefore sought to 
determine if the combination of a BH3 mimetic and Smo antagonist would be synergistic in a 
cohort of primary AML samples.  
Experimental design was as described in section 5.1.10. Four samples (AML 1002, AML 013, AML 
018 and AML 022) were cultured with ABT-199 (19.5nM), glasdegib (2.67µM) and the combination 
of ABT-199 (19.5nM) and glasdegib, (2.67µM) as described in Methods 2.2.1.2.6. We selected 
those samples used to analyse the effect of ABT-199 alone and in combination with Ara-C 
(section 5.3.10) to ensure selected samples were responsive to ABT-199. A response, whilst not 
significant had been shown with a concentration of 19.5nM. Considering our previous data 
(section 5.1) we hypothesised the addition of glasdegib would strengthen the response seen 
following culture with ABT-199 alone. A concentration of 2.67µM is representative of the 
recommended clinical dose 407. Cell counts and the assessment of cell viability was performed by 
trypan blue dye exclusion at 72hrs. All experiments were performed in technical duplicate, 
Figure 5.3.11.1. 
Figure 5.3.10.3: Culture of an unselected cohort of primary de novo AML cells with the 
combination of ABT-199 and Ara-C for 72hrs caused a statistically significant alteration in cell cycle 
kinetics (n=3).  
The primary samples AML 1002, AML 013 and AML 022 were recovered as described in Methods 
2.2.1.2.5. Recovered cells were seeded at a concentration of 1.5x105/ml, exposed to ABT-199 (19.5nM 
and 1.15µM), alone and in combination with Ara-C (100nM) and cultured for 72hrs as described in 
Methods 2.2.1.2.6. Cells were harvested and stained with PI prior to analysis by flow cytometry. The 
proportion of cells within each cell cycle phase (G0-G1, S, G2-M and Sub G0) as determined by PI, and 
analysis by flow cytometry is shown in this bar graph. Each bar represents the mean percentage from 
three independent experiments with error bars indicating SD.  
ABT-199 at both concentrations (19.5nM and 1.15µM) led to a greater reduction in the proportion of 
quiescent ‘resting’ cells and increase in dying / dead cells than Ara-C alone; the effect was more 
marked with the higher concentration of 1.15µM. Statistical significance was reached following culture 
with ABT-199 (1.15µM) and Ara-C with a reduction in the proportion of G0-G1 (p=0.025) and S (p=0.007) 
and increase in the Sub G0 fraction (p=0.021). 
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There was a reduction in the number of live cells following culture with ABT-199 though this was 
not significant (p=0.114); this was consistent with results obtained from this cohort in section 
5.1.10, validating our previous results. In this instance whilst an increase in cell death was 
demonstrated the results were not significant (p=0.064). The addition of glasdegib, at our 
selected concentration, did not lead to a further reduction in live cells or dead cells (p=0.122 
and p=0.074 respectively). We have previously shown the reduction in proliferation following 
culture with ABT-199 to be consequent to an increase in early and late apoptosis by Annexin V / 
7AAD, Figure 5.3.10.2. We therefore sought to determine if the addition of glasdegib to ABT-199 
affected the degree of cell apoptosis. As before apoptosis was assessed by Annexin V / 7AAD 
staining and flow cytometry analysis. Culture with ABT-199 alone and in combination with 
glasdegib led to a reduction in the proportion of live cells though the results were not 
significant, Figure 5.3.11.2. There was a statistically significant increase in the proportion of 
early apoptotic cells following culture with ABT-199 alone, with a statistically significant 
increase in the proportion of late apoptotic cells following culture with ABT-199 in combination 
with glasdegib. There was no difference in the proportion of dead cells across all experimental 
arms. We plan to repeat this to determine if the addition of glasdegib to ABT-199 causes an 
additive effect.  
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Figure 5.3.11.1: Proliferation, as determined by the trypan blue dye exclusion, following culture 
of an unselected cohort of primary, de novo AML MNCs (n=4) with ABT-199 (19.5nM) and glasdegib 
(2.67µM) alone, and in combination, for 72hrs.    
The primary samples AML 1002, AML 13, AML 018, and AML 022 were recovered as described in Methods 
2.2.1.2.5. Recovered cells were seeded at a concentration of 1.5x105/ml and cultured with glasdegib 
(2.67µM), ABT-199 (19.5nM) and the combination of glasdegib (2.67µM) and ABT-199 (19.5nM) for 72hrs 
as described in Methods 2.2.1.2.6. Each bar represents the mean cell number x104/ml (alive and dead) 
as determined by trypan blue dye exclusion with error bars indicating the SD. All experiments were 
performed in technical duplicate. 
There was a reduction in the number of live cells following culture with ABT-199 though this was not 
significant; the addition of glasdegib to ABT-199 did not enhance this effect. Glasdegib, as a single 
agent, did not affect cell proliferation within this cohort of primary de novo AML cells.  
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Glasdegib and ABT-199, as single agents, had not affected cell cycle kinetics in our unselected 
cohorts of primary AML samples. We had however shown glasdegib to affect cell cycle kinetics in 
select AML cell lines. We therefore sought to determine if the combination of these two small 
molecule inhibitors would affect cell cycle kinetics, assessed by PI staining and flow cytometry.  
Figure 5.3.11.2: Apoptosis, as determined by Annexin V / 7AAD staining, following culture of an 
unselected cohort of primary, de novo AML MNCs (n=4) with ABT-199 (19.5nM) and glasdegib 
(2.67µM) alone, and in combination, for 72hrs.    
The primary samples AML 1002, AML 13, AML 018, and AML 022 were recovered as described in Methods 
2.2.1.2.5. Recovered cells were seeded at a concentration of 1.5x105/ml and cultured with glasdegib 
(2.67µM), ABT-199 (19.5nM) and the combination of glasdegib (2.67µM) and ABT-199 (19.5nM) for 72hrs 
as described in Methods 2.2.1.2.6. Apoptosis was assessed by Annexin V / 7AAD staining and analysis by 
flow cytometry. The proportion of viable, apoptotic (early and late) and dead cells are shown. Each bar 
represents the mean total number of events with error bars indicating SD. 
ABT-199, alone and in combination with glasdegib, resulted in an increase in apoptosis, with a 
reduction in the percentage of live cells though the results were not significant. The addition of 
glasdegib did not enhance the affect of ABT-199 alone. Glasdegib alone did not affect cell viability as 
measured by Annexin V / 7AAD.  
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Glasdegib reduced the proportion of cells in the G0-G1 fraction with a consequent increase in 
the sub G0 fraction though the results were not significant. Interestingly this increase in the Sub 
G0 fraction, primarily consisting of dead and dying cells and consequent cell debris, was not 
evident by Annexin V / 7AAD though a non-significant increase in dead cells by trypan blue dye 
exclusion was seen (p=0.074). Consistent with previous results ABT-199 did not affect cell cycle 
kinetics. Interestingly the addition of ABT-199 to glasdegib was shown to reduce the effect of 
glasdegib alone on cell cycle kinetics. In the future, once our CFC and re-plate protocol has been 
optimised, it would be interesting to study the effect of these two small molecule inhibitors on 
colony-forming ability and subsequently their self-renewal capacity. Would an additive effect be 
demonstrated in long-term assays? 
 
 
5.3.12 Discussion 
BCL-2 is strongly associated with a wide range of malignancies; elevated expression thought to 
occur in approximately half of all malignancies 504–508. Whilst its association with AML has long 
been recognised, BCL-2 is an independent prognostic factor and predictor of remission 517. More 
recently, quiescent CD34+CD33-CD13- AML cells, in contrast to their normal counterparts, have 
been shown to highly express BCL-2 519,520. The increased functional reliance of leukaemic cells 
upon BCL-2, especially primitive cells, thought to be responsible for MRD, in comparison to 
normal haematopoietic cells makes it an exciting therapeutic target, and an area of intense 
research.  
Figure 5.3.11.3: Cell cycle kinetics, as determined by the PI assay, following culture of an 
unselected cohort of primary, de novo AML MNCs (n=4) with ABT-199 (19.5nM) and glasdegib 
(2.67µM) alone, and in combination, for 72hrs. 
The primary samples AML 1002, AML 013, AML 018, and AML 022 were recovered as described in Methods 
2.2.1.2.5. Recovered cells were seeded at a concentration of 1.5x105/ml and cultured with glasdegib 
(2.67µM), ABT-199 (19.5nM) and the combination of glasdegib (2.67µM) and ABT-199 (19.5nM) for 72hrs 
as described in Methods 2.2.1.2.6. Cells were subsequently harvested and stained with PI prior to 
analysis by flow cytometry. The proportion of cells within each cell cycle phase (G0-G1, S, G2-M and 
Sub G0) as determined by PI, and analysis by flow cytometry is shown in this bar graph. Each bar 
represents the mean percentage from four independent experiments with error bars indicating SD. 
Glasdegib led to a reduction in the percentage of ‘resting’ cell (G0-G1 fraction) with a consequent 
increase in dying cells (the sub G0 fraction) as determined by PI staining (p=ns). ABT-199 did not affect 
cell cycle kinetics within this cohort of primary AML samples. The combination of glasdegib and ABT-199 
did not enhance this effect.  
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In accordance with published data, we have shown BCL-2 and MCL-1 to be up-regulated in select, 
genetically diverse AML cell lines. Interestingly, there was >100-fold difference between the 
highest and lowest expressers, suggesting a variable dependence on BCL-2. Further, the pro-
apoptotic regulator BAX was also shown to be up-uegulated, indicating cell survival and 
maintenance results from a careful balance between the pro- and anti-apoptotic family 
members. Considering the variance in expression across each Bcl-2 family member it would be 
interesting to assess this expression alongside other important regulators of cell death such as 
p53, located upstream of BCL-2 697. Further, it is important to recognise these cell lines have 
been immortalised, with gene expression performed following culture of each cell line in optimal 
conditions. Had time allowed the impact of cellular stress and, in contrast, culture in the 
presence of supporting stromal cells would have been an interesting concept to explore further. 	
The heterogeneous response both between, and within, our selected cell lines following culture 
with each of the three Bcl-2 inhibitors is particularly interesting. Importantly, whilst these small 
molecule inhibitors are referred to as ‘Bcl-2 inhibitors’ they function by targeting the BH3-
binding domain, blocking BH3-domain-mediated heterodimerisation, inducing apoptosis. It is the 
BH3 domain that is vital in the promotion of cell apoptosis 698. ABT-199 was developed through 
reverse engineering of ABT-263; whilst ABT-199 retains the high-affinity interactions with two 
hydrophobic pockets within the BH3 domain it has been modified electrostatically to specifically 
interact with Arg103 (specific to BCL-2). All three of our selected inhibitors bind the BH3 domain 
of BCL-2, though with different potency: ABT-199 >> TW-37 > HA14-1 559,681,699,700. In addition, 
TW-37 binds MCL-1 and to a lesser degree BCL-xL. Whilst our IC50 data for the MOLM-13 and MV4-
11 cell lines correlates with the inhibitory effect of each of the drugs on BCL-2, the response of 
the genetically diverse OCI-AML3 and THP-1 cell lines to ABT-199 and TW-37 suggests that, whilst 
less potent, the dual inhibitory action of TW-37, targeting both BCL-2 and MCL-1, may be more 
effective in some instances. The inhibitory effect of TW-37 must not be considered in isolation 
however, with consideration given to the knowledge that it binds Bcl-xL. Progression of ABT-737, 
a first generation BH3-mimetic, was prevented due to dose limiting toxicity - thrombocytopenia, 
seen as a consequence of its binding to Bcl-xL 232.  
We showed expression of total BCL-2 protein to contrast with that of BCL-2, discussing potential 
explanations within the text. Perhaps, more interesting, is how this contrasts with the universal 
expression of BCL-2 in primary human AML samples, and marked up-regulation relative to our 
normal controls, as assesed by IHC on FFPE BMTs (section 3.1.8). It would be interesting to 
measure BCL-2 in primary human samples by western blotting and further, to correlate these 
results with gene expression to ascertain if the degree of discordancy seen in cell lines is 
mirrored by primary cells. It is important to consider this potential discrepancy when analysing 
cell line data and further, when translating in vitro cell line work – if ABT-199 sensitivity is 
determined by BCL-2 levels, primary AML cells may therefore be far more sensitive than cell line 
data might suggest.  
It is interesting to consider the inhibitory effect of the BCL-2 inhibitors, in particular ABT-199, in 
parallel to the levels of expression of BCL-2 in our cell lines. Previous in vitro studies in diffuse 
large B cell lymphoma (DLBCL) had shown a positive correlation between BCL-2 levels and 
sensitivity to ABT-199 701. BCL-2 is also highly expressed in follicular lymphoma (FL); in vitro 
studies showing FL cell lines and primary cells to be highly sensitive to ABT-199 though, in 
contrast to results seen with DLBCL, no correlation with BCL-2 expression was seen, rather ABT-
199 sensitivity was dependent upon expression of BIM 702. In select AML cell lines, a positive 
correlation between BCL-2 and sensitivity to ABT-199 has been reported 682; this same study 
showed levels of BCL-xL to inversely correlate with ABT-199 sensitivity and a non-significant 
trend to anti-correlation with MCL-1 682. We hypothesised BCL-2 expression would positively 
correlate with the degree of cell death. We showed the OCI-AML3 cell to be relatively resistant 
to ABT-199 and the MOLM-13 to be highly sensitive to ABT-199-mediated cell death. However 
BCL-2, as assessed by Western blot, suggested a potential threshold of effect, with those cell 
lines showing higher levels being relatively resistant to the effects of ABT-199, conflicting with 
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published data 682. In this respect, the Bcl-2 family regulates cell survival, and apoptosis; a 
carefully controlled balance between the pro- and anti-apoptotic family members determining 
cell fate, rather than simply Bcl-2. Further, analysis of an ABT-199-resistant FL cell line found 
increased levels of MCL-1 and phosphorylation of BCL-2 to contribute to the resistant phenotype 
702. To further consider these discrepant results it would be important to assess expression of 
other Bcl-2 family members - MCL-1, BCL-xL and pBCL-2 (phosphorylation of Bcl-2 at serine 70 
required for full and potent supprression of apoptosis 688,689,703), to analyse expression ratios, and 
to correlate this with the levels of BCL-2 and inhibitory effect. This work would link with that to 
determine the mechanism underlying the heterogeneous response within select cell lines 
following culture with ABT-199 and TW-37. 
The Bcl-2 family regulates all major types of cell death 468, Figure 1.12, though their core 
function is the regulation of MOMP, in turn regulating the release of proteolytic proteins 486. We 
confirmed ABT-199 induced cell death through the mitochondria in the sensitive MOLM-13 cell 
line and not in the resistant OCI-AML3 cell line. Further ABT-199 was seen to target the G0-G1 
fraction. It would be interesting to utilise agents such as Hoechst-33343low/Pyronin-Ylow to 
separate the G0 and G1 stages to ascertain whether ABT-199 is capable of targeting this 
population; of particular importance considering LSCs are considered predominantly quiescent.  
During the write up of this thesis, updated results from a phase I/II study analysing ABT-199 
(venetoclax) with LDAC in those ineligible to receive intensive therapy were presented at EHA 
2017 704. Subsequently, in July 2017 the FDA granted venetoclax breakthrough therapy 
designation for use in combination with LDAC in treatment-naïve elderly patients with AML who 
are ineligible for intensive chemotherapy. With an ORR of 61% (37/61 subjects) and a CR rate of 
21% it will be interesting to see if a genetic subtype or molecular profile can indicate treatment 
response. In vivo, will a positive correlation between BCL-2 and clinical response be seen? Or, is 
the association of BCL-2 with AML indicative of deregulated apoptosis (a causative mutation not 
currently recognised) - targeting the process at any level, thereby disrupting the balance 
towards apoptosis rather than cell survival?  It will be interesting to see if these questions are 
addressed when clinical trial data is published.  
In conclusion, whilst there is a clear rationale for the use of Bcl-2 inhibitors in cancer 
therapeutics, it is important to consider Bcl-2 is not unique to cancerous cells, indeed the 
apoptotic process is vital in maintaining normal tissue homeostasis. Further, whilst in theory 
ABT-199 should be highly active in FL, responses have been disappointing; a xenograft model 
showing acquired resistance developed easily 702. Considering the mechanism driving increased 
BCL-2 in AML remains to be determined, it will be interesting to see responses out with the 
clinical trial setting, and longer follow up data from those trials already presented / published. 
Additionally the relative resistance of OCI-AML3 cells to ABT-199 requires further investigation, 
results of a phase II trial studying ABT-199 as a single agent in patients with AML unsuitable for 
intensive therapy or with R/R disease showed superior responses in those with mutations in 
genes regulating methylation 524. The combination of decitabine and vorinostat, epigenetic 
agents, has been shown to overcome ABT-199 resistance in FL cell in vitro 702 and a phase I study 
of venetoclax with azacitidine or decitabine presented at ASCO in 2016 showed a response in 76% 
(26/34 subjects) 523. Finally, whether Bcl-2 inhibitors will find a role in combination with 
intensive treatment remains to be determined - will concerns over the risk of unacceptable 
toxicity affecting regenerating normal tissues prove to be well founded 705?  
The ABC transporters similarly play an important role in normal physiology, responsible for the 
transport, or efflux, of a huge variety of compounds, across plasma and intracellular membranes. 
Drug resistance is one of the primary causes of treatment failure and disease relapse 215,532 with 
the ABC transporters representing a major mechanism of chemoresistance; increased expression 
of thirteen of the ABC transporters linked to chemoresistance 218,526,534.  
Chemoresistance is well recognised in AML; members of ABC family confer an independent 
adverse prognostic factor, are up-regulated in poor prognostic WHO subtypes 540,544 and efflux 
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anthracyclines 218. Despite these findings the role of the ABC transporters in AML remains 
contentious with debate surrounding expression patterns in normal and leukaemic CD34+CD38- 
haematopoietic cells 539,540,545. We confirmed expression of five members of the ABC transporter 
family, each associated with chemoresistance, with select genetically diverse AML cell lines. 
Marked variation in expression, both within and across each ABC transporter, was shown. It 
would be interesting to evaluate expression following culture with cytotoxic agents such as Ara-C 
and following co-culture with supportive stromal cells. Further, to analyse expression of the ABC 
transporters in sorted cell populations, both normal and malignant – whilst minimal short-term 
effect is seen do these agents allow us to obtain superior drug concentrations within the CSC? 
Will long-term data find a reduction in disease relapse?  
Within the clinic the first three generations of ABC inhibitors including cyclosporin, elacridar, 
verapamil and zosuquidar, have shown limited or no benefit, high doses being required to 
achieve effect with significant adverse effects and unwanted drug-drug interactions reported. 
Many of the toxicity issues are considered to arise due to abundant expression of the ABC 
transporters by normal tissues, in particular within the liver, kidney and brain, leading to the 
adverse accumulation of cytotoxic agents within these organs. The limited success has, in part, 
been considered to result from the broad, and overlapping, specificity of ABC transporters 
expressed by tumours. Our data is consistent, showing no additional benefit when select ABC 
transporter inhibitors were combined with Ara-C in genetically diverse AML cell lines. Expression 
did not correlate with response. Considering the importance of concentration ratios for many 
chemotherapeutic agents, in particular the ratio of cytarabine to daunorubicin in the intensive 
management of AML, it would be interesting to study the effect of the ABC transport inhibitors in 
combination with both agents. Further, given the difficulties translating in vitro data into the 
clinic it would be interesting to perform the assays in, perhaps more reliable, preclinical assays 
such as those utilizing supportive stromal cells; with positive results needing to be tested within 
an in vivo model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 267	
6 Final conclusions and future directions  
AML originates from a CSC, the term encompassing a group of aggressive haematological 
neoplasms. AML is a clinically, morphologically and genetically heterogeneous disease 1,150,154,162. 
It is this complexity which, whilst ensuring AML is a fascinating disease to study, means despite 
huge advances in our knowledge and understanding, obtained through extensive research and 
international trials, with molecularly and immunologically targeted therapies now available 706, 
clinicians still face the challenge of curing only the minority 707. Indeed our understanding of the 
molecular biology of AML has far-outpaced the development of new and effective therapeutics 
though with the FDA approving five new agents in 2017 this may, excitingly, be about to change. 
Advances in both technology and our understanding are however not only shaping the future for 
AML but far wider, forging the way for cancer research.  
The hedgehog signalling pathway is highly complex, and is intricately involved in developmental 
processes. Aberrant activity has been demonstrated in a variety of malignancies 259,262,367,368, 
linked to tumour growth, progression and drug resistance; in myeloid malignancies it has been 
shown to be vital in the maintenance and expansion of the CSC 252,344,375–377. Components of the 
pathway, Smo and Gli, considered as promising targets for cancer therapeutics - sonidegib and 
vismodegib (Smo inhibitors) both receiving FDA approval for the treatment of advanced or 
metastatic BCC 708 709. To date however, out with BCC, these small molecule inhibitors have 
shown limited efficacy though results of a Phase I study combining sonidegib with conventional 
chemotherapy (etoposide and cisplatin) in patients with extensive small cell lung cancer has 
shown promising results 710. To translate knowledge of the Hh signalling pathway into AML and, 
further, to determine whether it represents a clinically effective therapeutic target careful 
consideration must first be given to the clinical trial setting. 
The UK national trial, NCRI AML 19 711, highlights how our advancing knowledge and technology is 
being translated into clinical practice. Building upon data from previous trials 712,713 it aims to: 
(1) refine the current standard of care, and improve outcome whilst reducing treatment-related 
morbidity and mortality; (2) risk stratify according to the calculated risk index 204, adjusting 
treatment accordingly; (3) determine the relevance of MRD, detected molecularly and 
immunophenotypically; and (4) identify potential molecular markers, correlating these with 
clinical outcome.  
To risk stratify is to seek to tailor management to both the disease, by considering response to 
first cycle of chemotherapy and cytogenetics, and the patient, by considering patient-specific 
factors such as age, presenting white cell count and performance status. This approach 
recognises the marked inter- and intra-patient heterogeneity, importantly classifing many more 
patients as poor risk than the MRC classification 158 with significant implications to the patient’s 
prognosis and potential treatment journey. In essence, on a national scale, it seeks to 
‘personalise’ medicine.  
Whilst the NCRI AML trials have sought, and continue to seek, to improve outcomes by risk 
stratifying those younger, fitter patients, new, novel agents have been notably lacking from 
these and other intensive trials. Investigators seeking to incorporate newer agents into current 
standard-of-care regimens are faced with many challenges: the comparatively low incidence of 
AML, its intrinsic heterogeneity and, often, its aggressiveness, dictating a clinical urgency for 
treatment initiation and not infrequently patients dying before a measurable benefit can be 
determined. Intense effort does however continue. There are currently 271 open phase I-III trials 
listed by the EU Clinical Trials register 223 with an exciting armourary of new, and in some cases, 
novel agents being utilised. Five drugs were approved by the FDA in 2017 – venetoclax 704, 
enasidenib 714, CPX-351 715, midostaurin 716 and gemtuzumab ozogamacin 709. Indeed, whilst the 
newest agent included in the NCRI AML 17 trial was Gemtuzumab ozogamacin, first used in the 
treatment of AML in 2000 717 the current NCRI AML 19 trial incorporates CPX-351. CPX-351 a 
liposomal formulation of Ara-C and daunorubicin, delivers these drugs in a 5:1 molar ratio direct 
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to the cell, optimising synergy and minimising drug antagonism 718. A phase III study comparing 
CPX-351 to DA in newly diagnosed t-AML and AML-MRC recently published an improvement in OS 
to 9.56 months with CPX-351 versus 5.95 months with DA 715.  
Further, a new model, “pick-a-winner”, has recently been brought into trial design, enabling a 
larger number of agents to be investigated within a given period 719,720; this template is used in 
the current NCRI Low Intensity (LI)-1 trial. This trial is important to consider for another reason 
pertinent to the field of AML clinical research and targeted therapies. It has moved away from 
the single agent approach, instead combining novel therapies with current standard-of-care in a 
bid to improve patient outcome. The rationale for combinational therapies is substantial 707,721, 
the complex and progressive genetic landscape of AML enabling the disease to bypass molecular 
targets and become resistant to single-agent therapy 722.  
Another challenge for investigators is eligibility criteria or patient selection. By focusing on those 
unable to tolerate intensive treatment as in the NCRI LI-1 trial or those with R/R disease, there 
is the potential to lose or negate any beneficial effect that might be seen in a broader patient 
cohort. AML of the elderly, in many respects considered a distinct entity 723, whilst R/R disease 
has demonstrated a more resistant phenotype 724 by virtue of the clinical history, and further 
been exposed to the selective pressure of treatment. This patient cohort should however not be 
ignored.  
Although it is an exciting time for translational medicine the attrition of experimental therapies, 
and the associated time and resources, raises concerns over current experimental, preclinical, 
models. Whilst the limitations of immortalised cell lines and in vitro liquid culture are well 
recognised, increasingly the limitations of primary, patient-derived leukaemia cells are becoming 
apparent. Most notable is the concern of subpopulation or ‘clonal’ selection, deriving a 
population of cells not wholly representative of AML, defined by its genomic complexity and the 
presence often of multiple coexisting molecularly defined clones 151. Another concern regarding 
in vitro models is the absence of a supporting microenvironment. Whilst assays utilising 
supporting stroma cells and xenotransplantation models may provide more reliable results, the 
limitations must be recognised and considered when interpreting results. Our unique observation 
that haematopoietic cells possess primary cilia within the BM microenvironment yet loose / 
disassemble or ‘switch off’ these organelles once they leave the BM environment beautifully 
illustrating this point.  
Technology has allowed us to begin to unravel and appreciate the genetic complexity of AML. 
AML does not derive from a single “driver” mutation as seen in CML, transformed from a ‘fatal 
cancer to a manageble chronic disease’ by the small molecule inhibitor imatinib. Rather AML has 
been shown to develop after normal HSPCs acquire a relatively small number of “driver” 
mutations, additional mutations stochastically acquired. In this respect it will be interesting to 
see how next-generation sequencing is incorporated into clinical practice, will it enable 
selection of small molecule inhibitors or further enable targeted combinational therapies, 
‘precision medicine’? Mutational profile and burden, however, is clearly not the sole factor in 
determining AML cell behaviour; on average five pathogenic mutations and an additional eight 
mutations are identified in de novo AML at diagnosis 721, far fewer than seen in solid tumours 725. 
A significant proportion of AML appear cytogenetically and genetically normal, yet gene 
expression signatures tell a different story 721. The Cancer Genome Atlas described 16 distinct 
subgroups of AML. These subgroups were classified according to unsupervised analyses using 
Pearson's correlation coefficient, 2856 probe sets (2008 annotated genes and 146 short 
sequences of unknown genes) utilised to define the gene-expression profiles 381. Subsequent to 
this the NEJM published a study in 2016 analysing gene expression patterns and relationships, 
correlating these genotypes with clinical data 726. ‘5234 driver mutations involving 76 genes, or 
regions, in 1540 patients were identified’ with 96% of patients shown to harbor at least one 
driver mutation 726. Utilising a Bayesian statistical model patients were classified according to 
their compound genotype, with 11 non-overlapping subgroups defined; three genomic categories 
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emerging beyond the existing WHO classification: chromatin–spliceosome, TP53–aneuploidy, and 
provisionally, IDH2R172 mutations 726. It will be interesting to see how these studies are 
incorporated into clinical practice; a sub study within the NCRI AML 17 trial highlighting how 
molecular results can drastically alter a patient’s prognosis and thus the treatment offered and 
further, can be performed and available within an acceptable time frame to be useful clinically. 
This sub study focused on NPM1 mutated AML, demonstrating that sequential assessment of this 
molecular marker provided treatment defining prognostic information. Ongoing positivity after 
cycle two predicting disease relapse, with a superior efficacy to that seen using current 
diagnostic molecular markers, influencing decisions regards treatment escalation to SC 
transplantation 727. Nor does AML consistently express an immunological target as seen in B-cell 
lymphomas, the anti-CD20 monoclonal antibody rituximab radically improving prognosis for the 
majority of these patients. There is however intense efforts to further define the LSC, to 
differentiate it from its counterpart the HSC, with whom it shares the CD34+CD38− 
immunophenotype 112,121. To date work has shown preferential expression of a number of cell 
surface proteins including CD25, CD32, CD41, CD44, CD47, CD93, CD96, CD123, CLL-1 and TIM-3 
in LSCs relative to HSCs 133,600,728–733; these markers defining subpopulations and potentially 
involved in the evolution of mutated ‘pre-leukaemic’ HSCs to LSCs 734. Excitingly, CD44, CD47 
and CD123 have been shown to be therapeutically targetable in in vitro and murine studies 
600,731,735 and whilst the results of a phase I study in R/R AML using an anti-CD44 monoclonal 
antibody (NCT01641250) showed limited efficacy 736 evaluation of a CD123 x CD3 Dual Affinity 
Re-Targeting (DART®) Bi-Specific Antibody (NCT02152956) and the anti-CD47 monoclonal 
antibody Hu5F9-G4 (NCT02678338) in R/R AML and high risk MDS are ongoing, with the results 
eagerly awaited.  
Single cell assays are rapidly developing, enabling ‘genome-scale’ molecular information to be 
studied at the individual cell level. Whilst significant challenges remain in the analysis, 
integration, and interpretation of single cell omic data the results are eagerly awaited. Will this 
technology enable us to begin to understand the genetic changes allowing the development of 
different dominant clones?  
There is considerable evidence to support the role of the Hh signalling pathway in AML 381. Data 
showing it to be active 69, associated with an inferior OS and poor prognostic markers 379–382 and 
to confer drug resistance 378,379. Whilst its role in normal haematopoiesis remains controversial 
253,362–364 importantly genetic inhibition of canonical signalling through a SMO knockout did not 
adversely affect normal haematopoiesis 363,366 affording Smo inhibition a therapeutic window. In 
2016, serial transplantation studies using the NOD/SCID/IL2rγnull mouse model showed the Smo 
inhibitor PF-04449913 to reduce the leukaemic potential of AML cells 618. Interestingly, whilst in 
vitro work using the Marimo cell line demonstrated minimal cell death the quiescent population 
was reduced. Further, PF-04449913 sensitised primary AML cells and two genetically distinct AML 
cell lines cells (Marimo and MOLM-14) to Ara-C. This demonstration of a synergistic action is 
particularly exciting; knowledge of the complex interplay between the intrinsic and extrinsic 
signals governing CSC behaviour and the genomic complexity and clonal heterogeneity seemingly 
suggesting combinational therapies will be required to translate these insights into clinically 
effective interventions. Whilst a number of questions still remain unanswered, Pfizer recently 
reported promising results from its phase I/II trial studying the effect of glasdegib with LDAC in 
those ineligible to receive intensive therapy presented at ASH 2016 654.  
Whether the new generation of molecularly and immunologically targeted therapies prove 
sufficiently beneficial, and tolerated, to be brought into mainstream treatment algorithms 
remains to be seen. Whether agents thought to offer little benefit were not fully explored 
clinically, due to the heterogeneity of AML, is an important question to raise, as is the concern 
that if we select certain subtypes do we risk missing a beneficial unexpected effect in other 
patients? With our increasing knowledge, will we see a return of some of these once shelved 
agents to the treatment of specific subtypes or categories of AML, such as arsenic trioxide in the 
management of APML, or the incorporation of non-chemotherapeutic agents such as antibiotics 
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alongside existing cytotoxic therapies? 
In addition to future work discussed through the text in this section I wish to present some 
interesting preliminary results. We had considered work by the Copland group showing MSC co-
culture to protect CD34+ CML cells against imatinib-induced apoptosis (unpublished) with recent 
studies indicating the importance of this microenvironment in AML 254. Recognising the 
limitations of liquid culture, we therefore considered whether the effect of Smo inhibition would 
be abrogated when cells were co-cultured. In this respect we first considered a number of 
stromal cell lines. We found HS-5, M210-B4 and SL-SL cell lines to express all components of the 
Hh signalling pathway at a gene and protein level, and to possess primary cilia. The M210-B4 and 
SL-SL cell lines, both murine BM-derived stromal cell lines, were selected as they are frequently 
used in LTC-ICs whilst the HS-5 stromal cells are human-derived used, as described in Methods 
2.2.1.2.5, by our group to support primary AML cells post thawing. Having demonstrated the Hh 
pathway to be present in stromal cells we sought to evaluate the effect of pharmacological Smo 
inhibition using cyclopamine with fascinating results. The stromal cell lines were >100-fold more 
sensitive to cyclopamine than our selected AML cell lines when cyclopamine was added during 
cell passage with all cells dead at 24hrs following culture with concentrations as low as 500nM. 
In contrast all stromal cell lines were able to tolerate cyclopamine, up to a concentration of 
20µM, with no evidence of cell death by trypan blue dye exclusion, once >75% confluent. This 
preliminary data clearly shows the Hh pathway to be present, and functionally active, in our 
selected stromal cell lines and to be fundamentally dependent upon cellular dynamics. In future 
work we plan to build upon these observations and to determine whether stroma induced Hh 
signalling plays a role in supporting AML cell lines and primary AML cells in short and long-term 
culture. Additionally, as previously discussed, whilst cell lines serve as useful experimental 
models they may not always accurately represent primary cells 627. We therefore sought to 
further develop the existing primary MSC bank within the Copland laboratory. MSCs were derived 
by the plastic adherence method as discussed in methods 2.2.1.2.7. MSCs were derived from the 
BM of 9 primary de novo AML samples, 4 CP-CML samples, 5 BC-CML samples and 3 normal 
samples. A cell bank with cells cryopreserved from passage 2 through 6 for each sample with 
paired RNA, protein and CM is now available for further evaluation. CML MSCs were generated for 
a colleague, Dr G A Horne. In the future it would be interesting to determine the: 
(1) Expression of the Hh pathway at a gene and protein level in all MSCs both normal and 
AML 
(2) Presence or absence of the Hh ligands in CM, and if present to determine the 
concentration secreted by AML in comparison to normal MSCs 
(3) Effect of cyclopamine on MSCs both normal and AML 
(4) Effect of cyclopamine on primary human AML cells co-cultured with primary MSCs  
We had hypothesised co-culture would abrogate the effect of Smo inhibition, implying either a 
regulatory role of the microenvironment or a different mode of pathway activity in the presence 
of stromal cells. A result that would mirror previously published work in mature B cell 
malignancies	363. Further, it would lend a potential explanation to the conflicting results seen 
when using Smo antagonists in vitro and in vivo 618. Interestingly, and in keeping with our 
hypothesis, during the write up of this PhD glasdegib was reported to nullify resistance to Ara-C 
in AML cell lines co-cultured with HS-5 stromal cells, sensitising these cells to Ara-C induced 
apoptosis 618. 
 
All forms of cancer arise from abnormal growth, when the balance between cell death and 
survival is disturbed. In AML both increased proliferation and decreased cell death are well 
recognised. Whilst standard treatment results in remission rates of 60-80% in younger patients, 
only 30-40% survive 5 years 205. Disease relapse and progression is largely attributed to the LSCs, 
extensive work showing these cells to be innately less sensitive to treatment 23,126. We have 
considered the Hh signalling pathway, one of the self-renewal pathways, seeking to further 
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understand its role in the pathogenesis of AML. Fascinatingly we have shown inhibition of Smo in 
vitro to seemingly shift the balance between cellular self-renewal and differentiation properties. 
Further, we have sought to understand the relationship between pro- and anti-apoptosis, in a 
situation in which the balance clearly favours cell survival, seeking to determine if components 
of the apoptotic pathway can be targeted to shift the balance to favour apoptosis.  
Whilst the role of small molecule inhibitors in such a heterogeneous and aggressive disease as 
AML remains to be determined, personally I consider myself fortunate to be involved in the care 
of these patients during this new and immensely exciting era.  
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Appendix 1 
UPN Sex Age WHO 
Subtype 
Mutn 
 
Gene  
 
IHC  
 SMO Seq 
NGS 
 
ICC  
1A F 57 AML NOS FLT3-ITD Y Y Y Y Y 
1B 
F 
43 AML NOS 
FLT3-ITD, 
NPM1 Y Y Y Y 
Y 
1E M 75 AML NOS N/A Y Y Failed Failed Y 
1F 
F 
60 AML NOS 
FLT3-ITD, 
NPM1 Y Y Y Y 
Y 
1G M 72 AML NOS NONE Y Y   Y 
1H F 26 AML NOS N/A Y Y Y  Y 
1K F 81 AML NOS NONE Y Y Y Y Y 
1L F 84 AML NOS N/A Y Y Y Y Y 
1N M 87 AML NOS NONE Y Y Y Y Y 
31 M 34 AML NOS BCR-ABL Y Y Y Y Y 
32 
F 
49 AML NOS 
FLT3-ITD, 
NPM1 Y Y Y Y 
Y 
33 
M 
80 AML NOS 
NPM1, 
CEBPα Y Y   
Y 
6 F 63 AML NOS NONE Y Y Y   
7 M 43 AML NOS FLT3-D835 Y Y Y Y  
8 M 51 AML NOS NONE Y Y Y  Y 
15 M 71 AML NOS NPM1 Y Y Y   
16 M 57 AML NOS FLT3-ITD Y Y Y Y  
18 F 46 AML NOS FLT3-D835 Y Y Y Y  
1J F 60 AML - MDS  NONE Y Y Y Y Y 
1 F 72 AML - MDS  NONE Y Y Y Y Y 
4 M 65 AML - MDS NONE Y Y  Y  
5 F 73 AML - MDS  FLT3-ITD Y Y Failed Failed  
19 F 72 t-AML NONE Y Y Y Y Y 
20 F 86 t-AML N/A Y Y Y Y  
22 F 75 t-AML NONE Y Y Y   
23 M 79 t-AML N/A Y Y Y Y  
1M M 73 AML - R PML-RARA Y Y   Y 
27 M 72 AML - R PML-RARA Y Y Y Y  
28 M 76 AML - R PML-RARA Y Y Y Y  
29 F 63 AML - R PML-RARA Y  Y Y  
34 F 42 AML - R inv16 Y Y Y Y  
1D 
M 
57 AML - R 
MLLT3-
KMT2A Y 
Y 
Y  Y 
Y 
1C F 37 AML MLL N/A Y  Y Y Y 
1E F 30 AML MLL N/A Y Y   Y 
36 F 60 AML – R PML-RARA Y  Y Y  
10 F  AML NOS N/A Y  Y    
12 M 67 AML NOS N/A Y  Y   
 
25 
M 
52 AML – R 
BCR-ABL, 
RUNX1/RU
NXT1 Y 
 
Y   
 
1M F 65 N/A N/A Y Y   Y 
14 M 84 AML NOS N/A Y  Y Y Y 
30 M 65 AML NOS N/A Y Y Y Y Y 
34 
F 
57 AML – R 
RUNX1/RU
NXT1 Y 
Y 
Y Y 
Y 
36 M 43 AML NOS N/A Y   Y  Y  Y  
1P 
F 
75 AML – R 
CBFB-
MYH11 Y  
 Y   
AML36 
M 
78 
AML – R RUNX1/RU
NXT1 Y 
  Y  
AML51 M 59 AML NOS N/A    Y  
AML40 F 66 AML NOS N/A Y   Y  
AML53 N/A N/A AML NOS N/A    Y  
AML47 M 58 N/A N/A    Y  
AML35 M 44 N/A N/A Y   Y  
AML12 F 66 AML - MDS  N/A Y   Y  
AML009 N/A N/A N/A N/A Y     
AML31 F 57 t-AML N/A Y     
AML18 N/A N/A AML NOS N/A Y   Y  
AML005 N/A N/A AML NOS N/A Y     
AML43 M 67 AML NOS N/A Y     
AMLAMcG N/A N/A N/A N/A Y   Y  
AML27 N/A N/A AML NOS N/A Y     
AMLAG50 N/A N/A N/A N/A Y   Y  
AML22 N/A N/A N/A N/A Y     
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AML1002 N/A N/A AML NOS N/A Y     
AML008 N/A N/A AML NOS N/A Y     
AML011 N/A N/A N/A N/A Y   Y  
AML013 N/A N/A AML NOS FLT3-ITD Y   Y  
AML014  N/A N/A AML NOS N/A Y     
AML015 N/A N/A AML NOS N/A Y     
AML016 N/A N/A N/A N/A Y   Y  
AML017 N/A N/A N/A N/A Y   Y  
AML019 F 47 AML – R PML-RARA Y     
AML020ER N/A N/A N/A N/A Y     
AML021 N/A N/A AML NOS N/A Y   Y  
AML020W
M 
N/A N/A AML NOS N/A Y     
AML023 N/A N/A AML - MDS  N/A Y   Y  
AML024 N/A N/A N/A N/A Y   Y  
AML025 N/A N/A AML - MDS  N/A Y   Y  
AML027DA N/A N/A N/A N/A      
AML028RR N/A N/A N/A N/A      
AML029LB F 52 AML NOS N/A      
AML030 
F 35 AML – R RUNX1/RU
NX1T1 
Y   Y  
AML032 N/A N/A AML NOS N/A Y     
AML034 N/A N/A N/A N/A Y   Y  
AML037 N/A N/A N/A N/A      
AML044JR N/A N/A AML NOS N/A Y     
AML045JS F 82 AML NOS N/A      
 
UPN 
Treatment 
Cytogenetics- 
diagnosis 
Cytogenetics - 
relapse 
1A 
AML 17 – DA (90) cytarabine - remission after #1. Died 
28/05/14 multi organ failure - liver/neuro/resp/sepsis 
46,XX,add(11)(?p15)[
3]/46,XX[17] 
N/A 
1B 
AML 17 - DA (90) cytarabine - remission after #1. CEP 701 
randomisation. VUD allogeneic PBSCT 08/12. Chronic GVHD 
- extracorporeal photophoresis. In remission. 46,XX 
N/A 
1E 
2003- prostate Ca - treated with radiotherapy, then 
zoladex - bony mets 2011. DA - suboptimal response, 
switched to low dose cytarabine (20mg BD) - completed 6 
cycles - dx grew threw - palliative. Died 05/2012.  
46,XY,del(8)(p?21),a
dd(21)(q22)[12]/46,
XY[3] 
N/A 
1F 
AML 17 - high-risk arm (ADE) - RIC allogeneic PBSCT 
27/1/11 relapsed D100 (20/5/2011). Died 05/2011. 46,XX 
46,XX,?der(4)?t(4;15)(
?p16;?q21),del(9)?(?q1
3)[3]/46,XX[17] 
1G AML 16 trial - DA + Gemtuzomab - CR after #1. Died. 
48~50,XY,+6,del(11)(
q23),add(16)(?p),+2~
3mar[cp7] 
N/A 
1H AML 17 - ADE + Myelotarg 6 - CR #1. Remission 3 years out. 
47,XX,+8. Additional 
5'MLL signal 
N/A 
1K Not fit for treatment. Died 07/2010. 49,XX,+8,+8,+20[21] N/A 
1L 
Supportive care - spontaneous remission 07/2014. Remains 
in remission.  46,XX 
N/A 
1N Supportive care. Died 04/2012. 46,XY N/A 
31 
AML 17 - high dose DA (90) then consented to high-risk arm 
- CR #1. VUD allo PBSCT 03/2012. Remains in remission.  
51,XY,+4,+6,+8,t(9;2
2)(q34;q11.2),+10,+1
3 
N/A 
32 
AML 17 - 2xDA60; 2high dose AraC - CR#1. Relapsed 5/12 - 
FLAG-IDA, VUD PBSCT 05/2014 - relapsed during 
transplant. Died 07/2014.  46,XX 
46,XX,ins(15;17)(q22;
q21q2?3) 
33 Declined palliative chemotherapy. Died 05/2013.  45,X,-Y[7]/46,XY[13] N/A 
6 
AML 17 – DA (90) - CR #1 (4% blasts) subsequently stratified 
as high risk (DCLO). VUD PBSCT 12/2012. Remains in 
remission.  46,XY 
N/A 
7 
AML 17 - DA - CR #1. Relapsed 8/12 - FLAG-IDA, MIDA - 
second CR. VUD PBSCT 04/2014. 07/2014 PTLPD - 
Rituximab.  46,XX 
46,XX,add(3)(p1?),ad
d(11)(p15.?)[cp6]/46,
XX[24] 
8 
AML 17 - high-risk arm (ADE) + Gemtuzimab (6) - CR #1 
(5%balsts). Metastatic colorectal Ca 05/2011. Died 
06/2011.  
46,XY,?i(1)(q10),-
8,add(11)(q2?1),add(
12)(q2?1),add(17)(q2
5),del(19)(p13),+mar 
N/A 
15 
AML 16 - intensive (ADE + ATRA) - failed to obtain CR after 
#2. Died large intracranial bleed - 02/2012. 46,XY 
N/A 
16 Died 12/2011 sepsis/multiorgan failure.  
39~41,XY,del(1)(q?21
q?42),?t(1;2)(q?13;q3
3),add(2)p?23),?t(3;2
1)(p1?4;q?21),add(4)
(q?22),-
5,add(6)(q?24),-
N/A 
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7,?add(8)(p?21),add(
9)(p?13),add(11)(p1?
),-14,add(14)(p1?),-
16,-
17,?t(17;22)(p?11;q?
11),-
18,add(18)(q?22),-
20,-21,-
22,add(22)(q?22),+2~
4mar,+dm[12] 
18 
Off trial - 2xADE; high dose cytarabine - CR#1. RIC PBSCT 
11/2010. Remission 4 years out.  46,XY 
N/A 
1J 
Off trial - DA - failed to obtain CR after #1 - palliative. 
Died 05/2010. 
49,XX,+8,+12,?del(18
)(q?) +20,-
21,+mar[3] 
N/A 
1 
DA - CR#1. Marked cardiac toxicity - maintenance chemo - 
low dose AraC (30 # to date) 46,XX 
N/A 
4 
DA - failed to obtain CR after #1. Matched PBSCT 12/2010. 
Died 01/2011 - multiorgan failure. 47,XX,+8[20] 
N/A 
5 Evolved from CMML-2. Low dose AraC. Died 04/2013. 46,XY[20] 
47,XY,+X[9]/ 
46,XY[11] 
19 
AML 17 - DA (60) - CR #1. Very frail post #1 - long delay - 
started low dose AraC 11/2012. Died 04/2014. 46,XX[20] 
46,XX,del(7)(q32)[5]/
46,XX[15 
20 Died, no further information available. 
45~46,XX,-
7,del(7)(q22q35),i(1
7)(q10)[cp17]/46,XX[
3] 
N/A 
22 Azacitidine (7#). Died 09/2013.  46,XX N/A 
23 No information available.   
47,XY +8[1] 
/46,XY[19] 
N/A 
1M AML 17 - Idarubicin + ATRA - CR #1. Remains in remission.  
46,XY,t(15;17)(q22;q
21)[10]/47,XY,t(15;1
7)(q22;q21),+8[3]/46
,XY[4] 
N/A 
27 AML 17 - Idarubicin + ATRA. Died. Sample failed N/A 
28 
AML 17 - ATRA + arsenic trioxide - CR #1. Remains in 
remission.  
46,XY,t(15;17)(q22;q
1?)[3]/46,XY[17] 
N/A 
29 No information available.   
46,XY,t(15;17)(q22;q
21)[4]/46,XY[16] 
N/A 
34 AML 17 - DA - CR #1. Remains in remission.  
46~48,XX,del(7)(q3?)
,inv(16)(p13.1q22),+
20,+22[cp20] 
N/A 
1D 
AML 17 - CR #1 - ADE, DClo. Sibling donor allogeneic PBSCT 
03/2011. Increasing percentage host derived T cells - 
05/2012 - relapsed 06/2012 - chemo + DLI 11/2012 second 
CR. GVHD lungs. Died GVHD 12/2013. 
46,XY,add(11)(q23)[
5]/46,XY[15] 
N/A 
1C 
2xDA, 2x high dose AraC, ICE - morphological remission #1; 
FISH remission #3. VUD 11/2009 (not in MR at time of 
transplant) - MR and 100% donor chimerism. cGVHD. 
Relapse 5/12 post transplant. Supportive care. Died 
08/2010.  
46,XX,t(6;11)(q27;q2
3)[7]/46,XX[13] 
N/A 
1E 
AML 17 – DA (90) - CR #1. (2xDA, 1xhigh dose AraC) - MR 
but unquantifiable levels AML ETO transcript. Remains in 
remission.  
46,XX,t(8;21)(q22;q2
2)[14]/46,XX[6] 
N/A 
36 
AML 17 - DA + Gemtuzumab - CR #1. Completed tx 
12/2013. Remains in remission. N/A 
N/A 
10 AML 17 – DA (90) - 10% after #1; CR#2.  46,XX N/A 
12 
AML 17 - ATRA + arsenic - CR #1. Remains in remission 4 
years out.  
46,XY,del(7)(q3?5),t(
15;17)(q22;q2?1)[12]
/46,XY[2] 
N/A 
25 CR #1.  46,XY N/A 
1M Died 08/2011 with sepsis.  
46,XX,del(5)(q1?3),d
er(11)t(11;13)(q2?3;
q1?2),del(12)(p13),-
13,-17,-
18,+21,+2~6mar,inc[
cp10] 
N/A 
14 
AML 16 intensive - DA - CR #1. Stopped after 2# (06/2010) 
due to sepsis and poor count recovery. Relapsed 11/2010. 
Died 12/2010. 46,XY 
N/A 
30 
AML 17 - CR #1 but +RTPCR. Relapsed 10/2012 - int chemo 
(?FLAG-IDAx3). Sib allo RIC PBSCT 04/2013 - CR, low level + 
RTPCR. Cranial relapse - IT chemo - stopped 04/2014 due 
to progression.  Died 05/2014 - intracerebral AML. 
46,XY,t(8;21)(q22;q2
2),del(9)(q2?1.11q2?
2)[cp14] 
N/A 
34 
AML 15 - CR. CNS Relapse 05/2006 MUD PBSCT 09/2006. 
Died 12/2006.  
46,XY,t(8;21)(q22;q2
2)[14] 
N/A 
36 AML 15 - CR #1. Relapsed 2005 post all PBSCT. Died 49,XY,+9,+14,inv(16) 46,XY,inv(16)(p13;q2
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11/2005. (p13;q22),+22[18]/4
6,XY[3] 
2)[3]/46,XY[27] 
1P Died 01/2006 - multi organ failure.  N/A  
AML36 I cycle azacitidine. Died sepsis.  
47 XY, +11[4]/46, 
XY[6].  
N/A 
AML51 DA, 1 cycle, no CR, then supportive care. 
N, 46 XY, 
del(12)(p?11.2),add(
14)(p11.1) 
N/A 
AML40 DA x1, WCC fell to 0.8, died during induction. 46 XX N/A 
AML53 N/A N/A N/A 
AML47 RAvVA study, Aza+ vori. Alive. 46 XY N/A 
AML35 N/A N/A N/A 
AML12 
Previous MDS.  
FLAG IDA x1 – failed to achieve CR – died AML 
 46 XX 
N/A 
AML009 N/A N/A N/A 
AML31 
N/A 47 XX, +4[2]/48, 
idem, +10[3]/48, 
idem, der 
(2)?t(2,17(q37;q21),
+10[8]/46,XX[2] 
N/A 
AML18 N/A 46 XY N/A 
AML005 N/A N/A N/A 
AML43 Supportive care. Dead (AML and sepsis) trisomy 9 N/A 
AMLAMcG N/A N/A N/A 
AML27 N/A N/A N/A 
AMLAG50 N/A N/A N/A 
AML22 N/A N/A N/A 
AML1002 N/A N/A N/A 
AML008 N/A N/A N/A 
AML011 N/A N/A N/A 
AML013 N/A N/A N/A 
AML014  N/A N/A N/A 
AML015 N/A N/A N/A 
AML016 N/A N/A N/A 
AML017 
AML 15 - CR #1. Relapsed 2005 post all PBSCT. Died 
11/2005. 
49,XY,+9,+14,inv(16)
(p13;q22),+22[18]/4
6,XY[3] 
46,XY,inv(16)(p13;q2
2)[3]/46,XY[27] 
AML019 AML 17, Myelotarg, Arsenic and Atra, x4. CR 1. Alive t(15,17) N/A 
AML020ER N/A N/A N/A 
AML021 N/A N/A N/A 
AML020W
M 
AML 17 - CR #1 but +RTPCR. Relapsed 10/2012 - int chemo 
(?FLAG-IDAx3). Sib allo RIC PBSCT 04/2013 - CR, low level + 
RTPCR. Cranial relapse - IT chemo - stopped 04/2014 due 
to progression.  Died 05/2014 - intracerebral AML. 
46,XY,t(8;21)(q22;q2
2),del(9)(q2?1.11q2?
2)[cp14] 
N/A 
AML023 N/A N/A N/A 
AML024 N/A N/A N/A 
AML025 N/A N/A N/A 
AML027DA 
AML 15 - CR. CNS Relapse 05/2006 MUD PBSCT 09/2006. 
Died 12/2006.  
46,XY,t(8;21)(q22;q2
2)[14] 
N/A 
AML028RR N/A N/A N/A 
AML029LB DAx2, HD AraC x1, AML17. CR1. Alive  N/A 
AML030 FLAGX2, HD AraC x2, not in trial. CR1. Alive 45,X,-X, t(8,21) N/A 
AML032 
AML17, DAx2, HD AraC x1. CR1. Alive 
 
46 XX N/A 
AML034 N/A N/A N/A 
AML037 N/A N/A N/A 
AML044JR N/A N/A N/A 
AML045JS Supportive care. Died. 46 XY N/A 
UPN, unique patient number; Mutn, mutation(s) present at diagnosis; Gene, gene expression 
performed; IHC, IHC performed; SMO Seq, SMO Sequencing performed; NGS, Next-generation 
sequencing performed; ICC, ICC performed; AML-NOS, AML not otherwise specified; AML-MDS, 
AML with MDS related changes; t-AML, therapy related AML; AML-R, AML with recurrent 
abnormalities; N/A not available; Y, analysis performed. 
 
